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Abstract 
Ewing’s sarcoma family of tumours (ESFT) are aggressive tumours with a tendency to 
metastasise, which is associated with poor outcome. ESFT are characterised by an EWS-ETS 
gene rearrangement, most commonly EWS-FLI1. However, the mechanism of tumour 
formation is poorly understood and the cell of origin unclear. Since Wnt signalling is 
frequently deregulated in pathological conditions including cancer I have examined the 
potential role of Wnt signalling in ESFT cell lines and two novel in vitro models of ESFT 
development.   
Components of the Wnt signalling pathway were expressed in all 6 ESFT cell lines studied. 
A lentiviral-based luciferase assay measuring TCF/LEF mediated signalling was successfully 
developed and demonstrated that the canonical Wnt signalling pathway is active in ESFT 
cell lines. Assays developed to investigate the activity of the noncanonical Wnt signalling 
pathway indicated that active Rac1 is expressed in some ESFT cell lines, and that ESFT cell 
lines are highly migratory. 
Two complementary model systems were utilised to investigate Wnt signalling in the 
initiation of ESFT. Firstly, analysis of reprogrammed ESFT cells showed an increase in 
response of the canonical Wnt signalling pathway to Wnt3A, and an increase in active Rac1 
expression. Furthermore Wnt signalling components were differentially expressed in 
reprogrammed cells. The induction of EWS-FLI1 expression in human embryonic stem (hES) 
cells increased canonical Wnt signalling and expression of active Cdc42. These cells had an 
altered phenotype and were more migratory. EWS-FLI1 expression also resulted in 
differential expression of Wnt signalling components including DKK2, DKK4, FZD8, Wnt4 
and Wnt5A. 
These data demonstrate that both the canonical and noncanonical Wnt signalling 
pathways may be important in the initiation of ESFT. Further elucidation of the role of 
these pathways and the individual components in tumour development could inform the 
development of novel therapeutics that could prevent tumour metastasis and relapse. 
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1. Introduction 
1.1 Cancer 
1.1.1 Biology of cancer 
Cancer is responsible for more than 10% of deaths worldwide. In 2012 there was an 
estimated 14.1 million new cases of cancer worldwide, and 8.2 million people died from 
the disease (GLOBOCAN 2014). The number of cases is expected to rise by 70% over the 
next two decades to 25 million per year. There are over 200 different cancers currently 
described that, from both a clinical and scientific view point, appear remarkably diverse 
reflecting the complexity and intricate nature of cancer development and progression. 
Despite this, a set of common capabilities have been described which are acquired by 
almost all types of cancers (Figure 1.1). These hallmarks were first proposed by Hanahan 
and Weinberg in 2000, and have recently been updated as a result of continued research 
and understanding to include; a metabolic switch to from oxidative phosphorylation to 
glycolysis, and also evasion of immune system surveillance (Hanahan and Weinberg 2000, 
Hanahan and Weinberg 2011). 
Cancer is a genetic disease caused by inherited or acquired mutations in deoxyribonucleic 
acid (DNA). Traditionally cancer development has been considered clonal, akin to the 
theory of Darwinian evolution, whereby a genetic change gives a selective advantage to a 
cell and its progeny.  Over time, subsequent mutations develop so that eventually cancer 
occurs (Foulds 1954, Nowell 1976). It is now understood that most cancers develop due to 
mutations in two types of genes; tumour suppressor genes (TSG) and oncogenes. Tumour 
suppressor genes such as p53 (Lane and Crawford 1979, Linzer and Levine 1979),  
retinoblastoma protein (pRB) (Friend et al. 1987) and PTEN (Li et al. 1997) encode proteins 
which function to suppress the cancer phenotype, for example by maintaining correct 
control of the cell cycle (Harris, 1971). Therefore mutations resulting in loss of expression 
of TSG are common in cancer. In contrast, oncogenes are mutated or overexpressed forms 
of genes (known as proto-oncogenes) that can cause cancer by mechanisms such as 
promoting increased proliferation or preventing apoptosis. Examples include the myc 
family of transcription factors (Paynes et al, 1982) and the Rat sarcoma (Ras) family of 
regulatory guanosine triphosphate-ases (GTPases) (Chang et al. 1982). 
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In most cases, cancer does not result from a single mutation. It is hypothesised that there 
may be a single oncogenic driver such as a mutation in a TSG or oncogene that results in 
the accumulation additional mutations, for example through disruption of cell cycle control 
or of DNA repair mechanisms. Early in vitro experiments showed that cells require at least 
two genetic aberrations before they are transformed, and work in familial cancer 
syndromes led Knudson to propose the ‘two hit’ hypothesis where patients with one 
inherited mutation in RB1 require one additional mutation to occur for cancer to develop 
(Knudson 1971). More recently it has been hypothesised that 5 mutations are required for 
non-inheritable cancers to occur (Weinberg 2014). As these additional mutations occur, 
the cell acquires the capabilities described as the hallmarks of cancer. 
 
 
 
Figure ‎1.1 The process of cancer development including the hallmarks of cancer The key 
characteristics or ‘hallmarks’ of a cancer cell are shown in blue. Adapted from 
Hanahan and Weinberg (2000) and Pelengaris and Kahn (2013). 
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1.1.2 Metastasis 
The spread of cancer to other regions of the body is known as metastasis, this process is 
one of the hallmarks of cancer (Figure 1.1). Patients may present with metastatic disease, 
or may develop metastasis sometimes decades after the primary tumour was excised 
and/or treated. For metastasis to occur, cancer cells must acquire capabilities for local 
invasion, intravasation into a blood vessel, transport through the circulation, extravasation 
out of the vessel, formation of micrometastases and finally colonisation in the new site 
(Fidler 2003). In the case of carcinomas this process involves the cancerous polarised 
epithelial cells undertaking a dramatic change in morphology and dissolving intercellular 
connections to become invasive and motile, often known as the epithelial-to-mesenchymal 
transition (EMT). The reverse process, mesenchymal-to-epithelial transition (MET) is 
thought to be important in seeding tumour cells at distant metastatic sites (Wells et al. 
2008). In non-epithelial cancers the process of metastasis is less well documented, 
however MET has been described in sarcoma and linked to a better prognosis (Yang et al. 
2014), highlighting the importance of mesenchymal characteristics in the process of 
migration.  Metastatic disease is responsible for 90% of deaths from cancer (Weinberg 
2014) therefore understanding this process and the cells involved is extremely important 
to increase treatment success and cure of cancer patients.  
1.1.3 Cancer initiating cells (CICs) 
The clonal evolution model of cancer suggests that each cell within the tumour has an 
equal potential to acquire mutations which lead to growth advantage and therefore 
generate new tumours. This hypothesis was challenged in the 1970s when it was shown 
that only a subpopulation of cells have the ability to initiate and maintain tumour growth 
(Hamburger and Salmon 1977). This led to the development of a hierarchical model, where 
a subpopulation of cells have the ability to self-renew, differentiate and regenerate 
tumours. These cells have many similar properties to normal stem cells such as the ability 
to self-renew, multipotent differentiation potential and the expression of stem cell-
associated markers such as CD133 (Zhu et al. 2009). For this reason these cells were 
termed cancer stem cells (CSC); or more accurately, since they do not represent true stem 
cells, cancer initiating cells (CIC).  
The first definitive evidence for CICs was in acute myeloid leukaemia (Bonnet and Dick 
1997), this was followed by the demonstration of CICs in solid tumours of the breast (Al-
Hajj et al. 2003) and brain (Singh et al. 2003). To date, CICs have been identified in 
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numerous other tumour types including prostate (Collins et al. 2005), pancreatic  (Li et al. 
2007), colon (O'Brien et al. 2007) and more recently the Ewing’s sarcoma family of 
tumours (ESFT) (Suvà et al. 2009).  
There still remains much controversy over the origin of CICs (Figure 1.2). Studies have 
suggested they may arise from normal stem cells that have gained malignant mutations 
(Bonnet and Dick 1997, Schepers et al. 2012), or from progenitor cells which acquire self-
renewal capacity (Cozzio et al. 2003). It has also been shown that differentiated cancer 
cells can re-acquire self-renewal capacity and stem-like characteristics, and this may occur 
upon exposure to microenvironmental factors (Vermeulen et al. 2010, Chaffer et al. 2011). 
Therefore it is possible that CICs arise from different cells in different tumour types.  
Whatever the origin of CICs, they have important implications for the successful treatment 
of cancer.  It has been suggested, at least in some cancer types such as pancreatic cancer 
(Hermann et al. 2007), that CICs are responsible for metastasis. This hypothesis is 
supported by the fact that the process of metastasis requires stem-cell characteristics such 
as self-renewal. Importantly, CICs have also been shown to be more resistant to current 
cancer treatment. This is likely due to a variety of different mechanisms. CICs have been 
shown to have increased expression of ABC drug transporters and intracellular 
detoxification enzymes. CICs have also been shown to have more efficient DNA repair 
mechanisms and may upregulate anti-apoptotic proteins (Alison et al. 2012). In addition, 
CICs share another stem-cell phenotype in that they are relatively quiescent, meaning 
cytotoxic agents that target rapidly dividing cells do not kill the CICs. Indeed it has been 
shown experimentally and in patient samples that chemotherapy targets the non-CIC cells 
and therefore enriched for a more aggressive CIC population that can go on and 
recapitulate the tumour (Hermann et al. 2007, Dylla et al. 2008, Li et al. 2008). Therefore in 
many cancers it is believed that CICs are responsible for the failure of treatment, relapse 
and progression. 
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Figure ‎1.2 The dynamic cancer initiating cell (CIC) model CICs differentiate to give rise to 
the bulk of the tumour (black arrows). Alternatively (or additionally) signals from the 
microenvironment lead to dedifferentiation of tumour cells (red arrows). Adapted 
from Vermeulen et al. (2012)..  
 
1.1.4 Cancer treatment 
The clinical treatment of cancer depends on the type of cancer and location of the 
tumour(s), as well as the stage of disease (Pelengaris and Khan 2013). Surgery was once 
the only treatment for cancer and still offers the best chance of a cure for many patients. 
Surgery is most often used in combination with radiotherapy and/or systemic 
chemotherapy. In some cases chemotherapy is given to reduce tumour bulk prior to 
surgical excision to improve the ease of surgery and reduce the risk of disease spread 
resulting from surgery (DeVita and Chu 2008). Chemotherapy may also be given after 
complete surgical resection in an attempt to target remaining cancer cells including 
subclinical micrometastases (Weinberg 2014). For most cancer patients cytotoxic drugs 
remain the only current chemotherapy treatment option available. Cytotoxic agents non-
specifically target highly proliferating cells, exploiting the lack of growth regulation in 
cancer cells (DeVita and Chu 2008). These drugs are classed according to their mode of 
action which may include alkylating the DNA (e.g. alkylating agents such as 
cyclophosphamide), forming interstrand cross-links between DNA (e.g. platinum 
compounds such as cisplatin), intercalating between base pairs within DNA (e.g. 
anthracyclines such as doxorubicin), destabilising microtubules (e.g. vincristine) or 
interacting with DNA-associated proteins such as topoisomerases (e.g. Topoisomerase II 
inhibitors such as etoposide). Most cytotoxic agents are given in combination as their 
synergistic or additive actions increase the amount of cancer cell kill (DeVita and Chu 
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2008). In addition, some cytotoxic agents may have more than one mode of action, for 
example doxorubicin is an alkylating agent but can also intercalate DNA and inhibit 
topoisomerase II function (Gewirtz 1999). Although cytotoxic agents have been used for 
many years, their non-specific action means they also target highly proliferative normal 
cells such as those of the immune system and lining the gastrointestinal tract. This leads to 
side effects such as tiredness, hair loss, vomiting, diarrhoea and susceptibility to infection. 
These effects may be dose-limiting or even lethal. Furthermore, many cytotoxic agents 
work by inducing irreversible damage in DNA, with the hope this will induce apoptosis in 
cancer cells (DeVita and Chu 2008). However, if the cells survive, then this damage could 
increase the number of mutations meaning cytotoxic treatment could actually select for 
more aggressive clones that may repopulate the tumour (Weinberg 2014). In addition, 
some cancer patients, especially children are at increased risk of developing a second 
cancer during their lifetime (Wasilewski-Masker et al. 2009, Friedman et al. 2010) 
indicating that cytotoxic agents also damage the DNA of normal cells. 
Our knowledge of the molecular alterations within cancer cells has increased dramatically 
over the past few decades. One of the fundamental reasons for this is the development of 
new technologies such as next-generation sequencing (NGS) which has enabled whole 
cancer genomes to be mapped, and provided valuable information about the specific 
mutations which occur in each individual tumour. However, interpreting this data, 
understanding the biological implications and translation of this knowledge to more 
effective and less toxic treatments has proved challenging. For example recent whole 
genome sequencing of one melanoma revealed 33,000 different somatic mutations 
(Pleasance et al. 2010). One challenge is understanding which of these are driver 
mutations promoting tumour growth and which are simply passenger mutations that have 
occurred but that do not contribute to the tumorigenic phenotype. However in some 
cancer types, identification of mutations that are common in (at least a subset) of patients 
has resulted in the generation of novel targeted therapies. For example, approximately 
20% of lung cancer patients have mutations in the EGFR gene (Rosell et al. 2009), and up to 
70% of these patients exhibit a clinical response when treated with EGFR inhibitors such as 
gefitinib or erlotinib (Mok et al. 2009, Rosell et al. 2012). Another example of targeted 
therapy is in melanoma in which the BRAF gene is mutated in up to a third of tumours, and 
these patients respond to vemurafenib, a BRAF inhibitor (Flaherty et al. 2010). 
Unfortunately tumours often become resistant to targeted therapies, by acquiring 
additional mutations or by upregulating alternative signalling pathways (Remon et al. 
2014). Importantly research has shown that even within tumours heterogeneity exists 
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meaning different mutations may be present in different parts of the tumour (Gerlinger et 
al. 2012). This raises the issue of how patients should be stratified to receive personalised 
therapy, since if a single tumour biopsy is taken this may not represent the biology and 
genetics of the entire tumour mass. Nevertheless, the goal of further understanding the 
biology of individual tumours in order to deliver personalised therapy remains important 
for the future treatment of cancer patients 
1.2 Ewing’s sarcoma family of tumours (ESFT) 
1.2.1 Biology of ESFT 
Ewing’s sarcoma family of tumours (ESFT) are rare solid tumours including Ewing’s 
sarcoma, peripheral primitive neuroectodermal tumours (pPNET) and Askin’s tumour. ESFT 
most frequently arise in children and young adults between the ages of 10 and 24 years, 
with an incidence of approximately 1.8 per million 0-49 year olds. There is slightly higher 
incidence in males than females (ratio 1.4 : 1) (McNally et al. 2012). Most ESFT arise in the 
bone, commonly in the pelvis (26%), long bones of the lower extremities such as the femur 
(20%) or the bones of the chest wall (16%) (Bernstein et al. 2006). However, in around 15% 
of cases the primary tumours arise in a variety of extra osseous sites (Grier 1997).  
Morphologically, ESFT consists of sheets of small, poorly differentiated round cells with 
scant cytoplasm and large nuclei with little mitotic activity. Immunohistochemisty shows 
that in more than 90% of cases ESFT cells express the cell surface membrane protein CD99 
(Ambros et al. 1991). Membrane expression of CD99 is used to diagnose ESFT and 
distinguish them from other small round cell tumours (Weidner and Tjoe 1994). 
1.2.2 Genetic abnormalities in ESFT 
ESFT are characterised by a unique non-random chromosomal translocation between the 
EWS gene on chromosome 22q12 with a member of the ETS gene family of transcription 
factors. In 85% of ESFT this is FLI1 on chromosome 11q24, which generates the chimeric 
EWS-FLI1 fusion protein (Delattre et al. 1992). Other EWS-ETS translocations have been 
identified in the remaining 15% of cases including EWS-ERG or very rarely EWS-ETV, EWS-
E1AF1 or EWS-FEV (Burchill 2008) (Table 1.1). The identification of these gene 
rearrangements has led to the classification of Ewing’s sarcoma, pPNET and Askin’s 
tumours into a common group with similar histogenesis known at the ESFT. More recently, 
the World Health Organization (WHO) have renamed this family ‘Ewing Sarcoma’. 
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However, this term is limited as it doesn’t reflect the range of tumours within the family, 
and in addition, ESFT was first described by James Ewing (Ewing 1921), therefore the term 
‘Ewing’s’ sarcoma’ is more accurate.  
 
 Table ‎1.1 EWS fusion types in ESFT *Alternative fusion types have been identified 
depending on where the breakpoint arises in different exons of the FLI1 gene. EWS= 
Ewing Sarcoma Breakpoint Region 1, FLI1= Friend leukemia integration 1 
transcription factor  ERG= ETS related gene, ETV1 = ETS translocation variant 1, E1AF 
= Early region 1A enhancer binding protein, FEV = Fifth Ewing variant.  
 
All reported fusion proteins contain at least the N-terminal 7 exons of EWS containing the 
EWS activation domain (Herrero-Martin et al. 2011), and the DNA-binding domain of the 
ETS fusion partner. Both domains are required for the oncogenic function. The fusion 
proteins are known to localise to the nucleus and bind DNA in a site-specific manner and 
are thought to function as aberrant transcription factors.  
Being the most common, EWS-FLI1 is the most studied fusion protein and has been shown 
to have numerous downstream targets that contribute to the pathogenesis of ESFT. 
Microarray analyses have revealed EWS-FLI1 both up- and down-regulates downstream 
targets (Hancock and Lessnick 2008, Kauer et al. 2009). Interestingly, initial studies 
suggested EWS-FLI downregulates many more genes than it upregulates (Prieur et al. 2004, 
Smith et al. 2006). The fusion protein has been reported consistently to upregulate genes 
involved in proliferation and survival including PDGFC, IGF1, MYC, CCND-1, NKX2-2 and 
suppress genes involved in apoptosis and growth inhibition for example  p21, p57kip, 
TGFβRII and IGFBP3 (Riggi and Stamenkovic 2007, Ross et al. 2013). EWS-FLI1 can also 
initiate oncogenic pathways even when the DNA-binding domain of FLI1 is mutated, 
Fusion Transcript Translocation Frequency of occurrence 
EWS-FLI1 Type I* t(11;22)(q24;q12) 60% 
EWS-FLI1 Type II* t(11;22)(q24;q12) 25% 
EWS-ERG t(21;22)(q22;q12) 10% 
EWS-ETV1 t(7;22)(q22;q12) <1% 
EWS-E1AF t(17;22)(q12;q12) <1% 
EWS-FEV t(2;22)(q33;q12) <1% 
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indicating that the fusion protein activates pathways independent of FLI1 DNA binding 
(Welford et al. 2001). A variety of different signalling pathways have been linked to 
pathogenesis of ESFT, although it is not clear if this is due to expression of the fusion 
protein or cooperating mutations which have occurred. A number of studies have shown 
that the insulin-like growth factor 1 (IGF-1) pathway is important in ESFT (Yee et al. 1990, 
Scotlandi et al. 1996, Toretsky et al. 1997). More recently the Wnt signalling pathway has 
also been linked to the pathogenesis of ESFT (discussed in Section 1.3.5).  
Although the EWS-ETS fusion proteins have been identified as the main genetic drivers of 
malignancy, secondary genetic abnormalities have been described in over 80% of ESFT 
(Burchill 2008). Chromosome gain is observed more frequently than loss in ESFT, with 
more complex karyotypes associated with a worse prognosis (Roberts et al. 2008). In 
particular, gains of chromosomes and 8 and 12 are common and can occur together 
(Maurici et al. 1998). However the prognostic implication of these chromosomal 
abnormalities is not clear (Roberts et al. 2008). The most common secondary aberrations 
detected in ESFT are deletions of the CDKN2A locus on chromosome 9p and in genes that 
regulate the G1 cell cycle checkpoint. For example, inactivation of the CDKN2A region 
which codes for p16 occurs between 13-39% of primary ESFT (Tsuchiya et al. 2000, Maitra 
et al. 2001, Lopez-Guerrero et al. 2001, Brownhill et al. 2007). The primary mechanism of 
this inactivation appears to be homozygous deletion, the p16 promoter is rarely 
methylated (Tsuchiya et al. 2000, Lopez-Guerrero et al. 2001, Brownhill et al. 2007). Some 
studies have associated mutation or deletion of p16 with worse survival  (Tsuchiya et al. 
2000, Wei et al. 2000), although other studies have reported no prognostic significance of 
deletion of p16 gene (Brownhill et al. 2007, Lopez-Guerrero et al. 2011). In contrast to p16, 
deletions or mutations of the tumour suppressor gene TP53 are rare in ESFT. However, 
when present TP53 aberrations are associated with poor overall survival (de Alava et al. 
2000, Lopez-Guerrero et al. 2001).  
1.2.3 Model systems to study ESFT initiation and development 
Unlike other sarcomas such as osteosarcoma that show some lineage-specific 
differentiation, ESFT present as  undifferentiated tumours that reveal little insight into the 
cell of origin. When first described in 1921, Ewing proposed an endothelial origin (Ewing 
1921). However early studies found that cell surface antigens associated with the 
neuroectodermal lineage were expressed on ESFT (Lipinski et al. 1986). Most Ewing’s 
sarcomas arise in the bone, but about 15% of primary ESFTs arise in extra osseous sites. 
The wide range of organs and tissues from which ESFTs can arise, along with their 
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histological features of poor differentiation and both mesenchymal and neuroectodermal 
characteristics has fuelled a debate as to their cell of origin. 
Although characterised by the presence of an EWS-ETS fusion such as EWS-FLI, it is not 
known how or in what cell type these fusion proteins lead to ESFT formation. It is 
understood that EWS-FLI1 acts an aberrant transcription factor, and has been shown to 
regulate genes that are critical for ESFT tumorigenesis. Therefore many researchers have 
developed systems to induce expression of the fusion protein in different cell types in an 
approach to understand the process of tumour initiation, with the hope this may lead to 
the development of improved therapeutics.  
Initial experiments used murine fibroblast NIH/3T3 cells that can be readily transformed by 
EWS-FLI1, to identify genes regulated by the fusion protein (May et al. 1993, Braun et al. 
1995). However, more recently it has been shown that the gene expression profile of 
NIH/3T3 cells does not accurately represent the expression profile of ESFT tumour samples 
(Braunreiter et al. 2006, Hancock and Lessnick 2008). Therefore researchers have 
developed model systems in which EWS-FLI1 is expressed in human cell types, and it has 
been shown that the phenotype and gene expression changes that occur when EWS-FLI1 is 
expressed appear to be cell type specific. This has lead to the hypothesis that there is a 
specific permissive cellular environment in which the EWS-FLI fusion protein is tolerated 
and this leads to the initiation of ESFT. For example, in some human cells such as 
fibroblasts, rather than being oncogenic, EWS-FLI1 induces cell cycle arrest (Lessnick et al. 
2002). In other cell types such as neuroblastoma (Rorie et al. 2004) and 
rhabdomyosarcoma (Hu-Lieskovan et al. 2005) expression of EWS-FLI1 has been shown to 
induce an ESFT phenotype along with upregulating genes associated with neuronal 
differentiation (that are also expressed in ESFT) such as MAPT. It has therefore been 
suggested that the neuroectodermal characteristics observed in ESFT may be acquired 
though the upregulation and downregulation of EWS-FLI1 target genes, rather than 
reflecting the cell of origin.  
A recently emerged concept is that ESFT may arise from a pluripotent or multipotent 
progenitor cell, and that EWS-FLI1 may interfere with normal differentiation thus inducing 
the tumour phenotype. Many reports have suggested that the cell of origin may be a 
mesenchymal stem cell (MSC). The term MSC is generally used to describe cells which can 
differentiate towards mesodermal lineages including osteoblasts, chondrocytes and 
adipocytes. However, there is still controversy over how these cells are defined therefore 
these cells are also often referred to as mesenchymal progenitor cells (MPCs) or bone 
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marrow stromal cells. MSCs are found in the bone marrow and a number of other tissue 
sites therefore it is believed that the MSC-origin theory could explain the broad tissue 
distribution of ESFT. A number of model systems have been used to support the hypothesis 
that MSCS are the ESFT cell of origin. For example, unlike other cell types, human MSCs 
tolerate the forced expression of the EWS-FLI1 fusion protein. Importantly it has been 
observed that ESFT cell lines where EWS-FLI1 has been inhibited with RNAi display a MSC 
gene expression profile, and these cells have the ability to differentiate into osteoblasts 
and adipocytes (Tirode et al. 2007). It has been reported that the gene expression profile 
of MSCs expressing EWS-FLI1 is similar to ESFT, but not to other bone and soft tissue 
tumours (Riggi et al. 2008). Interestingly, it has been shown that MSCs derived from 
paediatric rather than adult donors display different expression profiles upon EWS-FLI1 
induction. Paediatric MSCs containing EWS-FLI1 have increased expression of EWS-FLI1 
target genes such as IGF1 and NKX2.2, and have an expression profile that more closely 
resembles that of ESFT, compared to adult MSCs (Riggi et al. 2010).  
Importantly however, so far none of the populations of MSCs with EWS-FLI1 expression 
have been reported to form tumours in vivo. Consequently it is not clear whether MSCs are 
simply tolerant of EWS-FLI1 expression, and the genetic and phenotypic alterations 
observed are a manifestation of the EWS-FLI1 fusion itself, or if additional genetic 
abnormalities are required for ESFT initiation. In support of the latter hypothesis, in a 
transgenic mouse model of ESFT with conditional expression of EWS-FLI1 in the 
mesoderm-derived tissues of the limb, sarcomas did not spontaneously form unless p53 
was also deleted. This suggests that expression of EWS-FLI1 alone may not be enough to 
induce transformation in vivo. Interestingly, these transgenic mice also had shortened 
limbs and muscle atrophy, supporting the hypothesis that EWS-FLI1 impairs differentiation 
of cells. Indeed, in mouse MSCs it has been reported that expression of EWS-FLI1 blocks 
differentiation along osteogenic and adipogenic lineages (Torchia et al. 2003), although in 
human MSCs with EWS-FLI1 expression some degree of differentiation has been reported 
(Riggi et al. 2008). 
Despite this evidence, there is still controversy as to the definitive cell of origin of ESFT. For 
example, another recent study has demonstrated that neural crest stem cells (derived 
from human embryonic stem cells) and neuromesenchymal stem cells can tolerate 
expression of EWS-FLI1, and this leads to an alteration in EWS-FLI1 target genes (von 
Levetzow et al. 2011). However, this could be explained by the finding that at least the 
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initial population of MSCs that form during development derive from neuroepithelim  and 
neural crest cells rather than mesoderm (Takashima et al. 2007).   
The hypothesis that EWS-FLI1 contributes to a pluripotent, undifferentiated state is 
supported by the fact that expression of EWS-FLI1 in paediatric MSCs induces expression of 
the stem cell markers CD133, Oct4, Sox2 and Nanog (Riggi et al. 2010). This primitive state 
may be further understood by the study of ‘reprogrammed’ ESFT cells. The reprogramming 
of cells to induced pluripotent stem (iPS) cells was first described in mice, and 
subsequently in human cells using adult dermal fibroblasts by lentiviral transduction of the 
key pluripotency genes Oct4, Sox2, Klf4 and c-Myc (Takahashi and Yamanaka 2006, 
Takahashi et al. 2007). Since iPS cells exhibit many characteristics of human embryonic 
stem (hES) cells, including self-renewal and pluripotency, they are being used extensively in 
the field of regenerative medicine and in modelling human disease.  
Such model systems have provided important insights into how ESFT initiates and 
develops. Even so, is it not currently understood precisely what genetic events are 
required for initiation of ESFT or in what specific cell type ESFT initiates. It may be that 
ESFT can arise in multiple cell types i.e. there may be several permissive cells of origin. This 
would also explain the wide range of sites in which ESFT arises.  
Further understanding of the cell of origin of ESFT is important, particularly as CICs have 
recently been identified in ESFT based on expression of the cell surface marker CD133 
(Suvà et al. 2009). These CICs express the stem cell markers Oct4, Sox2 and Nanog and 
importantly, like MSCs, can differentiate along adipogenic, osteogenic, and chondrogenic 
lineages. Although it was subsequently shown that CD133 expression is very 
heterogeneous in ESFT, and CD133+ cells are not consistently more resistant to 
therapeutics (Jiang et al. 2010), work in other cancer types has suggested that CICs cells 
may be responsible for disease relapse (Section 1.1.3). Therefore further investigation into 
the biology of these cells in ESFT may improve our understanding of how to prevent 
relapse and resistance to therapy in patients.  
1.2.4 Treatment of ESFT 
The outcome of patients with ESFT has been significantly improved since the 
implementation of multimodal therapy, and patients with localised disease now have up to 
75% chance of long-term survival (Thacker et al. 2005). In most cases complete surgical 
resection is the standard treatment where possible, with chemotherapy given both pre- 
and postoperatively. There are no randomized control trials comparing radiotherapy and 
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surgery for local control. However, radiotherapy is suggested when complete surgical 
resection is not possible (Schuck et al. 2003).  Unfortunately,  ESFT display an aggressive 
behaviour with a tendency to metastasise primarily to the lung, bone and bone marrow. 
Approximately 25% of patients have overt metastases at presentation (Grier 1997, Cotterill 
et al. 2000, Thacker et al. 2005, Bernstein et al. 2006) but up to 50% of patients without 
clinically detectable metastasis at diagnosis will relapse with distant metastatic disease 
after surgery if systemic chemotherapy is not given.  
Metastatic disease is considered the most adverse prognostic factor for ESFT and patients 
with metastasis to the bone or bone marrow have a 5-year survival rate of less than 25% 
(Paulussen et al. 1998, Cotterill et al. 2000). In addition, despite aggressive treatment, 30-
40% of patients have a recurrence and of these only 50-60% achieve partial or complete 
remission to second line treatment (Shankar et al. 2003, Barker et al. 2005).  
ESFT are treated with chemotherapy regimens including actinomycin D, doxorubicin, 
etoposide, cyclophosphamide, vincristine and ifosfamide. There is no internationally 
defined standard treatment for ESFT and in the UK, patients are treated as part of clinical 
trials. In the recently completed Euro-EWING 99 trial patients received vincristine, 
ifosfamide, doxorubicin and etoposide (VIDE) induction chemotherapy and were then 
randomised according to disease-risk. Standard risk patients received either  vincristine, 
actinomycin D and ifosfamide (VAI) or vincristine, actinomycin D and cyclophosphamide 
(VAC). High risk patients receiving VAI or high-dose busulfan-melphalan megatherapy 
followed by autologous stem-cell transplantation. Although the high risk arm did not 
recruit the expected number of patients, the study recommended the VAC regimen for 
consolidation treatment of standard risk patients. Unfortunately there was a high degree 
of toxicity associated with the VIDE induction regimen, including stomatitis (inflammation 
of the mouth and lips) and infections (Juergens et al. 2006). Some secondary malignancies 
have also been reported although the complete data has not been published. The newly 
opened Euro-EWING 2012 trial will compare the VIDE regimen to the standard 
chemotherapy regimen used in the USA, where much fewer side effects have been 
reported. In the USA patients receive alternating cycles of vincristine-doxorubicin-
cyclophosphamide followed by ifosfamide-etoposide and finally vincristine-
cychlophosphamide (VDC/IE/VC) as induction chemotherapy. The Euro-EWING 2012 trial 
will also compare treatment with the bisphosphonate Zoledronic acid. Biphosphonates 
inhibit  bone resorption  and are therefore used extensively to treat osteoporosis and local 
bone loss (Bone et al. 2004). Biphosphonates have also been used for the treatment of 
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bone metastasis in patients with breast (Powles et al. 2006)  and prostate (Berry 2006) 
cancer. Zoledronic acid has been shown to inhibit the growth of ESFT cell lines in vitro, and 
also inhibit the growth of bone tumours in mouse models of ESFT (Odri et al. 2010). 
Interestingly, when combined with ifosfamide, zoledronic acid exerted synergistic effects 
resulting in an inhibition of tumour growth that was similar to three cycles of ifosfamide 
alone.  
Despite ongoing clinical trials, the survival rate of patients with recurrent or metastatic 
disease has not improved for many years. In addition, such aggressive treatment can result 
in debilitating side effects and even secondary cancers. Survivors of ESFT have been shown 
to be particularly at risk of developing thyroid and breast cancers and sarcoma, especially 
when radiotherapy has been given (Kuttesch et al. 1996, Wasilewski-Masker et al. 2009). 
Therefore there remains a real need to gain understanding of the biology of ESFT in order 
to develop more selective, effective and less toxic agents.  
As the EWS-ETS fusion proteins are specific to ESFT cells they are an attractive target for 
therapy. Although it may not be possible or financially attractive to pharmaceutical 
companies to target the fusion specifically, drug screens have identified existing agents 
that target the fusion proteins. For example, the antibiotic mithramycin can inhibit EWS-
FLI1 (Grohar et al. 2011). This drug suppresses tumour growth in ESFT xenograft models 
and is currently being investigated in a phase I/II trial in children with ESFT. Other drugs 
targeting EWS-FLI1 are also in pre-clinical development such as the small molecule YK-4-
279. This compound interferes with the interaction between EWS-FLI1 and RNA helicase A, 
a critical mediator of EWS-FLI1 activity (Erkizan et al. 2009).  
An alternative approach to identify useful therapeutic options is to develop our 
understanding of the cellular mechanisms and pathways affected by the fusion proteins. 
The IGF signalling pathway has been known to be have a role in ESFT tumorigenesis for a 
number of years. Emerging evidence has suggested that this pathway may actually be 
directly regulated by EWS-FLI. It has been shown that EWS-FLI downregulates IGFBP3 (IGF 
binding protein 3) (Prieur et al. 2004), and it is suggested this increases the amount of free 
IGF-1, thus stimulating tumour growth. In addition, data has shown that a group of 
microRNAs that negatively modulate the IGF pathway, are repressed by EWS-FLI 
expression (McKinsey et al. 2011). In the clinic, targeting the IGF pathway in ESFT patients 
has resulted in modest responses. A phase II clinical trial using a humanised IGF-1R 
antibody showed an overall response rate of just 10-15% (Pappo et al. 2011). However this 
study indicated that the response rate was better in patients with bone based primary 
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tumours, which are more common in younger patients. A more recent study has reported 
a 30% response rate when a monoclonal IGF-1R antibody (cixutumumab) was combined 
with a mTOR inhibitor (temsirolimus), including a complete response in a patient 
previously resistant to IGF-1R antibody therapy (Naing et al. 2012). Despite perhaps 
disappointing initial clinical results, there is strong evidence for the role of IGF signalling in 
ESFT so future work is ongoing to predict patients who will respond to this type of therapy 
and to target resistance networks (Kovar et al. 2012). 
Recently, there have been a number of studies demonstrating that poly ADP ribose 
polymerase (PARP) inhibitors may be effective against ESFT. Research was performed at 
the Wellcome Trust Sanger Institute to screen over 600 cancer cell lines for sensitivity to 
130 different drugs currently in preclinical or clinical evaluation (Garnett et al. 2012). A 
surprising result was the sensitivity of some ESFT cell lines to the PARP inhibitor olaparib 
(AZD2281). This observation has been confirmed by other researchers and it has also been 
demonstrated that EWS-FLI1 expression directly increases sensitivity of cells to PARP1 
inhibition (Brenner et al. 2012).  Importantly, olaparib was not effective as a single agent in 
xenograft models of ESFT, though combination with temozolamide showed regression of 
tumour growth (Brenner et al. 2012).  A phase II clinical trial is ongoing to study the effect 
of olaparib in adults with recurrent or metastatic ESFT, and a phase I trial is recruiting to 
investigate the combination of olaparib and temozolamide in younger ESFT patients 
(Grohar and Helman 2013). 
Although exciting, novel therapeutics have not yet shown dramatic responses in ESFT 
patients. There is still research ongoing to identify other signalling pathways which may be 
targeted, especially in metastatic disease. For example, a recent study by Schaefer et al. 
(2008) used Affymetrix microarray technology to compare the gene expression profile of 
20 localised tumours to 7 metastatic tumours, and found that components of the Wnt 
signalling were differentially expressed. In addition, Wnt signalling was associated with 
resistance to chemotherapeutics used in the VIDE regimen (Schaefer et al. 2008).  Studies 
have also shown that when EWS-FLI1 expression is induced in cells, components of the 
Wnt signalling pathway are upregulated (Hu-Lieskovan et al. 2005). Wnt signalling is 
important in normal mesenchymal stem cell development and differentiation.  Therefore 
further investigation of this signalling pathway in ESFT may help us to understand the 
molecular mechanisms behind ESFT initiation, metastasis and response to therapy (Section 
1.3.5). 
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1.3 Wnt signalling 
Wnt proteins are a family of secreted lipid-modified glycoproteins that are evolutionally 
conserved in metazoan organisms (H. Clevers 2006). Wnt proteins act as cell-cell 
communication molecules and function as morphogens that are secreted from one cell or 
tissue type to activate surface receptors and signal transduction components in 
neighbouring cells (Zecca et al. 1996), thereby regulating processes such as cell 
proliferation, survival and differentiation (H. Clevers 2006). Signalling by Wnt proteins is 
one of the fundamental mechanisms that controls key developmental processes such as 
tissue patterning, cell migration and cell proliferation. In the adult, Wnt signalling regulates 
hematopoiesis, osteogenesis, angiogenesis and adipogenesis and is therefore critical to 
maintain tissue homeostasis (Wend et al. 2010). 
1.3.1 Wnt ligands 
In humans 19 Wnt ligands have been identified. They are cysteine-rich proteins of 
approximately 350-400 amino acids that share 20-85% amino acid identity (MacDonald et 
al. 2009). The cysteine residues are thought to form disulfide bonds, ensuring correct 
folding of the proteins, and all Wnts have an N-terminal signal peptide for secretion; 
therefore all Wnt ligands are predicted to be secreted (Willert and Nusse 2012). Early 
studies showed that Wnts are highly hydrophobic and adhere tightly to membranes and 
the extracellular matrix. Murine Wnt3A was the first Wnt protein to be purified and 
biochemically analysed, in part due to its relatively efficient secretion (Willert et al. 2003). 
Wnt3A has been found to undergo two types of lipid modifications, firstly a palmitate 
attached to the N-terminal cysteine (Willert et al. 2003), which has subsequently been 
identified in most other Wnt proteins. In addition, a palmitoleoyl attached to serine at 
position 209 (Takada et al. 2006);  this is also believed to be conserved amongst the Wnts. 
These lipid modifications have been shown to be essential for Wnt secretion and signalling 
activity (Takada et al. 2006), and are the reason that Wnts are so hydrophobic. They are 
believed to anchor Wnts to the lipid bilayer, possibly to create a high enough 
concentration for secretion to take place. Wnt proteins also have multiple glycosylations 
which is believed in part to explain their solubility despite having lipid modifications 
(Willert and Nusse 2012). The number of glycosylation events varies between ligands; 
Wnt1 has four and Wnt3A has two N-linked glycosylations  (Willert et al. 2003, Willert and 
Nusse 2012) and secretion of Wnt3A and Wnt5A is impaired if the glycosylation sides are 
mutated (Komekado et al. 2007, Kurayoshi et al. 2007). Although Wnt proteins have been 
-17- 
 
 
described to activate either canonical or noncanonical pathways, there is no structural or 
sequence basis for this distinction (Willert and Nusse 2012). It is likely that the cellular 
context dictates which pathway is activated rather than any inherent property of the Wnt 
ligands. For example, Wnt5A is generally considered a ‘noncanonical’ ligand, but has been 
shown to activate the canonical pathway in certain contexts (Mikels and Nusse 2006). 
Once secreted, Wnts can become both short- and long-range signalling molecules, with the 
capacity to reach up to 20 cell diameters away (Zecca et al. 1996). Considering they are 
largely insoluble and membrane bound it is not fully understood how Wnts diffuse and 
distribute through the aqueous extracellular space. However, various theories have been 
suggested. For example, Wnts may form multimers or ‘micelles’ that shield the 
hydrophobic lipid adducts. Alternatively or possibly in addition, Wnts could bind to 
lipoprotein particles or form a matrix with heparin sulfate proteoglycans (HSPGs) and 
distribute by lateral diffusion (MacDonald et al. 2009). There is evidence that several of 
these mechanisms are active, and seem to depend on cellular context and developmental 
status. 
1.3.2 Wnt signalling pathways 
Wnt signalling is generally divided into three main pathways; the canonical Wnt/β-catenin 
and the noncanonical pathways; Wnt/Ca2+ and planar cell polarity (PCP). The canonical 
pathway is the most widely studied and best understood of the three pathways (Moon et 
al. 2004). 
1.3.2.1 Canonical Wnt signalling 
The canonical Wnt signalling pathway involves the regulation of the key mediator, β-
catenin. In the absence of Wnt ligands, β-catenin is recruited to a ‘destruction complex’ 
that contains the scaffolding proteins, adenomatous polyposis coli (APC) and Axin (Farr et 
al. 2000). Two kinases also residing in the complex, glycogen synthase kinase (GSK)-3β and 
casein kinase (CK)-I, sequentially phosphorylate a set of conserved serine and threonine 
residues in the amino terminus of β-catenin, which targets it for proteosomal degradation 
(Yost et al. 1996, Amit et al. 2002). In the absence of Wnt this destruction complex is 
constitutively active, resulting in the degradation of β-catenin, and maintaining low levels 
in the cytoplasm. In this situation, the target genes of β-catenin are kept repressed by 
interacting with T-cell factor (TCF) and lymphoid enhancer-binding protein (LEF) protein 
family members, along with co-receptors histone deacetylase (HDAC) and Groucho 
(Cavallo et al. 1998). Various secreted antagonists such as Dickkopf (DKK) and Frizzled-
Figure 1 
Wnt secretion 
Wnts are lipid modified and 
glycosylated in the ER, which 
involved Porcupine. Wnts are 
escorted by Wntless to the plasma 
membrane from the Golgi for 
secreion. Wntless is retrieved by 
enodytosis and recycled to the Golgi 
by the retromer complex. After 
secretion Wts may for multimers, or 
bind to lipoprotein particles or 
HSPGs to facilitate short- or long-
range signalling. 
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related protein (sFRP) family members can interact with extracellular Wnt ligands to 
prevent activation of the pathway (Kawano and Kypta 2003, Moon et al. 2004). The DKK 
family of proteins are generally considered to be inhibitors of the canonical Wnt signalling 
pathway as they bind and sequester the co-receptors low density lipoprotein (LDL)-
receptor related proteins (LRP) 5 and 6 (Mao et al. 2001, Semënov et al. 2001). However, it 
has been shown that DKK2 can either promote or inhibit canonical Wnt signalling 
depending on the cellular context. It is thought that at low levels of LRP5/6 DKK2 acts as a 
Wnt inhibitor whereas with high levels of LRP-5/6 DKK2 activates the pathway, possibly 
because DKK2 can bind directly to LRP-6 to activate canonical Wnt signalling (Li et al. 
2002). 
For Wnt signalling to occur, a Wnt ligand must bind with a member of the Frizzled (FZD) 
family of seven-pass transmembrane receptors and one of the co-receptors, LRP 5/6 
(Peters et al. 1999, Tamai et al. 2000). There are 10 FZD genes in mammals and it is 
believed Wnt binding induces the formation of FZD-LRP5/6 complexes, although this has 
not been demonstrated in vivo. Evidence has shown there is functional redundancy among 
FZD receptors. LRP6 is essential for embryogenesis whereas LRP5 is more important in 
bone homeostasis (MacDonald et al. 2009). In the canonical Wnt signalling pathway Wnt 
binding recruits Axin and the destruction complex to the plasma membrane, where Axin 
binds to the cytoplasmic tail of LRP 5/6. Axin is then degraded, thereby decreasing β-
catenin degradation. In addition, Wnt ligand binding also induces activation of the 
phosphoprotein Dishevelled (Dvl) which prevents GSK3β binding to Axin, further reducing 
the phosphorylation and degradation of β-catenin, and increasing its post-translational 
stability (Moon et al. 2004). As levels of β-catenin rise, it accumulates in the nucleus where 
it interacts with DNA-bound TCF/LEF family members to activate the transcription of target 
genes. The conversion of the TCF repressor complex into a transcriptional activator 
complex involves the displacement of Groucho, and recruitment of the histone acetylase 
CREB-binding protein (CBP) or its closely related homolog, p300 (Takemaru and Moon 
2000). Canonical Wnt signalling target genes are diverse with over 100 identified to date. 
Many are known to be involved in tumorigenesis, others in development and stem cell 
maintenance (H. Clevers 2006). Many of the Wnt signalling components themselves are 
TCF/LEF targets such as DKK1, Wnt3A, Axin and LRP6, which highlights the ability of Wnt/β-
catenin to regulate itself and the importance of keeping the Wnt signalling pathway under 
tight control. 
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Figure ‎1.3  Overview of canonical Wnt signalling (A) In the absence of Wnt proteins, β-
catenin is recruited to a ‘destruction complex’ and is phosphorylated and targeted 
for proteosomal degradation. β-catenin levels in the cytoplasm remain low and the 
target genes of β-catenin are repressed by interacting with TCF/Lef proteins (B) 
When a Wnt protein binds to a member of the Fzd family of receptors and one of the 
co-receptors LRP 5/6, the destruction complex breaks down, β-catenin degradation 
is reduced and it accumulates in the nucleus where it interacts with DNA-bound 
TCF/Lef family members to activate the transcription of target genes. 
APC=adenomatous polyposis coli, CBP=CREB-binding protein, CK1=casein kinase I, 
DKK=Dickkopf, Dvl=Dishevelled, Fzd=frizzed, GSK3β= glycogen synthase kinase-3β, 
LDL=low density LRP=low density lipoprotein receptor-related protein, 
sFRP=secreted frizzled-related protein, TCF=T-cell factor. Adapted from Moon 
(2004). 
Wnt signalling OFF Wnt signalling ON 
(A) (B) 
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1.3.2.2 Noncanonical Wnt signalling 
The noncanonical Wnt signalling pathways are β-catenin-independent and are generally 
thought to be involved in cell migration and polarity (Sugimura and Li 2010a). The two 
major pathways are the Wnt/PCP pathway and Wnt/Ca2+ pathway. Wnt proteins that play 
a role in these pathways include Wnt5A, Wnt4, Wnt11 and Wnt7A (Wang 2009). In the 
Wnt/PCP signalling pathway Wnt ligands and FZD interact with an alternative co-receptor, 
ROR2, which recruits Dvl to the membrane. Dvl is also important in canonical Wnt 
signalling and different domains within Dvl, including DIX, PDZ and DEP, diverge different 
downstream pathways (Habas and Dawid 2005). Activation of the DEP domain leads to 
activation of small GTPases such as RhoA and Rac (Oishi et al. 2003). These in turn activate 
c-Jun N-terminal kinase (JNK) signals which have cytoskeletal effects and ultimately control 
cell polarity and motility (Boutros et al. 1998, Wang 2009). 
Wnt5A and Wnt11 are also known to activate Wnt/Ca2+ signalling. Here, Wnt binding to 
FZD results in the activation of heterotrimeric G proteins and the release of calcium from 
its intracellular stores (Malbon et al. 2001). The increase in intracellular calcium results in 
the activation of calcium dependent signalling molecules and the activation of calcium 
dependent effector proteins. Protein kinase C (PKC) may be activated which regulates 
many cellular processes including the small GTPase Cdc42  (Schlessinger et al. 2007). Cdc42 
is one of the key effectors of actin remodelling in the cytoskeleton, therefore this pathway 
has some overlap with the PCP pathway. An influx of intracellular calcium ions also 
activates calmodulin-dependent protein kinase II (CamKII) (Kuhl et al. 2000) which induces 
activation of TAK1 and NLK kinases in the MAPK pathway (Ishitani et al. 2003) (Figure 3). A 
further branch of the calcium pathway is calmodulin-mediated activation of calcineurin, a 
protein phosphatase known to activate the NFAT transcription factor (Saneyoshi et al. 
2002). The calcineurin-NFAT pathway is one of the major noncanonical pathways in 
vertebrates and is known to be involved in numerous diseases, including cancer.  Both 
CaMKII-TAK1-NLK and NFAT-mediated transcription can antagonize β-catenin- dependent 
canonical Wnt signalling, meaning the canonical and noncanonical pathways are not 
usually active in the same cell (Ishitani et al. 2003).  
1.3.2.3 Alternative Wnt receptors 
To add another level of complexity to Wnt signalling, there are also membrane proteins 
other than FZD receptors that contain Wnt-binding domains, and these may be equally 
important receptors for Wnts. The atypical tyrosine kinase Ryk possesses a Wnt inhibitory 
 
-21- 
 
 
factor (WIF) domain and is also important in transducing Wnt signals during axon guidance, 
and can bind both canonical and non-canonical Wnts (van Amerongen et al. 2008). Ryk can 
bind Wnt1 and activate TCF/LEF dependent transcription. However, Ryk can also signal via 
the release of intracellular calcium when bound to Wnt5A and activate src (Wouda et al. 
2008). The complexity of Wnt signalling, and the fact that Wnts can induce a variety of 
different responses in different cell types could be due to the complexity of receptor 
configurations that are possible. It may be receptor configuration and not the intrinsic 
properties of the Wnt family members that dictate which pathway is activated.  
Figure ‎1.4 Overview of noncanonical Wnt signalling In the Wnt/PCP signalling pathway, 
Wnt ligands and FZD interact with an alternative co-receptor, ROR2. This leads to 
activation of small GTPases such as RhoA and Rac, and these in turn activate c-Jun N-
terminal kinase (JNK) signals which have cytoskeletal effects and ultimately control 
cell polarity and motility. In the Wnt/Ca2+ signalling pathway, Wnt binding to FZD 
results in the activation of heterotrimeric G proteins and the release of calcium from 
its intracellular stores. This leads to activation of calcium dependent signalling 
molecules such as PKC which activates the small-GTPase Cdc42.  CamKII is also 
activated which induces activation of TAK1 and NLK in the MAPK pathway. This 
antagonises β-catenin-dependent canonical Wnt signalling. Calcium signalling also 
activates calcineurin, a protein phosphatase known to activate the NFAT 
transcription factor. PKC=protein kinase C, CamKII=calmodulin-dependent protein 
kinase II, NLK=nemo-like kinase, TAK1=TGF-beta-activated kinase 1, NFAT=nuclear 
factor of activated T-cells, MAPK=mitogen-activated protein kinase. Adapted from 
Sugimura and Li (2010).  
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1.3.3 Wnt signalling in normal cells 
Through its role in directing cell proliferation, cell polarity, fate determination and tissue 
patterning, Wnt signalling is known to regulate development of many of the tissues and 
organs in the body (van Amerongen and Nusse 2009). Wnt signalling remains essential 
throughout life in self-renewing tissues such as the gut, hair follicles and haematopoietic 
cells (H. Clevers 2006). These tissues all contain stem cells which have the unique ability to 
self-renew and to differentiate into more specialised cells. 
The role of Wnt signalling in stem cell biology varies according to the cellular context. In 
some circumstances Wnt appears to be important for maintenance of multi- or 
pluripotency but has also been implicated in the differentiation of stem and progenitor 
cells. Wnt signalling is particularly important in the stem cells of the intestine. Mutation of 
the TCF family member TCF4 in mice results in the absence of the stem/progenitor cell 
compartment in crypts of the small intestine (Korinek et al. 1998). In addition, inhibition of 
Wnt signalling by transgenic expression of the endogenous inhibitor DKK1 in adult mice 
induces the complete loss of crypts (Kuhnert et al. 2004).  
Wnt signalling is also important in bone development due to its role in controlling MSC 
differentiation. MSCs can differentiate into osteoblasts and adipocytes and their fate is 
determined by transcription factors Runx2 and PPAR-γ, respectively (Sugimura and Li 
2010b). The Wnt signalling pathways act at different stages in the process of 
differentiation (Figure 1.5). Recently, it has been shown that the noncanonical ligand 
Wnt5A is important in the fate determination of MSCs. Wnt5A promotes osteogenesis by 
suppressing PPARγ activation and activating Runx2 in the ST2 mesenchymal progenitor cell 
line (Takada et al. 2007). In contrast, the canonical ligand Wnt3A has been shown to 
maintain a proliferating MSC population, and suppress osteogenesis (Boland et al. 2004). 
Wnt/β-catenin signalling also appears to suppress adipogenesis by suppressing expression 
of PPARγ and inducing osteogenesis by increasing RUNX2 expression. Interestingly, the 
canonical Wnt inhibitor DKK1 is secreted from mature osteoblasts which indicates a 
feedback loop exists to regulate osteogenesis (Qiang et al. 2008). 
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Figure ‎1.5 Wnt signalling in the regulation of MSC differentiation MSCs can differentiate 
into osteoblasts and adipocytes and this is regulated by transcription factors Runx2 
and PPAR-γ, respectively. Wnt5A is important in fate determination and promotes 
osteogenesis and inhibits adipogenesis. The canonical Wnt signalling pathway is 
important at later stages of differentiation and promotes the maturation of 
preosteoblasts. The Wnt inhibitor DKK1 is secreted from mature osteoblasts to 
regulate osteogenesis. Adapted from Takada et al. 2009.  
 
1.3.4 Wnt signalling in cancer 
During development and normal adult homeostasis, the activity of Wnt signalling is tightly 
regulated. Disruption of this balance is frequently linked to development of pathological 
conditions such as cancer.  
1.3.4.1 Canonical Wnt signalling in cancer 
Nuclear accumulation of β-catenin demonstrated by immunohistochemistry has been used 
as evidence of an activated canonical pathway in a variety of human tumours including 
colorectal, lung, breast, cervical, skin and liver (Camilli and Weeraratna 2010). In 
MSC
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hepatocellular carcinoma, nuclear β-catenin accumulation has been linked to poorly 
differentiated morphology, high proliferation and poor prognosis (Endo et al. 2000, 
Inagawa et al. 2002).  
This aberrant accumulation of β-catenin has been attributed to mutations or epigenetic 
variation in various members of the signalling pathway. Activating β-catenin mutations at 
one of the phosphorylation sites that prevent its degradation have been identified in 50% 
of colon cancers (Sparks et al. 1998). Mutations in β-catenin have also been reported in 
brain tumours (Zurawel et al. 1998), ovarian (Palacios and Gamallo 1998) and prostate 
cancer (Voeller et al. 1998). Many other mutations affecting other members of the 
signalling cascade have been identified, in particular those that affect the interaction of β-
catenin with the destruction complex, leading to an increase in β-catenin levels. For 
example, truncating mutations in APC leading to loss of function occurs in around 80% of 
sporadic cancers (Powell et al. 1992), and this leads to inappropriate stabilisation of β-
catenin and aberrant transcription of genes including c-myc and cyclin D1. 
1.3.4.2 Noncanonical Wnt signalling in cancer 
The noncanonical signalling pathway is less frequently investigated in cancer. In part this is 
because it is more difficult to ascertain the role of noncanonical signalling since the 
downstream effector molecules are involved in many other signalling pathways.  
The ligand most widely studied in noncanonical signalling is Wnt5A which can have either a 
tumour suppressive or oncogenic function depending on the cancer type. It is possible that 
Wnt5A plays a role in tumour suppression by inhibiting the canonical Wnt signalling 
pathway (Ishitani et al. 2003). Consistent with this hypothesis expression of Wnt5A is 
decreased in colorectal cancer (Ying et al. 2008), neuroblastoma (Blanc et al. 2005), ductal 
breast cancer (Jonsson et al. 2002) and leukaemia (Ying et al. 2007). Furthermore, Wnt5A 
has been shown to inhibit migration of thyroid (Kremenevskaja et al. 2005) and colon 
cancer (Dejmek et al. 2005) cell lines. However, in contrast overexpression of Wnt5A has 
been reported in pancreatic (Ripka et al. 2007), prostate (Wang et al. 2007) and gastric 
cancer, where it enhances the motility of malignant cells, promotes tumour invasion and 
correlates with advanced disease and poor prognosis (Kurayoshi et al. 2006). Studies have 
also shown increased motility and migration of melanoma cells when Wnt5A is 
overexpressed, and in melanoma tissue samples there is a correlation between high 
expression of Wnt5A and higher grade of tumour (Weeraratna et al. 2002).  
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1.3.4.3 Wnt signalling in cancer initiating cells (CICs) 
As previously discussed (Section 1.1.4), CICs have been identified in a number of different 
cancer types and have been shown to have stem-cell characteristics. This has lead to the 
suggestion that the same signalling pathways, including Wnt, may be involved in their 
maintenance and proliferation. Interestingly, many of the cell surface markers that have 
been used to identify and isolate potential CICs such as LGR5, CD44, CD24 and Epcam are 
direct Wnt targets (Takahashi-Yanaga and Kahn 2010). High canonical Wnt signalling has 
been shown to identify CICs in colorectal cancer (Vermeulen et al. 2010) and lung cancer 
(Teng et al. 2010). Canonical Wnt signalling has also been shown to increase the clonogenic 
potential and self-renewal in putative leukemic stem cells in acute myeloid leukaemia 
(AML) (Ysebaert et al. 2006, Kawaguchi-Ihara et al. 2008). In addition, Wnt signalling is 
associated with the CIC population in breast cancer (Li et al. 2003, Li et al. 2008), squamous 
cell carcinoma (Malanchi et al. 2008) and hepatocellular carcinoma (Yang et al. 2008). 
1.3.5 Wnt signalling in ESFT 
Expression of components of the Wnt signalling pathway have previously been detected in 
ESFT cell lines using RT-PCR analysis. In a panel of nine ESFT cell lines Wnt10B mRNA was 
detected in all cell lines, along with Wnt5A, Wnt11 and Wnt13 in at least 7 of the cell lines. 
In addition, mRNA expression of the receptors FZD2, FZD3, FZD4, FZD7 and FZD8 and the 
co-receptors LRP-5 and -6 were reported (Üren et al. 2004).  
More recent studies have also identified that Wnt signalling may be important in the 
development of ESFT. For example, Wnt signalling targets/components such as c-myc, 
cyclin D1 and Wnt5A have been shown to be highly associated with primary ESFT, and also 
differentially expressed when EWS-FLI1 was induced in rhabdomyosarcoma cells (Hu-
Lieskovan et al. 2005). Other studies have used microarray analysis in an attempt to 
understand the differences between localised and metastatic disease, and have shown 
that  Wnt signalling or Wnt signalling components may be important. Firstly, Schaefer et al. 
(2008) compared the gene expression profile of 20 localised to 7 metastatic tumours, and 
demonstrated Wnt signalling was the pathway most significantly different between the 
two groups of tumours, indicating different Wnt signalling may have a role in ESFT 
metastasis. In addition, the authors investigated the response of ten ESFT cell lines to 
drugs commonly used in the treatment of ESFT and reported that Wnt signalling was one 
of 77 pathways that was altered following treatment with all four drugs in the VIDE 
regimen. In a different study, the microarray profile of 30 primary and seven metastases 
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were investigated and linked to event-free survival. It was found that the small GTPase 
Rac1, which is involved in PCP noncanonical signalling, could discriminate patients with a 
poor or good prognosis (Scotlandi et al. 2009).  Taken together these studies suggest that 
Wnt signalling could be involved in both the initiation and progression of ESFT. 
There are some reports detailing the response of ESFT cells to exogenous Wnt ligands. For 
example, treatment of the TC32 ESFT cell line with the canonical ligand Wnt3A induces 
morphological changes in these cells, with the presence of long cytoplasmic extensions 
resembling neuronal axons (Üren et al. 2004, Endo et al. 2008). Wnt3A treatment also 
increases migration of TC32 cells by more than five-fold. However, importantly Wnt3A 
treatment does not lead to any change in proliferation, survival or growth of TC32 cells in 
soft agar (Üren et al. 2004). It has also been shown that treatment of ESFT cell lines with 
the noncanonical Wnt ligand Wnt5A increases migration (Zhe et al. 2012).  
Interestingly a number of different studies have identified that the DKK family of proteins, 
in particular DKK1 and DKK2, may be important in ESFT.  In ESFT DKK1 mRNA is reported to 
be downregulated, and DKK2 mRNA upregulated in both ESFT cell lines and tumours 
(Staege et al. 2004, Miyagawa et al. 2009, Navarro et al. 2010, Hauer et al. 2013). It has 
been suggested that this upregulation of DKK2 may be a direct consequence of EWS-ETS 
fusion proteins directly interacting with the promoter region of DKK2 (Miyagawa et al. 
2009). However, this has been disputed since knockdown of EWS-FLI1 in ESFT cell lines has 
no effect on DKK2 expression (Hauer et al. 2013). Nevertheless, an increase in DKK2 mRNA 
expression has been measured when EWS-ETS fusion proteins (including EWS-FLI1, EWS-
ERG and EWS-E1AF) are expressed in mesenchymal progenitor cells (Miyagawa et al. 
2009). More recently, it has been shown by constitutive knockdown of DKK2 in cell lines 
(by retroviral RNAi), that DKK2 increases migration and invasiveness of ESFT, and mediates 
osteolysis (Hauer et al. 2013). The same study reported that DKK2 stimulates rather than 
inhibits canonical Wnt signalling, as constitutive knockdown decreased nuclear β-catenin 
and decreased downstream targets of canonical Wnt signalling such as cyclin D1. 
In contrast to DKK2, in non-ESFT cell lines including HeLa and HEK293T cells, EWS-FLI1 has 
been shown to inhibit DKK1 expression (Navarro et al. 2010). Since DKK1 is itself a target of 
canonical Wnt signalling, the authors of this study investigated if EWS-FLI1 had more 
general effects of Wnt target genes. They found that the fusion protein directly interacts 
with the TCF/LEF family member LEF1, potentially interfering with the formation of β-
catenin/LEF complexes, and therefore repressing canonical Wnt signalling. The study also 
demonstrated that canonical Wnt signalling could not be stimulated in ESFT cell lines 
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unless EWS-FLI1 was knocked down. In agreement with this other studies have reported no 
cytoplasmic or nuclear staining of β-catenin immunohistochemistry in patient tumour 
samples (Üren et al. 2004), and no nuclear β-catenin in TC32 ESFT cells (Hu-Lieskovan et al. 
2005). Furthermore, using a canonical Wnt signalling reporter assay, no β-catenin 
mediated gene expression was reported in ESFT cell lines (Hu-Lieskovan et al. 2005). 
The current literature suggests that Wnt signalling may be an important pathway both in 
the initiation and progression of ESFT. However, the precise role of the different pathways 
in these processes has not been fully elucidated.  
1.4 Hypothesis and aims 
The hypothesis of my thesis is that, Wnt signalling is important in the initiation and 
progression of ESFT (Figure 1.6). More specifically that the canonical Wnt signalling 
pathway is important in the initiation of ESFT, and that the noncanonical pathway may 
become dominant in the progression and metastasis of ESFT due to its role in promoting 
migration and invasiveness, as has been demonstrated in other cancer types. 
 
The objectives of my research have therefore been to; 
1. Examine the expression profile of Wnt signalling components in ESFT cell lines 
(Chapter 2). 
2. Develop a functional assay to measure the activity of the canonical Wnt signalling 
pathway (Chapter 3). 
3. Optimise functional assays to investigate the activity of the noncanonical Wnt 
signalling pathway (Chapter 4). 
4. Investigate the activity of the Wnt signalling pathways in two model systems of 
ESFT initiation. Firstly, in reprogrammed ESFT cells (Chapter 5) and in human 
embryonic stem cells with inducible EWS-FLI1 expression (Chapter 6). 
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Figure ‎1.6 Summary of thesis hypothesis that canonical Wnt signalling is important in the 
initiation of ESFT and noncanonical Wnt signalling becomes dominant during disease 
progression by promoting invasion and migration.  
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2. Expression of Wnt signalling components in ESFT cell lines 
2.1 Introduction 
Aberrant Wnt signalling has been implicated in the initiation and progression of various 
different cancer types. The role of the Wnt signalling pathways in the development and 
progression of ESFT has not been widely studied. However the expression of various 
components of the Wnt signalling pathway have been described in ESFT samples and cell 
lines as summarised in Table 2.1. 
Component 
Function in Wnt 
signalling 
Source 
Detection 
method 
Reference 
Wnt4, 
Wnt10B, 
Wnt13,  
Canonical  Wnt 
ligands 
Cell lines RT-PCR (Üren et al. 2004) 
Wnt5A Noncanonical 
Wnt ligand 
Cell lines 
 
 
Tumour 
samples 
RT-PCR 
WB 
 
RTqPCR 
Microarray 
(Üren et al. 2004) 
(Jin et al. 2012) 
 
(Jin et al. 2012) 
(Hu-Lieskovan et al. 
2005) 
sFRP1 Secreted 
inhibitor of both 
pathways 
Cell lines 
 
Tumour 
samples 
RT-PCR 
 
MS-PCR 
(Üren et al. 2004) 
 
(Jin et al. 2012) 
sFRP2 Secreted 
inhibitor of both 
pathways 
Cell lines 
 
Tumour 
samples 
RT-PCR 
 
MS-PCR 
(Üren et al. 2004) 
 
(Jin et al. 2012) 
sFRP3 
 
 
 
Secreted 
inhibitor of both 
pathways 
Cell lines RT-PCR (Üren et al. 2004) 
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sFRP4 Secreted 
inhibitor of both 
pathways 
Cell lines RT-PCR (Üren et al. 2004) 
LRP5/LRP6 Co-receptors for 
Frizzled 
receptors 
 
Cell lines RT-PCR (Üren et al. 2004) 
FZD2 
 
Receptor for 
Wnt ligands 
Cell lines RT-PCR (Üren et al. 2004) 
FZD3 Receptor for 
Wnt ligands 
Cell lines RT-PCR (Üren et al. 2004) 
(Endo et al. 2008) 
FZD4 Receptor for 
Wnt ligands 
Cell lines RT-PCR (Üren et al. 2004) 
(Endo et al. 2008) 
FZD7 Receptor for 
Wnt ligands 
Cell lines RT-PCR (Üren et al. 2004) 
(Endo et al. 2008) 
FZD8 Receptor for 
Wnt ligands 
Cell lines RT-PCR (Üren et al. 2004) 
DKK1 Secreted 
inhibitor of both 
pathways 
Cell lines Microarray 
RTqPCR 
(Navarro et al. 2010) 
(Miyagawa et al. 2009) 
DKK2 Secreted 
inhibitor of both 
pathways 
Cell lines 
 
 
Tumour 
samples 
Microarray 
RTqPCR 
 
RTqPCR 
(Navarro et al. 2010) 
(Miyagawa et al. 2009) 
 
(Hauer et al. 2013) 
DKK4 Secreted 
inhibitor of both 
pathways 
Cell lines Microarray (Navarro et al. 2010) 
CELSR3 Component of 
noncanonical 
PCP pathway 
Tumour 
samples 
Microarray (Schaefer et al. 2008) 
CTBP2 Transcriptional 
co-repressor of 
canonical Wnt 
signalling 
Tumour 
samples 
Microarray (Schaefer et al. 2008) 
TCF1 Member of the 
TCF/LEF family 
of transcription 
factors 
Tumour 
samples 
Microarray (Schaefer et al. 2008) 
TCF4 
(TCF7L2) 
 
 
Member of the 
TCF/LEF family  
Tumour 
samples 
Microarray (Schaefer et al. 2008) 
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Rac1 Component of 
noncanonical 
PCP pathway 
Tumour 
samples 
Microarray (Scotlandi et al. 2009) 
Table ‎2.1 Components of the Wnt signalling pathways which have been detected in ESFT 
cell lines and samples The role in Wnt signalling and method of detection is shown 
for each component. RT-PCR=reverse transcriptase polymerase chain reaction (PCR), 
RTqPCR=quantitative reverse transcriptase PCR, MS-PCR= methylation-specific PCR, 
WB=western blot. 
   
To investigate Wnt signalling in cells it is common to profile the expression of these 
components, including protein expression of the Wnt ligands themselves. Of the 19 
members of the family, Wnt1 was the first Wnt protein to be identified and was initially 
linked to the formation of mammary tumours in mice (Nusse and Varmus 1982, Nusse et 
al. 1984). Indeed Wnt1 expression has been observed in human breast (Wong et al. 2002) , 
gastric and pancreatic (Katoh 2003) cancer cells, and increased expression linked to poor 
survival in glioma (Liu et al. 2011). Wnt3A is the most frequently investigated canonical 
Wnt ligand, in part due to the fact that is one of the few Wnt ligands which has been 
purified and structure analysed (Willert et al. 2003).  Treatment with recombinant Wnt3A 
protein or Wnt3A conditioned media is the most commonly used method to stimulate the 
canonical Wnt signalling pathway. In ESFT cell lines, Wnt3A protein has been shown to 
stimulate the formation of long cytoplasmic extensions, but not to increase proliferation 
(Üren et al. 2004, Endo et al. 2008). However, it has not been established if ESFT cell lines 
produce and secrete endogenous Wnt3A protein.  The noncanonical ligand Wnt5A has also 
been successfully purified and is the most extensively studied noncanonical Wnt ligand. 
The role of Wnt5A in cancer is complex as it can have both tumour suppressive and 
oncogenic properties depending on the cancer type. In ESFT, Wnt5A has been reported to 
be a ‘signature’ gene at diagnosis which is upregulated upon expression of EWS-FLI (Hu-
Lieskovan et al. 2005). Expression of Wnt5A has also been reported in ESFT cell lines (Üren 
et al. 2004) and recombinant Wnt5A protein has been shown to promote migration of ESFT 
cell lines (Jin et al. 2012).  
In addition to investigating the expression of different Wnt ligands, downstream 
components such as the key mediator β-catenin are also commonly investigated. When 
canonical Wnt signalling is activated, the degradation complex is inhibited meaning β-
catenin is not phosphorylated and therefore not degraded. Levels of β-catenin in the 
cytoplasm rise, and it translocates to the nucleus  where it can bind to TCF/LEF proteins to 
modulate the expression of target genes; expression of nuclear β-catenin is therefore 
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frequently used as a marker of activated canonical Wnt signalling (Burkhalter et al. 2011).  
High levels of nuclear β-catenin (increased canonical Wnt signalling) have been described 
and reported to predict for poor outcome in breast cancer (Lin et al. 2000) and colorectal 
cancer (Cheah et al. 2002). In contrast, in paediatric medulloblastoma, nuclear β-catenin 
and activation of the canonical Wnt signalling pathway is linked to favourable prognosis 
(Ellison et al. 2005, Fattet et al. 2009).  Active (nonphosphoryated) β-catenin can also be 
detected in cells with active canonical Wnt signalling using antibodies to specifically detect 
β-catenin dephosphorylayed at residues Ser37 and Thr41 (van Noort et al. 2002).  
The aims of the chapter were therefore to: 
1. Investigate the mRNA expression of components of the Wnt signalling pathway in 
a panel of ESFT cell lines by RTqPCR. 
2. Optimise antibodies for the detection of canonical and noncanonical Wnt ligands 
and investigate their protein expression in ESFT cell lines. 
3.  Investigate the subcellular localisation and phosphorylation status of β-catenin in 
ESFT cell lines to probe for activation of the canonical Wnt signalling pathway. 
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2.2 Materials and methods 
2.2.1  Tissue culture 
Six ESFT cell lines were studied (Table 2.1). All cell lines were substrate adherent and were 
routinely cultured on Primaria™ plastic (Falcon; BD Biosciences, Oxford, UK) in 75cm2 
flasks. Cells were passaged when they reached 85-90% confluency; media was aspirated 
from the flask and cells washed with 1X phosphate buffered saline (PBS; w/v, Oxoid 
Limited, Basingstoke, UK), followed by incubation with 5ml ethylenediaminetetracetate 
(EDTA, 0.1% in PBS; (w/v), Invitrogen™; Life Technologies, Paisley, UK) for 2 minutes (min). 
EDTA was removed, cells washed in PBS and then incubated with 5ml 1X Trypsin (0.25% 
(w/v) (Sigma-Aldrich, Dorset, UK), in 1X PBS) for 5 min, or until cells had completely 
detached from the plastic, as assessed by light microscopy; Olympus CKX41 (Olympus 
Microscopy, Essex, UK). For the SKES-1 cell line the EDTA incubation step was omitted. An 
equal volume of media containing 10% Foetal Calf Serum (FCS; v/v, Harlan Sera-Lab, 
Loughborough, UK) was added to the cells neutralise the trypsin. The cell suspension was 
centrifuged at 405g for 5 min and the resulting cell pellet resuspended in appropriate cell 
line specific media and reseeded into flasks or 6 well plates as required. Cells were 
maintained in a humidified chamber (Sanyo CO2 Incubator, MCO-2OAIC, Sanyo Gallenkamp 
Plc., Loughborough, UK) in 5% CO2 in air at 37°C. Cell lines were screened for mycoplasma 
contamination every 3 months by technical staff using the EZ-PCR mycoplasma test kit 
(Geneflow Ltd, Fradley, UK). For ESFT cell lines, expression and type of fusion transcript 
was verified by technical staff using reverse-transcriptase quantitative polymerase chain 
reaction (RTqPCR). 
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 Table ‎2.2 Characteristics of ESFT and cell lines used as  controls Details of the origin of 
the cell line and media used to maintain cultures are given. The EWS-ETS fusion type 
is given for ESFT cell lines. All cell lines are human origin unless otherwise stated. All 
media was purchased from Invitrogen™ unless otherwise stated. pPNET=peripheral 
primitive neuroectodermal tumour, N/A = not applicable, yr = years old. DMEM= 
Dulbecco’s Modified Eagle Medium. ATTC=American Type Tissue Collection (supplied 
by LGC Standards, Teddington, UK). 
 
Cell line ESFT Cell type Fusion 
transcript 
Origin 
(source) 
Media 
A673 Yes pPNET EWS-
FLI1 
Type I 
15yr female 
(ATCC) 
DMEM+ 10% 
FCS + 2mM 
Glutamine  
RD-ES Yes Ewing’s 
sarcoma 
EWS-
FLI1 
Type II 
19yr male. 
(ATCC) 
RPMI + 10% FCS 
+ 2mM 
Glutamine 
SKES-1 Yes Ewing’s 
sarcoma 
EWS-
FLI1 
Type II 
18yr male. 
(ATCC) 
McCoy’s 5a + 
15% FCS + 2mM 
Glutamine 
SK-N-MC Yes pPNET EWS-
FLI1 
Type I 
14yr female. 
(ATCC) 
DMEM + F12 + 
10% FCS + 2mM 
Glutamine 
TC32 Yes pPNET EWS-
FLI1 
Type I 
17yr female. 
(Gift: Dr 
Toretsky). 
RPMI + 10% FCS 
+ 2mM 
Glutamine 
TTC466 Yes Ewing’s 
sarcoma (extra 
osseous) 
EWS-
ERG 
Metastatic. 
(Gift: Dr Poul 
Sorenson). 
RPMI + 10% FCS 
+ 10% 
conditioned 
media + 2mM 
Glutamine 
A431 No Epidermoid 
carcinoma 
N/A (Gift: 
Professor M. 
Knowles) 
DMEM + 10% 
FCS + 2mM 
Glutamine 
NIH/3T3 No Mouse 
fibroblast 
N/A (Gift: 
Professor 
Tim Bishop) 
DMEM + 10% 
FCS + 2mM 
Glutamine 
L-
Wnt5A 
No Mouse 
fibroblasts 
overexpressing 
human Wnt5A 
N/A (ATCC) Modified DMEM 
(ATCC) +10% 
FCS + 4 mM 
Glutamine  
L-
Wnt3A 
No Mouse 
fibroblasts 
overexpressing 
human Wnt3A 
N/A (ATCC) As for L-Wnt5A 
HeLa No Cervical adeno-
carcinoma 
N/A (Gift: 
Professor M. 
Knowles) 
DMEM + 10% 
FCS + 2mM 
Glutamine 
-35- 
 
 
2.2.2 Determination of viable cell number 
Viable cell number was assessed using the trypan blue exclusion assay. Cells were 
trypsinised and resuspended in media as described (Section 2.2.1). Cell suspension (10μl) 
was added to an equal volume of trypan blue dye (0.4%; v/v, Sigma-Aldrich) and viable cell 
number assessed using the Neubauer haemocytomter. Non-viable cells appear blue as the  
permeable membrane allows uptake of the dye. The number of clear (viable) cells in 4 
areas of the grid were counted and the mean of these was calculated to give a value x 104 
cells/ml. Alternatively, the automated Vi-cell (Beckman Coulter, High Wycombe, UK) viable 
cell counter was used. This machine uses the same principle to measure viable cell number 
but in this case the addition of trypan blue and cell counting is automated. In this method, 
1ml of cell suspension is taken up by the machine, trypan blue added and viable cell 
number x 106 cells/ml, is calculated. All viable cell counts were performed in triplicate. 
 
2.2.3 SDS-PAGE and western blotting 
2.2.3.1 Preparation of protein extracts 
Cell lines were cultured in 75cm2 tissue culture flasks until 70% confluent. Media was 
aspirated, cells washed once with 5ml ice-cold 1X PBS, scraped into 2ml ice-cold PBS using 
a cell scraper (Sarstedt Ltd., Leicester, UK) and centrifuged at 405g for 5min. The 
supernatant was aspirated and the pellet resuspended in 200μl of Radio Immuno 
Precipitation Assay (RIPA) lysis buffer (1X PBS containing 1% (v/v) Nonidet P-40, 10mM 
sodium deoxycholate, 0.1% (w/v) sodium dodecyl sulphate (SDS)) with protease inhibitor 
cocktail (0.6mM phenymethylsulfonyl (PMSF), 1mM sodium orthovanadate, 25μM 
leupeptin, and 30μl/ml Aprotinin, all purchased from Sigma-Aldrich). Samples were 
incubated on ice for 30 min, and centrifuged at 12,470g at 4°C for 10 min. The resulting 
supernatant was retained as the soluble protein fraction. 
A 5μl aliquot of the cell lysate was added to 45μl deionized distilled (dd)H20 and retained 
for protein estimation. The remainder was added to an equal volume of 2X SDS loading 
buffer (100mM Tris-HCl (pH 8.3), 20% (v/v) Glycerol, 4% SDS, 0.2% (w/v) bromophenol blue 
(Sigma-Aldrich), 200mM dithiothreitol (DTT, Sigma-Aldrich)), stored in single use aliquots at 
-20°C. Where non-reduced samples were required, DTT was omitted from the buffer.  
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2.2.3.2 Determination of protein concentration 
The BioRad DC Protein Assay (Bio-Rad Laboratories Ltd, Hemel Hempstead, UK) based on 
the Lowry Assay (Lowry et al. 1951) was used to estimate protein concentration of all 
samples. All reagents are company proprietary. Briefly, a standard dilution curve was 
prepared of bovine serum albumin (BSA, Sigma-Aldrich) ranging from 0 to 2mg/ml in 10% 
RIPA lysis buffer. Each sample or standard (5μl) was pipette in triplicate into wells of a 96 
well microtitre place (Nunc-Immuno™, Nalge Nunc Intl., supplied by Fisher Scientific, 
Loughborough, UK). Working reagent SA was prepared by adding Reagent S (20μl) to 
Reagent A (1ml) and added to each well (25μl). Reagent B was then added (200μl) to each 
well and the plate was agitated for 10 seconds (s) followed by 15 min incubation at room 
temperature (RT). Absorbance of each well was read at 690 nm using a microplate reader 
(Titertek-Berthold Instruments, supplied by GeneFlow) Protein concentration in samples 
was determined from the standard curve generated from the BSA dilutions. 
2.2.3.3 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Mini-Protean II cell apparatus (Bio-Rad) was used throughout.  The appropriate percentage 
acrylamide gel was chosen according to the molecular weight of the protein of interest; for 
most proteins a 10% resolving gel solution was utilised. Acrylamide (10%; v/v, Severn 
Biotech. Ltd, Kidderminster, UK), 1.5M Tris (pH 8.8, MP Biomedicals Inc., supplied by Fisher 
Scientific), 0.1% SDS (w/v, BDH Laboratory Supplies, supplied by VWR Int. Ltd., 
Lutterworth, UK), 0.1% ammonium persulphate (w/v, Sigma-Aldrich), 0.006% N, N, N’, N’- 
Tetramethylethylenediamine (v/v, TEMED, Sigma-Aldrich)) were mixed and poured into 
the gel apparatus. The resolving gel was then overlayed with 2-methyl-2-butanol (Sigma-
Aldrich) until polymerized (approximately 30 min). The 2-methyl-2-butanol was removed 
and the resolving gel rinsed with ddH2O. The resolving gel was overlayed with a stacking 
gel (5% (v/v) acrylamide, 1 M Tris (pH6.8), 0.1% (w/v) SDS, 0.1% (w/v) ammonium 
persulphate, 0.01% (v/v) TEMED) and a comb placed in the solution taking care to avoid 
introduction of air bubbles. Once polymerised, the comb was removed and the wells 
washed with ddH2O to remove any non-polymerised acrylamide.  
The gel was transferred to the electrophoresis tank containing 2X SDS running buffer 
(25mM Tris-HCl (MP Biomedicals), 250mM Glycine (Sigma-Aldrich), 0.1% (w/v) SDS). 
Protein extracts (50µg) in 2 x SDS loading buffer were heated to 95°C for 5 min, centrifuged 
briefly at 12,470g to bring down any condensation from the tube lid, and loaded into the 
well alongside 5μl of LI-COR molecular weight marker (LI-COR Biosciences, supplied by 
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VWR). The gel was electrophorised at a constant voltage of 100 V until the bromophenol 
blue dye had reached the bottom of the gel. 
2.2.3.4 Electrophoretic transfer of proteins 
After completion of SDS-PAGE electrophoresis the stacking gel was removed and resolving 
gel placed in transfer buffer (25mM Tris, 192mM glycine, 20% (v/v) methanol, 0.01% SDS) 
for 5 min. The Bio-Rad transfer kit was assembled using Hybond C-extra supported 
nitrocellulose membrane (Amersham Biosciences, Little Chalfont, UK) against the gel, 3mm 
filter paper (Whatmann, supplied by GE Healthcare, Chalfont St Giles, UK) and two filter 
pads (Bio-Rad). Proteins were immunoblotted from the gel onto the nitrocellulose 
membrane at 100 V, with constant stirring using a magnetic flea, for 90 min at RT. 
2.2.3.5 Immunodetection of proteins 
The membrane was incubated in LI-COR blocking buffer (LI-COR Biosciences) with rapid 
agitation on an orbital shaker at RT for 1 hour (h): the content of the LI-COR locking buffer 
is company proprietary. The membrane was incubated in primary antibody diluted in an 
incubation solution (50% (v/v) LI-COR blocking buffer and 50% (v/v) PBS with 0.1% (v/v) 
Tween-20 (v/v; Sigma-Aldrich) (PBST)) overnight at 4°C with shaking on an orbital shaker. 
The specificity and concentration of primary antibodies (Table 2.3) to minimise background 
nonspecific binding were optimised using positive control cell extracts. Membranes were 
washed 3 x 5 min with PBS containing 0.1% Tween-20 (v/v, PBST) and subsequently 
incubated in the dark for 1 h in the appropriate secondary antibody at a concentration of 
1:5000, prepared in incubation solution as above. Membranes were washed 3 x 5 min in 
PBST and 1 x 5 min in PBS to remove Tween-20 residue. Membranes were visualised using 
the LI-COR Odyssey infrared imaging system (LI-COR Biosciences). Where quantification 
was required the intensity of the band of interest was assessed by densitometry using the 
LI-COR Odyssey software and protein expression was expressed as a ratio of the 
densitometry value of the target protein band relative to the value of the corresponding 
loading control protein, β-actin (Table 2.3). To check the efficiency of immunoblotting, 
membranes were stained using Ponceau S (Sigma-Aldrich) solution for 5 minutes, and 
rinsed using ddH2O to reveal the transferred proteins. Alternatively the Pierce Reversible 
Protein Stain Kit (Fisher Scientific) was used; membranes were washed in dH2O, stained for 
30s then washed 3 times in destain followed by a 5 min wash in destain. Finally 
membranes were washed once in dH2O. 
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Table ‎2.3 Antibodies and optimised antibody concentrations for western blots 
Concentrations of antibodies for western blot was determined empirically. All 
incubations with primary antibody were overnight at 4°C, secondary antibody 
incubations were for 1 h at RT unless otherwise stated. N/A = not applicable. 
Antibody Species Optimised 
concentration 
Positive 
control extract 
Supplier 
(Product code) 
Wnt1 Mouse 
monoclonal 
0.5 µg/ml NIH/3T3 Abcam Plc 
(Cambridge, UK; 
ab91191) 
Wnt5A Rat 
monoclonal 
2 µg/ml HeLa R&D Systems 
(Abingdon, UK; 
MAB645) 
Wnt3A Mouse 
monoclonal 
1 µg/ml L-Wnt3A R&D Systems 
(MAB1324) 
Total β-catenin Rabbit 
monoclonal 
0.2 µg/ml HeLa or A431 Abcam Plc 
(ab32572) 
Active β-
catenin  
Mouse 
monoclonal 
1 µg/ml A431 Millipore 
(supplied by 
Fisher Scientific; 
05-665) 
α- tubulin Mouse 
monoclonal 
0.4 µg/ml N/A Santa Cruz  
(supplied by 
Insight 
Biotechnology, 
Wembley, UK; sc-
5286) 
β- actin 
(reduced 
samples) 
Rabbit 
polyclonal 
0.06 µg/ml N/A Abcam Plc 
(ab8227) 
β- actin (non-
reduced 
samples) 
Mouse 
monoclonal 
0.5 µg/ml N/A Abcam Plc 
(ab8226) 
TATA-binding 
protein (TBP) 
Mouse 
monoclonal 
1.9 µg/ml N/A Abcam Plc 
(ab818) 
Secondary 
antibodies; 
anti-mouse 
(A21065), anti-
rabbit (A21076) 
N/A 0.4 µg/ml N/A Alexa fluor 680; 
Molecular 
probes, 
Invitrogen™ 
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2.2.4 Subcellular fractionation 
Subcellular fractions were prepared by differential centrifugation (Figure 2.1) modified 
from a method previously optimised for ESFT cells (Westwood et al. 2002). Cells were 
seeded onto Primaria™ 10 cm2 dishes and harvested at 70% confluency by washing with 
5ml ice cold 1X PBS and scraping into 1ml ice cold 1X PBS using a cell scraper. Cells were 
collected into 1.5ml eppendorf and pelleted by centrifugation at 160g for 5 min. Pellets 
were resuspended in 50µl iso-osmotic buffer (0.3M sucrose (Sigma-Aldrich), 10mM Tris.HCl 
(pH 7.5), 1mM EDTA) and a total protein sample was removed. The remaining solution was 
incubated for 5 min on ice before being passed through a 25 gauge needle for 30 strokes. 
Samples were then centrifuged at 4°C at 1000g for 10 min. The resulting supernatant was 
centrifuged at 4°C at 100,000g for 1 h, and this supernatant retained as the cytoplasmic 
fraction. The pellet from the first (1000g) centrifugation step was resuspended and 
centrifuged again at 4°C at 1000g for 10 min; this was repeated three times and the final 
pellet was retained as the nuclear fraction (Figure 2.1). All samples were resuspended in 
iso-osmotic buffer, a 5µl aliquot taken for protein estimation and the remaining sample 
combined with in an equal volume of 2X SDS loading buffer and stored at -20°C in single 
use aliquots The purity of fractions was confirmed by western blotting for α-tubulin 
(cytoplasmic) and TATA-binding protein (TBP, nuclear). 
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Figure ‎2.1 Cellular fractionation by differential centrifugation Cells were harvested, total 
protein extracted and fractions separated by differential centrifugation. Method 
previously optimized for ESFT cells (Westwood et al. 2002). 
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2.2.5 Flow cytometry  
The same antibodies previously used to detect Wnt1 and Wnt5A by western blot were also 
used for flow cytometry (Table 2.3). ESFT cells were seeded into Primaria™ 6-well plates at 
a concentration of 2 x 105 cells/well (1 x 105 cells/well for A673 cells). After 48 h cells were 
harvested as previously described (Section 2.2.1). Cells were fixed prior to staining by 
resuspending the pellet in 500μl 4% (w/v) paraformaldehyde (PFA; Sigma-Aldrich) in 1X 
PBS and incubating for 10 min at RT. All centrifugation steps were performed at 405g for 5 
min at RT. The cell suspension was centrifuged and resuspended in 200μl PBS, centrifuged, 
and the supernatant aspirated. In all cases cells were permeabilised by adding 500μl 0.1% 
(v/v) Triton X-100 (Amersham, GE Healthcare; in 5% FCS/PBS) and incubated on ice for 30 
min, followed by a wash in PBS as above. Cell pellets were subsequently resuspended in 
50µl primary antibody at the optimised concentration diluted in FACS buffer (10% (w/v) 
FCS in 1 xPBS) and incubated for 30 min at 4°C. Cells were centrifuged and the supernatant 
aspirated. Cells were washed by resuspending in 200μl FACS buffer, centrifuged and the 
supernatant aspirated. The cell pellet was then resuspended in 50µl fluorescent secondary 
antibody (goat anti-mouse, rabbit anti-rat both 1.25µl/ml; Southern Biotech supplied by 
Cambridge Bioscience, Cambridge, UK) diluted in FACS buffer for 30 min at 4°C, in the dark 
to protect the fluorescent tag from degradation by light. The cells were washed as 
described above and the resulting pellet resuspended in 500µl FACS buffer and analysed 
on the FACSCalibur™ (BD Biosciences) using an excitation laser of 480nm. A total of 10,000 
events for each sample were analysed and all experiments performed in triplicate. A no 
primary antibody control was used to assess non-specific binding of the secondary 
antibody. Data was analysed using BD Cell Quest™ (BD Biosciences). The fold change was 
calculated as the fluorescence of the target stained cells divided by the fluorescence of 
cells stained with secondary antibody only.  
2.2.6 RTqPCR 
2.2.6.1 Extraction of RNA from cell lines 
Cells were harvested from a 75cm2 flask when 70% confluent (unless otherwise stated), as 
previously described (Section 2.2.1), and the cell pellet stored at -80°C in single use 
aliquots. RNA was extracted using the RNeasy® mini kit (Qiagen, Crawley, UK). All buffers 
are company proprietary. Briefly, cells were resuspended in buffer RLT (600µl) and 
vortexed to ensure complete mixing. The lysate was passed through a QIAshredder spin 
column, centrifuged at 13,000 g for 2 min. The supernatant was added to an equal volume 
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of 70% ethanol and mixed well by pipetting. The sample was then added to an RNeasy spin 
column and centrifuged for 15 s at 8,000 g. The flow through was discarded and the 
column washed by adding buffer RW1 (350 µl) and centrifuged at 8 000 g for 15 s. To 
eliminate any contaminating genomic DNA, buffer RDD containing DNase I was added to 
the column membrane (80µl) and incubated for 15 min at RT. The column was washed by 
adding buffer RW1 (350µl) and centrifuged at 8,000g for 15 s. Buffer RPE (500µl) was 
added to the column and the column centrifuged at 8,000g for 15 s, the flow through was 
discarded and the same volume of buffer RPE added to the column and centrifuged at 
8,000g for 2 min. Finally the column was centrifuged at 13,000g for 1 min to remove 
residual flow through and RNase-free H20 (40µl; Sigma-Aldrich) added directly to the 
membrane and centrifuged for 1 min at 8,000g to elute the RNA. 
2.2.6.2 Spectrophotometric measurement of nucleic acid quantity and quality 
Absorbance of nucleic acids was measured at 260nm and 280nm using the Nanodrop 
(Labtech, Ringmer, UK). An absorbance ratio of 1.8-2.0 at 260/280 nm indicated the 
sample was free from any contaminants such as proteins or chemicals used in the 
extraction procedure. The quantity of RNA was determined assuming that a 40μg/ml RNA 
solution has an absorbance of 1 at 260 nm. 
2.2.6.3 Preparation of cDNA 
To generate complementary DNA (cDNA) the required concentration of RNA made up in 
10µl of RNase-free H2O was added to the reverse transcriptase (RT) reaction (5µl for RT- 
reactions). An RT negative (RT-) sample was prepared alongside each sample to ensure 
that any amplification detected is from the synthesised cDNA and not contaminating 
genomic DNA. The RNA was denatured by heating to 95°C for 5 min, cooled on ice for 5 
min and added to RT+ (30µl) and RT- (15µl) mixes (Table 2.4) Samples were incubated 
using the Techne TC-500 Thermal Cycler (Bibby Scientific Ltd, Staffordshire, UK) at 25°C for 
5 min, 50°C for 60 min and 70°C for 15 min, cooled on ice for 2 min and stored at -20°C. 
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 RT+ RT- 
Reagent 
Volume (µl, 
per sample) 
Final 
concentration 
Volume (µl, 
per sample 
Final 
concentration 
RNase-free H20 7.8  4.9  
1 x First-Strand Buffer 
(Invitrogen™) 
8 1X 4 1X 
dNTPs (Amersham 
Biosciences) 
4 1mM 2 1mM 
MgCl2 3.2 8mM 1.6 8mM 
Random Hexamer 
Primers (Invitrogen™) 
2 0.3µg 1 0.3µg 
RNasin® Plus RNase 
Inhibitor (Promega, 
Southampton, UK), 
1 16 units 0.5 16 units 
DTT (Invitrogen™) 2 0.1M 1 0.1M 
Superscript™ III Reverse 
Transcripase 
(Invitrogen™) 
2 200 units N/A N/A 
Total mix volume per 
sample (µl) 
30  15  
Table ‎2.4 Reagents in RT+ and RT- reactions dNTP = deoxyribonucleotide triphosphate, 
MgCl2 = magnesium chloride, DTT = dithiothreitol 
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2.2.6.4 Taqman gene expression array 
Gene expression of components of the Wnt signalling pathway were analysed using the 
TaqMan® Array Human WNT Pathway 96-well plate (Applied Biosystems; Life 
Technologies). cDNA was prepared as described previously (Section 2.2.5.3). Only an RT+ 
reaction was performed using a total concentration of 100ng RNA for each cell line. A PCR 
mix was made containing the RT mix (40µl), 1X Taqman® Universal PCR Master Mix 
(1080µl, Invitrogen™) made up in  RNase free H2O (1040µl). The plate was centrifuged at 
154g for 1 min before removing the lid and adding 20µl of PCR/cDNA mix to each well; 
each well contained cDNA generated from 10ng of RNA. MicroAmp® Optical Adhesive Film 
(Applied Biosystems) was used to cover the plate which was centrifuged at 154g for 1 min. 
Real time PCR was conducted using the 7500 Real-Time PCR System (Applied Biosystems); 
PCR/cDNA mix was incubated for 10 min at 95°C to activate the DNA polymerase followed 
by 40 cycles of denaturation at 95°C for 15 s and annealing/extension at 60°C for 1 min. 
Results were analysed using the 7500 system software (Applied Biosystems) and cycle 
threshold (Ct) values calculated.  Changes in expression of Wnt signalling pathway genes 
were determined using the comparative Ct method (Livak and Schmittgen 2001). The 
expression of each gene on the array was normalised to the expression of the 
housekeeping gene HRPT1 using the formula  
2-ΔCt 
Where ΔCt= Ct [gene] - Ct  [HRPT1]. 
Two-way hierarchical clustering of cell lines using complete linkage was carried out 
according to expression, using Gene Cluster 3.1 and visualised as a heat map using Java 
TreeView. 
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2.2.6.5 Assays-on-Demand™ 
cDNA was prepared as described previously (Section 2.2.5.3). The RT+ (cDNA) and RT- 
control sample were added to  PCR mixes for amplification of the target gene and the 
housekeeping gene PPIA (Table 2.5). Samples (25µl/well) were transferred in triplicate to 
MicroAmp® Optical 96-well plates (Applied Biosystems) and sealed with MicroAmp® 
Optical Adhesive Film. Real time PCR was conducted using the 7500 Real-Time PCR System 
and Ct values generated as described previously (Section 2.2.5.4). The target gene 
expression was normalised to the expression of PPIA, and made relative to a reference 
sample using the formula; 
2-ΔΔCt 
Where ΔCt = Ct [target gene] – Ct [PPIA]  
and ΔΔCt = ΔCt [test sample] – ΔCt [reference sample] 
Target Mix 
Volume (µl, per 
sample) 
Final concentration 
TaqMan Universal PCR Master Mix 50 1X 
20X Assay-on-Demand™ primer/probe 
mix (Applied Biosystems) 
5 1X 
RNase free H2O 25 - 
   
PPIA Mix 
Volume (µl, per 
sample) 
Final concentration 
TaqMan Universal PCR Master Mix 50 1X 
10μM PPIA Forward Primer                                              
5’-GGACCCAACACAAATGGTTCC-3’ 
2 200nM 
10μM PPIA Reverse Primer                                              
5’-CTTTCACTTTGCCAAACACCA-3’ 
2 200nM 
20μM PPIA probe 
5’ATGCTTGCCATCCAACCACTCAGTCTTG-
3’ 
0.5 100nM 
RNase free H2O 22.5 - 
Table ‎2.5 PCR mix reagents for RTqPCR using Assay-on-Demand™ (Applied Biosystems) 
and PPIA housekeeping gene 
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2.2.7 Statistics  
For the array analysis the inter-assay variance of housekeeping genes was analysed by one-
way analysis of variance (ANOVA) using statistical software R (Version 3.0.2 for OS 6) by Dr 
Helene Thygesen (University of Leeds).  The average variance (across non-household 
genes) was calculated between the cells lines (explained variance) and between technical 
repeats (unexplained variance). The optimal household gene would be one where the most 
variance is between the cell lines, giving the highest F-value, and the least variance 
between the technical repeats. All other analyses were undertaken by me using GraphPad 
prism 6 software. Wnt ligand (Wnt1/Wnt5A) protein expression detected by flow 
cytometry was analysed by one-way ANOVA when comparing all 6 cell lines. Variation 
between means of cell lines were compared using Bonferroni’s post hoc multiple 
comparison test and differences were considered significant when p<0.05.  
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2.3 Results 
2.3.1 mRNA expression of Wnt signalling components  in ESFT cell lines 
2.3.1.1 Profile by TaqMan® Wnt Pathway Array 
The mRNA expression of components of the Wnt signalling pathway were investigated 
using  TaqMan® Wnt Pathway Arrays (Applied Biosystems). The gene expression array 
contains 4 housekeeping genes; 18S, GAPDH, HRPT1 and GUSB. It was first necessary to 
determine which was the optimal housekeeping gene against which to normalise the 
expression of Wnt signalling components in ESFT cell lines. An ideal housekeeping gene is 
one that is ubiquitously expressed, whose expression is regulated in the same way as the 
target gene but whose expression is generally considered as constant, regardless of 
experimental conditions. 18S is a ribosomal RNA subunit and is highly abundant. Although 
it can be a reliable reference for total RNA mass, its synthesis is independent  from the 
synthesis of  mRNA therefore it was excluded (Radonić et al. 2004). It has been reported 
that GAPDH has many putative pseudo-genes (Sun et al. 2012) therefore this housekeeping 
gene was also disregarded. The variance of normalisation using HRPT1 and GUSB over each 
technical replicate was investigated, to examine the stability of expression across the 
replicates. Studies have shown that normalising to the mean of multiple housekeeping 
genes may be more accurate therefore the inter-assay variance was also calculated for the 
mean of HRPT1 and GUSB (Table 2.6).  
Table ‎2.6 Inter-assay variance of different housekeeping genes on the Wnt signalling 
array. *Inter-assay variance calculated using ANOVA as the ratio of the variance 
observed between the cell lines (explained variance) to the variance between the 
replicates (unexplained variance). The optimal housekeeping gene to use would be 
one where the variance between cell lines is greatest and between replicates 
minimal, therefore giving the highest F-value. 
Housekeeping gene Inter-assay variance (F-value)* 
HRPT1 1.23 
GUSB 1.16 
Mean of HRPT1 and GUSB 0.99 
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The inter-assay variance was lowest for HRPT1 (as this gave the highest F-value). Therefore 
this housekeeping gene was used to normalise expression of the Wnt signalling 
components in all subsequent experiments. 
Wnt signalling components were defined as being expressed if they had a Ct value of less 
than 40. Components of both the canonical and noncanonical Wnt signalling pathways 
were detected in ESFT cell lines, including those which have been reported to both 
promote and inhibit Wnt signalling (Figure 2.2 A).  mRNA expression of all 19 Wnt ligands 
was detected in at least one ESFT cell line. However, Wnt3A mRNA was only detected in 
RD-ES cells. All six ESFT cell lines expressed mRNA for all 9 Frizzled receptors (Figure 2.2 B). 
There was low expression of the Wnt ligands in all ESFT cell lines except for Wnt5A which 
had high, heterogeneous expression in all ESFT cell lines; RD-ES having the highest 
expression and A673 the lowest. 
Critical components of the canonical Wnt signalling pathway such as the key mediator β-
catenin (CTNNB1),  GSK3β, a component of the destruction complex and the co-receptors  
LRP5/6  were highly expressed in all six ESFT cell lines. Many of the FZD receptors were also 
highly expressed including FZD4 and FZD8. High levels of c-myc mRNA were also detected 
in ESFT cell lines consistent with previous studies reporting an increase in c-myc protein in 
ESFT cells (McKeon et al. 1988). 
Generation of a heat map using hierarchical clustering showed that the ESFT cell lines 
share expression of over 70% of Wnt signalling mRNAs (Figure 2.3). Overall, when 
considering all 91 components of the pathways which are represented on the array, there 
was high (red) expression of 22%, moderate (black) expression of 27% and low (green) 
expression of 42% of components in all the cell lines.  Genes with marked differential 
expression between the six cell lines included the inhibitors sFRP2 and FRZB and DKK2. 
Other components with differential expression included Porcn, which is involved in the 
production of Wnt ligands and LEF1, involved in transcription following activation of the 
canonical pathway. 
Figure ‎2.2 RNA expression of components of the Wnt signalling pathway in ESFT cell 
lines. Cells were harvested, total RNA extracted and expression level determined 
using the Taqman® Wnt signalling gene expression array. Data is presented as mRNA 
expression relative to the housekeeping gene HRPT1. (A) Expression of genes 
previously reported to be involved in the canonical, noncanonical pathways or both, 
separated into those that promote or inhibit the pathways. (B) Log expression of the 
above data focussing on the expression of Wnt ligands and Frizzled receptors. 
Results show the mean of two independent experiments, n=2 (±SEM)
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Figure ‎2.3 Heat map of expression of 
components of the Wnt signalling 
pathway in ESFT cell lines. Two-way 
hierarchical clustering of cell lines 
using complete linkage was carried 
out according to expression as 
determined by the Taqman® Wnt 
signalling gene expression array. Data 
are presented as mRNA expression 
relative to the housekeeping gene 
HRPT1 (Log scale). Colour shows high 
relative expression in red and low 
relative expression in green, with a 4 
fold change in expression 
represented by each of the 7 colours 
in between red (high) and green 
(low). Heat map is derived from the 
mean of two independent datasets. 
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2.3.2 Expression of Wnt ligands in ESFT cell lines 
To confirm the correlation between mRNA detected using the Wnt signalling array and 
protein, the expression of three Wnt ligand proteins was investigated in ESFT cell lines. 
2.3.2.1 Expression of Wnt1 protein 
2.3.2.1.1 Expression of Wnt1 protein by western blot 
Wnt1 was the first Wnt ligand to be identified and is a classic marker of the canonical Wnt 
signalling pathway, although its expression has not previously been described in ESFT 
(Üren et al. 2004). A band of 42 kDa corresponding to the predicted size of Wnt1 protein 
was detected in all ESFT cell lines (Figure 2.4 A). Expression of β-actin was used to check 
protein expression on the blot; expression was quantified by densitometry. There was 
comparable expression levels of Wnt1 in all ESFT cell lines, and in the positive control cell 
line NIH/3T3 (Figure 2.4 B).  
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Figure ‎2.4 Wnt1 protein expression in ESFT cells determined by western blot. (A) Total 
protein was extracted and expression of Wnt1 in 50ng of extract determined by 
western blot. β-actin was used to check for equal amounts of protein (control). 
Image shows a representative example (B) Protein expression was quantified by 
densitometry and expression calculated as the ratio of intensity of the Wnt1 to β-
actin band. Results shown are the mean of three independent experiments (± SEM). 
NIH/3T3= positive control cell line, MW= molecular weight marker in kDa. 
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2.3.2.1.2 Expression of Wnt1 protein by flow cytometry 
To confirm the expression of Wnt1 observed by western blot and investigate the 
heterogeneity of Wnt1 expression within cell lines, Wnt1 expression was also examined in 
ESFT cell lines by flow cytometry.   
There was heterogeneous expression of Wnt1 protein between ESFT cell lines when 
analysed by flow cytometry (Figure 2.5 A and B). Highest expression of Wnt1 was detected 
in A673 (median fluorescence; 27±5.5) and SK-N-MC (median fluorescence; 25±1) cell lines. 
The lowest levels of Wnt1 expression were detected in TC32 cells (median fluorescence; 
16±1.3). Statistical analysis using a one-way ANOVA confirmed cell lines had significantly 
different levels of Wnt1 expression (p=0.046).  
In all ESFT cell lines, when 10,000 events per sample were analysed, over 85% of 
permeabilised cells expressed Wnt1. This ranged from 85±0.8% in the TC32 cell line to 
95±0.6% in the SK-N-MC cell line. In all ESFT cell lines single expression peaks were 
observed, indicating homogeneous expression of Wnt1 within each cell line (Figure 2.5, top 
panel).   
 
 
 
 
 
(B
) 
  
 
 
 
 
 
 
 
 
 
 
 
Figure ‎2.5 Wnt1 protein expression in ESFT cells determined by flow cytometry ESFT cells were harvested, permeabilised and labelled for analysis of Wnt1 
expression by flow cytometry. (A) Representative cell scatter and fluorescence plots show cells in the presence (green) or absence (purple) of Wnt1 
primary antibody. The M1 region designates negative events and the M2 region positive events. (B) The median fluorescence of each peak was 
calculated and used to generate a mean fold level of Wnt1 expression relative to the no primary antibody control. Results are presented as the mean of 
three independent experiments, with three replicates per experiment (n=9) analysing 10,000 events per sample (± SEM).  
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2.3.2.1.3 Confirmation of Wnt1 mRNA detection by RTqPCR 
Wnt1 protein was detected in all ESFT cell lines by western blot and FACS, however Wnt1 
mRNA was only consistently detected in A673 cells by RTqPCR using the Wnt signalling 
pathway array. To confirm the results of the array I performed RTqPCR on RNA (100ng) 
extracted from all ESFT cell lines using a Wnt1 Assay-on-Demand™ (Applied Biosystems). 
These studies confirmed that Wnt1 mRNA was expressed by all ESFT cell lines (Figure 
2.6A). When RTqPCR was performed using cDNA generated from 100ng RNA, Wnt1 mRNA 
could be detected in all ESFT cell lines (Figure2.6 A). Results are expressed as relative gene 
expression using the ΔΔCt method (as described in Section 2.2.5.5). Although Wnt1 mRNA 
expression appears heterogeneous, with highest expression in SK-N-MC and lowest in 
SKES-1 cells, the Ct values are all within 2 Ct values (range= 36.4-37.8) indicating Wnt1 
mRNA expression is similar between all six ESFT cell lines.  This is in agreement with the 
pattern of Wnt1 protein expression observed by western blot analysis.   
The differences in mRNA expression observed between the Wnt signalling pathway arrays 
and Assay-on-Demand™ could be due to the fact that the arrays were performed using 
cDNA generated from 10ng RNA. When performing RTqPCR using the Assay-on-Demand™, 
Wnt1 mRNA could be detected in both SKES-1 cells and the positive control cell line, MCF7. 
However, when cDNA generated from 100ng RNA was used, the Ct values decreased from 
38 to 37.6 and from 37.6 to 38.8 in SKES-1 and MCF7 cells, respectively  (a lower Ct Value 
indicates increased expression) (Figure 2.6 B). This indicates the differences observed were 
due to the sensitivity of the Wnt signalling array at the concentration of RNA used in those 
experiments. 
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Figure ‎2.6 Wnt1 mRNA expression determined by RTqPCR RNA was extracted, RT 
performed and expression of Wnt1 determined by RTqPCR using a Wnt1 Assay-on-
Demand™ (Applied Biosystems) A) Wnt1 mRNA expression in ESFT cell lines using 
cDNA generated from 100ng RNA. B) Ct values determined from SKES-1 and MCF7 
(positive control) cells when cDNA generated from 10ng and 100ng of RNA was 
added to the RTqPCR reaction. Data presented as Wnt1 expression relative to the 
expression of the housekeeping gene PPIA, normalised to the positive control cell 
line MCF7. Results show the mean of triplicate wells in one experiment.  
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A) Wnt1 mRNA expression in ESFT cell lines relative to MCF7 cells 
B) Ct values generated in MCF7 and SKES-1 cells using cDNA generated from  10 or 
100ng of RNA 
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2.3.2.2 Expression of Wnt3A protein 
2.3.2.2.1 Expression of Wnt3A protein by western blot 
Wnt3A is the most commonly studied canonical Wnt ligand and overexpression has been 
shown to increase chemotactic migration in ESFT cells (Üren et al. 2004). Using an anti-
Wnt3A monoclonal antibody (MAB1324, R&D) a single band of 39 kDa was detected in 
mouse L-cells which overexpress human Wnt3A (L-Wnt3A; control) (Figure 2.7). However, 
no expression of Wnt3A was detected in any of the ESFT cell lines studied. Attempts to 
confirm the lack of Wnt3A protein expression in ESFT cells lines using an alternative 
antibody (ab81614, Abcam) were unsuccessful due to a large number of nonspecific bands 
(data not shown). Various optimisation steps were made in an attempt to improve the 
specificity of the antibody including testing a range of antibody dilutions (1:500-1:2000), 
extra washes with 0.1% PBST and executing SDS-PAGE electrophoresis at 4°C rather than 
room temperature, however these failed to eliminate the nonspecific bands. 
 
 
Figure ‎2.7 Wnt3A protein was not detected in ESFT cells Total protein was extracted and 
expression of Wnt3A in 50ng of extract determined by western blot. β-actin was 
used to check equal loading of protein in each well (loading control). L-Wnt3A = 
mouse L cells overexpressing human Wnt3A (positive control cell line). MW= 
molecular weight marker in kDa.  
 
MW L-Wnt3A A673 RD-ESkDa SKES-1 SK-N-MC
Wnt3A, 39 kDa
TC32 TTC466
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2.3.2.2.1 Confirmation of Wnt3A mRNA detection by RTqPCR 
Wnt3A mRNA was only detected in RD-ES cells, at low levels (Ct value=37) using the Wnt 
signalling pathway array. This is consistent with the lack of protein expression. However, I 
demonstrated that Wnt1 mRNA could be detected if cDNA generated from 100ng RNA was 
analysed using RTqPCR. When RTqPCR was performed specifically for Wnt3A mRNA using 
cDNA generated from 100ng RNA, expression was not detected in any ESFT cell line (Figure 
2.8 A). Although Ct values lower than 40 were detected in some cells lines, this was not 
consistent across the three wells in any cell line (Figure 2.8 B). The variance observed 
suggests that Wnt3A mRNA is not expressed in the ESFT cell lines studied. 
 
 
 
 
 
 
 
 
Figure ‎2.8  Wnt3A mRNA is not expressed in ESFT cell lines as determined by RTqPCR RNA 
was extracted, RT performed and expression of Wnt3A determined by RTqPCR A) 
Wnt3A mRNA expression in ESFT cell lines using cDNA generated from 100ng of RNA. 
Data presented as Wnt3A expression relative to the expression of the housekeeping 
gene PPIA, normalised to the positive control cell line MCF7. Results show the mean 
of triplicate wells in one experiment. B) Ct values obtained from the RTqPCR for both 
Wnt3A and PPIA. A higher Ct value corresponds to low expression, a Ct value of 40 is 
considered no detection.  
Cell Line 
Well 1 
(Ct) 
Well 2 
(Ct) 
Well 3 
(Ct) 
Ct 
Mean 
A673 37.75 36.05 40 37.9 
RD-ES 36.44 40 38.39 38.2 
SKES-1 40 40 40 40 
SK-N-MC 40 39.01 39.45 39.4 
TC32 40 40 38.01 39.3 
TTC466 40 35.56 37.79 37.7 
MCF7 29.32 29.46 29.36 29.3 
Well 1 
(Ct) 
Well 2 
(Ct) 
Well 3 
(Ct) 
Ct Mean 
20.76 21.02 20.83 20.87 
20.93 21.07 21.00 21.00 
18.86 18.84 18.89 18.86 
21.38 21.46 21.22 21.35 
20.39 20.36 20.20 20.31 
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20.44 20.21 20.06 20.24 
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2.3.2.3 Expression of Wnt5A protein 
2.3.2.3.1 Expression of Wnt5A protein by western blot 
Wnt5A is the most commonly studied noncanonical Wnt ligand, and had the highest mRNA 
expression out of the Wnt ligands detected using the Wnt signalling pathway array (Section 
2.3.1.1). Protein expression of Wnt5A was determined using a monoclonal antibody 
(MAB645, R&D) which only detects epitopes in an oxidised form, therefore the reducing 
agent DTT was omitted from the SDS loading buffers. Wnt5A protein was detected as a 
band at 42 kDa and expression was heterogeneous between ESFT cell lines (Figure 2.9 A). 
To check the amount of protein on the membrane expression of β-actin was examined 
using an anti- β-actin antibody which detects oxidised protein (ab8226, Abcam). Protein 
expression was quantified by densitometry and revealed RD-ES, SKES-1 and TC32 cells had 
higher expression of Wnt5A protein, than A673, SK-N-MC and TTC466 cell lines, when 
expression was normalised to that in the positive control cell line L-Wnt5A (Figure 2.9 B 
and C). These results are consistent with the Wnt signalling array data which showed 
mRNA expression of Wnt5A was highest in RD-ES and TC32 cell lines and lowest in A673 
and SK-N-MC (Figure 2.2). 
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Figure ‎2.9 Wnt5A protein expression in ESFT cells determined by western blot. (A) Total 
protein extract was prepared without DTT and expression of Wnt5A in 25µg extract 
determined by western blot. Expression of β-actin was used as a loading control. 
Representative of three independent experiments (B) Band intensity was quantified 
by densitometry and expression levels calculated as the ratio of the intensity of the 
Wnt5A band to that of the β-actin band and (C) normalised to the positive control 
cell line L-Wnt5A; L-cells overexpressing Wnt5A. Results in (B) and (C) show the 
mean of three independent experiments (± SEM). MW= molecular weight marker in 
kDa. 
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2.3.2.3.2 Expression of Wnt5A protein by flow cytometry 
Expression of Wnt5A protein was also investigated in ESFT cell lines by flow cytometry. 
There was less heterogeneity of Wnt5A expression between cell lines than that observed 
by western blot (Figure 2.10 A and B). Expression of Wnt5A was significantly higher in RD-
ES (median fluorescence; 10±0.5 compared to the other cell lines (median fluorescence 
range; 3.6 to 6.2). This is consistent with both the array and western blot data which 
demonstrated RD-ES had the highest expression of Wnt5A mRNA and protein, respectively.  
In ESFT cell lines, when 10,000 events per sample were analysed, there was a range in the 
percentage of cells expressing Wnt5A. In the TTC466 cell line only 45±2.9% of cells 
expressed Wnt5A whereas in the A673 cell line 67±3.6% of cells were positive for Wnt5A 
expression. In all ESFT cell lines single tight expression peaks were observed, indicating 
Wnt5A expression was similar between cells within each cell line (Figure 2.10, top panel).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎2.10 Protein expression of Wnt5A in ESFT determined by flow cytometry ESFT cells were harvested, permeabilised and labelled for analysis of Wnt5A 
expression by flow cytometry. (A) Representative cell scatter and fluorescence plots show cells in the presence (green) or absence (purple) of Wnt5A 
primary antibody. The M1 region designates negative events and the M2 region positive events. (B) The median fluorescence of each peak was 
calculated and used to generate a mean fold level of Wnt5A expression relative to the no primary antibody control. Results are presented as the mean of 
three independent experiments, with three replicates per experiment (n=9) analysing 10,000 events per sample (± SEM). 
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2.3.3 Subcellular localisation of β-catenin in ESFT cell lines 
Possible activation of the canonical Wnt signalling pathway was investigated by measuring 
the expression of β-catenin in the cytoplasm and the nucleus in ESFT cell lines by western 
blot of enriched nuclear and cytoplasmic fractions (Section 2.2.4, Figure 2.11). Enrichment 
of fractions was confirmed by western blot for the specific nuclear and cytoplasmic 
proteins TBP and α-tubulin, respectively (Figure 2.11 A). As there is no single protein 
expressed in all fractions, equal protein on the blot was confirmed by staining membranes 
with Ponceau S (Figure 2.11 B). Expression of β-catenin protein was identified in the 
nuclear fractions of all ESFT cell lines by western blot (Figure 2.11 A). Nuclear β-catenin 
expression was heterogeneous with the highest expression in the TC32 cell line and lowest 
expression in SKES-1 and RD-ES cells. Expression of β-catenin protein was low in the 
cytoplasmic fractions of all cell lines, consistent with the conclusion that β-catenin is 
translocated from the cytoplasm to the nucleus; and the hypothesis that the canonical Wnt 
signalling pathway is active in ESFT cell lines. 
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Figure ‎2.11 Subcellular localisation of β-catenin in ESFT cell lines. (A) Subcellular fractions 
were prepared by differential centrifugation and expression of β-catenin in 25µg of 
each fraction determined by western blot. Expression of TATA-binding protein (TBP)  
was used as a loading control for nuclear fractions and α-tubulin for cytoplasmic 
fractions. N= nuclear, C= cytoplasmic. (B) Ponceau S staining of membranes was used 
to check the amount of protein across each fraction. HeLa = positive control cell line. 
MW = molecular weight in kDa. Representative of two independent experiments.  
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2.3.4 Expression of active β-catenin in ESFT cell lines 
To further investigate activation of the canonical Wnt signalling pathway in ESFT cells, 
expression of the active form of β-catenin was determined by western blot. This was 
achieved using an antibody that specifically detects β-catenin in its active form; 
nonphosphorylated on Ser37 or Thr41 (Millipore, 05-665; (van Noort et al. 2002)). 
Expression of β-actin was used to confirm equal protein levels, and protein expression was 
quantified by densitometry. Total β-catenin was detected in all ESFT cell lines with 
heterogeneous expression; the highest levels were detected in A673 cells and lowest in 
SKES-1 (Figures 2.12 A and B). Nonphosphorylated (i.e. active) β-catenin was also detected 
in all ESFT cell lines (Figure 2.12 A). The percentage β-catenin that was nonphosphorylated 
was variable between biological repeats, as evidenced by the large error bars observed on 
Figure 2.12 C. The percentage of nonphosphorylated β-catenin ranged from 22-40% 
depending on the cell line with the greatest percentage in TC32 cells and the lowest in 
SKES-1. This is consistent with the nuclear localisation assay in which expression of β-
catenin was greatest in the nuclear fraction of TC32 cells, and lowest in SKES-1 cells. 
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Figure ‎2.12 Expression of the active form of β-catenin in ESFT cell lines. (A) Total protein 
was extracted and expression of total and active β-catenin in 50µg extract 
determined by western blot. Expression of the active form of β-catenin was 
investigated using an antibody (05-665, Millipore) which specifically detects the 
nonphosphorylated form. Expression of β-actin was used as a loading control. 
Representative of three independent repeats. (B) Protein band intensity was 
quantified by densitometry and total β-catenin expression calculated as the ratio of 
β-catenin to β-actin. Expression of active β-catenin was calculated as the ratio of 
active β-catenin to total β-catenin. Results in (B) and (C) show the mean of three 
independent experiments (± SEM). A431 and HeLa = positive control cells. MW = 
molecular weight in kDa.  
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2.4 Discussion  
In this chapter my data has revealed that components of the Wnt signalling pathway are 
expressed in ESFT cells lines. I have identified for the first time expression of the canonical 
Wnt ligand Wnt1, and confirmed expression of the noncanonical Wnt ligand Wnt5A, in all 
ESFT cell lines studied. In addition, I have shown that Wnt3A is not expressed in any of the 
ESFT cell lines investigated. Furthermore I have demonstrated that all ESFT cell lines 
studied expressed β-catenin in the nucleus and expressed the nonphosphorylated (active) 
form of β-catenin. Taken together this suggests that the canonical Wnt signalling pathway 
is active in ESFT cell lines grown under normal conditions. 
The results generated from the Wnt signalling array confirmed mRNA expression of 
components of the Wnt signalling pathway in ESFT cell lines. This included expression of 
Wnt ligands including Wnt4, Wnt10B, Wnt2B (Wnt13) and Wnt5A which have previously 
been detected in ESFT cell lines (Üren et al. 2004). In addition, in this study Wnt10B, Wnt11 
and Wnt5B mRNAs were also detected in all ESFT cell lines; expression of these Wnt 
ligands has not been previously reported in ESFT. All 19 Wnt ligands were expressed in at 
least one cell line, most had low expression with the exception of Wnt5A which will be 
discussed in more detail later in this discussion.  
Other components of the Wnt signalling pathways were also detected in ESFT cell lines 
including high expression of LRP5, LRP6 and FZD4 consistent with previous findings (Üren 
et al. 2004). A number of studies have suggested that members of the DKK family may be 
important in ESFT, and several reports have described expression of both DKK1 and DKK2 
in ESFT cell lines. Higher expression of DKK2 compared to DKK1 has been reported 
(Miyagawa et al. 2009, Hauer et al. 2013), which is consistent with my data. DKK2 has been 
shown to increase migration and invasion of ESFT cells (Hauer et al. 2013), whereas DKK1 is 
reported to decrease Wnt signalling in ESFT cells (Endo et al. 2008). I have also 
demonstrated high levels of c-myc mRNA expression in all ESFT cell lines, which is 
consistent with previous data on c-myc in ESFT (McKeon et al. 1988). Taken together these 
results suggest that the Wnt signalling array is generating informative results. 
My data also demonstrate expression of members of the secreted frizzled-related protein 
(sFRP) family including sFRP1, sFRP2, FRZB (sFRP3) and sFRP4 in ESFT cell lines consistent 
with the previous study by Uren et al., (2004). However, I have also identified sFRP5 in 
A673, RD-ES and SK-N-MC cell lines. This is in contrast to previous literature demonstrating 
that sFRP5 is methylated and sFRP5 protein is not expressed in these cell lines (Jin et al. 
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2012). This discrepancy may reflect partial methylation of the sFRP5 gene. The sFRP family 
are generally considered to be antagonists of both the canonical and noncanonical Wnt 
signalling pathways. This is because sFRP proteins have significant similarity to the 
extracellular domain of frizzled receptors, therefore they can bind and sequester Wnt 
ligands. Indeed, sFRP5 has been shown to inhibit migration of ESFT cell lines, suggesting it 
may inhibit the noncanonical Wnt signalling pathway (Jin et al. 2012). In this study the 
expression of some members of the sFRP family, in particular sFRP2 and FRZB (sFRP3) was 
differentially expressed across the ESFT cell lines. Although this observation could explain 
the differences in expression of nuclear and active β-catenin that were detected in ESFT 
cell lines, this does not seem to be the case as relatively high expression of both sFRP2 and 
FRZB was detected in TC32 cells even though these cells have the highest level of both 
nuclear and active β-catenin. Therefore other factors are likely to influence the activity of 
the Wnt signalling pathways. 
Heat map analysis revealed that the majority of Wnt signalling components had similar 
expression in all six ESFT cell lines. One notable exception was the noncanonical ligand 
Wnt5A which was the Wnt ligand with the highest mRNA expression in ESFT cell lines. 
Heterogeneous expression of Wnt5A protein was also observed; Wnt5A protein was 
highest in RD-ES and TC32 cell lines and lowest in A673 and cells. This is consistent with 
previous reports that Wnt5A expression is heterogeneously expressed in both ESFT cell 
lines and in ESFT samples, with higher expression detected in metastatic tumour samples 
(Jin et al. 2012). These observations suggest that the noncanonical Wnt signalling may be 
more prominent in some ESFT cells than others, as summarised in Table 2.7. In addition to 
Wnt5A protein, expression of the canonical Wnt ligands Wnt1 and Wnt3A were also 
investigated. I have demonstrated for the first time that Wnt1 is expressed in ESFT cell 
lines, although the levels of Wnt1 mRNA detected were low. It is not well understood how 
Wnt1 transcription is regulated. It has been reported that the homeobox protein Six3 
represses Wnt1 transcription by interacting with Groucho-related co-repressors and HDAC 
(Lagutin et al. 2003). In addition, it has been shown that certain microRNAs including miR-
21, miR-34a (Hashimi et al. 2009) and miR-152 (Huang et al. 2014) can repress 
transcription of Wnt1. My data also suggests that the Wnt1 protein may have a long half-
life as high protein levels were detected in all cell lines but RNA expression was very low, 
although to my knowledge the half-life has not been formally reported for Wnt1.  
Analysis of Wnt1 expression by flow cytometry revealed that in all cell lines the percentage 
of cells expressing this ligand was relatively homogeneous; over 85% of cells expressed 
Wnt1 in all cell lines. However for Wnt5A expression was more heterogeneous as the 
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percentage of cells expressing this ligand ranged from 45-67%. It would therefore be 
interesting to investigate co-expression patterns of these Wnt ligands in ESFT cell lines 
using flow cytometry. Although Wnt1 expression was not significantly different between 
the ESFT cell lines, the expression trend was the opposite to that observed for Wnt5A 
expression; i.e. with the highest expression observed in A673 and SK-N-MC cells. This data 
is summarised in Table 2.7 and further supports the hypothesis that some ESFT cells may 
be dominantly canonical or noncanonical, and others may be mixed. My data suggests that 
A673 and SK-N-MC cell lines may have active canonical Wnt signalling, and RD-ES, SKES-1 
and TC32 may primarily have active noncanonical Wnt signalling.  
In contrast to Wnt1 and Wnt5A, the canonical Wnt3A protein was not expressed in any 
ESFT cell line. Good antibodies to Wnt proteins have been very difficult to develop (based 
on information provided by the Nusse laboratory on the Wnt homepage: 
http://www.stanford.edu/group/nusselab/cgi-bin/wnt/). Indeed, in this study I struggled 
to find an antibody which specifically detects Wnt3A although I eventually optimised a 
monoclonal antibody produced by R&D which detects Wnt3A in L-cells overexpressing this 
protein. Although previous studies have treated ESFT cell lines with exogenous Wnt3A 
ligand, no expression of Wnt3A has been reported previously in ESFT cell lines which is 
consistent with my data. 
To investigate if the canonical Wnt signalling is constitutively active in ESFT cell lines, the 
subcellular localisation of β-catenin was investigated by differential centrifugation 
(Westwood et al. 2002) and western blot.  In all cell lines β-catenin was detected in the 
nucleus, with low levels detected in the cytoplasm. This is consistent with active canonical 
Wnt signalling and contradicts previous reports that β-catenin is only found in the 
cytoplasm of ESFT cells (Hu-Lieskovan et al. 2005, Scannell et al. 2013). Importantly, it has 
also been previously reported that β-catenin could not be detected in the cytoplasm or the 
nucleus of patient samples (Üren et al. 2004). It would therefore be interesting to 
investigate β-catenin localisation in patient samples using the antibody used in my study. 
Constitutive activation of the canonical Wnt signalling pathway was also supported by the 
detection of the active (nonphosphorylated) form of β-catenin in all ESFT cell lines. The 
antibody used in the current study has previously been shown to specifically detect β-
catenin dephosphorylayed at residues Ser37 and Thr41 (van Noort et al. 2002).. However, 
although total β-catenin levels were heterogeneous between ESFT cell lines, the ratio of 
active: total β-catenin was similar. This is in contrast to my prediction that, based on the 
expression of Wnt ligands, A673 and SK-N-MC ESFT cell lines would have increased levels  
 
 
 
Table ‎2.7 Summary of expression of canonical and noncanonical Wnt signalling components in ESFT cell lines ESFT cell lines predicted to have active 
canonical or noncanonical Wnt signalling pathways, based on mRNA and protein expression of Wnt1 (canonical ligand) and Wnt5A (noncanonical ligand). 
The activity of the canonical Wnt signalling pathway also predicted by expression of nuclear and active β-catenin. 
   
Cell Line 
Canonical or 
noncanonical
? 
Wnt1 expression Wnt5A expression β-catenin expression 
mRNA 
(2-ΔΔCt) 
Protein by 
western 
blot (ratio 
to β-actin) 
Protein by flow 
cytometry 
(median 
fluorescence/% 
positive) 
mRNA 
(2-ΔCt) 
Protein by 
western blot 
(ratio to β-
actin) 
Protein by flow 
cytometry 
(median 
fluorescence/% 
positive) 
Nuclear
? 
Active (ratio 
to total β-
catenin) 
A673 Canonical 
0.54 0.94  Highest 26.93/94  Lowest 0.12  0.25   Lowest 3.90/67 
Yes 0.28 
RD-ES Noncanonical 
0.80 0.91 22.61/94  Highest 2.05  Highest 1.04  Highest 9.7/46 
Yes 0.27 
SKES-1 Noncanonical 
Lowest 0.25 0.92 18.87/90  0.94  Highest 1.04 4.89/63 
Yes Lowest 0.22 
SK-N-
MC 
Canonical 
Highest 1.99 
0.94 
24.54/95 0.23  Lowest 0.14 5.84/58 
Yes 0.32 
TC32 Noncanonical
? 0.45 
0.89 
 Lowest 14.59/85   1.69  0.95 5.7/63 
Yes  Highest 0.39 
TTC466 Both? 
0.64 0.81 17.29/86  1.32 0.19 6.2/45 
Yes 0.27 
-7
1
- 
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of canonical Wnt signalling (Table 2.7). Nevertheless, taken together with the nuclear β-
catenin observed,  these results support the hypothesis there may be endogenous activity 
of the canonical Wnt signalling pathway in ESFT cell lines under normal growth conditions. 
In contrast to Wnt1 and Wnt5A, the canonical Wnt3A protein was not expressed in any 
ESFT cell line. Good antibodies to Wnt proteins have been very difficult to develop (based 
on information provided by the Nusse laboratory on the Wnt homepage: 
http://www.stanford.edu/group/nusselab/cgi-bin/wnt/). Indeed, in this study I struggled 
to find an antibody which specifically detects Wnt3A although I eventually optimised a 
monoclonal antibody produced by R&D which detects Wnt3A in L-cells overexpressing this 
protein. Although previous studies have treated ESFT cell lines with exogenous Wnt3A 
ligand, no expression of Wnt3A has been reported previously in ESFT cell lines which is 
consistent with my data. 
To investigate if the canonical Wnt signalling is constitutively active in ESFT cell lines, the 
subcellular localisation of β-catenin was investigated by differential centrifugation 
(Westwood et al. 2002) and western blot.  In all cell lines β-catenin was detected in the 
nucleus, with low levels detected in the cytoplasm. This is consistent with active canonical 
Wnt signalling and contradicts previous reports that β-catenin is only found in the 
cytoplasm of ESFT cells (Hu-Lieskovan et al. 2005, Scannell et al. 2013). Importantly, it has 
also been previously reported that β-catenin could not be detected in the cytoplasm or the 
nucleus of patient samples (Üren et al. 2004). It would therefore be interesting to 
investigate β-catenin localisation in patient samples using the antibody used in my study. 
Constitutive activation of the canonical Wnt signalling pathway was also supported by the 
detection of the active (nonphosphorylated) form of β-catenin in all ESFT cell lines. The 
antibody used in the current study has previously been shown to specifically detect β-
catenin dephosphorylayed at residues Ser37 and Thr41 (van Noort et al. 2002).. However, 
although total β-catenin levels were heterogeneous between ESFT cell lines, the ratio of 
active: total β-catenin was similar. This is in contrast to my prediction that, based on the 
expression of Wnt ligands, A673 and SK-N-MC ESFT cell lines would have increased levels 
of canonical Wnt signalling (Table 2.7). Nevertheless, taken together with the nuclear β-
catenin observed,  these results support the hypothesis there may be endogenous activity 
of the canonical Wnt signalling pathway in ESFT cell lines under normal growth conditions.  
It is important to note that nuclear localisation does not conclusively mean canonical Wnt 
signalling is active. It has been reported that the EWS-FLI1 fusion protein can compete with 
β-catenin for binding to LEF1, thereby inhibiting downstream canonical Wnt signalling. 
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Therefore simply observing nuclear β-catenin does not necessarily prove that canonical 
Wnt signalling pathway is active in ESFT cells.  
In other cancer types mutations in components of the Wnt signalling pathway such as β-
catenin and APC have been detected (Section 1.3.4.1). In this study the mutation status of 
the cell lines was not investigated since all ESFT cell lines expressed β-catenin. Furthermore 
it has been shown previously that mutations in CTNNB1 (β-catenin) are very rare in ESFT 
(Shukla et al. 2012). Nevertheless, it will be important in future studies to confirm that the 
cell lines used in this study do not have mutations which may affect the activity of the Wnt 
signalling pathways, such as truncating (loss of function) mutations in APC or mutations 
which prevent the phosphorylation (and subsequent degradation) of  β-catenin. 
To draw reliable conclusions based on the RTqPCR data generated from the Wnt signalling 
array it is imperative to report mRNA expression relative to the amount of cDNA analysed, 
to allow for comparisons of expression between samples. It is normal practice to use the 
expression of so called ‘housekeeping’ genes involved in cellular maintenance to normalise 
for differences in RNA input, RNA quality and the efficiency of the RT reaction. Currently 
there is no gold-standard housekeeping gene and there are conflicting reports as to which 
is the best housekeeping gene to use, most likely because this will be tissue/cell type 
dependent. The Wnt signalling array used in this study contains the housekeeping genes 
18S, GAPDH, HRPT1 and GUSB. 18S is a ribosomal subunit and is synthesised by RNA 
polymerase I (Radonić et al. 2004). This means regulation of 18S synthesis is independent 
of mRNA synthesis, therefore it is not a suitable reference gene to use and was excluded 
from the analysis. Studies have also demonstrated that GAPDH expression can be affected 
by various experimental conditions such as serum concentration (Schmittgen and Zakrajsek 
2000). In addition, GAPDH has been reported to have at least 67 pseudo-genes that share 
over 80% identity to the parental mRNA (Sun et al. 2012). Since it has been shown that at 
least some of these may be transcribed (Tso et al. 1985), and therefore potentially 
detected by RTqPCR,  we do not believe GAPDH is suitable to use as a housekeeping gene. 
In addition, both 18S and GAPDH are very highly expressed, ideally a housekeeping gene 
should have similar expression levels to the mRNAs of interest. An ideal housekeeping 
gene should also have relatively constant expression regardless of experimental 
conditions; therefore the inter-assay variability between replicates of the other 
housekeeping genes on the array was performed. In ESFT cell lines, the housekeeping gene 
with the lowest inter-assay variability was HRPT1. It has been shown previously that in a 
range of tissue types, expression of HRPT1 accurately reflects the expression of 10 other 
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commonly used housekeeping genes (de Kok et al. 2004), hence I have used HRPT1 against 
which to normalise my results.  
In summary, my results support the hypothesis that Wnt signalling may be active in ESFT. 
However, in the subcellular localisation studies, TBP and α-tubulin were used to confirm 
enrichment of the nuclear and cytoplasmic fractions, respectively. This demonstrated that 
the fractionation protocol was not completely efficient, and there was some 
contamination of both the nuclear and cytoplasmic fractions in some cell lines. Since my 
observations are not consistent with previous reports it would be especially important to 
confirm my observations. This could be performed using confocal microscopy to identify 
co-localisation of β-catenin with nuclear proteins such as TBP. 
The Wnt signalling array used to assess mRNA expression of Wnt components is a very 
useful high-throughput tool to investigate which components of the Wnt signalling 
pathway are expressed. However, since it is a pre-made commercial array it is not possible 
to choose which components are included. Unfortunately there are not many components 
of the noncanonical Wnt signalling pathway on this array meaning my data is not as 
informative for this pathway. I have attempted to separate components into those that are 
predicted to either promote or inhibit Wnt signalling. However, in reality this is very 
difficult as expression of a particular Wnt ligand or receptor does not definitively reveal 
which Wnt signalling pathway, if any, is activated. The Wnt signalling network is 
complicated, with many different components including many possible ligand/receptor 
complexes and inhibitors and these are still not completely understood. It is becoming 
evident however that Wnt ligands may activate different pathways depending on the 
cellular context and receptors present. For example, in C.elegans  Wnt1 has been shown to 
inhibit, rather than activate the activity of TCF (Smit et al. 2004) and Wnt5A can activate 
the canonical Wnt signalling pathway when bound to FZD4 (Mikels and Nusse 2006). Also 
in endometrial cancer cells, Wnt7A binding to FZD5 has been shown to activate the 
canonical Wnt signalling whereas Wnt7A binding to FZD10 activates the noncanonical 
pathway (Carmon and Loose 2008). In addition, inhibitors of the pathway such as members 
of the DKK family (Niehrs 2006) and sFRP family (Bovolenta, 2008), have been shown to 
inhibit but also activate Wnt signalling in some situations. I have attempted to investigate 
the activity of the canonical Wnt signalling pathway by investigating the downstream 
effector protein β-catenin. However, as discussed although this is the method used by 
many studies to investigate activation of the canonical Wnt signalling pathway this is not a 
true measure of the functional activity of the pathway. Furthermore, for the noncanonical 
Wnt signalling pathways there is no single protein (such as β-catenin) that can be easily be 
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detected to probe for activation. Therefore, to reliably investigate the activity of the Wnt 
signalling pathways in ESFT it is important to develop functional assays to measure 
signalling directly. 
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3. Developing an assay to measure the activity of the canonical Wnt 
signalling pathway in ESFT cell lines 
3.1 Introduction 
In the previous chapter I demonstrated that components of the canonical Wnt signalling 
pathway are expressed in ESFT cell lines. In addition, nuclear and unphosphorylated β-
catenin were detected in all ESFT cell lines, consistent with the hypothesis that the 
canonical Wnt signalling pathway is constitutively active in ESFT cell lines. However, in 
order to demonstrate this conclusively, in this chapter I have developed and optimised a 
reporter to directly measure activation of the canonical Wnt signalling pathway in ESFT 
cells. 
The most widely used technique to directly measure canonical Wnt signalling is to 
transiently transfect cells with a TOPFlash (or more recently SUPER-TOPFlash) reporter 
plasmid (Korinek et al. 1997, Veeman et al. 2003). These plasmids contain the firefly 
luciferase gene under the control of a promoter containing multiple repeats of the TCF/LEF 
transcriptional response elements (TRE). Therefore, when β-catenin enters the nucleus and 
binds to the TCF/LEF binding sites, firefly luciferase is expressed which can be detected 
using a highly sensitive quantitative luciferase assay. Cells are also transfected with a 
negative control plasmid, FOPFlash, which contains mutated TCF/LEF binding sites to 
ensure specificity of firefly luciferase expression upon canonical Wnt signalling. Using this 
approach previous studies observed no or extremely low canonical Wnt signalling activity 
in ESFT cells (Hu-Lieskovan et al. 2005, Navarro et al. 2010, Vijayakumar et al. 2011).  
However, this technique has a number of disadvantages. For example, unless 100% of the 
cells are transfected then the TOPFlash assay will only detect canonical Wnt signalling in a 
subpopulation of cells, which may not be representative of the whole population, meaning 
rare populations of cells could be missed. In addition, this assay relies upon a separate 
control plasmid constitutively expressing Renilla luciferase to control for transfection 
efficiency. It is therefore assumed that the transfection of TOPFlash and Renilla is identical, 
which may not be the case. Importantly it also relies on the ability to transiently transfect 
cells. ESFT cells are very difficult to transfect using currently available reagents such as 
Lipofectamine®2000 and FuGENE® or electroporation (unpublished observations).  
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More recently, a second method to investigate canonical Wnt signalling in cells using 
lentiviral reporter vectors has been described (Fuerer and Nusse 2010). Lentiviral vectors 
are single-stranded RNA viruses derived from the human immunodeficiency virus (HIV) 
that stably integrate into the host genome. To eliminate the possibility that a wild-type 
virus will be reconstituted through recombination, various safety alterations have been 
made. For example the accessory genes vif, vpr, vpu and nef have been eliminated 
(Zufferey et al. 1997). In addition, when making virus particles, cells are transfected with 
three separate plasmids. Firstly, cells are infected with the lentiviral expression plasmid 
containing the psi (ψ) packaging sequence and the transgene inserted between lentiviral 
long terminal repeats (LTRs) for target cell integration. Self-inactivating lentiviruses have 
been developed that have a mutation in the 3’LTR to prevent the vector RNA being 
transcribed in the transduced cells (Zufferey et al. 1998). The second plasmid transfected 
contains the packaging genes pol, gag, rev and tat and the rev-response element (RRE). In 
addition, a pseudotyping plasmid containing the G protein of the Vesicular Stomatitis Virus 
(VSV-G) envelope gene is transfected. This envelope protein allows lentiviruses to infect all 
mammalian cells, including nondividing cells (Burns et al. 1993, Akkina et al. 1996, Naldini 
et al. 1996). Lentiviral vectors have been developed which contain 7 repeats of the TCF 
binding site driving expression of either GFP or firefly luciferase (Fuerer and Nusse 2010). 
The vectors also contain a puromycin resistance gene to allow for selection of infected cells 
to generate a stably expressing cell population. These vectors could therefore be used to 
measure Wnt signalling in entire populations of cells, including cells that are normally 
difficult to transiently transfect. Endogenous Wnt signalling could be measured in cells as 
well as the response of cells to Wnt ligands.   
Treatment with exogenous Wnt ligands is often used to stimulate Wnt signalling in cells, 
thereby demonstrating the activity of the pathway. However, Wnt proteins are poorly 
soluble and when overexpressed in cell lines are largely associated with the extracellular 
matrix, and not secreted (Bradley and Brown 1990).  The first secreted and biologically 
active Wnt protein to be described was mouse Wnt3A (Shibamoto et al. 1998). It has been 
possible to purify biologically active mouse Wnt3A (Willert et al. 2003) and mouse Wnt5A 
(Mikels and Nusse 2006) proteins, however purification of other Wnt proteins has been 
less successful as they tend to form protein aggregates that are not biologically active 
(Willert and Nusse 2012). Rather than using purified Wnt proteins, a more cost effective 
and commonly used alternative is to use conditioned media from cells overexpressing Wnt 
proteins. Mouse L (L-M [TK¯]) cells  have been stably transfected with Wnt3A and Wnt5A, 
and conditioned media from these cells shown to contain biologically active Wnt3A and 
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Wnt5A, respectively (Willert et al. 2003, Mikels and Nusse 2006). However, the 
disadvantage of this approach is that conditioned media from these cells will contain other 
factors which may make interpretation of the results difficult. Therefore in an attempt to 
address this issue, conditioned media from the parental L cell line (which does not produce 
Wnt3A or Wnt5A protein) is used as a control.   
In addition to measuring the activity of canonical Wnt signalling using reporter systems, 
activation can be confirmed by measuring the expression of target genes downstream of 
the pathway. There are currently over 120 genes known to be downstream targets as listed 
on the Wnt homepage (http://www.stanford.edu/group/nusselab/cgi-bin/wnt/) and the 
specific up or down regulated genes appear to be cell type rather than signal specific  (H. 
Clevers 2006). It is not known whether there are genes that are universal targets of 
canonical Wnt signalling, although it has been suggested this is the case for Axin2 (Jho et 
al. 2002). Expression of β-catenin mRNA and protein has also been shown to increase after 
stimulation of cells with Wnt3A protein (Gujral and MacBeath 2010, Hernandez et al. 2012) 
suggesting this may also be an informative downstream target gene to investigate. 
The aims of this chapter were to: 
1. Optimise and validate a lentiviral reporter assay to measure the activity of 
canonical Wnt signalling. 
2. Measure the endogenous activity of Wnt signalling in ESFT cell lines. 
3. Investigate if the Wnt signalling pathway is activated by treatment with exogenous 
Wnt ligands. 
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3.2 Materials and Methods 
3.2.1 Cell lines and tissue culture 
ESFT cell lines were cultured as previously described (Section 2.2.1). HEK293T cells were 
obtained as a gift from Professor M. Knowles and maintained in DMEM supplemented with 
10% (v/v) FCS and 2mM glutamine on Corning® tissue-culture plastic HEK293T cells were 
passaged at least twice after thawing before being used for lentiviral particle production. 
L cells (CRL-2648), L Wnt-5A (CRL-2814) and L Wnt-3A (CRL-2647) cell lines were purchased 
from the ATCC (supplied by LGC Standards). All L cell lines were maintained in modified 
DMEM (30-2002, ATCC) containing 4 mM L-glutamine, 4.5 g/L glucose, 1 mM sodium 
pyruvate, and 1.5 g/L sodium bicarbonate and 10% FCS on Corning plastic. L Wnt-5A and L 
Wnt-3A cell lines were maintained in 0.6mg/ml and 0.4mg/ml G418 (Gibco®, Life 
Technologies), respectively, for one week upon arrival to confirm selection.  
All cell lines were passaged when 70% confluent as described previously (Section 2.2.1) 
and cultured in a humidified chamber in 5% CO2 in air at 37°C. Cell lines were screened for 
mycoplasma contamination every 3 months by technical staff using the EZ-PCR 
mycoplasma test kit (GeneFlow). 
3.2.2 Lentiviral transduction of cells 
3.2.2.1 Production of vector DNA 
Plasmids 7xTcf-eGFP.SV-40-PuroR (7TGP; plasmid 24305) and 7xTcf-FFLuc.SV40-PuroR 
(7TFP; plasmid 24308) (Fuerer and Nusse 2010) were purchased from Addgene 
(Cambridge, Massachusetts, USA), provided as transformed bacteria in a stab culture.  
3.2.2.1.1 Streaking out transformed bacteria 
Bacteria were streaked onto an agar plate containing LB agar with 100µg/ml ampicillin 
(amp; Sigma-Aldrich) using a sterile inoculation loop and incubated for 16 h at 37°C in a dry 
chamber (Sanyo Incubator). After this time a single colony was picked using a pipette tip, 
and used to inoculate a 5ml culture of LB medium (+ 100µg/ml amp) which was incubated 
for 16h at 37°C with vigorous shaking (approximately 300 rpm) in an incubator shaker 
(Innova® 4200, New Brunswick Scientific, supplied by Eppendorf UK, Stevenage, UK). The 
culture was then added to 200ml LB medium (+ 100µg/ml amp) and incubated at 37°C with 
vigorous shaking for a further 16h. The bacteria were harvested by centrifugation (6000 g 
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for 15 min at 4°C; Beckman Coulter Avanti® J-26 XP Centrifuge) and all traces of 
supernatant removed.   
3.2.2.1.2 Maxipreparation of DNA 
Vector DNA was isolated from the bacterial culture using the HiSpeed® Plasmid Maxi Kit 
(Qiagen). All reagents are company proprietary. The bacterial pellet was lysed by 
resuspending in 10ml Buffer P1 (containing RNase A). The solution was mixed thoroughly 
with 10ml Buffer P2 by shaking and incubated for 5 min at RT. An equal volume (10ml) of 
chilled Buffer P3 was added to the lysate and mixed immediately by inverting the tube 6 
times vigorously for the precipitation step to occur. The lysate was poured into the barrel 
of a QIAfilter Cartridge and incubated at RT for 10 min or until the precipitate containing 
genomic DNA, proteins and detergent was visible at the top of the cartridge. Meanwhile, a 
HighSpeed Maxi Tip was equilibrated by applying 10ml Buffer QBT and the column allowed 
to empty by gravity flow. Once the incubation was complete, the cap from the QIAfilter 
outlet nozzle was removed and the plunger gently inserted into the QIAfilter Maxi 
Cartridge and the cell lysate filtered into the equilibrated HiSpeed Tip. The cleared lysate 
was allowed to enter the resin by gravity flow and the HiSpeed Maxi Tip was washed with 
60 ml Buffer QC. Finally, the DNA was eluted with 15ml Buffer QF into a 50ml FalconTM 
tube. The DNA was precipitated by adding 10.5ml isopropanol at RT, mixed, and incubated 
for 5 min at RT. DNA was harvested by centrifugation (1900g for 45 min; Allegra® 6R 
Centrifuge, Beckman Coulter) and subsequently washed with 5ml 70% ethanol. A final 
centrifugation (1900g for 15 min) was performed and any residual ethanol removed by 
pipetting. The pellet was allowed to air-dry and finally resuspended in 300-500μl nuclease-
free water, as determined by the size of the pellet. DNA quality and quantity was 
measured using the Nanodrop as previously described (Section 2.2.5.2). 
3.2.2.2 Generation of lentiviral vectors in HEK293T cells 
All work with lentiviral vectors was carried out in a Class II tissue culture facility. All used 
liquids and tissue culture plastics were decontaminated with 10% (v/v) Virusolve® (AMITY 
Healthcare, Barnsley, UK) for at least 30 min before being disposed by autoclaving. After 
use the tissue culture cabinet was cleaned using 10% Virusolve. All equipment including 
gloves, tissues and used plastics were left in the Class II cabinet for at least 30 min after 
lentiviral vectors had been used, to eliminate any aerosols which may have been 
generated, prior to decontamination and disposal by autoclaving.  
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Lentiviral particles were produced using a second generation packaging system kit LENTI-
Smart™ (Invivogen, supplied by Source BioScience, Nottingham, UK) using HEK293T cells. 
This kit includes the packaging plasmids pLV-iVSV-G (encoding the viral envelope gene) and 
pLV-HELP (containing gag, pol, rev and tat genes) and LycoVec™ transfection reagent. To 
produce lentiviral particles, 12µg of the lentiviral cloning plasmid of interest (in 200µl) was 
added to one vial of Lenti-SMART™, mixed gently and incubated at RT for 15 min, then 
800µl of sterile H2O was added. Meanwhile, HEK293T cells were trypsinised and viable cell 
number quantified as previously described (Section 2.2.1). A total of 1 x 107 cells were 
added to 12ml of growth media in a 75 cm2 flask. The LENTI-Smart™ and cloning plasmid 
mixture was then added and mixed by pipetting. The flask was placed in the incubator, and 
the media replaced after 16 h. After 24 h the supernatant was collected and stored at 4°C, 
and 10ml fresh media added. After 48h the supernatant was harvested and pooled with 
the supernatant collected after 24 h. The combined supernatant was filtered using a 
0.45µm Aerodisc® PVDF filter (PALL Life Sciences, supplied by VWR) to remove viral and 
cell debris. Viral supernatant was stored in 1.5ml single-use aliquots at -80°C in a 
designated freezer for Class II material.  
3.2.2.3 Infecting target cells with lentiviral vectors 
Cells were trypsinised and seeded in 25 cm2  flasks at a density of 6 x 105 (except HEK293T 
and A673 cells which were seeded at 3 x 105) so that they would be 30-50% confluent the 
next day (Section 2.2.1). After 24h, the media was replaced with 1.5ml viral supernatant 
(prepared as described in Section 3.2.2.2) diluted in growth media as required, containing 
1 µg/ml hexadimethrine bromide (Polybrene®, Sigma-Aldrich). After 4h, the viral 
supernatant was discarded and replaced with normal growth media. After 48h the growth 
media was replaced with media containing 0.5µg/ml puromycin (Sigma-Aldrich) to select 
for cells transduced with the vector. Cells were maintained in selection for 1 week. Cells 
were used for experiments after a minimum period of 72h after infection to allow time for 
the gene of interest to be produced. Cells were maintained in Class II conditions (as 
described in Section 3.2.2.2) for at least 10 days after infection or until at least 2 passages 
had been performed, after this time lentiviral particles were no longer present. 
3.2.3 Measuring GFP expression in cells by flow cytometry 
Cells expressing GFP were trypsinised (Section 2.2.1) and centrifuged at 405g for 5 min. For 
cells which were still being maintained in Class II conditions a centrifuge with buckets and 
lids was used to minimise the release of aerosols, and these were thoroughly cleaned with 
10% Virusolve after use. After centrifugation the cell pellet was resuspended in 500µl 1% 
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PFA to fix the cells, followed by centrifugation (405g for 5 min). The cell pellet was then 
washed with 1X PBS, centrifuged (405g for 5 min), the supernatant discarded and the 
pellet resuspended in 1ml fresh PBS. After fixation, cells did not have to be handled in Class 
II containment. GFP expression was analysed by flow cytometry (FACSCalibur™, BD 
Biosciences) using an excitation laser of 480nm. A total of 10,000 events were measured 
for each sample and triplicate samples were analysed for each cell line. GFP expression was 
compared to control cells which had not been infected with a lentiviral GFP plasmid, and 
median GFP fluorescence and percentage of cells expressing GFP determined using 
CellQuest™ software (BD Biosciences).  
3.2.4 Titration of lentiviral vectors 
The titre of lentiviral vector produced using the LENTI-Smart™ kit was estimated using 
HEK293T cells infected with pLV-Green vector. HEK293T cells were chosen as they have a 
doubling time of between 18-25 h and are therefore recommended by the manufacturers 
of LENTI-Smart™. HEK293T cells were trypsinised (Section 2.2.1) and seeded at 5 x 104 
cells/well in 24 well plates. After 24h, cells in 3 of the wells were trypsinised and counted 
using the Vi-cell automated cell counter (Section 2.2.2) to provide a viable cell count at the 
time of infection. The following dilutions of pLV-Green viral supernatant in DMEM (+10% 
FCS) containing 1µg/ml Polybrene® were prepared; 1:2, 1:4, 1:8, 1:16, 1:32, 1:64 and 
1:128. The media was removed from remaining wells and 500µl of diluted viral 
supernatant was added (three wells per dilution). The plate was incubated for 4h at 37°C 
after which time the viral supernatant was removed and 1ml fresh DMEM (+10% FCS) 
added. The plate was incubated for a further 72h at 37°C to give time for GFP to be 
expressed. GFP expression was determined as previously described (Section 3.2.3).  
The lentiviral titre was calculated for each dilution using the following formula; 
(F × C  × D)  
      0.5 
where F is the frequency of GFP positive cells (percentage obtained divided by 100), C is 
the number of cells (calculated as the average from the cell counts performed at the time 
of infection) and D is the coefficient of dilution (i.e. 64 for 1:64 dilution. This is divided by 
the volume (in ml) of media used to infect the cells (0.5). The average titre was calculated 
from values gained from dilutions where the percentage of GFP positive cells was within 
the range 1-30% (as suggested by the LENTI-SmartTM kit manual) and was presented as 
transduction units (TU) per ml. 
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Using this titre the multiplicity of infection (MOI) could be determined in subsequent 
lentiviral infections. This is defined as the ratio of transduction-competent lentiviral 
particles to the number of cells being transduced.   
3.2.5 Luciferase assay 
Luciferase activity was measured using the Luciferase Assay System (E1500, Promega). In 
this assay, firefly luciferase catalyses the oxidation of luciferin to oxyluciferin. This reaction 
produces light which is measured using a luminometer. Prior to performing the assay 1X 
Passive Lysis Buffer (PLB; E1941, Promega) was prepared in dH20 and equilibrated to RT. 
Luciferase Assay Reagent (LAR) was prepared by adding Luciferase Assay Buffer (10ml) to 
one vial of Luciferase Assay substrate. Complete LAR was stored in working aliquots in the 
dark at -80°C. LAR was diluted 1:1 in dH20 and equilibrated to RT before use. To perform 
the assay, media was aspirated from adherent cells in 24-well plates and cells rinsed with 
500µl 1X PBS. PBS was aspirated and 100µl of 1X PLB added to each well and plates rocked 
on a plate shaker for 15 min at RT to lyse cells. Samples were transferred to individual 
wells of a round-bottomed 96-well plate and centrifuged at 154g for 1min to pellet cell 
debris. A 20µl aliquot of each sample was transferred to one well of a flat, solid-bottomed 
white 96-well plate (Falcon®, supplied by Scientific Laboratory Supplies (SLS), Nottingham, 
UK). Luminescence detection was performed using a luminometer with an auto injector 
(Mithras LB 940, Berthold, Harpenden, UK). The injector was washed with 70% ethanol (60 
cycles) and dH2O (60 cycles) before use. The injector was primed with LAR and the plate 
containing assay samples loaded onto the luminometer. The luminometer was 
programmed to dispense 100µl of LAR into each well, shake the plate, perform a 2s 
measurement delay followed by a 10s measurement read, before moving onto the next 
well. After use, the injector was unloaded and washed as described above.  
Luminescence of samples was reported in Relative Light Units (RLU) relative to the RLU of 
parental cells not infected with a luciferase reporter plasmid.  
3.2.6 L cell conditioned media 
3.2.6.1 Generating L cell conditioned media 
To prepare conditioned media (CM), L cells, L Wnt-5A and L Wnt-3A cells were trypsinised 
(Section 2.2.1) and split 1:10 into 10cm2 dishes (Primaria™) in 10ml culture media (Section 
3.2.1). After 4 days, the media was removed by aspiration and sterile filtered using a 0.2µm 
Aerodisc® filter (PALL Life Sciences), and 10ml of fresh culture media added to the cells. 
After 3 more days the media was removed by aspiration and the cells were discarded. 
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Media was sterile filtered and combined with the media removed after 4 days. The 
combined CM was frozen in single use (5ml) aliquots at -20°C.  
3.2.6.2 The effect of L cell conditioned media on the viability of ESFT cell lines 
ESFT and HEK293T cells were trypsinised (Section 2.2.3) and 2 × 105 cells/well seeded into 
Primaria™ 24 well plates in cell-type specific media.  A673 and HEK293T cell lines were 
seeded at 1 × 105 cells/well. After 24h, media was aspirated and replaced with 1ml of cell-
type specific media (control), L-cell CM, L-Wnt5A CM or L-Wnt3A CM. Viable cell number 
was determined for triplicate wells per condition after 24h and 48h using the trypan blue 
exclusion assay (measured with the automated vi-cell counter; Section 2.2.2). The viable 
cell number for wells treated with CM was calculated as a percentage of the viable cell 
number of wells cultured in cell-type specific media (control). 
3.2.6.3 Quantifying the concentration of Wnt3A in L-Wnt3A conditioned media 
CM was prepared from L cells and L-Wnt3A cells as previously described (Section 3.2.6.1).  
CM samples were analysed that had been collected 4 and 7 days after seeding cells, as well 
as pooled samples collected after 4 and 7 days. Pooled samples were either filtered using a 
0.2µm membrane, or left unfiltered. Each CM sample (20µl) was mixed with an equal 
volume of 2X SDS-loading buffer (Section 2.2.3.1) and loaded onto a 10% acrylamide gel 
alongside a range of concentrations of recombinant Wnt3A (10-30ng) in 40µl of 1X SDS-
loading buffer. SDS-PAGE was performed followed by western blotting for Wnt3A as 
described previously (Section 2.2.3). The densitometry of the recombinant protein bands 
was used to generate a concentration curve which was used to estimate the concentration 
of Wnt3A in the different samples of conditioned media, based on the densitometry of the 
bands. 
3.2.7 Measuring 7TGP reporter activity in cells 
Cells were plated into 24 well plates at 1 x 105 cells per well (except HEK293T and A673 
which were seeded at 5 x 104 cells well), in cell type specific media. After 24h the media 
was replaced with 500µl of conditioned media (as appropriate). Optimisation experiments 
were performed using HEK293T and SKES-1 cell lines. Cells were treated for varying lengths 
of time with L cell, L Wnt-5A or L Wnt3A CM (Section 3.2.6.1) or with recombinant Wnt5A 
(200ng/ml; R&D Systems) or varying concentrations of recombinant Wnt3A (R&D Systems). 
Using optimised conditions ESFT cell lines were treated with recombinant Wnt5A 
(200ng/ml) or Wnt3A (200ng/ml) for 24h Cells were harvested and GFP expression 
analysed by flow cytometry (Section 3.2.3).  
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3.2.8 Measuring 7TFP reporter activity in cells  
Cells were plated into 24 well plates at 1 x 105 cells per well (except HEK293T and A673 
which were seeded at 5 x 104 cells well) in cell type specific media. After 24h the media was 
replaced with 500µl treated media as previously described (Section 3.2.7). In optimised 
conditions the luciferase assay was performed 48h after seeding cells as previously 
described (Section 3.2.5). 
3.2.9 Viable cell number of ESFT cells treated with Wnt ligands 
Cells were trypsinised (Section 2.2.1) and seeded at 5 × 104 cells/well in 24-well Primaria™ 
plates in cell type specific media. After 24h media was replaced with normal growth media 
(control) or media containing rWtn3A (200ng/ml) or rWnt5A (200ng/ml). After 24, 48 and 
72h viable cell number was counted using the trypan blue exclusion assay (using the 
automated Vi-cell; Section 2.2.2). Triplicate wells were counted for each condition, at each 
time point. 
3.2.10 Detection of total and active β-catenin by western blot 
Cells were seeded in 6-well plates in cell type specific media. After 24h, for optimisation 
experiments HEK293T cells were treated for increasing lengths of time with Wnt3A. In 
optimised conditions, ESFT cells were treated with Wnt3A (200ng/ml) or Wnt5A 
(200ng/ml) for 4h. Total protein was extracted and the concentration quantified and 
samples (25µg) were analysed by SDS-PAGE as previously described using a 10% gel 
(Section 2.2.3). Expression of total and active β-catenin and β-actin (loading control) were 
detected using specific antibodies as previously described (Table 2.3). 
3.2.11 Statistics 
All analyses were undertaken using GraphPad prism 6 software. Data were analysed by 
ANOVA when comparing 3 or more conditions or cell lines as described previously (Section 
2.2.6). Differences in viable growth curves were analysed by linear regression comparing 
the slopes and intercepts of multiple lines. Differences between two means was analysed 
using an unpaired t test with Welch’s correction. In all cases, differences were considered 
significant when p<0.05.  
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3.3 Results 
3.3.1 Developing and optimising a lentiviral TCF reporter assay 
3.3.1.1 Titration of lentiviral vector 
Lentiviral vectors were generated using the LENTI-Smart™ kit (Invivogen). The titre of 
lentiviral vectors created using this method was determined in HEK293T cells using a 
lentiviral vector with constitutive GFP expression (pLV-Green). This enabled the number of 
infected cells to be easily quantified by flow cytometry. When HEK293T cells were infected 
with increasing dilutions of pLV-Green viral supernatant, the percentage of cells with GFP 
expression decreased in a dilution dependent fashion (Figure 3.1 A). The number of viable 
cells present was also determined and used to calculate the viral titre (as described in 
Section 3.2.4). The titre was determined from dilutions where the percentage of GFP 
positive cells was between 1-30% (as suggested in the LENTI-Smart™ technical manual) and 
was calculated as 1.5 x 106 TU/ml (Figure 3.1 B). Using this titre the MOI was calculated for 
subsequent experiments as the ratio of transduction-competent lentiviral vectors to the 
number of cells being transduced. 
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Figure ‎3.1 Calculating the lentiviral titre in HEK293T cells HEK293T cells were infected 
with pLV-Green lentiviral plasmid using the LentiSmart kit (Invivogen). Increasing 
dilutions of lentiviral supernatant and media were used to infect the cells for 4h. 
After 72h the cells were trypsinised, fixed with 1% PFA and analysed by flow 
cytometry to determine A) the percentage of GFP+ cells achieved by using different 
viral supernatant dilutions. B)  The number of viable cells/well was determined from 
untreated wells at the time of viral infection by trypan blue exclusion using the 
automated Vi-cell counter. The percentage of GFP positive cells and the number of 
cells present were used to determine the viral titre/ml for each dilution (as described 
in Section 3.2.4). Dilutions where the percentage of GFP positive cells was between 
1-30% (shown in bold) were used to calculate the mean transduction units/ml. 
Results shown as the mean of two independent experiments with 3 replicates per 
experiment (n=6). 
 
 
Lentiviral 
Dilution 
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3.3.1.2 Infection of ESFT cell lines with lentiviral GFP plasmid 
The lentiviral plasmid containing constitutive GFP expression (pLV-Green) was used to 
investigate the infection efficiency of lentiviral particles in ESFT cells. Using a MOI of 2, cells 
expressing GFP could be detected in all ESFT cell lines 72h after infection (Figure 3.2 A). 
The percentage of cells expressing GFP after infection with a MOI of 2 was 84±0.9% in TC32 
cells, but less than 20% in the other ESFT cell lines; ranging from 4±0.9% in SKES-1 cells to 
16±0.7% in A673 cells.  This could be clearly visualised by fluorescent microscopy (Figure 
3.1 C). Using an MOI of 4 rather than 2 did not increase the infection rate in SKES-1 cells 
(data not shown).  
In order to compare the activity of a reporter plasmid between the different cell lines it is 
important to ensure that the rate of lentiviral particle infection is similar. Ideally, infection 
rates should be below 20% to reduce the chance of multiple integrations of the reporter 
into the same cell, which would give an inaccurately high reporter reading (Salmon 2013).  
For this reason, A673, RD-ES, SKES-1, SK-N-MC and TTC466 cell lines were infected using a 
MOI of 2. This resulted in a similar level of GFP expression in these cell lines (median 
fluorescence range 14-22) (Figure 3.2 B). TC32 cells were infected at a MOI of 0.125, as this 
resulted in 15±0.08 of cells expressing GFP. The level of GFP expression in TC32 cells 
infected at this MOI was higher than in the other cell lines (median fluorescence= 43±1) 
(Figure 3.1 B). This may be important when interpreting future experiments as the reporter 
plasmid may also be expressed at higher levels in TC32 cells. 
  
 
 
 
 
 
 
 
 
 
 
Figure ‎3.2 Infection of ESFT cell lines with lentiviral GFP plasmid ESFT cell lines were infected with pLV-Green lentiviral plasmid using the LentiSmart kit 
(Invivogen). MOIs of 0.06-2 were used to infect the cells for 4h. After 72h the cells were trypsinised, fixed with 1% PFA and analysed by flow cytometry.  
A) The percentage of GFP positive cells and B) the level of GFP expression (median fluorescence) achieved by different MOI’s. Results show the mean of 
two independent experiments with three replicates per experiment (n=6) (±SEM) C) Representative images of GFP expression in A673, RD-ES and TC32 
cells, 72h after infection using an MOI of 2,  visualised using a fluorescent microscope. MOI= multiplicity of infection.
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3.3.1.3 Optimising measurement of canonical Wnt signalling activity using 7TGP 
and 7TFP reporter plasmids 
3.3.1.3.1 Confirming the activity and stability of the 7TGP and 7TFP reporter plasmids 
The activity of both the 7TGP (GFP) and 7TFP (firefly luciferase) reporter plasmids was 
initially tested in HEK293T cells which have been demonstrated to have active canonical 
Wnt signalling (Veeman et al. 2003).   
In HEK293T 7TGP cells, cells expressing GFP could be detected (Figure 3.3 A and B). In 
control (untreated) cells the percentage of cells expressing GFP was 4±0.1%, and these 
cells had a median GFP fluorescence of 14.7±0.03. This demonstrates that the 7TGP 
reporter construct can detect endogenous Wnt signalling in cell lines. When the HEK293T 
7TGP cells were treated with the canonical Wnt ligand Wnt3A (200ng/ml, 24h) both the 
percentage of GFP positive cells (43±2%, p<0.001) and the median fluorescence (43.5±6, 
p<0.05) significantly increased; indicating that treatment with Wnt3A protein stimulates 
canonical Wnt signalling, as measured using the 7TGP reporter. When GFP expression was 
examined in HEK293T 7TGP cells after the cells had been in culture for 3 months (Nov 
2012) there was no significant difference in the results obtained initially (Aug 2012), 
demonstrating the stability of expression of the 7TGP reporter in selected cell lines. 
In HEK293T cells transduced with the luciferase reporter (HEK293T 7TFP), luciferase 
activity could be detected in control (untreated) cells (8.5±0.1 x106 RLU), and this 
significantly (p<0.0001) increased after treatment with Wnt3A (200ng/ml, 24h) (223.5 ±1.7 
x106 RLU) (Figure 3.3 C). This demonstrates that the 7TFP vector can also detect 
endogenous canonical Wnt signalling in cell lines, and the stimulation of canonical Wnt 
signalling. Again, when the luciferase activity was examined in HEK293T 7TFP cells after 4 
months of culture (Feb 2013) the luciferase activity was not significantly different than 
when first recorded (Oct 2012), indicating the vector expression is stable in cells (Figure 3.3 
C) 
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Figure ‎3.3 Activation and stability of 7TGP and 7TFP plasmids in HEK293T cells HEK293T 
7TGP or HEK293T 7TFH  cells were seeded into 24 well plates and the next day 
cultured in media alone (untreated control) or 200ng/ml Wnt3A. After 24h, 7TGP 
cells were harvested by trypsinisation, fixed in 1% PFA and analysed by flow 
cytometry to determine A) the percentage of GFP positive cells and B) level of GFP 
expression (median fluorescence). After 24h, 7TFP cells were C) assayed for 
luciferase activity using the luciferase assay (Section 3.2.5). Results show the mean 
of two independent experiments at each time point, with 3 replicates per 
experiment (n=6) (±SEM). FFLuc = firefly luciferase. RLU = relative light units. 
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3.3.1.3.2 Optimising stimulation of canonical Wnt signalling in 7TGP cells with Wnt3A 
conditioned media 
Conditions for stimulating cells transduced with the 7TGP vector were optimised using 
HEK293T cells (positive control) and the SKES-1 ESFT cell line. Endogenous canonical Wnt 
signalling activity was detected in both cell lines at low levels; median GFP fluorescence 
was 14.7±0.03 in HEK293T 7TGP cells and 13±0.8 in SKES-1 7TGP cells (Figure 3.4 A). 
However, only a small percentage of cells expressed GFP in both HEK293T 7TGP (4±0.1%), 
and SKES-1 7TGP (0.15±0.04%) cells (Figure 3.4 B). 
As previously discussed, Wnt3A conditioned media is commonly used to stimulate the 
canonical Wnt signalling pathway. There was no increase in activity of the GFP reporter, or 
number of cells expressing GFP, after stimulation with L-cell (control) or L-Wnt5A 
conditioned media (CM) in either HEK293T 7TGP or SKES-1 7TGP cells (Figure 3.4 A and B). 
However, consistent with activation of the canonical Wnt signalling pathway, after the 
addition of L-Wnt3A CM, HEK293T 7TGP cells had increased GFP expression, as early as 4h 
after treatment (median GFP fluorescence; 25.8±0.29). Maximum GFP expression was 
observed after 24h (median GFP fluorescence; 109±13), this was a 7.4-fold increase 
compared to untreated cells. In HEK 293T 7TGP cells the percentage of cells expressing GFP 
increased after 8h treatment with L-Wnt3A CM (10.7±1.5%) and continued to increase 
over time until 72±1.5% of cells expressed GFP at 48h.  The activation of GFP expression 
was 3-fold less in SKES-1 7TGP cells, compared to that observed in HEK293T 7TGP cells.  In 
SKES-1 7TGP cells, both the maximum GFP expression level  (median fluorescence; 31±0.8) 
and percentage of cells with GFP expression (54±2.5%) was observed after 48h treatment 
with L-Wnt3A CM (Figure 3.4 A and B). 
In both HEK293T 7TGP and SKES-1 7TGP cell lines the viable cell number was reduced 
when cells were grown for more than 20h in L-cell CM compared to growth of control cells 
cultured in normal cell-type specific media (Figure 3.4 C). The viable cell number of SKES-1 
7TGP cells was reduced to 60±4.6% when grown in L-cell control CM, 72±4.6% in L-Wnt5A 
CM and decreased in a time-dependent manner with culture in L-Wnt3A CM to 33±0.7% 
after 48h. The viable cell growth of HEK293T 7TGP cells was reduced to a lesser extent; 
decreasing to 51±0.9% compared to that of control cells after 48h culture in L-Wnt3A CM 
(Figure 3.2 C) 
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Figure ‎3.4 Stimulation of 7TGP cell lines with L-cell conditioned media HEK293T 7TGP and 
SKES-1 7TGP cell lines were cultured in normal cell-specific media (control) or in L-
cell conditioned media or L-Wnt5A conditioned media for 24h or L-Wnt3A 
conditioned media for increasing periods of time. Cells were harvested, fixed with 
1% PFA and analysed by flow cytometry to determine A) median fluorescence of 
GFP+ cells and B) percentage of GFP+ cells. Inset shows a magnified view of the first 
9 conditions. C) Identically treated cells were harvested for analysis of viable cell 
number by trypan blue exclusion using the vi-cell automated cell counter. 
CM=conditioned media. Results presented from one experiment with three replicate 
wells (n=3) showing the mean (±SEM). 
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3.3.1.3.3  Viable cell number of ESFT cell lines cultured in L-cell conditioned media 
Culture of cells in L-cell CM reduced the viable cell number of SKES-1 7TGP cells (Section 
3.3.1.3.1), therefore the effect of L-cell CM on the growth of other ESFT cell lines was 
investigated. All ESFT cell lines and HEK293T cells had significantly reduced viable cell 
number when cultured in all three types of L-cell CM for 48h, compared to cell-type 
specific media (p<0.0001) (Figure 3.5 A and B). When ESFT cell lines were cultured in L-cell 
control media for 48h, all cell lines had less than 60% viable number compared to control 
cells (Figure 3.5, red bars). Viable cell number was reduced the least in TTC466 (56±3%) 
and the most in TC32 cells (23±2%). With the exception of TC32 cells, the decrease in 
viable cell number was greatest when cells were cultured in L-Wnt3A CM compared to L-
cell control CM (Figure 3.5 B). This decrease was significant in A673 and RD-ES cell lines 
(p<0.05).   
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎3.5 Growth of ESFT cell lines in L-cell conditioned media ESFT cell lines and 
HEK293T cells were cultured in normal, cell-type specific media (control), L-cell CM, 
L-Wnt5A CM or L-Wnt3A CM for A) 24h and B) 48h. Viable cell number was 
determined by trypan blue exclusion using the vi-cell automated cell counter. Results 
show mean of two independent experiments with three replicates per experiment 
(n=6) (±SEM).  
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3.3.1.3.4 Optimising stimulation of canonical Wnt signalling in 7TGP and 7TFP cells with 
recombinant Wnt3A protein. 
L-Wnt3A CM was shown to reduce the viable cell number of ESFT cells (Section 3.3.1.3.3). 
Therefore I investigated the possibility of using recombinant (r) Wnt3A protein (5036-
WN/CF, R&D) as an alternative method to stimulate the canonical Wnt signalling pathway 
but without reducing viable cell number.  HEK293T 7TGP cells showed a dose-dependent 
increase in GFP reporter activation after 24h treatment with rWnt3A (Figure 3.6 A and B). 
Maximum GFP expression was observed following treatment with 500ng/ml rWnt3A 
(median fluorescence; 103±1). However, this was 63% less than the expression observed 
after treatment with L-Wnt3A conditioned media for the same period of time (median 
fluorescence; 164 ±7) (Figure 3.6 A). When treated with rWnt3A (500ng/ml) 41±1% of 
HEK293T 7TGP cells expressed GFP after 24h, although this was again less than the 
percentage of cells expressing GFP after L-Wnt3A CM treatment (58±0.6%). Importantly, 
however the viable cell number of HEK293T 7TGP cells did not decrease when cells were 
cultured in 500ng/ml rWnt3A; this compares to a reduction of viable cell number  of 
25±3% when HEK293T 7TGP cells were grown in L-Wnt3A CM compared to DMEM (normal 
media) (Figure 3.6 C). 
When HEK293T 7TGP cells were  treated with rWnt3A (200ng/ml) or L-Wnt3A CM over a 
time course, maximum activation of the GFP reporter was observed after 24h of treatment 
(Figure 3.7 B). The activation observed after stimulation with rWnt3A was significantly less 
than the stimulation observed with L-Wnt3A CM (p<0.01, median fluorescence; 51±2 and 
109±13, respectively).  
HEK293T cells transduced with the luciferase reporter 7TFP (HEK293T 7TFP) were also 
maximally activated after 24h treatment with rWnt3A (200ng/ml) or L-Wnt3A CM (Figure 
3.7 C). Again, stimulation was significantly greater after treatment with L-Wnt3A CM rather 
than rWnt3A (p<0.01, 223 x105 compared to 283 x105 relative light units (RLU)). However 
the fold difference in activation between 7TFP cells treated with rWnt3A and L-Wnt3A CM 
was only 1.3-fold, this was significantly less(p<0.05) than the observed difference using the 
7TGP reporter (2.7-fold). 
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Figure ‎3.6 Stimulation of HEK293T 7TGP cells with L-cell CM  and recombinant Wnt3A 
protein HEK293T 7TGP cells were treated with L-cell CM, L-Wnt3A CM or increasing 
concentrations of recombinant Wnt3A protein (50-500ng/ml) for 24h. Cells were 
harvested, fixed with 1% PFA and GFP expression analysed using flow cytometry to 
determine A) median GFP fluorescence and B) percentage of GFP+ cells. C) 
Identically treated cells were harvested for analysis of viable cell number by trypan 
blue exclusion using the vi-cell automated cell counter and presented as percentage 
of HEK293T 7TGP control cells cultured in DMEM. Results show the mean of two 
independent experiments with three replicates per experiment (n=6) (±SEM). CM= 
conditioned media, r= recombinant. 
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Figure ‎3.7 Activation of GFP and luciferase reporter plasmids in HEK293T cells after 
treatment with L-Wnt3A CM and recombinant Wnt3A protein A) Schematic 
diagram of the 7TGP and 7TFP plasmids. Adapted from Fuerer et al., (2010). B) 
HEK293T 7TGP and C) HEK293T 7TFP cells were cultured  for 24h in normal media 
(control) or  in L-cell CM,  L-Wnt5A  CM or  for increasing lengths of time (2h-48h)  in 
Wnt3A (either  L-Wnt3A CM or rWnt3A (200ng/ml)). For HEK293T 7TGP cells GFP 
activation was analysed by harvesting cells, fixing in 1% PFA and the median 
fluorescence increase from parental cells quantified by flow cytometry. For HEK 293T 
7TFH cells luciferase activity was measured using the Luciferase Assay (Section 
3.2.5). Results are shown as the mean of two independent experiments with three 
replicates per experiment (n=9) (±SEM). CM= conditioned media, r= recombinant, 
FFluc= firefly luciferase. RLU= relative light units, PuroR= puromycin resistance.   
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3.3.1.3.5 Quantification of Wnt3A protein in L-Wnt3A conditioned media 
In both HEK293T 7TGP and HEK293T 7TFP cells, activation of canonical Wnt signalling was 
greater in response to L-Wnt3A conditioned media than in response to Wnt3A 
recombinant protein (Section 3.3.1.3.4). To investigate this observation further, the 
concentration of Wnt3A in the L-Wnt3A CM was quantified by western blot. The 
conditioned media used in previous experiments to treat cells consisted of media collected 
from L-Wnt3A cells after 4 and 7 days of culture, which was pooled and filtered through a 
0.2µm membrane.  The effect of pooling and filtering was therefore also investigated. 
A band corresponding to Wnt3A (approximately 37 kDa) could be detected in L-Wnt3A CM 
but not L-cell control CM (Figure 3.8 A). Densitometry was performed and a concentration 
curve generated from the rWnt3A samples which was used to estimate the concentration 
of Wnt3A in the L-Wnt3A CM samples (Figure 3.8 B). Analysis showed that CM collected 
from L-Wnt3A cells after 4 days of culture had the lowest concentration of Wnt3A 
(534ng/ml), the concentration of Wnt3A was increased to 642ng/ml in CM collected after  
7 days of culture. Pooling media collected at day 4 and day 7 did not increase the 
concentration of Wnt3A (641ng/ml) compared to using only media collected at day 7. 
Sterile filtering the CM through a 0.2µm membrane resulted in 9% of the Wnt3A protein 
being lost on the filter; the Wnt3A concentration was reduced from 642ng/ml to 587ng/ml. 
The concentration of the L-Wnt3A CM used in previous experiments (Day4 + 7, filtered) 
was estimated to contain 587ng/ml of Wnt5A protein, a much higher concentration than 
the concentration of rWnt3A used (200ng/ml), which explains why the conditioned media 
have a greater effect than the recombinant protein. 
The rWnt3A bands observed at 37 kDa correspond to the predicted molecular weight of 
Wnt3A. However, the Wnt3A protein in the L-Wnt3A CM was approximately 41.5 kDa 
(Figure 3.8 A). This may reflect post transcriptional modifications of the protein and could 
also contribute to the greater stimulatory effect of L-Wnt3A CM. 
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Figure ‎3.8 Quantifying the concentration of Wnt3A in L-Wnt3A CM L-Wnt3A cells were 
seeded into 10cm2 dishes and media collected after 4 and 7 days. Media was pooled 
and filtered through a 0.2µm Aerodisc® filter (PALL Life Sciences) as appropriate. L-
cell CM was used as a negative control. A) For quantification, 20μl of each sample of 
collected CM and increasing concentrations of recombinant Wnt3A protein were 
analysed by western blot to determine the concentration of Wnt3A. Densitometry 
was performed and B) a standard curve generated from the values of known 
concentrations of recombinant protein. The concentration of Wnt3A in the L-Wnt3A 
CM samples was determined from the standard curve. MW= molecular weight.  
  
  Day 4 Day 7 Day 4+7 
filtered 
Day 4+7 not 
filtered  
Densitometry of sample 0.55 1.91 1.21 1.9 
Concentration (in 20µl) 10.7 12.8 11.7 12.8 
Concentration/ml 533.8 642.3 586.5 641.5 
(A) 
 
(A) 
(B) 
 
(B) 
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3.3.2 Measuring the activity of the canonical Wnt signalling pathway in 
ESFT cell lines 
3.3.2.1 7TGP reporter activity in ESFT cell lines 
In ESFT cell lines transduced with the  7TGP reporter plasmid,  endogenous activity of the 
canonical Wnt signalling pathway was detected in RD-ES (fold change from parental cells; 
1.3±0.03) and SK-N-MC cells (fold change; 1.2±0.03). The activity of the pathway was low 
compared to HEK293T 7TGP cells (fold change; 1.9±0.07) (Figure 3.9 A, Parental vs. 7TGP 
Control). Treatment with rWnt3A (200ng/ml, 24h) significantly increased GFP reporter 
expression in all the ESFT cell lines, except TC32 and TTC466 (p<0.05). Activation was 
greatest in SK-N-MC cells (3±0.4-fold) and lowest in TTC466 cells (1.3±0.07-fold). The 
fluorescence plots generated reveal that even after treatment with Wnt3A, there is a 
population of cells that do not fluoresce consistent with heterogeneous activity of 
canonical Wnt signalling; some cells with high GFP expression and others with medium, 
low and no GFP expression. Treatment with recombinant noncanonical ligand Wnt5A 
(200ng/ml, 24h) did not increase GFP reporter activity in any cell line, confirming the 
specificity of the reporter to detect canonical Wnt signalling activation. 
In all ESFT cell lines, less than 1% of cells had endogenous activity of the GFP reporter, and 
this was not increased with rWnt5A treatment (Figure 3.9 B). However, after treatment 
with rWnt3A (200ng/ml, 24h), the percentage of cells expressing GFP was significantly 
increased in all cell lines (p<0.05). After treatment with rWnt3A, the percentage of cells 
with GFP expression was significantly higher in SK-N-MC (p<0.05, 37±2%) and was 
significantly lower in TC32 (11±2%) and TTC466 (7±0.2%) (p<0.05) cells, compared to the 
other ESFT cell lines, consistent with heterogeneous effects of Wnt3A. 
  
- 101 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎3.9 GFP reporter activation in ESFT cell lines ESFT-7TGP and HEK293T-7TGP 
(positive control) cell lines were treated with rWnt5A (200ng/ml) or rWnt3A 
(200ng/ml) for 24h. Cells were harvested, fixed in 1% PFA and GFP reporter 
expression analysed by flow cytometry to determine A) median fluorescence and B) 
percentage cells with GFP expression. Inset shows magnified view of parental, 
control cells and cells treated with Wnt5A. Data is presented relative to the parental 
cell line without 7TGP reporter present. Results show the mean of three 
independent experiments with three replicates per experiment analysing 10,000 
events per sample (n=9) (±SEM) C) Representative fluorescence plots for A673, SK-N-
MC and TTC466 cell lines showing parental cells, 7TGP control cells and 7TGP cells 
after treatment with rWnt3A (200ng/ml, 24h). The M1 region designated negative 
events and M2 region positive events.   
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3.3.2.2 7TFP reporter activity in ESFT cell lines 
Endogenous reporter activity was detected in all ESFT cells transduced with the 7TFP 
plasmid (Figure 3.10 A, Parental vs. 7TFP Control). This is in contrast to ESFT cells 
transduced with the 7TGP plasmid where endogenous GFP expression could only be 
detected in RD-ES and SK-N-MC cell lines, and demonstrates the increased sensitivity of 
the firefly luciferase reporter. Relative to the parental cell lines with no 7TFP reporter 
present, endogenous luciferase activity appeared heterogeneous between ESFT cell lines; 
lowest in SKES-1 (217±24-fold) and highest in A673 (793±20-fold). However, the 
endogenous activity could not be compared statistically as a viable cell count was not 
performed, meaning there may have been variation in the number of cells assayed 
between cell lines.  Treatment with rWnt5A (200ng/ml, 24h) did not increase the luciferase 
activity in any ESFT cell line, consistent with the results observed using the GFP reporter. 
However, treatment with rWnt3A (200ng/ml, 24h) significantly increased the luciferase 
reporter activity in all cell lines (p<0.05) (Figure 3.10 A). When compared to the level of 
endogenous reporter activity within each cell line, the increase in luciferase reporter 
activity was heterogeneous between the cell lines (Figure 3.10 B). Significantly greater 
stimulation following treatment with Wnt3A was observed in RD-ES (188±14-fold), SKES-1 
(167±25-fold) and SK-N-MC (176±24-fold) cell lines (p<0.01). 
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Figure ‎3.10 Firefly luciferase reporter activation in ESFT cell lines ESFT-7TFP and HEK293T-
7TFP (positive control) cell lines were treated with rWnt5A (200ng/ml) or rWnt3A 
(200ng/ml) for 24h. Luciferase activity was determined using the Luciferase Assay 
(Section 3.2.5). A) Luciferase activity relative to the parental cell line with no 7TFP 
plasmid present presented as Log RLU B) Fold increase in luciferase reporter after 
Wnt treatment relative to 7TFP control (untreated) cells. Inset shows magnified view 
of control and Wnt5A treated cells. Results presented as the mean of three 
independent experiments with three replicates per experiment (n=9) (±SEM).   
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3.3.3 Effect of recombinant Wnt3A and Wnt5A on the viable cell number 
of ESFT cell lines. 
To confirm that the increase in GFP and luciferase reporter activity observed with rWnt3A 
treatment was not simply due to an increase in the number of viable cells, growth curves 
were carried out with ESFT cell lines in the presence of rWnt5A (200ng/ml) and rWnt3A 
(200ng/ml). Treatment with either Wnt3A or Wnt5A for up to 72h had no significant effect 
on the viable cell number of any ESFT cell line (Figure 3.11 A-F). 
Figure ‎3.11 ESFT viable cell number after treatment with Wnt3A and Wnt5A ESFT cell 
lines were seeded into 24 well plates and allowed to adhere for 24 h. Cells were 
treated with 200ng/ml rWnt3A or 200ng/ml rWnt5A for 24, 48, or 72h. Viable cell 
number was determined by trypan blue exclusion using the Vi-cell automated cell 
counter. Results are shown as the mean of two independent experiments with three 
replicates per experiment (± SEM).   
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3.3.4 Confirmation of downstream activation of the canonical Wnt 
signalling pathway 
3.3.4.1 Optimising conditions to detect increase in total and active β-catenin 
after treatment with Wnt3A 
To confirm that canonical Wnt signalling was activated by Wnt3A, I measured the levels of 
both total and active β-catenin in treated cells by western blot. An increase in intracellular 
β-catenin is known to be a downstream consequence of active canonical Wnt signalling 
(Gujral, 2010, Hernandez, 2012). Endogenous expression of both total and active 
(nonphosphorylated) β-catenin was detected in HEK293T cells after treatment with 
rWnt3A (200ng/ml) (Figure 3.12 A). The level of both active and total β-catenin was 
increased after 30 min (Figure 3.12 A and B). Densitometry revealed that the peak increase 
in both active and total β-catenin was observed after 4h treatment with rWnt3A; there was 
a 6-fold increase in both active (6±0.3) and total (6±0.2) β-catenin. The level of both active 
(4±0.3-fold) and total (2±0.2-fold) β-catenin remained elevated in HEK293T cells with up to 
24h treatment with Wnt3A. 
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Figure ‎3.12 Downstream activation of canonical Wnt signalling in HEK293T cells following 
treatment with Wnt3A HEK293T cells were seeded into 6 well plates and allowed to 
adhere overnight. Cells were maintained in normal media (control) or treated with 
200ng/ml Wnt3A for increasing lengths of time (15 min-24h). A) Total protein was 
extracted and expression of total and nonphosphorylated (active) β-catenin analysed 
by western blot. Expression of β-actin was used as a loading control. Representative 
of two independent repeats. B) Bands were quantified by densitometry and total 
and active β-catenin expression levels calculated as ratios compared to β-actin 
expression. Results presented as the mean of two independent experiments (±SEM). 
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(B) 
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3.3.4.2 Level of total and active β-catenin in ESFT cells after Wnt3A treatment 
The expression levels of both total and active β-catenin were investigated by western blot 
in ESFT cells after treatment with Wnt3A (200ng/ml, 4 h). In addition, expression of cyclin 
D1 was examined as it is a reported downstream target of canonical Wnt signalling 
(Shtutman et al. 1999). The level of both total and active β-catenin was increased in 
HEK293T cells after treatment with Wnt3A, however the 2-fold increase was less than the 
6-fold increase observed in previous experiments  (Section 3.3.4.1) (Figure 3.13 A,B and C). 
In ESFT cell lines, an increase in total β-catenin was detected in RD-ES (3.5-fold) and SKES-1 
(2.5-fold) following treatment with Wnt3A, but not in the other cells lines (Figure 3.13 A 
and B). In some cell lines for example A673 and TTC466 there was a decrease in total β-
catenin after treatment with Wnt3A. In SK-N-MC cells, total β-catenin levels were 
increased (1.6-fold) after treatment with Wnt5A (200ng/ml, 4h).  An increase in active β-
catenin was only observed in SKES-1 cells (1.3-fold) (Figure 3.13 A and C). A slight increase 
in cyclin D1 expression was detected in RD-ES (1.2-fold), SKES-1 (1.3-fold) and  SK-N-MC 
(1.7-fold) cells after treatment with rWnt3A, however an increase in cyclin D1 expression 
was also detected after treatment with rWnt5A in A673 (2-fold) and TC32 (1.2-fold) (Figure 
3.13 A and D). 
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Figure ‎3.13 Downstream activation of canonical Wnt signalling in ESFT cells after 
treatment with Wnt3A ESFT and HEK293T (positive control) cells were seeded into 6 
well plates. After 24h cells were maintained in normal media (control) or treated 
with rWnt3A (200ng/ml) or rWnt5A (200ng/ml) for 4h.  A) Total protein was 
extracted and expression of total and nonphosphorylated (active) β-catenin, and 
cyclinD1 analysed by western blot. Expression of β-actin was used as a loading 
control. Bands were quantified by densitometry and expression of B) Total β-catenin 
calculated as the ratio compared to β-actin expression C) Active β-catenin calculated 
as the ratio compared to total β-catenin expression and D) CycinD1 calculated as the 
ratio compared to β-actin expression.  
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3.4 Discussion 
In this chapter I have optimised and validated an assay to measure the functional activity 
of canonical Wnt signalling using a lentiviral luciferase reporter system. Using this assay, 
endogenous Wnt signalling activity was detected in all ESFT cell lines. This is in 
concordance with research which was published during the course of the current study, 
which also demonstrated endogenous canonical Wnt signalling in the CHLA25 ESFT cell line 
using the 7TFP reporter plasmid (Scannell et al. 2013). These data are in contrast to 
previous studies in ESFT cells where no or extremely low basal canonical Wnt signalling 
could be detected, and was not stimulated following treatment with Wnt3A (Hu-Lieskovan 
et al. 2005, Navarro et al. 2010, Vijayakumar et al. 2011). These differences most probably 
reflect the use of the less sensitive TOPFlash reporter assay, rather than the luciferase 
based assay system I have used in my studies.   
Consistent with previous studies, ESFT cell lines were successfully infected with lentiviral 
vectors (McKinsey et al. 2011, Iida et al. 2013). The infection rate of lentiviral particles in 
TC32 cells was greater than in the other ESFT cell lines.  The lentiviral vectors used were 
pseudotyped with the VSV-G envelope protein which has been shown to increase the 
infection capabilities of lentiviruses to almost all mammalian cells, including nondividing 
and difficult to infect cells (Akkina et al. 1996, Naldini et al. 1996).  It has recently been 
shown that low-density lipoprotein receptor (LDLR) is the main receptor for VSV, and 
therefore the entry method of VSV-G pseudotyped lentiviral vectors into cells (Finkelshtein 
et al. 2013). Although LDLRs are ubiquitously expressed in all human cells, the level of 
expression may be heterogeneous, and upregulation of LDLR has been reported in 
colorectal cancer (Lum et al. 1999). Therefore, ESFT cell lines may have differential 
expression of the LDLR which may explain the differences observed in infection rates.  To 
compensate for this observation, TC32 cells were infected using a lower MOI than the 
other cell lines. However this still resulted in greater median GFP expression level in these 
cells after infection with the pLV-Green plasmid. The consequences of this observation 
may be important as expression of the reporter plasmids may also be higher in TC32 cells, 
resulting in a falsely high estimation of canonical Wnt signalling. That said, endogenous 
canonical Wnt signalling activity measured using the 7TGP and 7TFH reporter plasmids was 
low in TC32 cells compared to the other ESFT cell lines.  
To activate the canonical Wnt signalling pathway in cells and to confirm the specificity of 
the reporter system, treatment with the canonical Wnt ligand Wnt3A is commonly used. In 
this study, the activation of canonical Wnt signalling was measured using the 7TGP and 
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7TFP plasmids in response to both conditioned media from L-cells overexpressing Wnt3A 
and recombinant Wnt3A protein. An important observation was that the viable cell 
number of all ESFT cell lines was reduced when cells were grown in L-cell conditioned 
media. One possible explanation for this reduced cell viability could be that the 
conditioned media used was DMEM (+10% FCS) and 5 out of 6 of the ESFT cell lines are not 
normally cultured in this media. However, this cannot be the only explanation since A673 
cells are routinely cultured in DMEM (+10% FCS) and yet treatment with L-cell conditioned 
media also significantly reduced viable cell number. A further consideration is the fact that 
the conditioned media is collected from L-cells after 4 and 7 days in culture (and 
subsequently pooled together), and so could have been partially expended and was 
therefore not optimal for culturing cells in the long time course experiments. Viable cell 
number was reduced when cells were grown in L-cell (control) and L-Wnt5A conditioned 
media and furthermore, viable cell number was not reduced in ESFT cell lines cultured in 
the presence of recombinant Wnt3A protein. This suggests that the decrease in viable cell 
number is not due to the Wnt3A protein. That said, some cell lines including A673 and RD-
ES cells had significantly lower viable cell number after 48h when treated with L-Wnt3A 
conditioned media compared to when cultured in L-cell control CM. This suggests that 
Wnt3A may be having an effect on the viable cell number of some cell lines. Since 
activation of the canonical Wnt signalling pathway by overexpression of Wnt3A can lead to 
upregulation of other proteins, L-Wnt3A CM also contains other secreted factors (Willert 
et al. 2003). For example, members of the fibroblast growth factor (FGF) family including 
FGF4 (Kratochwil et al. 2002) and FGF9 (Hendrix et al. 2006) have been shown to be 
induced by canonical Wnt signalling. This is potentially important as another FGF family 
member FGF2, has been shown to induce cell death in ESFT cell lines (Westwood et al. 
2002). It would therefore be useful to carry out a protein profile on L-Wnt3A conditioned 
media to elucidate what else is secreted by these cells. However, taken together my data 
suggest that conditioned media is not suitable for treating ESFT cell lines, as any change in 
canonical Wnt signalling may be due to a stress response in cells being cultured in 
conditions which they do not tolerate or by contaminating factors within the conditioned 
media and not necessarily Wnt3A itself. 
In HEK293T cells transduced with both 7TGP and 7TFP reporter plasmids, canonical Wnt 
signalling was activated to a greater extent by L-Wnt3A conditioned media than 
recombinant Wnt3A protein. This is perhaps surprising as the concentration of Wnt3A in 
the conditioned media has been previously reported to be 200ng/ml (Willert et al. 2003).  
This is the concentration of recombinant protein used in this study, and increasing the 
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concentration to 500ng/ml did not increase the activation of canonical Wnt signalling in 
HEK293T 7TGP cells, to that observed after treatment with L-Wnt3A conditioned media. 
However, I found that the concentration of Wnt3A in L-Wnt3A conditioned media was 
almost 600ng/ml, which may explain the differences observed. This could be confirmed by 
directly comparing the activity of the canonical Wnt signalling pathway when cells are 
stimulated with 200ng/ml recombinant Wnt3A and L-Wnt3A conditioned media that had 
been diluted to an equivalent concentration. In addition, the Wnt3A detected in 
conditioned media had a higher molecular weight than the recombinant Wnt3A protein. 
Wnt3A is known to be glycosylated and acylated. In particular, the palmitic acid attached 
to cysteine 77 has been shown to be critical for the activity of Wnt3A (Willert et al. 2003). 
Therefore, it is possible that recombinant Wnt3A lacks this post-transcriptional 
modification and this could also explain the differences in activity observed. Finally, as 
previously mentioned, overexpression of Wnt3A is known to lead to upregulation of 
factors downstream of canonical Wnt signalling such as FGF proteins, therefore it is 
possible that some of these factors may also additionally activate canonical Wnt signalling 
after treatment with L-Wnt3A CM.  
In ESFT cells, using the 7TGP (GFP) reporter plasmid, endogenous Wnt signalling could only 
be detected in RD-ES and SK-N-MC cell lines, whereas using the 7TFP (luciferase) reporter 
endogenous activity was measured in all cell lines. These data demonstrate that firefly 
luciferase is a more sensitive reporter gene than GFP. This is in agreement with current 
literature indicating that luciferase reporter genes can deliver 10- to 1000-fold higher assay 
sensitivity than GFP (Vidugiriene et al. 2008). Fluorescent reporters such as GFP rely on 
photons of light to excite the sample and the emission of photons is detected. 
Fluorometers cannot precisely distinguish between the photon influx and photon emission, 
meaning there will inherently be low background levels of fluorescence when using GFP 
reporters, which makes detecting very small changes extremely difficult. In addition, 
although GFP is not endogenously expressed in mammalian cells, cellular metabolites such 
as flavins may fluoresce resulting in autofluorescence, which can limit the specificity of the 
GFP reporter assay. Indeed, autofluorescence was detected in all parental ESFT cell lines 
that had not been transduced with the 7TGP reporter, limiting the sensitivity of the assay. 
In contrast, the luciferase assay chemistry is based on an exothermic chemical reaction 
whereby beetle luciferase is oxidised to oxyluciferin by firfely luciferase, which produces 
light. As luciferase is not expressed in mammalian cells there is no background and the 
assay is very specific. In addition, current assay technologies mean that less than 10,000 
molecules per sample can be detected, this allows for a large dynamic range with changes 
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in light production across four to eight orders of magnitude  detected in the linear range of 
the assay (Fan and Wood 2007).  Another important consideration is the fact that GFP has 
a longer half-life (around 26h) compared to luciferase (3-4 h) meaning a GFP reporter is 
less able to detect dynamic changes in Wnt signalling (Vidugiriene et al. 2008). However, 
the disadvantage of using a luciferase reporter is that it is not possible to examine the 
expression in individual cells, therefore differences in canonical Wnt signalling in sub-
populations of cells could not be investigated. Since less than 1% of ESFT cells had 
endogenous canonical Wnt signalling activity detected using the 7TGP reporter this is a 
limitation. 
Using both reporter plasmids the activity of the canonical Wnt signalling pathway was 
significantly increased in all ESFT cell lines after treatment with recombinant Wnt3A. This is 
in contrast to a previous study which reported that canonical Wnt signalling could not be 
stimulated in ESFT cell lines (Navarro et al. 2010). It has been reported that this was 
because the EWS-FLI1 protein represses canonical Wnt signalling by interacting with β-
catenin/TCF complexes. My data suggest this is not the case and this will be further 
investigated in Chapter 6.  In both 7TGP and 7TFP transduced cells, the response to Wnt3A 
was greatest in RD-ES, SKES-1 and SK-N-MC cell lines and lowest in A673 and TTC466 cell 
lines (summarised in Table 3.1). This is not consistent with the pattern of active 
(nonphosphorylated) β-catenin previously observed (in Chapter 2) which was similar 
between ESFT cell lines, but highest in TC32 cells. High expression of nuclear β-catenin was 
also detected in A673 and TTC466 cell lines, demonstrating the weaknesses of investigating 
β-catenin expression and localisation as markers for the activity of the canonical Wnt 
signalling pathway.  In 7TGP transduced cells, the percentage of GFP expressing cells was 
also significantly increased in all ESFT cells after the addition of recombinant Wnt3A. 
However the maximum positivity observed was only 37% (in SK-N-MC cells) and GFP 
expression was only observed in a maximum of 7% of TTC466 cells. In ESFT cell lines the 
fluorescent plots revealed a peak of negative cells with wide tail, consistent with 
heterogeneous expression of GFP, some cells with high expression and others with median 
or low expression. The fact that not all cells had GFP expression may reflect the lack of 
sensitivity of the GFP reporter or indicate that some ESFT cells within cell lines are not 
capable of activating Wnt signalling. This could be due to the expression levels of activator 
and/or inhibitor proteins. For example, canonical Wnt signalling was increased the most in 
SK-N-MC and SKES-1 cell lines following treatment with Wnt3A, and these cell lines had 
lower expression of the FRZB inhibitor and higher expression of the activators LEF1 and 
Wnt10A (in Chapter 2). 
 Cell Line 
Predicated Canonical 
or noncanonical 
(based on Wnt ligand 
expression) 
Active  β-catenin 
expression (ratio to 
total β-catenin) 
GFP reporter Luciferase reporter 
Endogenous activity 
(median 
fluorescence/% 
positive cells) 
Response to Wnt3A 
(fold increase in 
fluorescence/% 
positive cells) 
Endogenous 
activity 
(Luminescence) 
Response to Wnt3A 
(fold increase in 
luminescence) 
A673 Canonical 0.28 
0.94/0.4 1.63/19 Highest  792.93 32.83 
RD-ES Noncanonical 0.27 
Highest  1.30/0.2 2.42/27 668.79 Highest  187.71 
SKES-1 Noncanonical Lowest 0.22 
1.12/0.1 2.55/29 Lowest  217.03 Highest  166.67 
SK-N-
MC 
Canonical 0.32 
1.23/0.7  Highest 3.94/37 562.86 Highest  176.15 
TC32 Noncanonical? Highest 0.39 
1.06/0.2 1.95/12 365.23 92.48 
TTC466 Both? 0.27 
Lowest 0.85/0.2  Lowest 1.36/7 327.97  Lowest  24.21 
 
Table ‎3.1 Summary of results of assays used to measure canonical Wnt signalling in ESFT cell lines  ESFT cell lines were predicted to be either canonical or 
noncanonical based on expression of Wnt1 and Wnt5A (Chapter 2). Expression of active β-catenin was measured by western blot in Chapter 2. 
Endogenous activity of canonical Wnt signalling in ESFT cell lines was measured using both GFP and firefly luciferase reporters. Canonical Wnt signalling 
was stimulated by adding 200ng/ml recombinant Wnt3A for 24h. 
-1
1
3
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Recombinant Wnt5A had no effect on activity of either reporter, showing that the assay is 
specifically detecting canonical Wnt signalling. Previous studies have suggested Wnt5A 
may inhibit canonical Wnt signalling (Mikels and Nusse 2006), however my data does not 
demonstrate this.  It is important to note that although ESFT cell lines respond to 
exogenous Wnt3A they do not express Wnt3A (Chapter 2). However, since all cell lines 
have endogenous active canonical Wnt signalling it is likely that other canonical Wnt 
ligands such as Wnt1 and Wnt10B which are expressed are endogenously activating the 
canonical pathway. In Chapter 2 I predicted that A673 cells may have high endogenous 
canonical Wnt signalling based on the expression of Wnt1 and Wnt5A. Interestingly these 
cells did have the highest level of canonical signalling in untreated cells, measured using 
the more sensitive 7TFP reporter. Interestingly in all cell lines, there was no correlation 
between endogenous canonical signalling activity and stimulation with Wnt3A ligand; 
SKES-1 had the lowest level of canonical Wnt signalling measured by both the 7TGP and 
7TFP reporters, but was stimulated the most by the addition of exogenous Wnt3A 
(summarised in Table 3.1). 
To demonstrate that activation of the GFP and luciferase reporter were truly measuring 
canonical Wnt signalling, I attempted to measure downstream targets of the pathway. It is 
not known what downstream factors are activated following activation of the canonical 
Wnt signalling pathway in ESFT cells. In concordance with previous findings, recombinant 
Wnt3A did not increase the viable cell number of ESFT cells (Üren et al. 2004). This 
observation was supported by the lack of consistent increase of cyclin D1 in ESFT cells after 
treatment with Wnt3A. In HEK293T cells an increase of total and active 
(nonphosphorylated) β-catenin was observed, reaching a maximum at 4h, and remaining 
elevated up to 24h consistent with previous reports (Gujral and MacBeath 2010). However, 
results were less conclusive when active β-catenin was investigated in ESFT cell lines.  It 
may be that the dynamics of β-catenin upregulation is different in ESFT cells, or that 
detection of total and active β-catenin by western blot is not sensitive enough to detect 
small changes in expression. It has been reported that Axin2 is universally upregulated in 
cells following treatment with Wnt3A. Although a specific and sensitive antibody to Axin2 
for use in western blots is not available (unpublished observations), expression of Axin2 
mRNA has been shown to be increased in ESFT cells after treatment with Wnt3A (Scannell 
et al. 2013). Therefore future work could use RTqPCR to detect changes in Axin2, β-catenin 
and possibly other potential downstream targets over a time course after stimulation with 
Wnt3A.  
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Further work to validate the reporters used could involve inhibiting components of the 
Wnt signalling pathway. ESFT cells could be treated with recombinant forms of 
endogenous inhibitors of the pathway such as sFRP2, to show that this also reduces the 
activity of the reporter. A disadvantage of these proteins is that they inhibit both canonical 
and noncanonical Wnt signalling. As an alternative, small molecules have been developed 
which specifically target the interaction between β-catenin and TCF4 such as iCRT 14 
(Gonsalves et al. 2011). Molecules such as this could therefore also be used in ESFT cell 
lines to show that the reporters are specifically measuring canonical Wnt signalling in these 
cells. 
In summary I have optimised a lentiviral based luciferase assay using the 7TFP plasmid to 
measure the activation of canonical Wnt signalling at endogenous levels and after 
treatment with recombinant Wn3A. I have demonstrated that all the ESFT cell lines studied 
have active canonical Wnt signalling, and this can be further stimulated by treatment with 
Wnt3A. The downstream consequences of this activation so far remain elusive, as Wnt 
ligands do not alter the viable cell number of ESFT cells, so further investigation of the 
effect of Wnt signalling in ESFT cells is required. 
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4. Developing assays to measure the activity of the noncanonical 
Wnt signalling pathway in ESFT cells 
4.1 Introduction 
In the previous chapter I optimised an assay which enabled me to investigate the activity of 
the canonical Wnt signalling pathway in ESFT cell lines. The aim of the current chapter is to 
develop assays to measure the activation of the noncanonical Wnt signalling pathway.  
Noncanonical Wnt signalling is the term used to describe any pathway that is activated by 
Wnt proteins but is β-catenin independent. The best described of these are the planar cell 
polarity (PCP) and calcium (Ca2+) pathways. However, the activity of these noncanonical 
Wnt signalling pathways is more difficult to measure. Unlike canonical Wnt signalling there 
are numerous downstream effector molecules that can be activated. In addition, these 
molecules are often involved in many other signalling pathways making interpretation of 
results difficult. 
In the Ca2+ pathway, activation by Wnt5A has been shown to lead to intracellular release of 
Ca2+ thereby activating Ca2+ dependent signalling molecules such as PKC and CaMKII 
(Sheldahl et al. 1999, Kühl et al. 2000, Kang et al. 2007). The phosphatase calcineurin  can 
also stimulate and activate the NFAT transcription factor, which regulates the expression of 
downstream targets (Saneyoshi et al. 2002). Activation of the Ca2+ pathway can therefore 
be measured by detecting an increase in intracellular Ca2+, by probing for upregulation of 
these downstream effector proteins and using a NFAT reporter assay.   
The PCP pathway has been shown to activate small GTPases of the Rho family including 
Rac1 as well as downstream kinases such as JNK (Boutros et al. 1998, Habas et al. 2003). In 
addition, the Ca2+ pathway can also activate the small GTPase Cdc42 via PKC (Choi and Han 
2002). This means that detection of active GTPases is a useful approach to investigate the 
activity of multiple branches of the noncanonical Wnt signalling pathway. The Rho family 
of small GTPases, including Rac1 and Cdc42, act as molecular switches by alternating 
between an active GTP-bound and inactive GDP-bound state. The Rho family of effector 
proteins specifically recognise the active GTP-bound form. This has been used 
experimentally to design pull-down assays using the Cdc42/Rac Interactive Binding (CRIB) 
region of the effector protein p21 activated kinase I (PAK) (Burbelo et al. 1995). PAK-CRIB 
has a high affinity for both Rac1 and Cdc42 in their GTP-bound states, making it ideal for 
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affinity purification of active proteins from cell samples. PAK-CRIB is made as a glutathione-
S-transferase (GST) fusion protein, coupled to sepharose beads and used to pull-down 
active (GTP-bound) Rac1 and Cdc42 from lysates (Benard et al. 1999). Although the 
relationship between noncanonical Wnt signalling and Rho GTPase activation has been 
primarily described in Drosophila, this assay has been successfully used in mammalian cells 
to detect activation of Rac1 and Cdc42 following treatment of cells with the noncanonical 
Wnt5A protein (Habas et al. 2001, Habas et al. 2003). 
A common function of many of the noncanonical Wnt signalling pathways is to regulate the 
cytoskeleton to coordinate cell migration and polarity (Hans Clevers 2006). Therefore, 
assays to measure migration are often used as an indirect measure of the activation of 
different noncanonical Wnt signalling pathways (Dissanayake et al. 2007). As migration is 
an important process in the metastatic process of cancer this might suggest that 
noncanonical Wnt signalling is involved in this process. To understand the potential role of 
Wnt signalling in migration and metastasis of ESFT cells, I have therefore optimised and 
utilised a migration assay. 
Scratch assays are frequently utilised to investigate migration. A confluent adherent 
monolayer of cells is manually wounded often using a pipette tip and the time for closure 
of the wound is then monitored by imaging (Liang et al. 2007). Although convenient, this 
assay has a number of disadvantages. Firstly it relies upon the generation of confluent 
adherent monolayers that do not lift off when the scratch is made. Any gaps in the 
monolayer would obviously affect the results. However, many ESFT cell lines such as SKES-
1 and TTC466 grow in colonies and begin to stack when confluent (unpublished 
observations). Consequently these cells do not form a 100% confluent monolayer and 
therefore are not suitable for analysis using the scratch assay. In addition, the manual 
wound formation can be very variable in width (unpublished observations), meaning that 
many assays need to be performed to get reliable results. The scratch assay is also 
confounded by cell proliferation rather than migration, especially if assays are run over 
long periods of time, although the use of tame-lapse microscopy to track individual cells 
may be possible.  
Chemotaxis assays are also commonly used to assess cell migration. Such assays are mostly 
based on the original Boyden chamber assay (Albini and Noonan 2010) in which single cells 
in suspension are placed in an upper chamber and media containing an attractant such as a 
chemokine or growth factor is placed in a lower chamber. A permeable membrane 
separates the chamber, often coated with matrix proteins such as collagen or fibronectin 
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to encourage migration of cells from the upper to lower chamber. After a set period of 
time, the membrane is removed and the number of cells that have migrated onto the 
lower side quantified. If extracellular matrix such as Matrigel™ is used to coat the 
membrane then this assay can also be used to quantify invasion of cells through the 
Matrigel™ in addition to migration. However, the use of enzymatically-digested single cells 
in these assays means that they do not recapitulate the in vivo situation of cells escaping 
from a tumour in order to migrate. 
More recently, 3D models of migration have been developed in an attempt to more closely 
model the conditions within the tumour and the surrounding microenvironment. For 
example, nonadherent, heterogeneous aggregates of cells or ‘spheroids’ have been formed 
from cancer cell lines that have been shown to contain gradients of cell proliferation 
oxygen and nutrients (Sutherland et al. 1986, Rodríguez-Enríquez et al. 2008). If these 
spheroids  are then embedded in extracellular matrices such as Collagen I or Matrigel™ or 
transferred onto plastic coated with a matrix protein, invasion and migration of cells can 
be observed and quantified  (Nowicki et al. 2008, Vinci et al. 2013). These 3D assays are 
more representative of the metastatic process in vivo (Zimmermann et al. 2013). 
The aims of this chapter were to; 
1. Optimise and validate an assay to measure Rac1/Cdc42 activation after treatment 
with recombinant Wnt5A. 
2. Optimise and validate a migration assay using cell line-derived 3D spheroids. 
3. Use these optimised assays to measure the activity of the noncanonical Wnt 
signalling pathway in ESFT cell lines. 
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4.2 Materials and Methods 
4.2.1 Rac1/Cdc42 pull-down assay 
4.2.1.1 Preparing PAK-CRIB protein 
Glycerol stocks of BL21(DE3)pLysS competent E.coli expressing pGEX GST-PBD were a kind 
gift from Dr Georgia Mavria (University of Leeds). A loop of glycerol stock was used to 
inoculate 50ml of LB Medium (containing 100μg/ml amp), and the culture incubated at 
37°C for 17h with vigorous shaking. The culture was added to 450ml of LB Medium 
(+100μg/ml amp) and incubated at 37°C with vigorous shaking until the optical density 
(OD) of the culture at 600nm was 0.3 (as assessed using a Jenway 6705 
Spectrophotometer, supplied by Bibby  Scientific). This indicated the bacteria had reached 
the mid-log growth phase. Expression of GST-PBD was then induced by adding 0.3mM of 
isopropyl β-D-1-thiogalactopyranoside (IPTG; Sigma-Aldrich) and the culture incubated for 
a further 3h at 37°C with shaking. Bacteria were harvested by centrifugation at 5163g for 
20min at 4°C, and pellets stored at -80°C until required. Bacterial pellets were thawed on 
ice and lysed with 20ml ice-cold bacterial lysis buffer (10mM MgCl2, 1mM PMSF, 1mM DTT 
made in 1X Tris-Buffered Saline (TBS; 50mM Tris-HCL, 50mM NaCl, pH 7.5)) and sonicated 
(Vibra CellTM, Sonics & Materials, Stowmarket, UK) in 30s bursts for a total of 3min (with a 
30s incubation on ice in between each sonication). After sonication, Triton X-100 was 
added to a concentration of 1% (v/v) and the solution incubated for 30min at 4°C with 
gentle agitation. Lysates were clarified by centrifugation at 12470g for 30min at 4°C and 
snap-frozen in 5ml aliquots (enough for 12 pull-down samples) at -80°C.  
4.2.1.2 Binding GST-PAK-CRIB protein to beads 
To generate enough beads to analyse 12 samples, immediately before each pull-down 
experiment PAK-CRIB lysate (5ml; generated as described in Section 4.2.1.1) was thawed 
on ice. Meanwhile, 500μl Glutathione SepharoseTM 4B beads (GE Healthcare) (due to slurry 
this equates to approximately 375μl of beads) were washed with 10ml 1X TBS, centrifuged 
at 500g for 1min at 4°C, then washed twice with Rac wash buffer (10mM MgCl2, 1mM DTT, 
1X cOmplete protease inhibitor cocktail (Roche, Welwyn Garden City, UK) in 1X TBS), 
followed by centrifugation at 500g for 1min. The prepared beads were then added to the 
thawed cleared lysate and incubated for 1h at 4°C with gentle agitation. PAK-CRIB bound 
beads were pelleted by centrifugation at 500g for 1min at 4°C, the supernatant discarded 
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and beads washed 4 times with Rac wash buffer, and finally centrifuged at 500g for 1min, 
the buffer discarded and beads aliquoted into 60μl aliquots in screw-capped eppendorfs. 
4.2.1.3 Quantification of GST-PAK-CRIB protein bound to beads 
To quantify the concentration of PAK-CRIB bound to beads, PAK-CRIB bound beads were 
prepared as described (Section 4.2.1.2) and 10μl and 25μl of beads (mixed 1:1 with SDS-
loading buffer) were loaded onto a 12% acrylamide gel alongside BSA standards (0.5, 1, 
2.5, 5, 10 μg) in SDS loading buffer. SDS-PAGE was performed as previously described 
(Section 2.2.5) and the gel stained with Coomassie blue (0.025% Coomassie Brilliant blue R 
250, 40% (v/v) methanol, 7% (v/v) acetic acid in dH2O) overnight. The gel was destained 
(40% (v/v) methanol, 7% (v/v) acetic acid in dH2O) for 3h or until the blue background had 
disappeared, and the gel scanned using the ChemiDocTM MP (Bio Rad). Bands were 
quantified using the ChemiDocTM MP imaging system and a standard curve generated from 
the known concentrations on BSA. The curve was used to estimate the concentration of 
PAK-CRIB in 10μl and 25μl of bead solution. 
4.2.1.4 Performing Rac1/Cdc42 pull-down assay 
Cells were seeded in 10cm2 dishes at an appropriate density to be 70% confluent after 48h; 
either 1 × 106 (A673), 1.5 × 106 (RD-ES, SKES-1, TC32, TTC466) or 2 × 106 (SK-N-MC). Cells 
were treated with 5ml of media (control) or media containing 200ng/ml Wnt5A for 
increasing periods of time (5min-2h; HeLa and SKES-1) or for 30min with increasing 
concentrations of Wnt5A (50-200ng/ml; SKES-1). ESFT cell lines were treated with 
200ng/ml Wnt5A for 30min in cell-line specific media. To harvest cells for detection of 
active Rac1/Cdc42, media was removed and cells were washed on ice twice with ice-cold 
1X TBS. Cells were scraped into ice-cold Rac lysis buffer (900μl; 50mM Tris (pH 7.4), 10% 
(v/v) glycerol (Sigma-Aldrich), 1% (v/v) Nonidet® P40 substitute (NP-40; Fluka, Sigma-
Aldrich), 5mM MgCl2, 100mM NaCl, 1mM DTT, 1X cOmplete protease inhibitor cocktail in 
dH2O) using a cell scraper and samples pipetted to ensure complete lysis. To clarify the 
lysate samples were centrifuged at 12470g for 15min at 4°C. A total protein sample 
(12.5μl) was removed and mixed 1:1 with loading buffer and used to detect total 
Rac1/Cdc42. The remaining cleared lysate was added to 60μl GST-PAK-CRIB beads 
prepared as described (Section 4.2.1.2) and incubated on a rotating wheel for 45min at 
4°C. Samples were centrifuged at 500g for 1min at 4°C, the supernatant discarded and the 
beads washed twice with 1ml Rac wash buffer (Section 4.2.1.2). Finally the wash buffer 
was discarded and the beads resuspended in 60μl 2X loading buffer and split into two 30μl 
aliquots for detection of Rac1 and Cdc42. Total protein and pull-down samples were 
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heated at 95°C for 10min and loaded onto 10% Bis-Tris polyacrylamide gels and SDS-PAGE 
performed. Initial experiments were carried out using SDS-loading buffer (as described 
Section 2222), Bis-Tris gels (3.5mM Bis-Tris HCl (pH 6.8), 10% (v/v) acrylamide, 1% (w/v) 
APS, 0.0025% (v/v) TEMED) using 1X MES-SDS electrophoresis running buffer (GeneFlow) 
and run at 100V at 4°C. Later experiments were carried out using the CriterionTM XT system 
(Bio-Rad) using XT sample buffer, 10% Bis-Tris pre-cast XT gels and XT-MES running buffer. 
Electrophoretic transfer was carried out as previously described (Section 2.2.5). 
Immunodetection of proteins was carried out (Section 2.2.3.5) using antibodies to Rac1 
(1μg/ml; Millipore (05-389)) and Cdc42 (1:1000, Cell Signalling (11A1)).  
4.2.1.5 Determining the specificity of Rac1 and Cdc42 antibodies 
Total protein from HEK293T cells was extracted (Section 2.2.5). Protein extracts from 
HEK293T cells over expressing human Rac1 (sc-116394) and human Cdc42 (sc-110467) 
were purchased from Santa Cruz Biotechnology. Samples were loaded onto 10% 
acrylamide gels and SDS-PAGE performed (Section 2.2.5), and probed for Rac1 and Cdc42 
expression using antibodies (Section 4.2.1.4). 
4.2.2 Generation of spheroids from cell lines 
Cells were harvested by trypsinsation and counted using the trypan blue exclusion assay 
and haemocytometer (Section 2.2.5). Cells were suspended in cell-type specific culture 
medium at 5 × 103 cells/ml and 200μl of cell suspension added to each well of a round-
bottomed low adherence 96-well plate (Corning®, supplied by Fisher Scientific) to give 1 × 
103 cells per well. PBS was added to empty wells to humidify the plate, and the plate 
incubated at 37°C for 4 days. 
4.2.3 3D migration assay using cell spheroids 
The migration assay was adapted from a previously published method (Vinci et al. 2013) 
Cell spheroids were formed as described previously (Section 4.2.2). For optimisation 
experiments, Primaria™ flat-bottomed 96-well plates were left uncoated or coated with 
gelatin from bovine skin (0.1% (w/v; (Sigma-Aldrich) in sterile dH2O) or Matrigel™ 
(prepared as described in Section 5.2.1) for 1h at 37°C. Subsequent experiments with ESFT 
cell lines plates were coated with 0.1% gelatin (see results section 4.3.3.3). After this time 
the coating substrate was removed and replaced with 200μl of cell-type specific culture 
medium either untreated (control) or containing 1.5X the required final concentration of 
Wnt ligand (i.e. 300ng/ml of Wnt5A or 300ng/ml Wnt3A). From the wells containing the 
cell spheroids, 100μl of media was removed and discarded. The remaining 100μl of media 
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(containing the cell spheroid) was gently pipetted into the centre of a flat-bottomed 
coated well. Each well was imaged at 4X magnification at this time point (0h) and then 
every 24h up to 72h.   
Images were analysed using Volocity® software (Perkin Elmer, Cambridge, UK). Using the 
freehand drawing tool, the outline of the spheroid at 0h was traced to give the area 
covered (in number of pixels). At each subsequent time point the edge of the central 
spheroid (if present) was traced as well as the edge of migrating cells (migration zone). The 
migration zone was taken as the area containing at least 70% of migrating cells, as opposed 
to the maximum distance migrated by any single cell. The Migration Index (MI) at each 
time point was calculated as the area of the migration zone at that time point, minus the 
area of the core at that time point, relative to the area of the core at 0h. 
4.2.4 3D invasion assay using cell spheroids  
Cell spheroids were formed as previously described (Section 4.2.2). To assess invasion into 
Matrigel™, an aliquot of Matrigel™ was thawed on ice at 4°C overnight. From the wells 
containing the spheroids 100μl of media was removed from each well and discarded. 
Gently, 100μl of Matrigel™ containing 200ng/ml Wnt5A, if required, was added to the well 
containing the spheroid and allowed to set at 37°C for 1 hr. Once set, 100μl of cell-type 
specific media containing 200ng/ml Wnt5A, if required, was added to the well.  
To assess migration in collagen, a solution containing 4mg/ml collagen type I (Rat tail, BD 
Biosciences), 0.5X DMEM:F12 and 58mM NaOH was prepared. From the wells containing 
the spheroids, 190μl media was removed and discarded and 100μl of the collagen solution 
gently added and incubated at 37°C for 10min to allow to set. Finally, 100μl of cell-type 
specific culture media containing 2X the final concentration of Wnt5A (i.e. 400ng/ml) if 
required, was added to the well.   
In both conditions, each well was imaged at 4X magnification at this time point (0h) and 
then every 24h up to 72h.   
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4.3 Results  
4.3.1 Optimisation of Rac1/Cdc42 pull-down assay 
4.3.1.1 Quantification of PAK-CRIB protein 
The protocol used for active Rac1/Cdc42 pull-down was adapted from Pelligrin and Mellor 
(2008). Immunoprecipitation of active Rac1/Cdc42 will be dependent on the concentration 
of PAK-CRIB protein present in each assay, it is recommended that 30-100µg of PAK-CRIB 
protein is used for each pull-down sample (Pellegrin and Mellor 2008). To quantify the 
amount of PAK-CRIB protein used per pull-down in my optimised method, samples of GST-
PAK-CRIB protein  bound to glutathione beads were prepared as described (Section 
4.2.1.2) and loaded alongside known concentrations of BSA (Figure 4.1 A). Densitometry 
was performed and a standard curve of BSA generated so that the concentration of protein 
in the PAK-CRIB samples could be quantified (Figure 4.1 B).  It was calculated that 10µl of 
sample (i.e. 5μl of beads) contains 3.9µg PAK-CRIB protein which would equate to 47µg 
PAK-CRIB in each pull-down (using 60μl beads). 
 
 
 
 
 
Figure ‎4.1 Quantification of PAK-CRIB bound to glutathione-sepharose beads PAK-CRIB 
protein was prepared and allowed to bind to glutathione-sepharose beads for 1h at 
4°C. A) Beads were washed, mixed 1:1 with SDS-loading buffer and loaded onto a 
10% polyacrylamide gel alongside known concentrations of BSA (0.5-10µg). 
Electrophoresis was performed and the gel stained with Coomassie blue. B) After 
imaging, densitometry was performed to generate a standard curve for BSA, this was 
used to quantify the concentration of PAK-CRIB bound to the beads. MW= molecular 
weight. 
Sample Densitometry of band Concentration of PAK-CRIB 
10µl beads 41 3.9 
25µl beads 74 9.5 
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4.3.1.2 Validation of Rac1 and Cdc42 antibodies 
PAK-CRIB will bind to both active Rac1 and Cdc42, therefore it is possible to pull-down both 
proteins in the same assay. However, Rac1 and Cdc42 have a similar molecular weight and 
structure, so it was necessary to test the ability of available antibodies to distinguish 
between the two proteins. Anti-Rac1 antibody detected a band at 21 kDa corresponding to 
the predicted molecular weight of Rac1. This band was faint in the HEK293T parental cells, 
consistent with low level expression (Figure 4.2 A).  A strong band was detected in 
HEK293T cells overexpressing Rac1 (Rac1-293T) but there was no band observed in cells 
overexpressing Cdc42 (Cdc42-293T). The anti-Cdc42 antibody also detected a band at 21 
kDa (Figure 4.2 B). The anti-Cdc42 antibody did not detect a band in the HEK293T cells 
overexpressing Rac1 (Rac1-293T), but detected a strong band in HEK293T cells 
overexpressing Cdc42 (Cdc42-293T). These results demonstrate the specificity of both 
antibodies. 
 
 
Figure ‎4.2 Specificity of anti-Rac1 and anti-Cdc42 antibodies HEK293T control extracts and 
HEK293T cells overexpressing either Rac1 (Rac1-293T) or Cdc42 (Cdc42-293T) were 
analysed by western blot for expression of both Rac1 and Cdc42 to confirm the 
antibodies were specific. MW= molecular weight.  
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4.3.1.3 Stimulation of cells with recombinant Wnt5A 
The protocol to measure active Rac1/Cdc42 following treatment with Wnt5A was 
optimised using HeLa cells (as a positive control). In addition, the SKES-1 cell line was 
included to confirm that using the optimised method in HeLa cells it was also possible to 
measure active Rac1/Cdc42 in ESFT cell lines.  Densitometry was performed and expression 
of active Rac1 (21 kDa) expressed relative to the expression of total Rac1 (21 kDa) in each 
sample. Endogenous active Rac1 was detected in both HeLa and SKES-1 cells (Figure 4.3 A 
and B). In HeLa cells treatment with Wnt5A (200ng/ml) increased expression of active Rac1 
after 5 min, with maximum activation observed after 30min (1.5-fold) (Figure 4.3 C). 
Wnt5A (200ng/ml) also increased active Rac1 expression in SKES-1 cells after 30 min 
treatment (1.2-fold). 
In SKES-1 cells, there was a dose-dependent increase in active Rac1 expression after 30 min 
Wnt5A treatment (Figure 4.4 A and B).  Greatest activation of Rac1 in SKES-1 cells was 
observed after treatment with 200ng/ml Wnt5A (1.2-fold) (Figure 4.4 B) 
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Figure ‎4.3 Expression of active Rac1 after in HeLa and SKES-1 cells after treatment with 
Wnt5A over time  A) HeLa and B) SKES-1 cells were seeded into 10cm2 dishes and 
grown until 70% confluent in normal growth media (containing FCS), then treated 
with rWnt5A (200ng/ml) for various lengths of time (5min-2h). Cells were harvested, 
a sample for total protein estimation removed, and active (GTP-bound) Rac1 was 
precipitated from the remaining sample using glutathione-sepharose beads bound to 
PAK-CRIB. Expression of active and total Rac1 was determined by western blot using 
10% Bis-Tris polyacrylamide gels (for SKES-1 a pre-cast Criterion™ gel was used 
(BioRad). Densitometry was performed and the ratio of active Rac1/total calculated 
in C) HeLa and D) SKES-1 cells. MW= molecular weight. 
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Figure ‎4.4 Expression of active Rac1 in SKES-1 cells after treatment with increasing 
concentrations of Wnt5A SKES-1 cells were cultured in 10cm2 dishes until 70% 
confluent before treatment with media containing increasing concentrations of 
rWnt5A (50-200ng/ml) for 30 min. Cells were harvested, a sample for total protein 
estimation removed, and active (GTP-bound) Rac1 was precipitated from the 
remaining extract using glutathione-sepharose beads bound to PAK-CRIB. Beads 
were washed, isolated and resuspended in 2X SDS-loading buffer. A) Expression of 
Rac1 in pull-down and total protein samples was determined by western blot using a 
10% Bis-Tris polyacrylamide gel B) Densitometry was performed and the ratio of 
active Rac1/total Rac1 calculated. MW= molecular weight in kDa. 
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4.3.2 Measuring active Rac1/Cdc42 in ESFT cell lines 
Expression of both active and total Rac1 were detected in ESFT cell lines. Two bands were 
observed in pull-down samples when the samples were run on pre-cast Bis-Tris 
polyacrylamide gels. The lower band was active Rac1, as this was the same molecular 
weight as total Rac1 (Figure 4.5 A). The level of total Rac1 was heterogeneous between cell 
lines; equal protein loading was confirmed by staining of the membrane (Figure 4.5 D). 
SKES-1 cells had the highest level of total Rac1 expression (densitometry= 185) this was 
11X higher than total Rac1 expression in A673, which had the lowest expression 
(densitometry= 17).  Endogenous expression of active Rac1 was detected in all ESFT cells, 
expression was heterogeneous between cell lines (Figure 4.5 A). Densitometry was 
performed and active Rac1 expression was calculated relative to the expression of total 
Rac1 in each sample. Results showed that A673 cells had the highest level of endogenous 
Rac1 activity (Ratio= 2.9) and SKES-1 cells had the lowest activity (Ratio; 0.09). Although 
not tested statistically, an increase in expression of active of Rac1 was observed after 
treatment with Wnt5A (200ng/ml, 30min) compared to control (untreated cells) in SKES-1 
(3- fold), TTC466 (2-fold) and SKNMC (0.8-fold) cell lines. However, in the other three ESFT 
cell lines there was a decrease in active-Rac1 expression after Wnt5A stimulation (Figure 
4.5 B). 
Low levels of both total and active Cdc42 were detected in ESFT cell lines (Figure 4.5 C). 
The level was so low that densitometry could not be performed though equal loading was 
confirmed by staining of the membrane (Figure 4.5 D). Active Cdc42 appeared  higher in 
A673 and TTC466 cells, compared to the other cell lines, but no clear increase was 
measured after treatment with Wnt5A (200ng/ml,  30 min). 
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Figure ‎4.5 Expression of active Rac1 and Cdc42 in ESFT cell lines ESFT cells were cultured 
in 10cm2 dishes until 70% confluent then treated with rWnt5A (200ng/ml) for 30min. 
Cells were harvested, a sample removed for total protein estimation, and  active 
(GTP-bound) Rac1 and Cdc42 precipitated from the remaining extract using 
glutathione-sepharose beads bound to PAK-CRIB. Beads were washed, isolated and 
the sample split for analysis of Rac1 and Cdc42. Expression of  A) Rac1 and C) Cdc42 
in pull-down and total protein samples was determined by western blot using pre-
cast Bis-Tris acrylamide gels (BioRad). Images are representative of three 
independent experiments.  B) Densitometry was performed and the ratio of 
active/total Rac1 calculated. Results show the mean of three independent 
experiments (±SEM). D) Equal loading of samples was determined by staining the 
membrane using the Pierce reversible protein stain kit (Section 2.2.3.5). 
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4.3.3 Optimisation of 3D migration assay 
To investigate downstream activation of the noncanonical Wnt signalling in ESFT cells 
following treatment with Wnt5A protein, a 3-dimensional migration assay was developed. 
4.3.3.1 Validation of 3D migration assay in U87MG cells 
The migration assay used was developed from a previously published method, using 
U87MG cells that are known to be highly migratory cells (Vinci et al., 2013). U87MG cells 
formed compact spheroids; 3D clusters of non-adherent cells, when plated into round-
bottomed, ultra-low adherent 96-well plates and cultured for 4 days (Figure 4.6 A). When 
spheroids were transferred onto 0.1% gelatin-coated flat-bottomed plates, cells migrated 
out from the central spheroid core in a radial fashion consistent with reports from Vinci et 
al., (2013). Analysis of migration was performed using Volocity® software (Perkin Elmer). 
The area covered by the spheroid at 0h (Figure 4.6 B, purple circle) was determined (by the 
number of pixels). At each time point the migration zone (MZ) was quantified as the area 
covered by migrating cells (Figure 4.6 B, orange circle) minus the area covered by the 
spheroid core at that time point (Figure 4.6 B, green circle). The MZ was then normalised 
to the size of the core at 0h to give the migration index (MI). The average MI in U87MG 
cells after 72h was 61±8. 
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Figure ‎4.6 Quantifying migration in U87MG cells U87MG cells were seeded (1000 
cells/well) into round-bottomed, ultra-low adherence, 96-well plates (CoStar; 
Corning) to form spheroids. After 4 days, spheroids were transferred to flat-
bottomed 96-well plates coated with 0.1% gelatin. A) Cells were imaged every 24h, 
up to 72h and B) the migration was quantified using Volocity® software. The 
migration index (MI) at each time point was calculated as the area of the migrating 
cells minus the area of the core at that time point, relative to the area of the core at 
0h. 
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4.3.3.2 Formation of spheroids from ESFT cell lines 
ESFT cell lines formed spheroids when seeded in round-bottomed, ultra-low adherent 96 
well plates (1000 cells/well) (Figure 4.7 A). After 4 days the size of the spheroids formed 
was significantly different between the ESFT cell lines (p<0.001). A673 cells formed the 
largest spheroids (47328±3516 pixels) and RD-ES the smallest spheroids (21232±1939 
pixels) (Figure 4.7 B).  A673, RD-ES, SK-N-MC and TTC466 cells lines formed compact 
spheroids with a defined edge, whereas spheroids formed by SKES-1 and TC32 cells were 
looser with irregular edges, and tended to break apart easily during transfer to flat-
bottomed plates (Figure 4.7 A) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎4.7 Spheroids formed by ESFT cell lines ESFT cell lines were seeded into round-
bottomed, ultra-low adherent 96-well plates (1000 cells/well). A) After 4 days 
spheroids were imaged and B) the area covered by the spheroid quantified using 
Volocity® software. Results are presented as the mean of three independent 
experiments with three replicates per experiment (n=9) (±SEM).   
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4.3.3.3 Migration of ESFT cell lines on different substrates 
The 3D migration assay used describes migration on gelatin coated plates. It was 
investigated if a substrate coating is necessary for ESFT cell line migration, and if so, which 
is the optimum substrate to use.  
All ESFT cell lines studied migrated when plated onto plastic coated with gelatin (0.1%) 
(Figure 4.8). After 72h, A673 cells migrated the most (MI; 39±3) and SKES-1 the least (MI; 
6±0.6). A673 and TC32 cells also migrated on Primaria™ plastic but to a lesser extent (3- 
and 4-fold less, respectively). Only A673 cells migrated on Matrigel™ coated plastic and this 
was 2.5-fold less than migration on gelatin (Figure 4.8 A). Therefore, subsequent migration 
assays were carried out on gelatin coated plastic.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎4.8 ESFT cell  migration on different substrates A) A673 B) SKES-1 and C) TC32 ESFT 
cell lines grown as spheroids were transferred  onto flat-bottomed 96 well plates 
coated with either 0.1% gelatin or Matrigel™ or directly onto Primaria™ plastic (BD). 
Spheroids were imaged every 24h and the area covered by migrated cells quantified 
using Volocity® software. Images are 48h post plating. Dotted lines show the edge of 
migrating cells. Results show the migration index at each time point; the area 
covered by migrating cells, minus the area of the spheroid at the time point, relative 
to the size of the spheroid at Day 0. Results show the mean of three wells within one 
experiment (±SEM). 
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4.3.4 ESFT cell line migration in response to Wnt5A and Wnt3A 
All ESFT cell lines grown as spheroids migrated when plated on gelatin coated plastic. The 
pattern of migration of the cells over 72h was different between cell lines (Table 4.1). In 
some cell lines such as A673 and TTC466, the cell spheroid could no longer be seen after 
24h, and cells migrated radially as a sheet (Figure 4.9 A, lower panels). In contrast, SKES-1 
and TC32 maintained a distinct spheroid core, which increased in size over 72h. In TC32 
cells, individual cells appeared to migrate from the spheroid core (Figure 4.9 A, middle 
panels).  In untreated (control) cells after 72h, migration was greatest in TTC466 cells (MI; 
29±3.9) and A673 (MI; 26±3.6) and was significantly lower in SKES-1 (p<0.05, MI; 7±0.4) 
(Figure 4.9 A and B). Treatment with rWnt5A (200ng/ml) or Wnt3A (200ng/ml) into the 
media at 0h did not have a significant effect on the MI of any ESFT cell line, or the pattern 
of migration (Figure 4.9 A and B). 
 
Table ‎4.1 Phenotype of ESFT cell spheroid migration over 72h ESFT cell lines grown as 
spheroids for 4 days were plated onto gelatin (0.1%) coated plastic and imaged every 
24 h, up to 72h.  
Cell Line 
Appearance of 
spheroid core (over 
72h) 
Appearance of migrating cells  
(over 72h) 
A673 Absent by 24h Sheet of cells migrating radially 
RD-ES Absent by 48h 
Sheet of cells migrating radially, with a defined 
migratory front 
SKES-1 
Increased in size by 
4.4±0.2 - fold 
Ring of cells, increasing gradually in size 
SK-N-MC Absent by 48h 
Sheet of cells migrating radially with a defined 
edge 
TC32 
Increased in size  by 
10.8±0.7 - fold 
Individual cells moving out radially 
TTC466 Absent by 24h 
Sheet of cells migrating radially with a defined 
edge 
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Figure ‎4.9 Migration of ESFT cell lines with and without treatment with Wnt3A and 
Wnt5A ESFT cell lines were grown as spheroids and plated onto flat-bottomed 96 well 
plates coated with 0.1% gelatin, in normal media (control) or media containing a final 
concentration of 200ng/ml  rWnt3A or 200ng/ml  rWnt5A. Images were taken every 24h 
and the area covered by migrating cells quantified using Volocity® software to calculate the 
migration index (Section 4.2.3) A) Representative images after 72 hrs. B) Results presented 
as the migration index of three independent experiments with three replicates per 
experiment (n=9) (±SEM). 
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4.3.5 Correlation between pull-down and migration assays 
There was a very weak correlation between active Rac1 and migration in ESFT cell lines, 
both endogenous levels (R2=0.16) and when treated with Wnt5A (200ng/ml; R2= 0.15) 
(Figure 4.10 A and B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎4.10 Correlation between active Rac1 and migration index ESFT cells There was a 
weak correlation in the activation of Rac1 measured using the pull-down assay, and 
the migration index (at 72h) of ESFT cells either when (A) untreated or (B) when cells 
were treated with 200ng/ml Wnt5A.  
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4.3.6 Measuring the invasion of ESFT cells 
In addition to migration, the invasion of ESFT cells was also investigated as a downstream 
measure of noncanonical Wnt signalling. To measure the invasion of ESFT cell lines, 
spheroids were grown for 4 days as previously described and then embedded in collagen  
or Matrigel™, and imaged every 24h for 3 days. No invasion of ESFT cells was observed, 
when spheroids were embedded in collagen, with the exception of A673 where a few small 
processes could be observed (Figure 4.11 A, inset). No invasion was seen when spheroids 
were embedded in Matrigel™ (Figure 4.11 B). Addition of Wnt5A or Wnt3A to the collagen 
or Matrigel™ to a final concentration of 200ng/ml did not induce invasion in any ESFT cell 
line (data not shown). 
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Figure ‎4.11 Invasion of ESFT cells in Collagen I and Matrigel™ ESFT cell lines were grown 
as spheroids and then suspended in A) collagen (Type I; rat tail) or B) Matrigel™ and 
imaged every 24h for up to 72h. 
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4.4 Discussion 
In this chapter I have successfully optimised assays to measure and quantify Rac1/Cdc42 
activation and the migration of ESFT cells. However, I have been unable to conclusively 
determine the activity of noncanonical Wnt signalling in ESFT cell lines using these assays. 
The recombinant PAK-CRIB-GST protein was used to pull-down GTP-bound Rac1 and Cdc42 
from cell lysates. The ability of this assay to isolate GTP-bound Rac1 was determined using 
HeLa cells stimulated with EGF. A time-dependent increase in GTP-bound Rac1 could be 
measured in HeLa cells after treatment with recombinant Wnt5A protein, however this 
increase was relatively small (1.5-fold). This is similar to a previous study which showed 
Wnt5A was able to activate Rac1 by 2-fold in HeLa S3 cells (Sato et al. 2010). Although S3 
cells are a clonal derivative of the HeLa cell line, they may have different characteristics to 
the parent line. This may explain the difference in absolute magnitude of effect when cells 
were treated with Wnt5A. In addition, the concentration of PAK-CRIB used in the study by 
Sato et al. (2010) has not been given and therefore the differences in the magnitude of 
response may reflect differences in the concentration of ligand used and the sensitivity of 
the assay. Also, in the study by Sato et al. (2010) HeLa cells were serum starved for 36h 
before the addition of Wnt5A. It has been reported in HEK293T cells that serum starvation 
is necessary to detect Rac1 activation under normal growth conditions because in the 
presence of serum basal levels of active Rac1 are high (Habas et al. 2001, Habas et al. 
2003). Indeed it is often suggested that cells are starved for serum before pull-down assays 
are performed to ensure low levels of active GTPase in the control condition (Pellegrin and 
Mellor 2008). However, ESFT cell lines do not tolerate serum starvation well (unpublished 
observations) and serum starvation was not appropriate in this case since I wanted to 
detect the levels of active Rac1/Cdc42 in ESFT cell lines under normal growth conditions to 
determine endogenous noncanonical Wnt signalling.  
In ESFT cell lines both total and active (GTP-bound) Rac1 were detected. High levels of total 
Rac1 did not necessarily correlate to high levels of GTP-bound Rac1; A673 cells had the 
lowest level of total Rac1 but the highest level of active Rac1. Active Rac1 was 
heterogeneous between ESFT cell lines suggesting endogenous noncanonical Wnt 
signalling activation is also heterogeneous. 
Another important observation is that the cell lines that had the highest level of 
endogenous active Rac1 expression were those that had the lowest levels of endogenous 
Wnt5A protein (Chapter 2), as summarised in Table 4.2. It may be the case that in these 
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cell lines another noncanonical Wnt such as Wnt11 is responsible for activating 
noncanonical Wnt signalling; both A673 and TTC466 expressed higher levels of Wnt11 
mRNA compared to the other cell lines (Chapter 2). Alternatively, Rac1 activation in these 
cells may be downstream of other signalling pathways rather than noncanonical Wnt 
signalling. Indeed, Rac1 has been shown to be activated in the RD-ES and CHLA-10 ESFT cell 
lines downstream of phosphoinositide 3-kinase (PI3K) signalling  (Mendoza‐Naranjo et al. 
2013, Kamura et al. 2010).  
An increase in active Rac1 expression was detected after treatment with Wnt5A but only in 
SKES-1 and TTC466 cell lines.  Small GTPase pull-down assays are usually performed over a 
short time course of 30s to 10 min (Pellegrin and Mellor 2008), however in the current 
study Wnt5A was added to the cells for 30 min before the assay was performed. Thirty 
minutes was optimised from studies using HeLa and SKES-1 cells. It is possible the time 
course of response to Wnt5A are different in different cell lines. The active Rac1 levels 
were very low in the cell lines that did not respond to treatment with Wnt5A, and so any 
small response may be beyond the limits of detection of this assay. Nevertheless to my 
knowledge this is the first time that activation of Rac1 in response to Wnt5A has been 
reported in ESFT cells, which suggests noncanonical Wnt signalling is active or at least can 
be stimulated, in some ESFT cell lines. 
In contrast to Rac1, total Cdc42 expression was very low in ESFT cell lines and almost no 
active Cdc42 was detected. This is in concordance with previous findings in the RD-ES cell 
line (Kamura et al. 2010) and suggests the small GTPase Rac1 is more important in 
noncanonical Wnt signalling in ESFT cells. 
Although the pull-down method is currently the most convenient and widely used  assay to 
measure Rac1/Cdc42 activation, in agreement with other researchers (Dr Georgia Mavria, 
personal communication), I have found the method to be problematic and quite variable. 
These assays also have the disadvantage that they detect Rac1/Cdc42 in total cell 
populations and so any sub-populations with potentially high noncanonical Wnt signalling 
may be missed. More recently technologies such as fluorescence resonance energy 
transfer (FRET) have been used to detect small GTPase activation. In these assays a donor 
fluorophore is fused to the GTPase, and an acceptor fluorophore fused to the GTPase-
binding domain of the effector protein (for example PAK-CRIB). When the GTPase is 
activated, binding to the effector will bring the two fluorophores close enough together 
that light emitted by the donor activates the acceptor (Aoki and Matsuda 2009). This assay 
can be used to observe activation of small GTPases in single cells. 
  
 
 
 
 
 
 
 
 
 
 
Table ‎4.2 Summary of the results of the assays used to measure the activity of the noncanonical Wnt signalling pathway in ESFT cell lines Expression of 
Wnt5A mRNA and protein was determined in Chapter 2. To measure the activity of the noncanonical Wnt signalling pathway; expression of active Rac1 
was determined by western blot and the migration of cells was assayed using a 3D migration assay. 
 
Cell Line 
Wnt5A expression Active Rac1  Migration 
mRNA 
(2-ΔCt) 
Protein by 
western blot 
(ratio to β-
actin) 
Protein by flow 
cytometry 
(median 
fluorescence/% 
positive) 
Endogenous 
expression 
(ratio to total 
Rac1 
expression ) 
Stimulated with 
Wnt5A  
(ratio to total 
Rac1 expression) 
Migration 
(Migration Index at 
72h) 
Stimulated 
with Wnt5A 
(Migration 
index at 72h) 
A673 
 Lowest 0.12  0.25   Lowest 3.90/67  Highest 2.98  Highest 2.67 26.2 25.4 
RD-ES 
 Highest 2.05  Highest 1.04  Highest 9.7/46 0.29  Lowest 0.11 21.6 21.3 
SKES-1 
 0.94  Highest 1.04 4.89/63   Lowest 0.09 0.29  Lowest 6.76  Lowest 7.1 
SK-N-MC 
0.23  Lowest 0.14 5.84/58 0.23 0.27 11.6 13.6 
TC32 
  1.69  0.95 5.7/63 0.19 0.12 25.3 23.5 
TTC466 
 1.32 0.19 6.2/45 0.46 0.89  Highest 28.8 Highest 29.1 
-1
4
2
- 
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In concordance with previous literature (Lawlor et al. 2002), I found ESFT cell lines 
spontaneously formed spheroids when cultured in low adherence conditions. It has been 
shown the spheroids formed from ESFT cell lines closely resemble primary ESFT reflected 
by cell morphology, cell-cell adhesions and kinase activation (Lawlor et al. 2002). In my 
studies the size and morphology of spheroids formed from ESFT cells was highly variable. 
This may reflect differences in E-cadherin expression since  previous studies in TC32 and 
TC71 cells have shown that  spheroid formation is dependent on E-cadherin and activation 
of downstream signalling pathways including Ras and PI3K (Kang et al. 2007).  
All ESFT cell lines migrated from the spheroids when plated onto a gelatin-coated surface. 
The pattern and extent of migration was different between cell lines. This may be a result 
of differences in active noncanonical Wnt signalling since A673 and TTC466 cells which had 
the highest endogenous level of active Rac1 showed the greatest migration capacity (Table 
4.2). However my analysis showed that overall there was no direct correlation between 
Rac1 activation and migration. Although migration is often used as an end point when 
attempting to measure the noncanonical Wnt signalling pathway, migration is a highly 
complex process. For example transcriptional targets of the EWS-FLI1 fusion protein such 
as CD99 and caveolin-1 have been shown to modulate ESFT cell line migration (Sáinz-
Jaspeado et al. 2010, Kreppel et al. 2006). The receptor ERBB4 has also been shown to be 
highly expressed in ESFT cell lines, activate Rac1 (via PI3K signalling), and promote 
migration (Mendoza‐Naranjo et al. 2013). Therefore, differential expression of these and 
other proteins may also explain the differences in migration seen. 
Migration was not increased in any ESFT cell line by the addition of recombinant Wnt5A 
protein. This is in contrast to a previous study which showed Wnt5A increased the 
migration of ESFT cell lines including A673 and RD-ES (Jin et al. 2012). This is perhaps 
surprising since the study by Jin et al. (2012) used the same cell lines and the same 
recombinant Wnt5A protein (albeit at a lower concentration). However, the researchers 
measured chemotaxis using a transwell assay in response to the chemoattractant CXCL12, 
rather than migration on gelatin. As mentioned previously, chemotaxis assays measure the 
directional migration of single dissociated cells whereas the assay I have used measures 
migration from a spheroid. These assay differences could therefore explain the disparities 
observed. In the previous study in ESFT cell lines, migration was quantified after 18h of 
Wnt5A treatment (Jin et al. 2012). However, in my assay images to measure migration 
were taken after a minimum of 24h. Although there was no significant difference in 
migration in ESFT cell lines after Wnt5A treatment at this time point, it is possible that 
Wnt5A had an effect earlier in the time course and this was missed in my analysis. 
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Nevertheless, using the migration assay I have optimised, I failed to show an increase in 
migration in response to Wnt5A in PC3 and HeLa cells, which has previously been 
described using the same recombinant protein (Yamamoto et al. 2007, Jin et al. 2013). It 
would therefore be important to confirm that the recombinant Wnt5A protein used in my 
experiments is biologically active, which could be done by reproducing precisely the 
experiments described by Jin et al. (2012) or by using a positive control cell line such as 
melanoma which is known to migrate in response to Wnt5A (Weeraratna et al. 2002).  
In my study migration was analysed by calculating a migration index; the area of the 
migration zone minus the area of the core. The ‘migration zone’ was defined as the area 
covered by at least 70% of cells. Therefore this method of analysis did not take into 
account the maximum migration of an individual cell. In some cell lines there were 
individual cells that migrated beyond the migration zone and these were missed from my 
analysis and this may have affected the results obtained. However, overall, the migration 
assay is a less informative way to measure noncanonical Wnt signalling since the results of 
these assays can be confounded by many other factors that can influence migration. The 
pull down assay is a direct measure of one component of the noncanonical pathway, 
however there are technical difficulties in measuring this and the assay is not very 
sensitive. 
In contrast to migration, invasion of cells from ESFT spheroids into collagen or Matrigel™ 
was not observed, either in the presence or absence of Wnt5A. When spheroids were 
embedded in Matrigel™ they continued to increase in size demonstrating that the cells 
were still viable, however no invading cells could be seen by light microscopy. Invasion of 
ESFT cells in transwell assays using Matrigel™ coated membranes has been described 
previously (Kamura et al. 2010, Mendoza‐Naranjo et al. 2013). Again this discrepancy could 
be attributed to the difference in assaying individual dissociated cells compared to those in 
a 3D spheroid.  
In summary, I have optimised methods to detect active Rac1/Cdc42 in cells, and migration 
and invasion of cells using a 3D spheroid assay. I have shown that active Rac1 is expressed 
endogenously in all ESFT cell lines, and in some cell lines can be further activated by the 
addition of Wnt5A. I have also demonstrated that all ESFT cell lines are migratory, but that 
Wnt5A does not alter their migration. However the complexity of migration means that 
this is not suitable as an end-point measure of the noncanonical Wnt signalling pathway. It 
has been difficult to draw any definitive conclusions regarding the activity of noncanonical 
Wnt signalling in the ESFT cells lines investigated. As summarised in Table 4.2, in some cell 
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lines such as A673 and TTC-466 there was a correlation between active Rac1 and 
migration, thus strengthening the hypothesis that noncanonical Wnt signalling is active in 
these cells. However overall there was no correlation between active Rac1 and migration 
in the cell lines, although this may be due to the low sensitivity of the pull-down assay. In 
addition, there was an inverse correlation between Wnt5A expression in the cell lines, and 
the activity of noncanonical signalling determined by measuring active Rac1 expression 
and migration. Taken together these data make it difficult to conclude if noncanonical Wnt 
signalling is active in these cells. Furthermore, measuring activation of noncanonical Wnt 
signalling is problematic, as unlike the canonical pathway, there are a number of 
downstream effector molecules which can be activated, and these are involved in other 
signalling pathways. For example, as mentioned, Rac1 has been shown to be activated in 
ESFT cells downstream of PI3K signalling (Kang et al. 2007, Mendoza‐Naranjo et al. 2013). 
Therefore to further understand the role of noncanonical Wnt signalling in ESFT cells it 
would be necessary to investigate the activation of other effector molecules. For example, 
phosphorylated JNK, phosphorylated c-Jun (Jin et al. 2012) or phosphorylation of PKC 
isoforms and subsequent translocation to the plasma membrane after Wnt5A treatment 
(Dissanayake et al. 2007). Immunofluorescence could also be used to examine changes in 
the actin cytoskeleton in cells after treatment with noncanonical Wnt ligands. It would also 
be important to investigate the effect of Wnt5A knock-down on ESFT cells. Wnt5A 
expression could be inhibited using RNAi, and the effect of this on Rac1 and Cdc42 
expression, and on migration could be investigated. This would help to elucidate whether 
noncanonical Wnt signalling, or other signalling pathways such as PI3K are responsible for 
the observed phenotypes, such as migration, of ESFT cells. 
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5. Wnt signalling in reprogrammed ESFT cells 
5.1 Introduction 
In the previous two chapters I have developed assays to measure the activity of both the 
canonical and noncanonical Wnt signalling pathways. In this chapter my aim is to use these 
assays to measure Wnt signalling in reprogrammed ESFT cell lines, in an attempt to 
understand how Wnt signalling may be important in the initiation and development of 
ESFT.  
Recently it been shown that like normal somatic cells, cancer cells such as chronic myeloid 
leukaemia (Carette et al. 2010) and gastrointestinal cancers including oesophageal, 
stomach, colorectal, liver and pancreatic cells (Miyoshi et al. 2010), can also be 
reprogrammed. As well as providing a renewable source of tumour material to study, it is 
hoped that reprogramming cancer cells will aid understanding of the cellular programs 
involved in the initiation and development of disease (Fernandez et al. 2013). For example, 
it has been recently shown that reprogrammed cells derived from pancreatic ductal 
adenocarcinoma (PDAC), when injected subcutaneously into mice generated premalignant 
lesions which later progressed back to invasive cancer (Kim et al. 2013). The ability to study 
the early stages of tumour development is vitally important and this is extremely difficult 
in ESFT since the cell(s) of origin are not known, and patients often present with advanced 
disease (Ross et al. 2013). Therefore, we hope that reprograming ESFT cells will elucidate 
more about the cancer initiating cell, that is responsible for metastasis and drug resistance, 
and it may be possible to identify pathways that can be targeted to develop novel 
therapeutics.  
In our laboratory we have reprogrammed an ESFT cell line with a EWS-ERG fusion (TTC466) 
by transient transfection of one plasmid containing all four OSCK genes (Oct4, Sox2, c-Myc 
and Klf-4). Three different clones of transfected TTC466 cells have been studied and 
compared to three clones from a control TTC466 cell line transfected with GFP. In 
particular one clone, referred to as OSCK4, has been validated and has shown upregulation 
of stem cell markers, the ability to form embryoid bodies which can be differentiated to 
various different germ layers, and an increased ability to form subcutaneous tumours in 
vivo.  
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Reprogrammed cells are maintained in embryonic stem cell culture conditions to maintain 
their undifferentiated state. This usually involves growing cells on a feeder layer of mouse 
embryonic fibroblasts (MEFs) (Thomson 1998, Takahashi et al. 2007). However, it is not 
fully understood how MEF cells support self-renewal. There are undefined components in 
the media that could influence experimental results and the presence of a feeder layer can 
be problematic for downstream assays. For these reasons feeder-free culture systems have 
been developed using various using matrices to replace the feeder cells. In our laboratory, 
for the culture of hES cells we use Matrigel™ hESC-qualified matrix and mTeSR™1 media. 
mTesR™1 is a serum-free medium containing a DMEM:F12 base and 12 other defined 
factors including BSA, FGF2, TGFβ and LiCl (Ludwig et al. 2006, Akopian et al. 2010). It has 
been shown by the international stem cell initiative consortium to support the 
maintenance of a panel of embryonic stem cells, and also iPS cell lines (Akopian et al. 2010, 
Chen et al. 2011). 
The aim of this current chapter is to; 
1. Develop a feeder-free growth method for optimum maintenance of 
reprogrammed and control TTC466 cell lines 
2. Investigate the activity of the canonical Wnt signalling pathway in reprogrammed 
ESFT cells using the firefly luciferase reporter system 
3. Investigate the activity of the noncanonical Wnt signalling pathway in 
reprogrammed ESFT cells using Rac1/Cdc42 pull-down and migration assays.  
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5.2 Materials and methods 
5.2.1 Feeder-free stem cell culture 
Reprogrammed (OSCK4) cells were maintained in complete mTeSR™1 media (STEMCELL 
Technologies, Grenoble, France). Complete media was prepared by thawing 5X 
Supplement (100ml) at 4°C overnight and adding it to 400ml Basal Medium. Complete 
media was frozen at -20°C in aliquots and working solution stored at 4°C for a maximum of 
2 weeks.  
5.2.1.1 Coating plastics with hESC-qualified Matrigel™ 
All culture plastics were coated with Matrigel™ hESC-qualified matrix (BD Biosciences, 
supplied by VWR) prior to use. Matrigel™ was prepared in single use aliquots in cryovials 
according to the dilution factor provided by the manufacturer (typical volume range = 270-
350µl), stored at -20°C and thawed on ice at 4°C overnight prior to use. To coat plastics, 
one aliquot of Matrigel™ was added to 25ml of chilled DMEM/F12 in a chilled 50ml Falcon 
tube, and mixed well. The diluted Matrigel™ was used to completely coat plastics as 
required (e.g. 2ml per 25 cm2 flask) and incubated at RT for 1 h.  Coated plastics were 
stored, wrapped in Clingfilm and stored at 4°C for up to 7 days. 
5.2.1.2 Routine culture of cells maintained in mTeSR™1 
OSCK4 cells were passaged using the same method used for human embryonic stem (hES) 
cells grown in feeder-free conditions using mTeSR™1. All cells were cultured in 25cm2 flasks 
(Nunc™, Fisher Scientific)  coated in Matrigel™ as previously described (Section 5.2.1.1). 
When cell colonies were beginning to merge, mTeSR™1 was aspirated from the flask and 
replaced with 1.5ml collagenase IV (1mg/ml Gibco™, Life Technologies, in DMEM/F12) and 
incubated for 5 min at 37°C. In this time, the Matrigel™ was aspirated from pre-coated 
flasks (Section 5.2.1.1) and replaced with fresh mTeSR™1. The cells were viewed using a 
light microscope to observe the edges of colonies beginning to detach, at this time the 
collagenase was aspirated and replaced with 3ml mTeSR™1. Colonies were mechanically 
dissociated using a fine-tip plastic Pasteur pipette (Alpha laboratories, Eastleigh, UK) whilst 
being viewed under a light microscope placed in the tissue culture hood. When all colonies 
had been detached, the solution was pipetted up and down gently 3 times to further 
dissociate the colonies, and the appropriate volume (depending on the split ratio) placed 
into the pre-prepared new flasks. Prior to incubation, flasks were gently shaken to ensure 
an even distribution of cells across the entire flask. Cells were maintained at 37oC in 5% 
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CO2 in 95% air. Media was aspirated and replaced with 5ml fresh mTeSR
TM1 daily to inhibit 
spontaneous differentiation. Cells were routinely split 1:4 every 3-4 days.    
5.2.1.3 Formation of single cell suspension from cells maintained in mTeSR™1 
Where a single cell suspension was required, OSCK4 cells were washed with 1X PBS and 
then incubated with 0.2X Trypsin/5mM EDTA (in 1X PBS) for 30s or until cells had 
completely detached. An equal volume of media containing 10% FCS was added to 
neutralise the trypsin and the suspension centrifuged at 403g for 3 min. Cells were 
resuspended in mTeSR™1 and viable cell number was determined using the Neubauer 
haemocytometer as previously described (Section 2.2.2).  
5.2.2 Routine culture of GFP control cells 
GFP1, GFP3 and GFP4 cells were maintained on Matrigel™ coated plastic prepared as 
previously described (Section 5.2.1.1). Cells were maintained in RPMI containing 10% 
conditioned media, collected from GFP cells and filtered using a 0.2µM membrane prior to 
use. GFP cells grew as a monolayer and were therefore passaged using trypsinisation as 
described for the parental TTC466 cell line (Section 2.2.3). 
5.2.3 Determining viable cell number of OSCK4 and GFP cell lines 
Cells were trypsinised as previously described (GFP, Section 2.2.1; OSCK4, Section 5.2.1.3) 
and seeded at 2 × 104 cells/well in 24-well Primaria™ plastic plates either uncoated or 
coated with Matrigel™ as previously described (Section 5.2.1.1). GFP and OSCK4 cells were 
seeded either in RPMI (+10% conditioned media) or mTeSR™1. After 24, 48 and 72h cells 
were counted by trypan blue exclusion using the automated vi-cell as previously described 
(Section 2.2.2). Triplicate wells were counted for each condition, at each time point. 
5.2.4 Analysis of Wnt signalling components using RTqPCR  
RNA was extracted from three GFP clones (GFP1, GFP3, GFP4) and from OSCK4 cells from 
confluent 10cm2 dishes as described previously (Section 2.2.5.1). RNA was extracted at 
three separate time points to give three biological repeats. Gene expression of 
components of the Wnt signalling pathway was analysed using the TaqMan® Array Human 
WNT Pathway 96-well plate (Applied Biosystems), as described (Section 2.2.5.4). 
Expression of sFRP5, Wnt16, FGF4 and DKK2 was confirmed by specific RTqPCR using 
TaqMan® Assay-on-Demand™ (Applied Biosystems) primer/probe mixes (Table 5.1). 
Expression of the housekeeping gene PPIA was used for normalisation as described 
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previously (Section 2.2.5.5). Results were analysed using the comparative ΔCt method 
(Section 2.2.5.4).  
 
Gene Probe exon position Amplicon length (bp) Product code 
sFRP5 1-2 69 Hs00169366_m1 
Wnt16 2-3 104 Hs00365138_m1 
FGF4 1-2 130 Hs00999691_m1 
DKK2 2-3 88 Hs00205294_m1 
 
Table ‎5.1 Wnt signalling component TaqMan® Assay-on-Demand primer/probe product 
information bp=basepair 
 
5.2.5 Cloning of 7TFH vector 
5.2.5.1 Plasmid digestion 
The 7×Tcf-FFluc.SV40.PuroR (7TFP) plasmid was digested with 20 U (units) SalI-HF (High 
Fidelity; New England Biolabs (NEB), Hitchin, UK) and the pBABE Hygro plasmid digested 
with 20 U SalI-HF and 5 U ClaI (NEB). DNA (1µg) was added to a restriction enzyme (RE) mix 
containing 1X NEBuffer 4 (NEB) and 20 U of RE in nuclease-free H2O to a total volume of 
30µl. Samples were incubated for 2h on a heating block at 37°C. To create blunt ends 3' 
overhangs were removed and 3' recessed ends filled in using DNA Polymerase I, Large 
(Klenow) Fragment (NEB). 1.5 U of Klenow was added to the RE mix along with 1mM dNTPs 
and incubated for 15min at 25°C. To stop the reaction, 10mM EDTA was added and the mix 
incubated for 20 min at 75°C. Samples were immediately electrophoresed on an agarose 
gel to separate the fragments.  
5.2.5.2 Agarose gel electrophoresis 
Agarose (1% (w/v) Invitrogen™) was dissolved in 150ml 1X Tris-Borate-EDTA (TBE) Buffer 
(90mM Tris, 90mM Orthoboric acid (Sigma-Aldrich) and 2mM EDTA at pH 8) by heating 
gently in a microwave. The solution was cooled to approximately 60°C and ethidium 
bromide added (0.5 µg/ml, Sigma-Aldrich) to allow visualisation of the DNA under ultra 
violet (UV) light. The solution was mixed by gentle agitation and poured into a Horizon™ 
agarose gel tray (Invitrogen™) and a comb inserted. The gel was incubated at RT for 1h to 
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solidify and then placed into an electrophoresis tank in 1X TBE buffer.  Samples were 
diluted 1:6 in gel loading buffer (0.4 mM Ficoll (Type 400; Sigma-Aldrich), 17.3 mM SDS, 0.4 
mM Bromophenol blue (Sigma-Aldrich) and 5.6 mM Orange G (Sigma-Aldrich)) and loaded 
into the gel alongside Quick-Load® 1 kilobase (kb) DNA ladder (10 μl containing 
Bromophenol blue; NEB), to allow for confirmation of the size of DNA fragments. The gel 
was electrophoresed at 80 V for 90 min. Products were visualised under UV light using a 
trans-illuminator (BioRad). A nuclease-free H2O sample was included as a negative control. 
5.2.5.3 DNA extraction from an agarose gel 
The required fragments of DNA namely the 7TFP vector (minus puromycin, approx. 8000 
bp)) and hygromycin resistance gene (approx. 1500 bp) were excised from the agarose gel 
using a sterile scalpel. DNA was extracted using the GenElute™ kit (Sigma-Aldrich). All 
solutions are company propriety. Briefly, gel slices were placed in a 1.5ml Eppendorf at 
55°C in Gel Solubilisation Solution (3:1) with occasional vortexing until completely 
dissolved (approximately 10min). Meanwhile, Column Preparation Solution (500µl) was 
added to a GenElute Binding Column, the column centrifuged (16,000 g for 1min) and the 
solution discarded. Once the gel had dissolved, isopropanol (100%) was added 1:1, mixed 
by pipetting and added to the prepared binding column, 700µl at a time, and the column 
centrifuged (16,000 g for 1min). After all the solubilised gel had been passed through, the 
column was washed twice with Wash Solution (700µl) and centrifuged as above between 
each wash. Finally, the empty column was centrifuged to remove any excess ethanol. The 
column was transferred to a new collection tube and the DNA eluted by centrifugation into 
30µl of nuclease-free dH2O. DNA quality and quantity was determined using the Nanodrop 
as described previously (Section 2.2.5.2). 
5.2.5.4 Calf-intestinal alkaline phosphatase (CIP) treatment 
Calf-intestinal alkaline phosphatase (CIP) was used to dephosphorylate the 5’ end of the 
empty 7TFP vector and therefore prevent religation. CIP was added to extracted 7TFP 
vector DNA in 1X NEBuffer 3 (NEB) to a final concentration of 0.5 U/µg of DNA and 
incubated for 1h at 37°C. 
5.2.5.5 DNA ligation 
The hygromycin resistance gene was ligated into the 7TFP vector at a ratio of 3:1 in a mix 
containing 1X T4 DNA Ligase Buffer (NEB), 200 U T4 DNA Liagse (NEB) and dH2O. The 
mixture was mixed gently by pipetting and incubated at 16°C overnight using the Techne 
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TC-500 Thermal Cycler. A no hygromycin gene control was included to check for self-
ligation of the 7TFP vector. 
5.2.5.6 Bacterial Transformation 
XL-1 Blue competent cells (Stratagene, supplied by Fisher Scientific) were thawed slowly on 
ice. For each transformation, 100µl of competent cells were added to a pre-chilled round-
bottomed polypropylene tube (Falcon, Fisher Scientific). Ligated DNA (1µl) was added 
directly and incubated on ice for 20 min. The solution was then placed in a water bath at 
exactly 42°C for 45s and placed on ice for 2min. Super Optimal broth with Catabolite 
repression (SOC) medium (250µl) was then added and the tube incubated for 1h at 37°C 
with vigorous shaking. Transformed bacteria were streaked onto LB Agar plates as 
previously described (Section 3.2.2.1.1). 
5.2.5.7 DNA isolation by minipreparation 
Twelve clones were selected from LB Agar plates and minipreparation performed to isolate 
a small quantify to DNA for analysis. Each colony was picked using a pipette tip and 
inoculated into 5ml LB medium (+100µg/ml amp) and incubated for 16h at 37°C with 
vigorous shaking. The GenElute™ Plasmid Miniprep Kit (Sigma-Aldrich) was used to isolate 
DNA. All reagents are company proprietary. Bacterial cultures (3ml) were transferred to 
microcentrifuge tubes and the bacteria pelleted by centrifugation (12,000g, 1 min). The 
pellet was resuspended in 200µl Resuspension Solution and mixed gently by pipetting until 
clear (5 min). Cell debris was precipitated by adding 350µl Neutralization/Binding Solution 
and debris pelleted by centrifugation (12,470 g, 10 min). Meanwhile, a GenElute Miniprep 
Binding Column was prepared by adding 500µl of the Column Preparation Solution 
followed by centrifugation (12,000 g, 1min), and the flow through discarded. The cleared 
lysate was then loaded onto the prepared column and the column centrifuged (12,470 g, 1 
min), the flow through discarded and the column washed with 750µl Wash Solution 
(containing ethanol). The column was centrifuged (12,000g, 1 min) and the flow through 
discarded before centrifuging again (maximum speed, 2 min) to remove any residual 
ethanol. Finally the column was transferred to a fresh collection tube and the DNA eluted 
by adding 100µl nuclease-free H2O to the column and centrifugation (12,000g, 1 min). DNA 
quantity and quality was measured using the Nanodrop as previously described (Section 
2.2.5.2). 
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5.2.5.8 Identifying correctly cloned vector constructs 
To identify which of the 12 clones contained the correct vector contruct, a sample of each 
clone was digested using restriction enzymes EcoRI and HindIII (Section 5.2.5.1) and 
separated on an agarose gel (Section 5.2.5.2). Using the vector maps, it was predicted that 
vector digests should contain unique fragments of 1576 bp and 2040 bp. Clones with these 
fragments were expanded from the initial 5ml stock produced (Section 5.2.5.7) by adding 
200µl bacteria culture to 5ml LB medium (+100µg/ml amp) and incubating for 16h at 37°C 
with vigourous shaking. After this time the bacterial culture was added to 200ml LB 
medium (+100µg/ml amp) and incubated for a further 16h in the same conditions. Vector 
DNA was isolated using the HighSpeed® Plasmid Maxi Kit (Section 3.2.2.1.2). 
To confirm that the hygromycin resistance gene was inserted in the correct orientation, 
the two regions where 7TFP and hygromycin join were sequenced. Sequencing was 
performed using the BigDye® Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems). 
Forward and reverse primers were designed to sequence the overlap (Table 5.2). For each 
primer a BigDye® mix (7.5µl) was prepared containing 500ng vector DNA, 2µl BigDye® 
Reaction Mix, 1.5µl BigDye® Reaction Buffer, 0.5µl primers (3.2µM) made up in dH2O. 
Samples were loaded into a 96-well sequencing plate (Thermo Fisher) and incubated using 
GeneAmp® PCR System 9700 (Applied Biosystems) for 25 cycles of heating to 96°C for 10s, 
55°C for 5s and 60°C for 4min, then cooled to 4°C. To precipitate the DNA, 1µl of sodium 
acetate (3M, pH 5.2) and 25µl 95% (v/v) ethanol were added to each well and the plate 
incubated at RT for 30 min. After this time the plate was centrifuged at 1879g for 15min 
after which the supernatant was removed by gently tipping the plate onto filter paper. 
Ethanol (75µl of 70% solution) was then added to each well and centrifuged again as 
described above. After the ethanol had been removed the plate was inverted and 
centrifuged (420g, 1 min) to remove any excess ethanol. The plate was placed at 95°C for 1 
min to evaporate any residual ethanol and finally 15µl of Hi-Di™ Formamide (Applied 
Biosystems) added to each well. The plate was centrifuged (1879g, 1 min) then placed at 
95°C to denature the DNA, then placed on ice before sequencing was performed using the 
Hitachi 3130xl Genetic Analyzer (Applied Biosystems) 
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  Primer Sequence Primer Location 
Primer 1 5’-CGTGGATTACGTCGCCAG-3’ Forward from 7TFP into Hygro 
Primer 2 5’-CCAGCAGGCAGAAGTATG-3’ Forward after primer 1 
Primer 3 5’-CAGAGCTTGGTTGACGGC-3’ Forward from Hygro to 7TFP 
Primer 4 5’-CACGCCACGTTGCCTGAC-3’ Reverse from 7TFP into Hygro 
Table ‎5.2 Primers used to sequence clones 7TFH vector The position of the primers in the 
7TFH vector is shown in the schematic in Figure 5.6 A. 
 
5.2.6 Generation of cell lines transduced with 7TFH vector 
Lentiviral particles containing the newly cloned 7TFH vector were generated in HEK293T 
cells using the LENTI-Smart kit (Section 3.2.2.2).  HEK293T, OSCK4 and GFP3 cell lines were 
infected with lentiviral supernatant at an MOI of 2 (Section 3.2.2.3) and 48h after infection 
were selected using media containing 200 µg/ml Hygromycin (Invitrogen™) for 2 weeks. 
Cells were maintained in Class II conditions (as described in Section 3.2.2.2) for at least 10 
days after infection or until the cells had been cultured though at least 2 passages. 
5.2.7 Luciferase assay 
To test the activity of the 7TFH vector, HEK293T 7TP and HEK293T 7TFH cells were seeded 
at 5 × 104 cells in 24-well plates. OSCK4 7TFH and GFP3 7TFH cells were seeded at 1 × 105. 
After 24h the media on cells was replaced with normal growth media (control) or media 
containing rWnt3A (200ng/ml) or rWnt5A (200ng/ml). After a further 24h luciferase 
activity was determined using the Luciferase Assay (Section 3.2.5). 
5.2.8 Migration assay 
OSCK4 and GFP3 cells were grown as spheroids (Section 4.2.2) and the migration assay 
performed as previously described (Section 4.2.3). 
5.2.9 Rac1/Cdc42 pull-down assay 
OSCK4 and GFP3 cells were seeded at 2 × 106 cells in 10cm2 dishes and treated with normal 
growth media (control) or media containing 200ng/ml rWnt5A for 30min. Total and active 
levels of Rac1 and Cdc42 were determined using the pull-down assay as previously 
described (Section 4.2.1.4).  
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5.2.10 Statistics 
For the Wnt signalling array, the optimal housekeeping gene was selected as previously 
described (Section 2.2.6). Clustering analysis and analysis to determine if there was a 
significant difference between expression of Wnt signalling genes in GFP clones and OSCK4 
cells was performed by Mr John Alexander (University of Leeds). Differences in expression 
were analysed using the Limma package (Smyth 2004) using the software R (version 3.0.2 
for OS 6). The Limma package uses linear modelling to fit genes from cases (OSCK4) and 
controls (GFP clones) and find significant differences amongst them. All other statistical 
analyses were performed as described previously (Section 3.2.11).  
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5.3 Results 
5.3.1 Determining optimal growth conditions for OSCK and GFP cell lines 
Previously the OSCK (reprogrammed TTC466) and GFP1, GFP3 and GFP4 (control) cell lines 
had been generated and maintained on a feeder layer of immortalised MEF cells. However, 
for the functional assays I have developed to measure the activity of the canonical and 
noncanonical Wnt signalling pathway it was necessary to transfer the cells to a feeder-free 
culture system. In addition, to compare results generated from reprogrammed ESFT cells 
and human embryonic stem (hES) cells with inducible EWS-FLI1 expression (Chapter 6) it 
was essential that cells were grown in the same culture conditions. I therefore evaluated 
the viable growth of the OSCK4 and GFP3 cells in mTeSR™1  on a Matrigel™ coated surface 
(used in our laboratory to maintain hES) to growth on Primaria™ plastic plus RPMI 1640 
containing 10% conditioned media (CM), which is used to culture the parent TTC466 cells 
(Section 2.2.1, Table 2.1) 
GFP3 cells did not grow in mTeSR™1; viable cell growth was significantly reduced over 72h 
when cells were seeded into Primaria™ or Matrigel™ coated 24-well plates (p<0.0001)  
(Figure 5.1 A). Cells appeared rounded and the majority of cells did not adhere to either 
substrate (Figure 5.2 A). The viable cell number of GFP3 cells increased over 72h when cells 
were grown in RPMI  on both  Matrigel™  and  Primaria™ coated 24-well plates (Figure 5.1 
A) and the appearance of the cells down the light microscope was similar on both 
substrates (Figure 5.2 A). In contrast, the viable cell growth of OSCK4 cells increased over 
72h in all conditions; viable cell growth was greatest when OSCK4 cells were seeded  on 
Matrigel™ coated plates in mTeSR™1 although this difference was not significant (p=0.16) 
(Figure 5.1 B). When seeded on Primaria™ coated plates, OSCK4 cells grew in colonies, with 
more floating cells compared to growth on Matrigel™ coated plates, where cells grew as a 
homogenous monolayer (Figure 5.2 B). In optimal conditions, the viable cell growth of 
OSCK4 cells was significantly slower than that of GFP3 cells (p<0.0001). When seeded at 
the same cellular density, viable cell number after 72h of OSCK4 cells was 0.14 x 106 and of 
GFP3 cells 0.24 x 106  (Figure 5.1 A and B). In all future experiments, to eliminate any 
differences in cell behaviour due to substrate, both OSCK4 and GFP3 lines were cultured on 
Matrigel™ coated plastic. GFP3 cells were cultured in RPMI (+ 10% CM) and OSCK4 cells 
were cultured in mTeSR™1 
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Figure ‎5.1 Growth of GFP and OSCK cells on different substrates and in different media 
(A) GFP and (B) OSCK cells were seeded into 24 well plates either on Primaria™- or 
Matrigel™-coated plastic  and either in RPMI (+10% conditioned media) or mTeSR™1  
media. Viable cell number was determined by the trypan blue exclusion assay using 
an automated Vi-cell, every 24h. Results are the mean of two independent 
experiments with three replicates in each repeat (n=6) (± SEM). 
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Figure ‎5.2. Light microscope images of GFP and OSCK cells cultured on different 
substrates and in different media  Representative images 72h after seeding of GFP 
and OSCK cells grown on Primaria™ or Matrigel™ coated 24 well plates, in either 
RPMI (+ 10% CM) or mTeSR™1 media.  
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A) GFP 
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5.3.2 mRNA expression of Wnt signalling components in OSCK and GFP 
cells 
5.3.2.1 Profile by TaqMan® Wnt Pathway Array 
As discussed in Chapter 2, the TaqMan® Wnt Pathway Arrays (Applied Biosystems) contain 
4 housekeeping genes. It was necessary to determine which was the appropriate 
housekeeping gene to use to normalise expression of Wnt signalling components in GFP 
and OSCK4 cell lines, since this may be different to the housekeeping gene used for the 
ESFT cell line data. Therefore the expression of HRPT1 and GUSB over each technical 
replicate for OSCK4, GFP1, GFP3 and GFP4 cells was investigated, to examine the stability 
of expression across the replicates. Inter-assay variability was determined as previously 
described (Section 2.2.6). The variance was lowest using the mean of HRPT1 and GUSB (F-
value=2.72) compared to using HRPT1 (F-value= 3.60) or GUSB (F-value=3.83) alone. 
Therefore the mean of HRPT1 and GUSB was used to normalise the data for GFP and 
OSCK4 cell lines. 
RNA was analysed from three different GFP clones; GFP1, GFP3 and GFP4, and from one 
OSCK clone, OSCK4. Data from our laboratory has demonstrated that the OSCK4 clone has 
been reprogrammed and generates multiple cell types in vivo, and that the variation 
between the three GFP clones is very low (Andrea Berry, personal communication). 
Hierarchical clustering revealed that the technical repeats of the GFP clones cluster 
together, and the OSCK4 repeats cluster separately, consistent with previous observations 
in the laboratory (Figure 5.4). Of 91 components of the Wnt signalling pathway 
represented on the array, 88% (80/91) had similar expression in both the OSCK4 and GFP 
cells (Figure 5.3, Figure 5.4). Genes that were expressed at significantly different levels 
(p<0.05) and were changed by more than 2 Ct values between OSCK4 and GFP cells are 
shown in Table 5.2. The most significant change was observed in FGF4 (p<0.001); 
expression was increased by more than 6 Ct values in the OSCK4 cells compared to GFP 
cells. sFRP5 expression was also increased significantly (p<0.001) in OSCK4 cells along  with 
5  Wnt ligands; Wnt16, Wnt8B, Wnt3 (all p<0.001),  Wnt3A and Wnt1  (both p<0.05). In 
contrast the inhibitor DKK2 had significantly lower expression in OSCK4 cells (p<0.05). 
 
  
 
 
 
 
 
 
 
 
 
 
Figure ‎5.3 RNA expression of components of the Wnt signalling pathway in OSCK and GFP cells. OSCK4, GFP1, GFP3 and GFP4 cells were harvested, total RNA 
extracted and expression level determined using the Taqman® Wnt signalling gene expression array. Data presented as mRNA expression relative to the 
mean of the housekeeping genes HRPT1 and GUSB. Results of three independent experiments. Results show mean of all three GFP clones (n=9) and 
mean of OSCK4 (n=3) (±SEM). *= Genes that were expressed at significantly different levels (p<0.05) and were changed by more than 2 Ct values 
between OSCK4 and GFP cells (see Table 5.2) 
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Figure ‎5.4 Clustering of Wnt signalling components in OSCK and GFP cells. Expression of 
Wnt signalling components was determined (Figure 5.3) and hierarchical clustering was 
performed to generate a heat map. Red indicates low expression and pale yellow high 
expression. *= Genes that were expressed at significantly different levels (p<0.05) and 
were changed by more than 2 Ct values between OSCK4 and GFP cells (see Table 5.2)  
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Table ‎5.3 Genes with significantly different mRNA expression in OSCK cells compared to 
GFP cells Expression of genes was determined using the Taqman® Wnt signalling 
gene expression array and genes with significantly different expression in GFP and 
OSCK values identified by Limma analysis (Section 5.2.10). Ct values are given for the 
mean of GFP clones (GFP1, GFP3 and GFP4) and OSCK4 (±SEM). *A lower Ct value 
means higher expression therefore a reduction in Ct value indicates an increase in 
expression. A Ct value of 40 is considered no detection. 
  
Gene 
Significance  
(P value) 
Ct value 
in GFP 
Ct 
value 
in 
OSCK4 
Expression in 
OSCK4 relative to 
GFP*  
(Difference in Ct) 
 
Expression directly or 
indirectly controlled 
by reprogramming 
gene(s) (OSCK)? 
sFRP5 0.00043 
37.8 
±0.7 
27.5 
±0.5 
-10.3 -No 
FGF4 0.000000089 
39.7 
±0.2 
32.7 
±0.8 
-7 
-Yes, SOX2 activates 
FGF4 (Weber et al. 
2013) 
WNT16 0.000072 
36.5 
±0.5 
33.2 
±1.1 
-3.3 -No 
WNT8B 0.001216 
38.3 
±0.5 
33.1 
±1.4 
-5.2 
-Yes, Oct4 can activate 
Wnt8B expression 
(Katoh 2007) 
WNT3 0.000399 40 
37.2 
±1.4 
-2.8 -No 
WNT1 0.001521 
38.7 
±0.6 
34.4 
±0.4 
-4.3 
-Yes, Wnt1 can be 
activated by SOX2 
(Chen et al. 2012) 
DKK2 0.001723 
25.2 
±0.3 
29 
±0.4 
+3.8 -No 
RHOU 0.000399 
34.4 
±0.4 
31.2 
±1.1 
-3.2 -No 
DKK4 0.005169 
39.2 
±0.4 
36.9 
±0.4 
-2.3 -No 
WNT3A 0.005169 40 
38 
±1.9 
-2 -No 
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5.3.2.2 Validation of expression by RTqPCR 
The Wnt signalling pathway array only contains one well per target, per plate. Although I 
have performed three biological repeats it was necessary to validate the significant 
changes in mRNA expression detected using the Wnt signalling pathway array using 
RTqPCR for individual genes. The primer and probe mixes were purchased as Assays-on-
Demand™ (Applied Biosystems) and were identical to those used in the Wnt signalling 
pathway array with the exception of FGF4, where a different primer/probe mix was used. 
The same samples of RNA were used for both the Wnt signalling pathway arrays and 
validation RTqPCR reactions. However the Wnt signalling array was performed for all three 
GFP lines, whereas the validation experiments were only performed using GFP3. The 
pattern of expression was the same for both the Assay-on-Demand and array data; sFRP5, 
Wnt16 and FGF4 had higher expression in OSCK4 cells, whereas expression of DKK2 was 
higher in GFP3 cells. However, there were some differences in the magnitude of 
differences in expression detected using the two methods. When detected using the 
Assay-on-Demand, expression of sFRP5 was 14.2 Ct values lower in OSCK4 cells then GFP 
cells (Figure 5.5), whereas expression was only 10.3 Ct values lower when detected using 
the Wnt signalling pathway array (Table 5.2). In addition using Assays-on-Demand neither 
Wnt16 or FGF4 mRNA was detected in GFP cells, and the Ct values for OSCK4 cells were 
higher than those observed in the Wnt signalling array (Table 5.2). 
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Gene 
GFP3 
(Mean 
Ct 
value 
±SEM) 
OSCK4 
(Mean 
Ct 
value 
±SEM) 
Expression 
in OSCK4 
relative to 
GFP 
(Difference 
in Ct*) 
sFRP5 
37.8 
(±0.06) 
23.6 
(±0.24) 
-14.2 
Wnt16 40 
39.4 
(±0.12) 
-0.6 
FGF4 40 
38.9 
(±0.24) 
-1.1 
DKK2 
26.3 
(±0.04) 
29.6 
(±.13) 
+3.3 
PPIA 
22 
(±0.15) 
22 
(±0.14) 
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Figure ‎5.5 sFRP5, Wnt16, FGF4 and DKK2 mRNA expression determined by RTqPCR RNA 
was extracted, RT performed and expression determined by RTqPCR using Assays-
on-Demand (Applied Biosystems) A) sFRP5, Wnt16, FGF4 and DKK2 mRNA expression 
in GFP3 and OSCK4 cell lines using  cDNA generated from 10ng RNA. Data presented 
as target expression relative to the expression of the housekeeping gene PPIA (Log 
values). Results show the mean of triplicate wells in one experiment. B) Mean Ct 
values obtained from the RTqPCR. *A higher Ct value corresponds to low expression, 
a Ct value of 40 is considered no detection. 
   
Gene 
GFP3 
(Mean Ct value 
±SE ) 
OSCK4 
(Mean Ct value 
±SEM) 
Expression in 
OSCK4 relative to 
GFP 
(Difference in Ct*) 
Wnt signalling 
array result 
(Difference in Ct 
between GFP3 
and OSCK4) 
sFRP5 37.8 (±0.06) 23.6 (±0.24) -14.2 -9.8 
Wnt16 40 39.4 (±0.12) -0.6 -6.8 
FGF4 40 38.9 (±0.24) -1.1 -7 
DKK2 26.3 (±0.04) 29.6 (±.13) +3.3 +4 
PPIA 22 (±0.15) 22 (±0.14) 0 N/A 
-167- 
 
5.3.3 Activity of the canonical Wnt signalling pathway in OSCK and GFP 
cells 
5.3.3.1 Cloning of Hygromycin resistance gene into 7TFP vector 
Previous work has shown that the 7TFP luciferase reporter plasmid can be used as a 
sensitive measure of canonical Wnt signalling (Chapter 3). This system uses a puromycin 
resistance gene to select for cells which contain the plasmid to generate a cell population 
with stable expression. Since the OSCK vector also contains a puromycin resistance gene it 
was necessary to change the resistance gene in the 7TFP vector to allow selection of the 
OSCK cells for the luciferase reporter plasmid.   
The puromycin resistance gene was removed from the 7TFP vector and replaced with the 
hygromycin resistance gene from the pBABE Hygro vector (as described in Section 5.2.5). 
Twelve different clones were produced and each clone was digested with EcoR1 and 
HindIII to generate multiple fragments (Figure 5.6 B). Based on the restriction enzymes 
used and the plasmid map it was calculated that the size of full length undigested plasmid 
was 9581 bp and clones with hygromycin inserted and ligated in the correct orientation 
should have unique fragments of 1576 bp and 2040 bp. These fragments were identified in 
clones 1, 4 and 10 and were not present in the other clones (Figure 5.6 B). Clone 10 was 
expanded and purified plasmid DNA was further validated by sequencing the flanking 
regions of hygromycin resistance (Appendix). This new plasmid was termed pLenti 7xTcf 
Ffluc SV40-Hygro (7TFH). 
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Figure ‎5.6 Cloning of 7TFH plasmid A) Schematics of expression vectors 7TFP and 7TFH. 
For 7TFH the position of primers used for sequencing is also shown. Generated using 
PlasMapper Version 2.0 (Dong et al. 2004). To confirm correct cloning of the 7TFH 
plasmid, 12 clones were selected, DNA extracted and digested with EcoRI and 
HindIII. The resulting products were electrophoresed on an agarose gel containing 
ethidium bromide (0.5µg/ml) and visualised using UV light B) Clones with the correct 
vector sequence were predicted to have unique bands at 1576 and 2040 bp; lanes 
1,4 and 10. Bp= basepair, MW= molecular weight. 
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5.3.3.2 Confirming the luciferase reporter function of 7TFH plasmid 
To test the activity of the newly generated 7TFH vector, the luciferase activity in HEK293T 
7TFH cells was compared to that of HEK293T 7TFP cells. Endogenous activity was 
significantly increased in the 7TFH cells compared to that of the 7TFP by 57±4.4% (p<0.05). 
When stimulated with Wnt3A (200ng/ml for 24h) luciferase activity was significantly 
increased in both 7TFP and 7TFH cells compared to unstimulated cells, as expected. 
However, the luciferase activity in 7TFP and 7TFH cells stimulated with Wnt3A was not 
statistically different from each other (14.6±0.056 x106 and 15.4±0.048 x106 RLU, 
respectively) (Figure 5.7). This demonstrates that the reporter function of the 7TFH vector 
is equivalent to that of the original vector (7TFP). 
 
 
 
 
 
 
 
 
 
 
Figure ‎5.7 Confirming the functional activity of the cloned 7TFH reporter plasmid 
HEK293T 7TFP and HEK293T 7TFH cell lines were treated with 200ng/ml 
recombinant Wnt5A or Wnt3A for 24 h. Luciferase activity was determined using the 
Luciferase Assay (Section 3.2.5). Activation of the firefly luciferase reporter is shown 
relative to the parental cell line with no reporter plasmid (presented on the Log 
scale). RLU=Relative Light Units. 
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5.3.3.3 Measuring the activity of the canonical Wnt signalling pathway in OSCK 
and GFP cells 
Activity of luciferase activity is reported per 10,000 cells. There was no difference in the 
endogenous activity of the luciferase reporter between GFP3 7TFH and OSCK4 7TFH cells 
(GFP= 10±3 x104 RLU, OSCK=14±3.6 x104 RLU). Treatment with rWnt5A (200ng/ml, 24h) 
had no effect on the luciferase reporter activity in either GFP3 7TFH or OSCK4 7TFH cells. 
However, there was a significant increase in luciferase activity in both GFP3 7TFH and 
OSCK4 7TFH cells (p<0.05) after stimulation with Wnt3A (200ng/ml, 24h).This stimulation 
of luciferase reporter activity was greater in OSCK4 cells (150±105-fold) compared to that 
in GFP3 cells (20±4-fold). Although this difference was substantial it did not reach not 
significance (p=0.066). 
 
 
 
 
 
 
 
 
 
 
Figure ‎5.8  Luciferase reporter activity in GFP and OSCK cells. GFP3 7TFH and OSCK4 7TFH 
cell lines were treated with 200ng/ml recombinant Wnt5A or Wnt3A for 24h. 
Luciferase activity was determined using the Luciferase Assay (Section 3.2.5).  Data 
presented as luminescence per 10,000 cells (Log scale). Viable cell number was 
determined from identically treated cells by trypan blue exclusion using the Vi-cell 
automated cell counter. RLU=Relative Light Units. 
  
p =0.066 
*p <0.05 
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5.3.4 Activity of the noncanonical Wnt signalling pathway in OSCK and 
GFP cells 
5.3.4.1 Migration of OSCK and GFP cells 
Both GFP3 and OSCK4 cells formed compact spheroids when cultured on ultra-low 
adherence plastic. However after 4 days, the OSCK4 spheroids were almost double the size 
(62197±1848 pixels) of that of the GFP3 spheroids (32768±1147 pixels) (Figure 5.9 A and B, 
left panels). 
When spheroids were plated onto gelatin coated plastic, OSCK4 cells migrated out while 
still maintaining a central spheroid core (Figure 5.9 A). Consistent with previous 
observations in ESFT cell lines (Chapter 4), migration of OSCK4 cells on gelatin was greater 
than migration on Matrigel™ coated plastic (data not shown). After 72h, the MI of OSCK 
cells was 14±1.5 (Figure 5.9 A).  In contrast, the GFP3 cells migrated out radially as a flat 
monolayer, the spheroid core was lost within 24h (Figure 5.8 B). The MI of GFP3 cells was 
greater than that of OSCK4 cells (36±4). This is also greater than the migration observed in 
the parental TTC466 cell line (MI; 29 (±4)) (Section 4.3.4). The migration of GFP3 and 
OSCK4 cells was not increased at any time point by the addition of 200ng/ml recombinant 
Wnt3A or Wnt5A (Figure 5.9 A and B) 
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Figure ‎5.9 Migration of OSCK and GFP cells A) OSCK4 and B) GFP3 cell lines were cultured as spheroids for 4 days and plated onto flat-bottomed 96 well plates 
coated with 0.1% gelatin in media alone or media containing a final concentration of 200ng/ml  recombinant Wnt3A or Wnt5A. Images were taken every 
24h and area covered by migrating cells quantified using Velocity software.  Graphs show area migrated at 24, 48 and 72h relative to the area of the 
spheroid at 0h. Representative images are of control cells at 24, 48 and 72 h. Results of three independent experiments (±SEM). 
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5.3.4.2 Expression of active Rac1/Cdc42 in OSCK and GFP cells 
Active Rac1 and Cdc42 were calculated relative to the expression level of total Rac1 and 
Cdc42 in each sample. Active Rac1 was detected in both OSCK4 and GFP3 cell lines. In 
control cells, the level of basal active Rac1 was 2.7±0.5-fold higher in OSCK4 cells 
compared to GFP3 cells (Figure 5.10 A and B). With the addition of rWnt5A for (200ng/ml, 
30min) there was an increase in active Rac1 in the GFP3 cells (1.6±0.1-fold) and a slight 
(1.2±0.1-fold) increase in active Rac1 in OSCK4 cells (Figure 5.10 A and B).  Low levels of 
both total and active Cdc42 were observed in both OSCK4 and GFP3 cells (Figure 5.9 C). 
Basal active Cdc42 was slightly (1.2±0.2-fold) higher in OSCK4 cells compared to GFP3 cells 
(Figure 5.10 D). After treatment with rWnt5A for (200ng/ml, 30min), there was an increase 
in active Cdc42 in both GFP cells (1.4±0.2-fold) and OSCK4 cells (1.5±0.1-fold).  
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Figure ‎5.10 Expression of active Rac1 and Cdc42 in GFP and OSCK cell lines GFP3 and 
OSCK4 cell lines were cultured in 10cm2 dishes until 70% confluent. Cells were then 
treated with rWnt5A (200ng/ml) for 30min. Cells were harvested, a sample removed 
for total protein estimation, and  active (GTP-bound) Rac1 and Cdc42 were 
precipitated from the remaining extract using glutathione-sepharose beads bound to 
PAK-CRIB. Beads were washed, centrifuged and the sample split for analysis of Rac1 
and Cdc42. A) Expression of Rac1 in pull-down and total protein samples was 
determined by western blot. B) Densitometry was performed and the ratio of 
active/total Rac1 calculated and expressed relative to expression in GFP control cells. 
C) Expression of Cdc42 in pull-down and total protein samples was determined by 
western blot. D) Densitometry was performed and the ratio of active/total Cdc42 
calculated and expressed relative to expression in GFP control cells.  Error bars on 
graphs show mean (n=2) (±SEM). Images are representative of 2 independent 
experiments.   
(A) 
 
(A) 
(C) 
 
(C) 
(B) 
 
(B) 
(D) 
 
(D) 
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5.4 Discussion 
In this chapter I have successfully cultured reprogrammed TTC466 cells using a feeder free 
system and analysed these cells for activation of Wnt signalling. My data shows that  
expression of some components of the Wnt signalling pathway are altered in the 
reprogrammed cells, which may play a role in maintaining the primitive reprogrammed 
state. However, endogenous canonical Wnt signalling pathway is not upregulated 
compared to that in control (GFP) cells. Activation of the noncanonical Wnt signalling 
pathway may be increased in reprogrammed cells, since they have higher level of activated 
Rac1.  
Consistent with previous reports, reprogrammed TTC466 (OSCK4) cells could be 
maintained in feeder free conditions on hESC-qualified Matrigel™ in mTeSR™1 media (Sun 
et al. 2009, Chen et al. 2011). In fact, both GFP and OSCK4 cells grew better when cultured 
on Matrigel™ coated plastic than on Primaria™ plastic. This is not surprising as Matrigel™ is 
an extract of basement membrane proteins from the murine Engelbreth-Holm-Swarm 
(EHS) tumour and contains laminin, collagen IV, entactin and heparin sulphate 
proteoglycan (Kleinman et al. 1982). Matrigel™ has been shown to enhance attachment of 
normal and cancer cell lines to plastic (Albini et al. 1992), and also been shown to help 
maintain self-renewal and pluripotency in hES and iPS cells (Xu et al. 2001, Ludwig et al. 
2006, Sun et al. 2009). Control (GFP) cell lines did not grow in mTeSR™1 which is consistent 
with previous observations that ESFT cell lines do not grow in this media (Dr Andrew 
Gaffney, personal communication). As mentioned previously, mTeSR™1 contains 12 
defined factors including  FGF2 (200ng/ml), and FGF2 is known to induce cell death in ESFT 
cells at concentrations greater than 10ng/ml (Westwood et al. 2002). Although OSCK4 cells 
could tolerate maintenance in RPMI, viable cell number was greatest after culture in 
mTeSR™1. The ability of OSCK4 cells to grow in stem cell media is an indicator of their 
reprogrammed state. Data from our laboratory suggests that the OSCK4 population is 
heterogeneous, therefore growth of these cells in normal TTC466 media (RPMI) may 
promote outgrowth of partially reprogrammed populations. For these reasons it was 
concluded that OSCK4 cells should be grown in mTeSR™1 and GFP cells in RPMI. However, I 
cannot exclude the possibility that maintaining cells in different culture conditions may 
impact on the downstream assays performed to probe for Wnt signalling activity.  
To maintain self-renewal and pluripotency of hES and iPS cells, various feeder free systems 
have been developed that use different combinations of components to provide the 
optimal microenvironment for cell growth. It is becoming clear that it is the cross-talk 
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between key signalling pathways which is important in maintaining hES cells in an 
undifferentiated state. For example, mTeSR™1 contains TGFβ (23.5pM) which, through the 
Smad2, 3 pathway, activates downstream targets such as Nanog (Xu et al. 2008). In 
addition, insulin (3.92µM) potently activates PI3K/Akt signalling (Dalton 2013). mTeSR™1 
also contains FGF2 (100ng/ml) which is thought to maintain a basal level of ERK activity 
and also activate the PI3K pathway (Dalton 2013). Although it is not clear precisely what 
effect these signalling pathways have on Wnt signalling in hES cells, it is agreed that Wnt 
signalling plays an important role. It has been suggested that activation of PI3K signalling 
by FGF2 prevents ERK inactivation of GSK3β, allowing GSK3β to phosphorylate β-catenin to 
ensuring canonical Wnt signalling is low. Indeed, inhibition of GSK3β or treatment with 
Wnt3A has been shown to result in activation of the canonical Wnt signalling pathway and 
subsequently loss of self-renewal and mesodermal differentiation (Davidson et al. 2012, 
Singh et al. 2012). However, alternative studies have shown that activation of PI3K 
signalling by FGF2 leads to phosphorylation of GSK3β and therefore activation of Wnt 
signalling. This is in contrast to other reports which have shown inhibiting GSK3β helps to 
maintain undifferentiated hESCs (Ding et al. 2010). It is therefore still controversial 
whether active Wnt signalling promotes or inhibits self-renewal or differentiation in hES 
cells. Nevertheless, it is clear that growth in mTeSR™1 may have an effect in Wnt signalling 
in OSCK4 cells and this should be considered when interpreting my data.  
However, endogenous canonical Wnt signalling was no different in GFP cells and OSCK4 
cells. Both cell lines showed a significant increase in canonical Wnt signalling in response to 
exogenous Wnt3A protein. Although this response was greater in OSCK4 cells, the 
difference did not reach statistical significance. Nevertheless this difference may be 
biologically relevant for example OSCK4 cells may be more primed to respond to Wnt 
signals due to expression of particular cofactors, or due to decreased expression of 
inhibitors such as sFRP5 and DKK4. This will be discussed in further detail later. 
The OSCK factors have been shown to reprogram normal and cancer cells to a more 
primitive state, but it is not understood exactly how the factors work. As discussed, Wnt 
signalling is important in the maintenance of undifferentiated hES cells, therefore it is not 
surprising that Wnt signalling has also been shown to play a role in the reprogramming 
process and maintenance of iPS cells. However, as is the case for hES cells, the precise role 
of Wnt signalling in this process is controversial. Some studies report that Wnt signalling 
can promote reprogramming. For example, Wnt3A protein has been shown to aid 
reprogramming in the absence of c-myc (Marson et al. 2008) and activation of canonical 
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Wnt signalling also promotes reprogramming by somatic nuclear transfer (lluis, 2008). It 
has been shown that β-catenin binds to Oct4, Sox2 and Klf4, and has been hypothesised 
that this may help them bind to their endogenous promoters and increase transcription, 
thus promoting the reprogramming process (Zhang et al. 2014).  Conversely however, Oct4 
expression has been shown to functionally repress canonical Wnt signalling in both hES 
cells and non-stem cells (HEK293T) (Davidson et al. 2012). This apparent contradictory role 
of Wnt signalling could in part be explained by the different components of the canonical 
pathway. When signalling occurs, β-catenin translocates to the nucleus where it forms a 
complex with a TCF/LEF family member of transcription factors and also CBP or the closely 
related homolog p300, leading to expression of downstream target genes (Hecht et al. 
2000). It has been suggested that CBP/β-catenin interactions promote stem cell 
maintenance and p300/β-catenin interactions mediate transcriptional programs leading to 
differentiation (Teo and Kahn 2010). In addition, the TCF/LEF family is made up of Tcf1, 
Lef1, Tcf3 (TCF7L1) and Tcf4 and the function of individual TCF/LEF proteins can differ. For 
example although Tcf3 has been shown to co-occupy promoter regions of pluripotency 
genes such as Nanog with the factors Oct4 and Sox2 (Cole et al. 2008, Tam et al. 2008, Yi et 
al. 2008), ablation of Tcf3 has been shown to stimulate Nanog expression (Yi et al. 2011). 
Therefore it is thought Tcf3 acts as a transcriptional repressor in hESCs, whereas Tcf1 
activates transcription in response to β-catenin (Yi et al. 2011). In relation to 
reprogrammed cells, it has recently been shown that in the early stages of reprogramming, 
the Wnt signalling pathway is repressed by Tcf3 and Tcf4, and activation of Wnt signalling 
at this stage leads to a reprogramming block. However, in later stages, Wnt signalling aids 
reprogramming, and deletion of Tcf3/Tcf4 at this stage enhances iPS formation (Ho et al. 
2013).  
In the current study, using the Wnt signalling array, significantly higher expression of Tcf1, 
and lower expression of Tcf3 were detected in OSCK4 cells compared to GFP cells 
(although these genes were excluded from the analysis as the differences were less than 2 
Ct values). Although no difference in canonical Wnt signalling was detected using the Tcf-
reporter assay, this assay is not able to distinguish which endogenous Tcf family members 
are being activated, therefore there may be differences in canonical Wnt signalling 
between the GFP and OSCK4 cells which are not detectable using this assay. It would 
therefore be important to look at a panel of downstream Wnt target genes involved in 
both self-renewal and differentiation such as cyclin D1, survivin, Axin2, c-jun and EphB2 to 
understand fully what is happening in these cells. However, caution should be taken when 
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interpreting the results as it is possible Wnt signalling is promoted in OSCK4 cells due to 
the reprogramming factors themselves, and not related to the ESFT cellular background.  
Expression of other components of the Wnt signalling pathway in OSCK4 and GFP cells 
were also determined using the Wnt signalling array. Some components which had higher 
expression in OSCK4 cells such as FGF4, Wnt8B and Wnt1 have previously been shown to 
be activated by at least one of the OSCK factors themselves (Weber et al. 2013, Katoh 
2007, Chen et al. 2012). However, other Wnt ligands including Wnt16, Wnt3 and Wnt3A 
also had increased expression in OSCK4 cells and have not previously been linked to any of 
the OSCK genes. Other components such as sFRP5 were also highly overexpressed in 
OSCK4 cells. This is consistent with a previous study showing that sFRP5 is silenced through 
methylation in ESFT cell lines (Jin et al. 2012). The secreted frizzled-related proteins (sFRPs) 
are a family of Wnt signalling antagonists that inhibit Wnt signalling by competing with 
Wnt ligands for binding to Frizzled receptors. My data supports the hypothesis that 
reprogramming ESFT cells removes this methylation and restores sFRP5 expression. The 
previous study also demonstrated that treatment of ESFT cells lines with sFRP5 protein 
reduced migration, and therefore re-expression of sFRP5 in OSCK4 cells may explain the 
reduced migration observed by these cells in this study. 
RHOU (also known as Wrch-1) is a member of the Rho family of GTPases, related to Rac1 
and Cdc42, which has been shown to be activated by Wnt1 expression (Tao et al. 2001). 
Expression of this mRNA was also increased in OSCK4 cells compared to GFP cells. However 
this could be attributed to the increase in Wnt1 expression observed in OSCK4 cells, which 
may be the result of induced SOX2 expression. However, RHOU has also been shown to be 
activated downstream of PCP signalling (Faure and Fort 2011) and therefore may 
demonstrate activation of the noncanonical Wnt signalling pathway in OSCK4 cells, which 
corresponds with the increase in active Rac1 observed in these cells. This will be discussed 
further on in this Chapter. 
In contrast to the other Wnt components, expression of DKK2 was lower in OSCK4 cells 
compared to GFP cells. The DKK family of secreted proteins are generally considered to 
inhibit Wnt signalling by binding and sequestering the Wnt co-receptors LRP5/6 (Mao et al. 
2001, Semënov et al. 2001). However, DKK2 has been shown to either activate or inhibit 
Wnt signalling, depending on the cellular context (Niehrs 2006). It has been shown 
previously that DKK2 is highly expressed in ESFT cells compared to other paediatric and 
small round cell tumours (Miyagawa et al. 2009, Hauer et al. 2013). It has also been 
demonstrated that EWS-ETS fusion proteins interact with the promoter region of DKK2 to 
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increase expression (Miyagawa et al. 2009) and that DKK2 expression promotes invasion 
and migration of ESFT cells (Hauer et al. 2013). Therefore a reduction in DKK2 expression is 
consistent with reprogramming of the ESFT cells, and again may explain the reduction in 
migration seen in OSCK4 cells.  
Although the Wnt signalling array used in this study is a valuable tool for high-throughput 
assessment of mRNA expression of components of the pathway, it has some limitations. 
For example there is only one replicate on each plate (although three biological repeats 
were performed). Therefore to validate the results of the arrays, individual RTqPCR was 
performed for four of the Wnt components found to be significantly different between 
OSCK4 and GFP cells; namely sFRP5, Wnt16, FGF4 and DKK2. RTqPCR was performed using 
Assays-on-Demand which, except in the case of FGF4, contained the same primer/probe 
mixes that were used in the array. The same RNA was used for the validation experiments. 
The results of the individual RTqPCRs were almost identical to the array results for DKK2 
and was very similar for sFRP5, except higher expression was observed in OSCK4 cells than 
had been detected on the array. In the case of Wnt16 and FGF4 however, there was 
actually less mRNA detected using the Assays-on-Demand. This may reflect some 
deterioration of the RNA with storage. Nevertheless, the results demonstrate the 
sensitivity of the Wnt signalling array used in this study to detect components of the Wnt 
signalling pathway.  
To determine if the components I have identified as being differentially expressed in 
OSCK4 and GFP3 cells have an effect in the reprogramming process to a more primitive 
cell, it would be necessary to alter the expression of these proteins. Since FGF4, Wnt8B, 
Wnt1 and sFRP5 had higher expression in OSCK4 cells, expression of these proteins could 
be knocked down using RNAi. Conversely,  DKK2 expression was decreased in OSCK4 cells 
and therefore this protein could be overexpressed using stable transfection of the gene. 
The resulting phenotype of the OSCK4 cells could then be investigated using assays such as 
as proliferation, cell cycle analysis, colony formation and migration. 
As previously mentioned, expression of active Rac1 was higher in OSCK4 cells compared to 
GFP3 cells. It has been demonstrated that the noncanonical PCP pathway, and in particular 
Rac1 is important in the migration of neural crest stem cells (Mayor and Theveneau 2014). 
Since it has been hypothesised that ESFT cells may arise from cells of the neural crest (von 
Levetzow et al. 2011), it is possible this increase in Rac1 is a result of reprogramming of the 
ESFT cells. However, OSCK4 cells showed reduced migration compared to GFP cells. 
Although some single cells did migrate out from the spheroid in the migration assay, a 
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dense core still remained which was more similar to the phenotype observed in hES cells 
(Chapter 6) and may be explained by the increase in sFRP5 and decrease in DKK2 
expression as described previously. As mentioned in Chapter 4, CD99 is known to modulate 
ESFT cell migration. Interestingly, CD99 expression is maintained in OSCK4 cells but is more 
heterogeneous, with some cells having low expression (Andrea Berry, personal 
communication). This may be another explanation for the reduced migration observed in 
OSCK4 cells. It may be possible to knock down expression of Rac1 in OSCK4 cells, to 
determine what effect this has on migration. However, since Rac1 is important in other 
signalling pathways it would still be difficult to link the resulting phenotype to the Wnt 
signalling pathway.  Similarly if inhibitors were used such as BAPTA-AM, a Ca2+ chelator or 
Go6983, an inhibitor of PKC these also often affect other signalling pathways. 
In conclusion, it is very difficult to determine the role of Wnt signalling in the initiation of 
ESFT using reprogrammed cells. Although my data has shown differences in expression of 
Wnt signalling components in OSCK4 cells and an increased ability to respond to 
exogenous Wnt3A, the mTeSR™1 media and the OSCK reprogramming factors themselves 
may affect Wnt signalling and so make interpretation of the results difficult. In addition, 
using the TCF-reporter it is not possible to identify which TCF family members are being 
activated, so the effect of Wnt signalling on downstream pathways cannot be definitely 
concluded. Although the Rac1/Cdc42 pull-down assay only considers one pathway of the 
noncanonical Wnt signalling pathway my studies have shown increased Rac1 and 
consequently activation of noncanonical Wnt signalling in OSCK4 cells. Although this did 
not correlate with the pattern of migration observed, this reflects the limitation of using 
migration as an end point for noncanonical Wnt signalling.  Therefore it is important to 
utilise alternative models of ESFT initiation in order to investigate the role of Wnt signalling 
in this process. 
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6. Wnt signalling in hES cells with inducible EWS-FLI1 expression 
6.1 Introduction 
In our laboratory we have developed an in vitro system to model ESFT initiation in which 
the EWS-FLI1 fusion protein can be induced in human embryonic stem (hES) cells. hES cells 
are derived from the inner cell mass of a 4-5 day blastocyst, produced by in vitro 
fertilization (IVF) (Thomson 1998). These cells have unlimited self-renewal capacity and are 
pluripotent meaning that have the ability to differentiate into all three primary germ 
layers; mesoderm, endoderm and ectoderm (Thomson 1998). Using this model my goal has 
been to investigate the potential role of Wnt signalling in the development of the ESFT 
phenotype. 
Expression of EWS-FLI1 in hES cells was achieved using the TetON Advanced inducible 
expression system (Figure 6.1). This is a tightly regulated, highly responsive system which 
allows for robust expression of a gene of interest (GOI) using the tetracycline (Tet) 
derivative doxycycline (DOX) (Gossen et al. 1995, Urlinger et al. 2000).  The system 
components have been modified from bacteria where in the absence of Tet, the Tet 
Repressor (TetR) blocks expression of genes by binding to tet operator sequences (tetO). In 
the Advanced TetON system, mutant reverse Tet Repressors (rTetRs) have been produced 
which along with transactivation domains from herpes simplex virus VP16 protein, form 
the transactivator, rtTA-Advanced (TetON) (Urlinger et al. 2000). Cells are transfected with 
two vectors, the first containing the TetON transactivator and the second a Tet Response 
Element (TRE)-based expression vector containing the GOI. In the presence of DOX, TetON 
Advanced binds specifically and tightly to tetO sequences in TRE-Tight and activates 
transcription of the GOI, in this case EWS-FLI1. Since TRE-Tight lacks binding sites for 
mammalian transcription factors there is extremely low background expression of the GOI.  
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Figure ‎6.1 Induction of EWS-FLI1 expression using the TetON Advanced inducible 
expression system Cells are transfected with two vectors. The first vector results in 
constitutive expression of the rtTA-Advanced transactivator (TetON) containing the 
reverse Tet Repressor (rTetR) and activation domain (TA). The second vector 
contains the EWS-FLI1 gene downstream of Tet Response Element (TRE)-Tight 
containing repeats of the tet operator sequence (tetO) joined to a minimal CMV 
promoter. Only in the presence of doxycycline (DOX) does TetON bind to TRE which 
results in the expression of EWS-FLI1. If DOX is not present or is removed, EWS-FLI1 
is not expressed. Adapted from the TetON® Advanced Inducible Gene expression 
system User Manual (Clontech). 
 
 
The aims of this chapter were to: 
 
1. Investigate the phenotype and growth characteristics of hES cells with inducible 
EWS-FLI1 expression. 
2. Investigate the expression of Wnt signalling components in hES cells with and 
without EWS-FLI1 expression. 
3. Measure the activation of the canonical Wnt signalling pathway in hES cells with 
and without EWS-FLI1 expression. 
4. Measure the activation of the noncanonical Wnt signalling pathway in hES cells 
with and without EWS-FLI1 expression. 
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6.2 Materials and Methods 
6.2.1 Feeder-free embryonic stem cell culture 
Shef4 hES cells were a kind gift from Professor Peter Andrews (University of Sheffield). 
Parental Shef4 and Shef4EWS-FLI1.OFF cell lines were maintained in feeder-free culture 
conditions using Matrigel™ coated plastic and mTesR™1 medium as previously described 
(Section 5.2.1). 
6.2.2 Culture of Shef4EWS-FLI1.ON cells 
6.2.2.1 Inducing EWS-FLI1 expression in Shef4EWS-FLI1 cells 
A ready-to-passage flask of Shef4EWS-FLI1.OFF cells was dissociated into single cells using 
trypsin/EDTA (Section 5.2.1.3). Cells were seeded onto Matrigel™ coated (Section 5.2.1.1) 
plastic flasks, dishes or plates as required. The cell density was varied according to the type 
and length of downstream assay being performed. After 24h, media was replaced with 
mTeSR™1 containing doxycycline hydrochloride (DOX) (Fisher Scientific). For routine 
experiments 5µg/ml DOX was used. Media was replaced every 24h until downstream 
assays were performed, or for stock flasks until cells were 70% confluent. 
6.2.2.2 Passage of Shef4EWS-FLI1.ON cells 
Shef4EWS-FLI1.ON cells maintained in culture grew as an adherent monolayer. Therefore for 
routine passage cells were trypsinised as previously described (Section 5.2.1.3) and split 
1:3 into fresh flasks coated with Matrigel™ (Section 5.2.1.1).  
6.2.3 Detection of EWS-FLI1 in Shef4EWS-FLI1 cells 
To detect levels of EWS-FLI1, Shef4EWS-FLI1 cells were seeded at 2 × 105 cells/well in 6 well 
plates or 4 × 105 cells in T252 flasks as previously described (Section 6.2.2.1). After 24h, cells 
were treated with normal mTeSR™1 (control) or media containing DOX (range 1-5µg/ml) 
for up to 72h as required.  
6.2.3.1 RTqPCR 
To detect EWS-FLI1 mRNA, RNA was extracted from cells (Section 2.2.5.1) and RNA 
quantity and quality measured using the Nanodrop (Section 2.2.5.2). cDNA was prepared 
as previously described (Section 2.2.5.3). The RT+ (cDNA) and RT- control samples were 
added to PCR mixes for amplification of EWS-FLI1 (Table 6.1) and the housekeeping gene 
PPIA (Section 2.2.5.5, Table 2.5). RTqPCR was performed using the 7500 Real-Time PCR 
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System (Section 2.2.5.5). For detection of EWS-FLI1 cDNA was incubated at 50°C for 2min, 
heated to 95°C for 15min followed by 50 cycles of 95°C for 15s, 66°C for 1min and 72°C for 
90s. Gene expression was determined using the ΔΔCt method (Section 2.2.5.5) using TC32 
cells as the reference sample. 
EWS-FLI1 Mix 
Volume (µl, per 
sample) 
Final concentration 
TaqMan Universal PCR Master Mix 50 1X 
20 μM EWS Forward Primer                                              
5’-GTCAACCTCAATCTAGCACAGGG-3’ 
1 200nM 
20 μM FLI1 Reverse Primer                                              
5’-CTGTCGGAGAGCAGCTCCAG -3’ 
1 200nM 
20 μM EWS probe 
5’CTCCTACCAGCTATTCCTCTACACAGCCGACT-3’ 
1 200nM 
RNase free H2O 27 - 
Table ‎6.1 PCR mix reagents for RTqPCR to detect EWS-FLI1 
 
6.2.3.2 Western blot 
To detect EWS-FLI1 protein, total protein was extracted and SDS-PAGE performed followed 
by western blot as previously described (Section 2.2.5). Since no commercial antibody is 
available for EWS-FLI1, a rabbit anti-FLI1 antibody (Santa Cruz) was used at a concentration 
of 0.4µg/ml. This antibody detects the C-terminus of FLI1 and therefore detects bands 
corresponding to wild type FLI1 (51 kDa) as well as EWS-FLI1 (68kDa).  
6.2.4 Immunofluorescence 
Glass coverslips (22mm × 22mm; VWR) were sterilised by submerging in 100% ethanol and 
drying in air, this was repeated three times. Each coverslip was placed in one well of a 6-
well plate and coated in Matrigel™ (Section 5.2.1.1). Shef4EWS-FLI1.OFF and Shef4EWS-FLI1.ON cells 
were trypsinised (Section 5.2.1.3) and seeded at a density of 4 × 104 cells (Shef4EWS-FLI1.OFF) 
or 6 × 104 cells (Shef4EWS-FLI1.ON), suspended in 200µl of growth media. After 6h, once the 
cells had adhered to the coverslip the well was flooded with 3ml mTeSR™1 (containing 
5µg/ml DOX if required) and the cells incubated for a further 48h. If required, media 
containing rWnt5A (200ng/ml) was added to the well 24h prior to harvesting. To prepare 
the slides, media was aspirated and cells washed three times in 1X PBS. To fix the cells, 4% 
PFA was added to the cells for 15 min at RT. Cells were then washed 3 three times with 1X 
PBS, permeabilised using 0.1% Triton-X (in PBS) and finally washed three more times in 1X 
PBS. To stain the cytoskeleton (F-actin) cells were incubated with 1 unit of phalloidin (Life 
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Technologies) and 0.2µg/ml DAPI (Sigma-Aldrich) in 100µl in PBS in the dark for 30min. 
Cells were washed three more times with 1X PBS and mounted using Dako Faramount 
Aqueous Mounting Medium Ready-to-use (Dako, Ely, UK). Slides were analysed using the 
Axioplan 2 fluorescence microscope (Zeiss, Cambridge, UK) 
6.2.5 Determining viable cell number of Shef4 cells 
Cells which had been pre-treated as required were trypsinised as previously described 
(Section 5.2.1.3) and seeded at 5 × 104 cells/well in 24-well plates coated with Matrigel™ 
(Section 5.2.1.1). Cells were seeded either in RPMI (+10% conditioned media) or mTeSR™1 
as required. In some experiments after 24h cells were treated with either rWnt3A 
(200ng/ml) or rWnt5A (200ng/ml). After 24, 48 and 72h cells were counted using the 
automated vi-cell as previously described (Section 2.2.2). Triplicate wells were counted for 
each condition, at each time point. 
6.2.6 Analysis of Wnt signalling components using RTqPCR  
RNA was extracted (Section 2.2.5.1) from Shef4EWS-FLI1.OFF cells and Shef4EWS-FLI1.ON cells that 
has been treated with 5µg/ml DOX for 72h (Section 6.2.2.1). RNA was also extracted from 
Shef4 parental cells and Shef4 parental cells treated with 5µg/ml DOX for 72h. Gene 
expression of components of the Wnt signalling pathway were analysed using the 
TaqMan® Array Human WNT Pathway 96-well plate (Applied Biosystems), as described 
(Section 2.2.5.4).  
6.2.7 Generation of cell lines transduced with 7TFH vector 
Shef4EWS-FLI1 and Shef4 parental cells were infected with lentiviral supernatant at an MOI of 
2 (Section 3.2.2.3) and 48h after infection were selected using media containing 200 µg/ml 
hygromycin for 2 weeks. Cells were maintained in Class II conditions (as described in 
Section 3.2.2.2) for at least 10 days after infection or until at least 2 passages had been 
performed. 
6.2.8 Luciferase assay 
Shef4 parental and Shef4EWS-FLI1 cells were dissociated into single cells using trypsin/EDTA 
(Section 5.2.1.3). Cells were seeded to be approximately 60-70% confluent at the time the 
luciferase assay was carried out. Therefore the number of cells seeded varied depending 
on the treatment condition and length of experiment. Shef4 parental and Shef4EWS-FLI1 cells 
were seeded at 5 × 104 cells/well and assayed after 96h. For  Shef4EWS-FLI1.ON cells the 
seeding density ranged from 5 × 104 to 1 × 105 and were assayed 24-72h after adding DOX 
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(5µg/ml). Luciferase was determined using the Luciferase Assay (Section 3.2.5). If required, 
rWnt3A (200ng/ml) or rWnt5A (200ng/ml) was added 24h prior to the luciferase assay 
being performed.  
6.2.9 Detection of total and active β-catenin by western blot 
Cells were seeded in 6-well plates at a density 2 × 105 cells/well. After 24h, cells were 
treated with normal media (control) or media containing Wnt3A (200ng/ml) or Wnt5A 
(200ng/ml) for 4h. Total and active β-catenin were determined by western blot as 
previously described (Section 3.2.10). 
6.2.10 Migration assay 
Shef4EWS-FLI1.OFF and Shef4EWS-FLI1.ON cells that had been cultured in DOX (5µg/ml) for 72h 
were trypsinised (Section 5.2.1.3) and seeded at 500 cells/well in 96-well plates to form 
spheroids (Section 4.2.2). For optimisation experiments spheroids were encouraged to 
form by centrifuging the plate for 4min at 152g or by adding 10µM ROCK inhibitor (Y-
27632, Sigma-Aldrich). In optimised conditions ROCK inhibitor (10µM) was added to the 
cell suspension at day 0. Migration assays were performed to compare migration on 
different substrates and in response to Wnt ligands and analysed using Volocity® software 
(Section 4.3.2). 
6.2.11 Rac1/Cdc42 pull down assay 
Shef4EWS-FLI1 cells were trypsinised (Section 5.2.1.3) and seeded in 10cm2 dishes at a density 
of either 1.5 × 106 cells/dish (control) or 3 × 106 cells/dish (treated). After 24h, media 
containing 5µg/ml DOX was added to the dishes seeded at the higher concentration. After 
a further 72h the media was replaced with normal growth media (control) or media 
containing rWnt5A (200ng/ml) for 30 min. Expression of total and active Rac1 and Cdc42 
was determined as previously described (Section 4.2.1.4). 
6.2.12 Statistics 
Analysis of the Wnt signalling array was performed by Mr John Alexander (University of 
Leeds) as previously described (Section 5.2.10).. All other statistical analyses were 
performed as described previously (Section 3.2.11). 
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6.3 Results 
6.3.1 Characterising Shef4 cells with inducible EWS-FLI1 expression 
6.3.1.1 Expression of EWS-FLI1 mRNA in Shef4EWS-FLI1 cells 
The expression of EWS-FLI1 in Shef4EWS-FLI1 cells after the addition of DOX was confirmed by 
RTqPCR. EWS-FLI1 mRNA expression was increased in both a dose- and time-dependent 
manner (Figure 6.2 A and B). Expression of EWS-FLI1 mRNA was greatest after treatment of 
Shef4EWS-FLI cells with 5 μg/ml DOX for 72h. This level of expression was 1.16±0.18 -times 
that in the ESFT TC32 cell line (Figure 6.2 B). Expression of EWS-FLI1 was maintained at a 
similar level when Shef4EWS-FLI.ON cells were cultured continuously in DOX for up to 1 month 
(Figure 6.2 B). 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎6.2 Expression of EWS-FLI mRNA in Shef4EWS-FLI cells treated with DOX  Shef4EWS-
FLI1.OFF (control) cells were treated with A) increasing concentrations of DOX (1,2.5,5 
µg/ml) for 48h or B) 5 µg/ml DOX for increasing periods of time (24,48,72 h, 1 week, 
1 month). Total RNA was extracted and expression of EWS-FLI1 mRNA determined by 
RTqPCR. Data are presented as mRNA expression relative to the housekeeping gene 
PPIA and normalised to expression of EWS-FLI1 in TC32 control cell line. Results 
show the mean of two independent experiments with three replicates per repeat 
(n=6) (±SEM). 
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6.3.1.2 Expression of EWS-FLI1 protein in Shef4EWS-FLI1 cells 
Expression of EWS-FLI1 protein in Shef4EWS-FLI1 cells was confirmed by western blot. Since 
an antibody to EWS-FLI1 is not commercially available, an antibody that recognises the C- 
terminus of FLI-1 was used to detect the fusion protein (Santa Cruz, sc-356).  The antibody 
detects  multiple non-specific bands, in addition to endogenous FLI-1 protein, therefore  
the EWS-FLI1 band (68 kDa) was confirmed using TC32 positive control cells and TTC466 
cells, which contain a different fusion protein (EWS-ERG), as a negative control. EWS-FLI1 
protein was induced after DOX treatment in a dose- and time- dependent manner. EWS-
FLI1 protein could be detected after treatment with 2.5 and 5μg/ml DOX (Figure 6.3 A). 
Maximum expression of EWS-FLI1 protein was observed after treatment with 5 μg/ml DOX 
for 72h (Figure 6.3 B).  
 
 
 
 
 
 
 
 
Figure ‎6.3 Expression of EWS-FLI protein in Shef4EWS-FLI1 cells treated with DOX Shef4EWS-
FLI1.OFF (control) cells were treated with A) Increasing concentrations of DOX (1,2.5,5 
µg/ml) for 48h or B) 5 µg/ml DOX for increasing periods of time (24,48,72 h). Total 
protein was extracted and EWS-FLI1 protein detected by western blot, as a band at 
68 kDa present in the TC32 positive control, but not TTC466 negative control. 
Expression of β-actin was used as a loading control. MW= molecular weight in kDa. 
Images representative of two independent experiments. 
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6.3.1.3 Growth characteristics of Shef4EWS-FLI1 cells with EWS-FLI expression  
6.3.1.3.1 Phenotype of Shef4EWS-FLI1 cells with and without EWS-FLI1 expression 
Over the time period that EWS-FLI1 mRNA and protein was induced (24-72h) the 
phenotype of the Shef4EWS-FLI1.ON cells changed. The morphology of non-induced Shef4EWS-
FLI.OFF cells resembled that of the Shef4 parental cell line, cells growing on Matrigel™ coated 
plastic as undifferentiated stem cell colonies with very defined edges (Figure 6.4 A). 
Changes in the morphology of Shef4EWS-FLI1.ON were first noticed approximately 48h after the 
addition of DOX (5μg/ml). This is also the time point when the EWS-FLI1 protein was 
detected by western blot (Section 6.3.1.2). After 72h of DOX treatment, the Shef4EWS-FLI1.ON 
cells appeared larger and elongated, the colony edges were less defined and single cells 
migrated out to fill the gaps between colonies, reminiscent of the substrate dependent 
growth of the ESFT cell lines (Figure 6.4 B). Immunofluorescent staining of the actin 
cytoskeleton demonstrated Shef4EWS-FLI1.OFF cells tightly packed with an actin cable 
surrounding the colonies, and many cell-cell adhesions (Figure 6.5). After 72h DOX 
treatment, Shef4EWS-FLI1.ON cells began to lose this organised structure. There appeared to be 
fewer colonies, less cell-cell adhesions, more single cells and an increase in the number of 
cells with filapodia (Figure 6.4), although this was not quantified. After continued DOX 
treatment (1 month) the phenotype of the  Shef4EWS-FLI1.ON  continued to change, cells 
appeared much larger and had more stress fibres, although some smaller cells were still 
present (Figure 6.5). 
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Figure ‎6.4 Light microscopy of Shef4EWS-FLI.OFF and Shef4EWS-FLI.ON cells ShefEWS-FLI1 cells were 
seeded as a single cell suspension and cultured for 72h in the A) absence or B) 
presence of 5 µg /ml DOX. Representative images were taken every 24h.  
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Figure ‎6.5 Actin cytoskeleton in Shef4EWS-FLI.OFF and Shef4EWS-FLI.ON cells Shef4EWS-FLI.OFF, 
Shef4EWS-FLI.ON and Shef4EWS-FLI.ON (1 month) cell lines were seeded as single cells onto 
glass coverslips coated with Matrigel™. Cells were grown for 48h then fixed with 4% 
PFA, and stained with DAPI (blue) and phalloidin (green) and imaged using a 
fluorescent microscope.  
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6.3.1.3.2 Viable cell growth of Shef4 cells in doxycycline  
Following treatment of Shef4EWS-FLI1 cells with DOX, an increase in the number of floating, 
non-substrate adherent cells was observed. I therefore investigated whether the DOX may 
be killing some cells. Consistent with this possibility, DOX treatment reduced the viable cell 
number of Shef4 cell lines (Figure 6.6). The addition of 5 μg/ml DOX for 72h reduced the 
viable cell number of both Shef4 parental and Shef4EWS-FLI1 cells to 42±0.7% and 52±0.16% of 
the no treated (control) cells, respectively. This suggests the reduction in viable cell 
number is due to the effect of the DOX itself, not induced expression of the EWS-FLI fusion 
protein. 
When these Shef4 parental cells were re-challenged with DOX (5μg/ml) there was no effect 
on viable cell number after 72h (Figure 6.7, blue and green lines). In contrast however, 
Shef4EWS-FLI1.ON cells re-challenged with DOX (5µg/ml) had significantly reduced viable cell 
number after 72h (p<0.0001). Shef4EWS-FLI1.ON cells pre-treated with DOX for 1 month had 
significantly reduced viable cell number than those only pre-treated for 72h (p<0.05) 
(Figure 6.7, orange and red lines). This suggests that in both Shef4 parental and Shef4EWS-FLI1 
cells there is a sub-population of cells that are sensitive to DOX and these cells are killed by 
initial treatment with 5µg/ml DOX for 72h. In Shef4 parental cells the growth of the 
resistant population is not affected by further exposure to DOX. However, in Shef4EWS-FLI1.ON 
cells, even cells resistant to DOX show decrease in viable cell number, suggesting the 
induced EWS-FLI1 fusion protein is having an effect on the cell cycle of these cells.  
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Figure ‎6.6 Effect of doxycycline  on Shef4 and Shef4EWS-FLI1  viable growth Shef4 parental 
and Shef4EWS-FLI1 cells were seeded as single cells and cultured in the presence of 
increasing concentrations of DOX (2,2.5,5 µg/ml) for 72h. Viable cell number was 
determined by trypan blue exclusion using the Vi-cell automated cell counter. Data 
presented as a percentage of the viable cell number of control cells not treated with 
DOX. Results show mean of two independent experiments (±SEM). Stats = NS 
difference. 
 
 
 
 
 
 
 
 
 
Figure ‎6.7 Effect of doxycycline treatment on Shef4 viable cell number with time Shef4 
parental cells, Shef4 parental cells previously treated with DOX (72h), Shef4EWS-FLI1.OFF  
and Shef4EWS-FLI1.ON cells that had been previously treated with DOX for 72h or 1 
month were seeded in a single cell suspension in 24 well plates. Viable cell number 
was determined after 24, 48 and 72 h by trypan blue exclusion using the Vi-cell 
automated cell counter. Results show mean of three independent experiments 
(±SEM). 
0
20
40
60
80
100
120
C 1 2.5 5
V
ia
b
le
 c
e
ll 
n
u
m
b
e
r 
(%
 o
f 
co
n
tr
o
l)
Shef4 Shef4.EWS-FLI1
DOX (µg/ml)
* 
** = p<0.001 
* = p<0.05 
** 
 - 192 -   
 
 
6.3.1.3.3 Effect of different media on Shef4EWS-FLI viable cell number 
The reduction in viable cell number over an extended period of time in Shef4EWS-FLI1.ON cells 
appeared not to be due to DOX. I therefore tested the hypothesis that the Shef4EWS-FLI1.ON 
cells no longer tolerated being cultured in mTeSR™1, which is optimised to maintain 
undifferentiated embryonic stem cells. By transferring these cells to the growth conditions 
of ESFT cells I examined if these cells would tolerate the cancer cell media; such an 
adaption might reflect the development of a more differentiated ESFT-like cell, rather than 
a stem cell. However, when Shef4EWS-FLI cells were pre-treated with DOX for 24, 48 or 72h 
and then seeded into mTeSR™1(+DOX)  or RPMI(+DOX), the viable cell number was 
reduced in the ESFT RPMI culture conditions, regardless of the length of pre-treatment 
with DOX (Figure 6.8 A-C). In all cases, viable cell number was significantly reduced when 
Shef4EWS-FLI1.ON cells were grown in RPMI (+ DOX) compared to mTeSR™1(+ DOX) (p<0.05).  
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Figure ‎6.8 Shef4EWS-FLI1.ON viable cell number in mTeSR-™1 and RPMI Shef4EWS-FLI1 cells were 
treated with 5µg/ml DOX for either 24, 48 or 72 h. Resulting  Shef4EWS-FLI1.ON cells 
were trypsinised and seeded in a single cell suspension in mTeSR-™1 or RPMI 
(+5µg/ml DOX). Viable cell number was determined every 24h up to 72h using the Vi-
cell automated cell counter. Growth was compared to Shef4EWS-FLII1.OFF cells grown in 
mTeSR™1 (control). 
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Shef4EWS-FLI1.ON cells pre-treated with DOX (5µg/ml, 72h) and seeded in mTeSR™1+DOX grew 
as monolayers with very few colonies. Cells reached confluency after 2-3 days and could be 
continually passaged using Trypsin/EDTA (0.2X Trypsin/1mM EDTA). These cells did not 
resemble Shef4EWS-FLI1.OFF cells when examined down the light microscope; cells appeared 
larger, elongated and no longer grew in colonies (Figure 6.9 A and B). However,  although 
Shef4EWS-FLI1.ON  cells pre-treated with DOX (5µg/ml, 72h) and seeded in RPMI + DOX had 
some adherent cells, these did not appear to increase in number even after 5 days of 
culture (Figure 6.9 C and D). Therefore, Shef4EWS-FLI1.ON cells which remained in culture were 
maintained in mTeSR™1(+DOX). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎6.9 Light microscopy of Shef4EWS-FLI1.ON cells in mTeSR™1 and RPMI Representative 
images  48h after seeding of A) Shef4EWS-FLI1.OFF  control cells grown in mTeSR™1 and 
Shef4EWS-FLI1.ON cells previously cultured in mTeSR™1 + DOX for 72h, then seeded into 
B) mTeSR™1+DOX or C) RPMI+ DOX. D) Shef4EWS-FLI1+ cells after culture in RPMI +DOX 
for 5 days. 
A) Shef4EWS-FLI1.OFF in mTeSR™1 B) Shef4EWS-FLI1.ON in mTeSR™1 
+DOX 
C) Shef4EWS-FLI1.ON in RPMI + DOX D) Shef4EWS-FLI1.ON in RPMI + DOX (5 days) 
Confluent monolayer 
Adherent cells, no evidence of proliferation 
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6.3.2 mRNA expression of Wnt signalling components in Shef4EWS-FLI1 cells   
6.3.2.1 Profile by TaqMan® Wnt Pathway Array 
RNA from Shef4EWS-FLI1.OFF cells was compared to RNA from Shef4EWS-FLI1.ON cells that had 
been exposed to 5 μg/ml DOX for 72h. Expression of 94.5% (86/91) of Wnt signalling 
components was unchanged when EWS-FLI1 expression was induced in Shef4 cells (Figure 
6.10). Genes where expression changed by more than 2 Ct values are shown in Table 6.2.  
After the EWS-FLI1 fusion protein was induced in Shef4EWS-FLI1 cells, there was significantly 
increased mRNA expression of the Frizzled receptor FZD8 (p<0.05), and two noncanonical 
Wnt ligands Wnt4 and Wnt5A (both p<0.05). There was also increased expression of the 
canonical Wnt inhibitor DKK2 (p<0.05) but conversely decreased expression of the related 
inhibitor DKK4 (p<0.05). 
Expression of Wnt signalling components was determined for Shef4 parental cells and 
Shef4 parental cells treated with DOX (5μg/ml) for 72h to confirm that the expression of 
genes identified in Table 6.2  did not change due to the addition of DOX itself (data not 
shown).  
Table ‎6.2 Genes with significantly different mRNA expression in Shef4EWS-FLI1.ON cells 
compared to Shef4EWS-FLI1.OFF Expression of genes was determined using the Taqman® 
Wnt signalling gene expression array and genes with significantly different 
expression in Shef4EWS-FLI1.OFF and Shef4EWS-FLI1.ON cells identified by Limma analysis 
(Section 5.2.10). Ct values are given for the mean of two independent experiments 
(±SEM). *A lower Ct value means higher expression therefore a reduction in Ct value 
indicates an increase in expression. A Ct value of 40 is considered no detection. 
Gene 
P 
value 
Expression in  
Shef4EWS-FLI1.OFF 
(Ct value) 
Expression in  
Shef4EWS-FLI1.ON 
(Ct value) 
Expression  in 
Shef4EWS-FLI1.ON  
relative  to 
Shef4EWS-FLI1.OFF* 
(Change in Ct value) 
FZD8 
0.032 
28.1±0.6 24.2±0.6 -3.8 
DKK2 
0.014 
32.5±0.4 28.8±0.5 -3.7 
DKK4 
0.025 
27.1±0.1 30.6±1 +3.5 
WNT4 
0.012 
33.3±0.2 30.5±0.4 -2.7 
WNT5A 
0.013 
27.1±0.6 25.1±0.5 -2 
  
 
 
 
 
 
 
 
 
Figure ‎6.10 RNA expression of components of the Wnt signalling pathway in Shef4EWS-FLI1 cells Shef4EWS-FLI1.OFF and Shef4EWS-FLI1.ON cells that had been treated 
with DOX (5µg/ml) for 72h were harvested, total RNA extracted and expression level determined using the Taqman® Wnt signalling gene expression 
array. Data presented as mRNA expression relative to the geometric mean of the housekeeping genes HPT1 and GUSB. Results show mean of two 
independent experiments (±SEM). *= Genes that were expressed at significantly different levels (p<0.05) and were changed by more than 2 Ct values 
between Shef4EWS-FLI1.OFF and Shef4EWS-FLI1.ON cells (see Table 6.2) 
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6.3.3 Activity of the canonical Wnt signalling pathway in Shef4 cells with 
EWS-FLI1 expression 
6.3.3.1  Optimisation of luciferase reporter assay in Shef4 cells 
The endogenous activity of the 7TFH luciferase reporter plasmid in Shef4EWS-FLI1.OFF 7TFH cells 
was very variable and differed up to 15-fold between experimental repeats (range=2735- 
41985 RLU), unlike in other cell lines studied. For example in the ESFT cell lines the most 
variation observed was in the TC32 cell line but this difference was only 2.4-fold (range 
11711-27989 RLU). It was observed that In Shef4EWS-FLI1.OFF 7TFH cells the luminescence 
(measured per 10,000 cells) was higher when the assay was performed 24h after the cells 
had been seeded (41985 RLU) and reduced in a time dependent manner to 2735 RLU when 
the assay was performed 96h after seeding (Figure 6.11). This difference was not due to 
the confluency of the cells, as cell seeding density was optimised  so that the viable cell 
number was similar at the time of each assay (range= 0.25-0.38  x106 cells). It was 
hypothesised therefore that in Shef4 cells, the dissociation of cells by trypsinisation and 
subsequent plating may affect Wnt signalling. Therefore to control for this luciferase assays 
in Shef4 cells were always carried out 96h after seeding, regardless of the treatment 
condition.  
 
 
Figure ‎6.11 Effect of time in culture on the activity of luciferase reporter activity in Shef4 
7TFH cells Shef4EWS-FLI1.OFF cells were trypsinised seeded as a single cell suspension 
and luminescence determined after 24, 48, 72 and 96 h using the luciferase assay 
(Section 3.2.5). Cell seeding density was optimised so that cells were 50-60% 
confluent when assayed. RLU=relative light units.   
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6.3.3.2 Effect of doxycycline treatment on canonical Wnt signalling activity in 
Shef4EWS-FLI1 cells with time 
The activity of the luciferase reporter plasmid in Shef4EWS-FLI1.ON 7TFH cells was induced, 
compared to the level in Shef4EWS-FLI1.OFF 7TFH control cells, after 56h exposure to DOX 
(Figure 6.12). After 72h DOX treatment, luciferase activity was 2.6X the level of the control 
cells. With continued culture in DOX, the activity of the luciferase reporter continued to 
increase so that after 1 month of  DOX treatment the luminescence per 10,000 cells was 
significantly higher than  that of the control cells (p<0.01) (Figure 6.12). This suggests that 
canonical Wnt signalling is activated by the expression of EWS-FLI1. 
 
  
 
 
 
 
 
 
 
 
Figure ‎6.12 Luciferase reporter activity in Shef4EWS-FLI1.ON cells ShefEWS-FLI1 cells were treated 
with DOX for increasing periods of time (24h-1month). In all cases luminescence was 
determined 96h after seeding using the luciferase assay (Section 3.2.5). 
Luminescence was normalised to the viable cell number which was determined from 
identically treated wells by trypan blue exclusion using the Vi-cell automated cell 
counter. Data are presented as luminescence (per 10,000 cells) relative to Shef4EWS-
FLI1.OFF control. Results are of two independent experiments with 3 replicates in each 
experiment (n=6) presented as mean (±SEM).                                   
+ = only one repeat at 30h (n=3). 
0
1
2
3
4
5
6
7
8
9
24h 30h 48h 56h 72h 1 week 1 month
A
ct
iv
at
io
n
 o
f 
ca
n
o
n
ic
al
 W
n
t 
si
gn
al
lin
g 
(L
u
m
in
e
sc
e
n
ce
 r
e
la
ti
ve
 t
o
 S
h
e
f4
EW
S-
FL
I.
O
FF
)
DOX (5µg/ml)
**** 
* 
*       =p<0.05 
****=p<0.0001 
+ 
* 
- 199 - 
 
6.3.3.3 Activation of canonical Wnt signalling in Shef4 cells with and without 
EWS-FLI1 expression after treatment with Wnt ligands 
As previously described (Section 6.3.3.2), endogenous canonical Wnt signalling was 
significantly higher in Shef4EWS-FLI1.ON 7TFH cells that had been cultured in DOX for 72h 
(p<0.05) and 1 month (p<0.0001), compared to Shef4EWS-FLI1.OFF 7TFH cells not cultured in 
DOX. Canonical Wnt signalling was not increased in Shef4EWS-FLI1.OFF 7TFH control cells 
following treatment with Wnt5A (200ng/ml) or Wnt3A (200ng/ml) for 24h (Figure 6.13, 
blue bars). However, canonical Wnt signalling was significantly increased in Shef4EWS-FLI1.ON 
7TFH cells following the addition of Wnt3A (200ng/ml). This was observed in cells which had 
been cultured in DOX for 72h (p<0.01, red bars) and 1 month (p<0.05, green bars).   
  
 
 
Figure ‎6.13 Luciferase reporter activity in Shef4 cells with and without EWS-FLI1 
expression  after treatment with Wnt ligands Shef4EWS-FLI1.OFF and Shef4EWS-FLI1.ON   
cells cultured in DOX for 72h and 1 month were stimulated with 200ng/ml Wnt5A or 
Wnt3A for 24h. In all cases luminescence was determined 96h after seeding using 
the luciferase assay (Section 3.2.5). Luminescence was normalised to the viable cell 
number which was determined from identically treated wells by trypan blue 
exclusion using the Vi-cell automated cell counter.  Data are presented as 
luminescence (per 10,000 cells) relative to Shef4EWS-FLI1.OFF control. Results of three 
independent experiments with 3 replicates per experiment (n=9) showing mean 
(±SEM). RLU= relative light units. 
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6.3.3.4 Effect of doxycycline on canonical Wnt signalling in Shef4 parental cells 
The addition of increasing concentrations of DOX (1, 2.5,5 µg/ml) or treatment with 5µg/ml 
DOX plus Wnt5A (200ng/ml) or Wnt3A (200ng/ml) did not increase luciferase reporter 
activity in Shef4 parental 7TFH cells (Figure 6.14). This suggests that the effects seen in 
Shef4EWS-FLI1.ON 7TFH cells were due to the EWS-FLI1 fusion protein, not DOX treatment. 
 
 
 
 
Figure ‎6.14 Effect of exposure to doxycycline on the  activity of luciferase reporter 
plasmid in Shef4 cells Shef4 parental 7TFH cells were seeded as single cells and  24h 
later treated with increasing concentrations DOX (1, 2.5 5 µg/ml) for 72h or 5 µg/ml 
DOX for 48h + 200ng/ml Wnt5A or 200ng/ml Wnt3A (+DOX) for  a further 24h. 
Luminescence was determined using the luciferase assay (Section 3.2.5). 
Luminescence was normalised to the viable cell number which was determined from 
identically treated wells by trypan blue exclusion using the Vi-cell automated cell 
counter. Data are presented as luminescence (per 10,000 cells) relative to Shef4 
7TFH control. Results of three independent experiments with three replicates per 
experiment (n=9) showing the mean (±SEM). RLU= relative light units.  
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6.3.3.5 Confirmation that stimulation of Wnt signalling in Shef4EWS-FLI cells 
activates downstream targets  
To confirm the activation of canonical Wnt signalling measured using the firefly luciferase 
reporter plasmid, expression of downstream targets of canonical Wnt signalling were 
investigated in Shef4EWS-FLI1 cells. As shown in HEK293T cells (Chapter 3) expression of both 
active and total β-catenin should increase following activation of canonical Wnt signalling.  
The endogenous levels of both  total (1.5-fold) and active (1.2-fold)  β-catenin were 
increased modestly in Shef4EWS-FLI1.ON cells compared to Shef4EWS-FLI1.OFF  cells after 1 month 
culture with DOX (5µg/ml) (Figure 6.15). After treatment with Wnt3A (200ng/ml) for 4h, 
total (1.3-fold) and active (1.6-fold) β-catenin expression was increased in Shef4EWS-FLI1.OFF 
control cells. In Shef4EWS-FLI1.ON cells after treatment with Wnt3A, total β-catenin was 
increased 1.5-fold in cells treated with DOX for 72h, but actually decreased in cells treated 
with DOX for 1 month (Figure 6.15). In contrast active β-catenin was decreased in Shef4EWS-
FLI1.ON cells treated with DOX for 72h and was increased 1.2-fold in cells treated with DOX 
for 1 month.   
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Figure ‎6.15 Expression of β-catenin in Shef4EWS-FLI1 cells after stimulation with Wnt 
ligands. Shef4EWS-FLI1.OFF and Shef4EWS-FLI1.ON cells cultured in DOX for 72h and 1 month 
were stimulated with 200ng/ml Wnt5A or 200ng/ml Wnt3A for 4h. A) Total protein 
was extracted and expression of total and active β-catenin determined by western 
blot. Expression of β-actin was used as a loading control. Densitometry was 
performed to quantify the ratio of expression of B) total β-catenin to β-actin 
expression and C) active β-catenin compared to total β-catenin expression. 
MW=molecular weight in kDa. 
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6.3.4 Activity of the noncanonical Wnt signalling pathway in Shef4 cells 
with EWS-FLI1 expression 
6.3.4.1 Migration of Shef4 cells with EWS-FLI1 expression 
6.3.4.1.1 Optimisation of migration assay for Shef4 cells 
The migration assay I have optimised in Chapter 4 relies upon the initial formation of 
spheroids from cell lines. However, Shef4 cells plated into ultra-low adherence 96 well 
round-bottomed plates did not form spheroids; after 4 days of culture, single cells 
accumulated at the bottom of the well but did not aggregate (Figure 6.16, left panels). Two 
alternative methods were used to encourage the formation of spheroids by Shef4 cells. 
Centrifuging the plate (152g, 4 min) immediately after seeding cells did not induce 
spheroid formation (Figure 6.16, middle panels). Application of a selective Rho-associated 
kinase (ROCK) inhibitor has been reported to increase survival of dissociated hES cells and 
promote formation of spheroids also known as ‘embryoid bodies’ (Watanabe et al. 2007).  
Indeed, addition of the ROCK inhibitor (Y-27632, 10µM) to the media resulted in the 
formation of spheroids by both Shef4EWS-FLI1.OFF and Shef4EWS-FLI1.ON cells. The spheroids 
formed by Shef4EWS-FLI1.ON cells were significantly smaller by, on average, 37±3.5% 
(p<0.0001) Increased amounts of cell debris were visible in the bottom of the well, in 
which Shef4EWS-FLI1.ON cells had been cultured  which may be attributed to the reduction in 
cell viability observed when Shef4 cells are treated with DOX (Section  6.3.1.3).  
Cells within Shef4EWS-FLI1.OFF spheroids did not migrate out from the core of the spheroid 
unless plated onto Matrigel™, which is the substrate used for feeder free culture of Shef4 
cells (Figure 6.17 A). After 72h, the maximum MI of Shef4EWS-FLI1.OFF cells was 54±1.3 (i.e. 
cells had migrated over an area  54X that of the area covered by the core at 0h).  However, 
cells from Shef4EWS-FLI1.ON spheroids migrated when plated onto all three substrates. After 
72h, the migration index was greatest when spheroids were plated onto gelatin (63±1.7), 
and smallest when plated onto Primaria™ plastic (13±1.4) (Figure 6.17 B).  
  Single cells, not 
aggregated 
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Figure ‎6.16 Formation of spheroids from Shef4 cells Shef4EWS-FLI1.OFF and Shef4EWS-FLI1.ON cells 
which had been pre-treated with DOX for 72h were seeded into ultra-low adherent 
96 well plates (500 cells/well). Plates were either A) placed immediately in the 
incubator, B) centrifuged at 152g for 4 minutes or C) 10µM  ROCK inhibitor (Y-27632) 
added to the media. Representative images taken after 4 days are shown. 
 
 
 
 
 
 
 
 
Shef4EWS-FLI1.OFF
Centrifugation
(400g, 4 mins)
+ 10µM ROCK inhibitor 
(Y-27632)
Shef4EWS-FLI1.ON
Single cells and debris 
  
0
10
20
30
40
50
60
70
24h 48h 72h
M
ig
ra
ti
o
n
 In
d
ex
Gelatin Matrigel Primaria
0
10
20
30
40
50
60
70
24h 48h 72h
M
ig
ra
ti
o
n
 In
d
ex
Gelatin Matrigel Primaria
A) Shef4EWS-FLI1.OFF
Matrigel™ Primaria™
B) Shef4EWS-FLI1.ON
Gelatin (0.1%) Matrigel™ Primaria™
Gelatin (0.1%)
 
Figure ‎6.17 Migration of Shef4 cells with and without EWS-FLI1 expression on different substrates. Spheroids were formed from A) Shef4EWS-FLI1.OFF and B) 
Shef4EWS-FLI1.ON   cells and transferred into flat-bottomed 96 well plates coated with either 0.1% gelatin, Matrigel™ or directly onto Primaria™ plastic. 
Spheroids were imaged every 24 h and the area covered by migrated cells quantified using Velocity software. Images show spheroids 48h post seeding. 
Dotted lines show the boundary of migrating cells. Results are presented as the area covered by migrating cells relative to the size of the spheroid at Day 
0 (Migration Index) and given as the mean of three wells within one experiment (n=3) (±SEM)  
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6.3.4.1.2 Migration of Shef4EWS-FLI cells in response to Wnt ligands 
To enable comparison of the migration of Shef4EWS-FLI1 cells  and the migration of ESFT cell 
lines, Shef4EWS-FLI1 cell spheroids were plated onto gelatin coated plates in the presence of 
Wnt5A (200ng/ml) or Wnt3A (200ng/ml). Cells within Shef4EWS-FLI1.OFF spheroids did not 
migrate out of the core of the spheroid in response to either Wnt5A or Wnt3A (Figure 6.18 
A). In contrast, Shef4EWS-FLI1.ON cells did migrate. After 72h, the migration index of Shef4EWS-
FLI1.ON cells treated with both Wnt5A (44±3.3) and Wnt3A (41±1.7) was increased compared 
to control cells not treated with Wnt ligand (30±2.4)), however this difference did not 
reach statistical significance (Figure 6.18 B). 
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Figure ‎6.18 Migration of Shef4 cells with and without EWS-FLI1 expression  in response to Wnt ligands  Spheroids were formed from A) Shef4EWS-FLI1.OFF and B) 
Shef4EWS-FLI1.ON  cell lines and plated onto flat-bottomed 96 well plates coated with 0.1% gelatin in mTeSR™1 (+/- DOX) containing a final concentration of 
200ng/ml recombinant Wnt3A or 200ng/ml recombinant Wnt5A. Images were taken every 24h and the area covered by migrating cells quantified using 
Velocity software. Representative images show migration after 72h.  Results are presented as the area migrated at each time point relative to the area of the 
spheroid at 0h (Migration Index) and given as the mean of three independent experiments with three replicates per experiment (n=9)(±SEM). 
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6.3.4.2 Expression of active Rac1/Cdc42 in Shef4 cells with and without EWS-
FLI1 expression 
Active Rac1 was detected in both Shef4EWS-FLI1.OFF and Shef4EWS-FLI1.ON cells (Figure 6.19 A). 
The endogenous level of active Rac1 was 1.5±0.1-fold lower in Shef4EWS-FLI1.ON cells 
compared to Shef4EWS-FLI1.OFF (Figure 6.19 B). The expression of active Rac1 was increased in 
both cell lines following treatment with Wnt5A (200ng/ml) for 30min, however this 
increase was slightly greater in Shef4EWS-FLI1.OFF cells (1.6±0.1-fold) than in Shef4EWS-FLI1.ON 
cells (1.4±0.1-fold) (Figure 6.19 B). Cdc42 protein could also be detected in Shef4EWS-FLI1.OFF 
and Shef4EWS-FLI1.ON cells (Figure 6.19 C). In contrast to active Rac1, active Cdc42 expression 
was increased in Shef4EWS-FLI1.ON cells compared to Shef4EWS-FLI1.OFF cells (1.5±0.07-fold). 
However, after treatment with Wnt5A (200ng/ml, 30 min) the expression of active Cdc42 
decreased in both Shef4EWS-FLI1.OFF cells (1.8±0.05-fold) and in Shef4EWS-FLI1.ON cells (2.5±0.14-
fold) (Figure 6.19 D).  
Figure ‎6.19 Expression of active Rac1 and Cdc42 in Shef4 cells with and without EWS-FLI1 
expression Shef4EWS-FLI1.OFF and Shef4EWS-FLI1.ON cells were cultured in 10cm2 dishes 
until 70% confluent then treated with rWnt5A (200ng/ml) for 30min. Cells were 
harvested, a sample removed for total protein estimation and active (GTP-bound) 
Rac1 and Cdc42 were precipitated from the remaining extract using glutathione-
sepharose beads bound to PAK-CRIB. Beads were washed, isolated and the sample 
split for analysis of Rac1 and Cdc42 by western blot. A) Expression of active Rac1 
total Rac1 B) Densitometry was performed and the ratio of active/total Rac1 
calculated and expressed relative to expression in Shef4EWS-FLI1.OFF control cells. 
Results show mean of two independent experiments (±SEM).  C) Expression of active 
Cdc42 and total Cdc42. Representative of 2 independent experiments. 
(A) 
(B) (D) 
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6.3.4.2.1 Changes in actin cytoskeleton with Wnt5A 
Immunofluorescent staining of the actin cytoskeleton revealed treatment with Wnt5A 
(200ng/ml, 24h) had no observable effect on the actin cytoskeleton of Shef4EWS-FLI1.OFF or 
Shef4EWS-FLI1.ON cells (Figure 6.20).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎6.20 Actin cytoskeleton in Shef4EWS-FLI.OFF and Shef4EWS-FLI.ON cells treated with 
Wnt5A Shef4EWS-FLI.OFF, Shef4EWS-FLI.ON and Shef4EWS-FLI.ON (1 month) cells were seeded 
onto glass coverslips coated with Matrigel™. Cells were grown for 24h, then treated 
with Wnt5A (200ng/ml, fixed with 4% PFA, and stained with DAPI (blue) and 
phalloidin (green) and imaged using a fluorescent microscope. 
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6.3.5 Effect of Wnt ligands on the growth of Shef4 cells with and without 
EWS-FLI1 expression 
Recombinant Wnt3A (200ng/ml) and recombinant Wnt5A (200ng/ml) did not increase the 
viable cell number of the Shef4EWS-FLI.ON cell line, or on Shef4 parental cell lines (Figure 6.21). 
Although the viable cell number of Shef4EWS-FLI1.OFF cells was significantly different after 
treatment with Wnt ligands (p<0.05), treatment with Wnt5A or Wnt3A actually decreased 
the viable cell number compared to untreated (control) cells (Figure 6.21 A). 
 
 
Figure ‎6.21 Viable cell number of Shef4  cell lines following treatment with Wnt3A and 
Wnt5A A) Shef4EWS-FLI1.OFF B) ShefEWS-FLI1.ON C) Shef4 parental and D) Shef4 parental 
(treated with DOX) cell lines were seeded as a single cell suspension and allowed to 
adhere for 24h. Cells were treated with 200ng/ml recombinant Wnt3A or 
recombinant Wnt5A for 24, 48, or 72h and viable cell number determined by trypan 
blue exclusion using the Vi-cell automated cell counter. Results show the mean of 
two independent experiments with three replicates within each experiment (n=6) (± 
SEM).  
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6.4 Discussion 
In this chapter I have confirmed that expression of EWS-FLI1 can be induced in the Shef4 
hES cell line using the TetON Advanced inducible expression system. My data 
demonstrates that EWS-FLI1 expression alters the growth characteristics and morphology 
of Shef4 cells. Furthermore, EWS-FLI1 changes the expression of Wnt signalling 
components and activates a TCF-based luciferase reporter of canonical Wnt signalling in 
Shef4 cells. EWS-FLI1 expression also increases the migration of Shef4 cells, and increases 
endogenous expression of active Cdc42. Therefore it is possible that canonical and 
noncanonical Wnt signalling are activated in these cells. 
EWS-FLI mRNA expression could be detected in Shef4EWS-FLI1 cells after only 24h treatment 
with DOX, and the protein could be detected after 48h. My data confirmed that by 72h 
Shef4EWS-FLI1.ON cells expressed EWS-FLI1 mRNA at the same level as the TC32 ESFT cell line, 
and cells which were maintained in DOX for up to 1 month continued to express EWS-FLI1 
at this same level. This confirms that the TetON inducible system is functional for as long as 
DOX is present in the media. Previous data from our laboratory has shown that expression 
of EWS-FLI1 in Shef4 cells induced expression of the ESFT marker CD99, as well as 
significantly increasing mRNA expression of EWS-FLI1 target genes CAV1, COL11A1, IGF1, 
NKX2-2 and NROB1 (Dr Andrew Gaffney, personal communication). These data further 
support the conclusion that this system is an informative model of ESFT initiation. It is 
important to note that treatment of Shef4EWS-FLI1 cells with DOX reduced the viable cell 
number in a dose-dependent manner. It was hypothesised this was because expression of 
EWS-FLI1 was not tolerated in (at least a sub-population) of Shef4 cells, as has been shown 
in other cell types (Lessnick et al. 2002). This is consistent with the failure to identify stable 
EWS-FLI1-expressing Shef4 cells using a constitutive system (Dr Andrew Gaffney, personal 
communication). However, parental Shef4 cells also had reduced viable cell growth in the 
same concentrations of DOX. Therefore my data suggests that DOX is toxic to at least a 
sub-population of Shef4 cells, and the initial reduction in viable cell number is not related 
to the expression of EWS-FLI1. In this study 5µg/ml DOX was used to induce expression of 
EWS-FLI. This is higher than the concentration of DOX suggested by Clontech (the 
manufacturers of the TetON Advanced system).  However this high concentration was 
required to achieve a similar level of EWS-FLI1 expression in Shef4EWS-FLI1 cells to that 
observed in TC32 cells. Therefore this concentration was used despite the fact that it 
reduced the viable cell number of Shef4 cells. Despite this, once a resistant population of 
cells was established, Shef4 parental cells grown in DOX (5µg/ml) had identical growth to 
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that of Shef4 parental cells not grown in DOX. In contrast, Shef4EWS-FLI1.ON cells had 
significantly reduced viable cell growth, and this was further reduced the longer EWS-FLI1 
was expressed. My data therefore demonstrates that EWS-FLI does have an effect on the 
long term growth characteristics of Shef4 cells. This is consistent with a previous study 
where DOX-induced expression of EWS-FLI1 in mesenchymal stem cells resulted in 
apoptosis-independent growth inhibition (Miyagawa et al. 2008). Although this previous 
study did not observe any differences in the cell cycle profile of these cells, further analysis 
would be required in our hES system to understand the mechanisms behind this growth 
inhibition.  
In addition to the differences in viable growth observed, the phenotype of the Shef4 cells 
was altered following induction of EWS-FLI1. Shef4EWS-FLI1.ON cell colonies were less tightly 
packed with an increased number of highly migratory cells. In addition, although not 
quantified, there were obviously fewer cell-cell adhesions and a greater number of cells 
which had filopdia. After 1 month of DOX treatment the morphology of Shef4EWS-FLI1.ON cells 
had changed even more drastically. Some smaller cells were still observed, however there 
were many large cells, histologically similar to mesenchymal cells, which contained stress 
fibres. This observation suggests that although the expression of EWS-FLI1 remains 
constant over this time, the transformation of Shef4EWS-FLI1.ON cells is an on-going process. 
This transition of tightly packed embryonic stem cells to elongated mesodermal-like cells 
with filamentous actin cytoskeleton has been described previously (Kinney et al. 2014). The 
change in morphology observed is reminiscent of an EMT. Although commonly 
investigated in cancer this process is fundamental during development. For example, 
during gastrulation and when neural crest cells within the dorsal neural epithelium migrate 
and give rise to the peripheral nervous system and other derivatives (Thiery et al. 2009). To 
determine if the Shef4EWS-FLI1.ON cells are truly undergoing mesodermal differentiation it 
would be necessary to investigate the expression of other markers associated with EMT 
such as loss of E-cadherin, gain of N-cadherin and gain of vimentin expression. In addition, 
since spontaneous differentiation to mesodermal-like cells has been demonstrated around 
the edges of hES cells grown in feeder free conditions (Ullmann et al. 2007), it would be 
necessary to also stain for EWS-FLI expression to confirm that the cells with this 
morphology are not simply an outgrowth of cells already present in the Shef4 population 
and unrelated to the expression of EWS-FLI1. 
Shef4 cells were cultured in feeder-free conditions using mTeSR™1 on hES-qualified 
Matrigel™. As discussed previously (Chapter 5) mTeSR™1 medium is serum-free and 
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contains a number of defined factors, including FGF2, to maintain self-renewal and 
pluripotency in hES cells (Ludwig et al. 2006, Akopian et al. 2010).  ESFT cells cannot 
tolerate culture in mTeSR™1 (Dr Andrew Gaffney, personal communication), presumably in 
part due to the high concentration of FGF2. Therefore it was hypothesised that culture in 
this media may inhibit the emergence of transformed ESFT-like Shef4EWS-FLI1.ON cells. For this 
reason Shef4EWS-FLI1.ON cell growth in RPMI (typical ESFT media) was investigated to 
determine if this media more effectively supported the maintenance of Shef4 cells with 
EWS-FLI1. However, my data showed that this was not the case. Although a subpopulation 
of cells appeared to adhere, there was no evidence of cell growth after a week. This 
indicated that despite adopting a phenotype and expression profile similar to that of ESFT 
cells, Shef4EWS-FLI1.ON cells are still inherently stem cells which require growth in this defined 
media. However, growth in RPMI was only investigated after up to 72h after DOX 
treatment. Since the morphology of Shef4 EWS-FLI1.ON cells continued to change up to 1 
month after DOX treatment, it is possible that there would be a point that Shef4EWS-FLI1.ON 
cells could tolerate growth in RPMI, although this was not assessed in this study. The 
culture media used is clearly important since it has been shown that the expression profile 
of paediatric MSCs with EWS-FLI1 expression cultured in serum-free knock out (KO) media 
more closely resembled that of ESFT than the same cells grown in normal FCS-containing 
media Therefore, for longer term experiments it would be valuable to elucidate the 
optimal growth media to use for Shef4EWS-FLI1.ON cells.                                                                          
To investigate the role of the Wnt signalling pathway in the induction of the ESFT 
phenotype using the Shef4EWS-FLI1.OFF and Shef4EWS-FLI1.ON cells, initially the Wnt signalling 
pathway array was performed. Although expression of 95% of components of the pathway 
were similar in Shef4EWS-FLI1.OFF and Shef4EWS-FLI1.ON cells, there was a significant change in 
expression of a number of genes between the two cell types. Interestingly there was an 
increase in DKK2 expression and a decrease in DKK4 expression observed in Shef4EWS-FLI1.ON 
cells. This is the opposite pattern to that which was observed in the OSCK4 
(reprogrammed) ESFT cell line (Chapter 5). This further strengthens the hypothesis that the 
DKK family play an important role in the initiation of ESFT and will be discussed further in 
Chapter 7. Interestingly, it has been shown previously that DKK2 expression is increased 
when EWS-ETS fusion proteins are expressed in mesenchymal progenitor cells (Miyagawa 
et al. 2009). In Shef4EWS-FLI1.ON cells there was an increase in expression of the noncanonical 
Wnt ligands Wnt4 and Wnt5A compared to expression in Shef4EWS-FLI1.OFF cells. In addition, 
Shef4EWS-FLI1.ON cells had increased expression of the FZD8 receptor which is involved in both 
canonical and noncanonical Wnt signalling and is expressed in ESFT cell lines (Chapter 2). 
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An increase in expression of FZD8 has also previously been reported in MSCs with inducible 
EWS-FLI1 expression (Miyagawa et al. 2008). To investigate further if these components 
play causal role in ESFT development it would be necessary to manipulate their expression, 
by knock-down and overexpression, and investigate what effect this has on the 
phenotypes observed after expression of EWS-FLI1.  
As in previous chapters, the activity of the canonical Wnt signalling pathway was 
investigated using the 7TFH luciferase reporter system. It was observed that, consistent 
with previous reports in other hES cell lines, the endogenous level of canonical Wnt 
signalling was low in Shef4 cells (Dravid et al. 2005, Davidson et al. 2012). Interestingly, 
although the raw data was not shown, endogenous canonical Wnt signalling was higher in 
Shef4EWS-FLI1.OFF cells compared to Shef4 parental cells. It has previously been reported that 
endogenous Wnt signalling is heterogeneous in hES cell populations (Blauwkamp et al. 
2012). Therefore since the Shef4EWS-FLI1.OFF cells have been though two rounds of antibiotic 
selection, it is possible that a sub-population of cells with relatively high canonical Wnt 
signalling has been selected. It was also observed that endogenous canonical Wnt 
signalling activity, as measured using the luciferase reporter, was increased after Shef4EWS-
FLI1.OFF cells had been dissociated into single cells by trypsinisation and then plated. It is 
known that hES cells are extremely sensitive to dissociation into single cells, with replating 
efficiencies of between 1-5% reported (Amit 2000, Hasegawa et al. 2006). However it has 
been demonstrated that Wnt signalling can enhance survival of hES cells plated onto 
Matrigel (Dravid et al. 2005), and specifically increase the replating efficiency of 
dissociated hES cells (Hasegawa et al. 2006, Blauwkamp et al. 2012). Therefore, it is 
possible that Shef4 cells transiently increase canonical Wnt signalling when dissociated, 
which increases their survival. For this reason, canonical Wnt signalling was always assayed 
in Shef4 cells 96h after seeding to avoid this confounding my results. 
My data demonstrate that treatment of Shef4EWS-FLI1 cells with DOX increases luciferase 
reporter activity in a time-dependent manner between 48-72h. This is consistent with the 
time that the EWS-FLI1 protein can be detected in these cells, and therefore suggests that 
EWS-FLI1 is activating the canonical Wnt signalling pathway. However, as previously 
mentioned hES cells have been shown to have heterogeneous endogenous canonical Wnt 
signalling, therefore it could be that only Shef4 cells with endogenously high canonical Wnt 
signalling can tolerate expression of the EWS-FLI1 fusion. That said, luciferase reporter 
activity was further increased when Shef4EWS-FLI1.ON cells were cultured in DOX for 1 month. 
These data suggest therefore that the EWS-FLI1 protein does directly or indirectly activate 
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canonical Wnt signalling. In contrast to previous reports, the addition of Wnt3A did not 
increase canonical Wnt signalling in Shef4 EWS-FLI1.OFF control cells (Dravid et al. 2005, 
Blauwkamp et al. 2012). However, as previously described Shef4EWS-FLI1.OFF cells had higher 
endogenous canonical Wnt signalling than Shef4 parental cells. Therefore it is possible that 
the canonical Wnt signalling pathway was already maximally stimulated in these cells. In 
contrast, Wnt3A significantly increased canonical Wnt signalling in Shef4 EWS-FLI1.ON cells, and 
this difference was greater when cells had been cultured in DOX for 1 month. This 
difference in canonical Wnt signalling in Shef4EWS-FLI1.ON cells cultured for an extended 
period of time in DOX is consistent with the continued change in morphology that was 
observed. This data further supports the notion that Shef4EWS-FLI1.ON cells are undergoing 
continued adaptation. Importantly, the addition of DOX did not change the activity of 
canonical Wnt signalling in Shef4 parental cells, further strengthening the hypothesis that 
EWS-FLI1 (rather than any other confounding factors) affects canonical Wnt signalling.  
Previous studies modelling the initiation of ESFT have indicated that Wnt signalling may be 
involved in this process. For example, expression of EWS-FLI1 in MSCs increased expression 
of FZD4, FZD7, FZD8, TCFL2 and Cdc42 and down regulated DKK1 (Miyagawa et al. 2008). 
However, my study is the first to provide evidence suggesting  that the EWS-FLI1 protein 
activates canonical Wnt signalling in cells.  
I attempted to confirm the increased activation of canonical Wnt signalling in Shef4EWS-
FLI1.ON cells by investigating the expression of total and active β-catenin. Total, but not 
active, β-catenin was increased in Shef4EWS-FLI1.ON cells compared to Shef4EWS-FLI1.OFF cells. 
However active β-catenin was increased in both Shef4EWS-FLI1.OFF and Shef4EWS-FLI1.ON cells 
after treatment with Wnt3A. These results were therefore inconclusive. As discussed in 
Chapter 3, detection of β-catenin by western blot may not be sensitive enough to detect 
subtle changes in expression. There are hundreds of target genes of canonical Wnt 
signalling and it is not know which of these are up- or down-regulated in this particular 
cellular situation. However further studies could use RTqPCR to investigate mRNA 
expression of Axin2 and a panel of other potential target genes to investigate downstream 
activation of the canonical Wnt signalling pathway. 
The migration assay optimised in Chapter 4 was used to investigate migration in hES cells 
with inducible EWS-FLI1 expression. As previously described, the migration assay used in 
this study relies on the initial formation of cell spheroids. In the field of hES cells, non-
adherent cell aggregates are termed ‘embryoid bodies’ (EBs) and formation of EBs is the 
first step in many differentiation protocols (Outten et al. 2011). However, as discussed 
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previously, hES cells are sensitive to single cell dissociation and a selective Rho-associated 
kinase (ROCK) inhibitor (Y-27632) is widely used to promote EB formation and increase hES 
cell survival (Watanabe et al. 2007). It has been shown that the activation of Rho is 
responsible for dissociation-induced hES cell apoptosis by ROCK-mediated myosin light 
chain phosphorylation (Ohgushi et al. 2010). In agreement with these previous studies, 
Shef4 EWS-FLI1.OFF and Shef4EWS-FLI1.ON cells only formed spheroids in the presence of ROCK 
inhibitor. Interestingly, the spheroids formed by Shef4EWS-FLI1.OFF cells were significantly 
larger than those formed by Shef4EWS-FLI1.ON cells; this could be explained by the increased 
viable cell growth of these cells. When the spheroids were plated onto different 
substrates, Shef4EWS-FLI1.OFF cells only migrated when plated on hES-cell qualified Matrigel™. 
This is perhaps not surprising at this is the matrix routinely used for feeder-free growth of 
Shef4 cells. The Shef4EWS-FLI1.OFF cells spread out with a clearly defined edge and maintained 
a tight central core. In contrast Shef4EWS-FLI1.ON cells migrated the most when plated onto 
gelatin, as was observed in the ESFT cell lines. In Shef4EWS-FLI1.ON cells although a spheroid 
core still remained, highly migratory individual cells were observed. This is consistent with 
my previous observations that suggested the Shef4EWS-FLI1.ON cells may have undergone a 
transition to mesenchymal-like cells, which are known to be highly migratory. This is also 
consistent with transformation to an ESFT-like cell, as most of the ESFT cell lines studied in 
Chapter 4 were also highly migratory. Treatment with both Wnt5A and Wnt3A increased 
the migration of Shef4EWS-FLI1.ON cells after 72h, however this did not reach statistical 
significance. Interestingly Wnt5A mRNA expression was increased in Shef4EWS-FLI1.ON cells 
and this may in part explain the increase in migration observed in Shef4EWS-FLI1.ON cells. 
However, as previously discussed in Chapter 4, many of the downstream targets of EWS-
FLI1 have previously been shown to increase migration such as CD99 and caveolin-1 (Sáinz-
Jaspeado et al. 2010, Kreppel et al. 2006). Therefore it is not possible to directly link Wnt5A 
expression or the Wnt signalling pathway to the differences in migration observed. In 
future studies inhibition of Wnt5A expression by RNAi may increase understanding of the 
role that this protein is having. To my knowledge this is the first time an increase in 
migration has been specifically reported in a model where EWS-FLI1 has been induced into 
mammalian cells.  
When Shef4EWS-FLI1 cells were treated with Wnt5A, there was a modest but not statistically 
significant increase in migration. However, there was no change in the actin cytoskeleton. 
Importantly, for the immunofluorescence analysis, cells were treated with Wnt5A for 24h. 
It is therefore possible that changes in the actin cytoskeleton occurred at earlier time 
points and were missed in my analysis. The pull-down assays used were performed after 
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30 min of Wnt5A treatment and previous studies have reported Wnt5A has an effect 
within 1h of exposure (Mikels and Nusse 2006). Future experiments could test this by 
performing immunofluorescence after shorter treatments with Wnt5A. In addition, by 
using high throughput automated analysis such as the Operetta® system, which we have 
access to, easy quantification of parameters could be performed which would give more 
quantitative results. It is quite possible this would reveal changes to the actin cytoskeleton 
since an increase in active Rac1 was observed in both Shef4EWS-FLI1.OFF and Shef4EWS-FLI1.ON cells 
after treatment with Wnt5A for 30 min. With regards to differences between Shef4EWS-
FLI1.OFF and Shef4EWS-FLI1.ON cells, no difference in active Rac1 expression was detected. 
However, although levels of total Cdc42 were low, there appeared to be in increase in 
active Cdc42 in Shef4EWS-FLI1.ON cells. This is interesting since it has been shown that Cdc42 
specifically controls the formation of filopida (Samuel and Olson 2011, Yang et al. 2006), 
and an increase in filopoda was observed in Shef4EWS-FLI1.ON cells. This change in phenotype 
was more pronounced after Shef4EWS-FLI1.ON cells that had been cultured in DOX for 1 month. 
Therefore, it would be worthwhile to investigate Rac1 and Cdc42 activation in these cells. 
Rho GTPases including Rac1 and Cdc42 have been shown to play a key role in hES cell 
survival. This is demonstrated by the fact that that ROCK inhibition greatly increases the 
replating efficiency of hES cells, as previously discussed. It has been hypothesised that hES 
cell in colonies are reliant on actomyosin forces from adjacent cells to limit pro-apoptotic 
signals (Samuel and Olson 2011). Therefore it is evident that Rho GTPase signalling is 
important in hES cells, independent of Wnt signalling. This means it is more challenging to 
directly link the changes observed to active noncanonical Wnt signalling. However my data 
suggest that noncanonical Wnt signalling may also be activated in the initiation of ESFT. It 
would be interesting to inhibit Wnt signalling, using secreted inhibitors such as sFRP5 and 
investigate if this has an effect on the morphology of cells after EWS-FLI1 induction. 
In summary in this chapter I have validated the model system of EWS-FLI1 expression in 
Shef4 hES cells, and proved it to be a valuable tool to study ESFT initiation. I have 
demonstrated that components of the Wnt signalling pathway are altered upon EWS-FLI1 
expression. The most exciting result is the strong evidence to suggest that EWS-FLI1 
expression increases the activation of the canonical Wnt signalling pathway. This is the first 
time data has suggested this is the case, and may greatly increase our understanding of 
how, and in what cell type ESFT develops. In turn this could lead to the development of 
novel therapeutics to help prevent recurrence and metastasis. The next phase of this 
research would be to specifically inhibit key proteins such as DKK2, FZD8, Wnt4 and Wnt5A 
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and overexpress DKK4 (discussed in Chapter 7), which appear to be important, to further 
elucidate what role Wnt signalling has in the initiation of ESFT. 
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7. Final Discussion 
My hypothesis was that the canonical Wnt signalling pathway is important in the initiation 
of ESFT, and the noncanonical Wnt signalling pathway becomes dominant during disease 
progression and metastasis. The specific aims of this thesis were to: 
 Examine the expression profile of Wnt signalling components in ESFT cell lines. 
 Develop functional assays to measure the activity of both the canonical and 
noncanonical Wnt signalling pathways. 
 Investigate the activity of the Wnt signalling pathways in two model systems of 
ESFT initiation: in reprogrammed ESFT cells and in hES cells with inducible EWS-
FLI1 expression. 
 The main findings of this thesis are: 
 ESFT cells express many key components of the Wnt signalling pathway including 
the canonical and noncanonical ligands Wnt1 and Wnt5A. 
 Canonical Wnt signalling is active in ESFT cell lines, and can be stimulated by the 
addition of exogenous Wnt3A ligand. 
 Expression of EWS-FLI1 activates canonical Wnt signalling in hES cells and changes 
the expression of Wnt signalling components including FZD8, Wnt4, Wnt5A, DKK4 
and DKK2. 
 Expression of EWS-FLI1 in hES cells may stimulate noncanonical Wnt signalling 
since Wnt5A expression, active Cdc42 and cell migration were all increased upon 
expression of the gene fusion. 
These results suggest that EWS-FLI-induced canonical and noncanonical Wnt signalling may 
be important during the initiation of ESFT. This hypothesis is summarised in Figure 7.1. 
Although the mechanism for this activation was not elucidated, my data suggests that this 
may be due to increased expression of FZD8, and decreased expression of DKK4. Since 
DKK2 expression was also increased in hES cells following induction of EWS-FLI, this may 
also activate canonical Wnt signalling, in addition to promoting migration. Expression of 
the noncanonical ligands Wnt4 and Wnt5A were also increased upon expression of EWS-
FLI1, however the potential role of the noncanonical Wnt signalling in the initiation of ESFT 
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was more difficult to determine as there are no assays available to specifically measure the 
activity of this pathway. 
  
 
 
 
 
 
 
 
 
Figure ‎7.1 Summary of main findings and hypothesised mechanisms of Wnt signalling 
activation during ESFT initiation  
7.1 EWS-FLI1 activates canonical Wnt signalling 
To my knowledge this is the first report providing data to suggest that EWS-FLI1 directly 
activates canonical Wnt signalling. This is an extremely important observation as it 
suggests that Wnt signalling may be an important pathway in the initiation of ESFT. EWS-
ETS fusion proteins are known to be necessary for ESFT initiation, however they are not 
sufficient to transform all normal cell types. It is believed that a permissive cellular 
environment is required to support expression of the fusion protein, and that additional 
mutations or aberrations in certain signalling pathways are also important in the initiation 
of the tumour phenotype. My results indicate that activation of the canonical Wnt 
signalling pathway may be important in this initiation process.  
The observation that EWS-FLI1 activates canonical Wnt signalling in hES cells is supported 
by my data to show that active canonical Wnt signalling in all ESFT cell lines studied. 
Although another recent report has described basal canonical Wnt signalling in the CHLA25 
ESFT cell line (Scannell et al. 2013), these data are in contrast to most previous studies in 
ESFT-like cell 
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ESFT cells where no or extremely low basal canonical Wnt signalling could be detected (Hu-
Lieskovan et al. 2005, Miyagawa et al. 2009, Navarro et al. 2010, Vijayakumar et al. 2011). 
This is most probably due to differences in experimental design as previous studies had 
used the less sensitive TOPFlash reporter assay, rather than the lentiviral vector used in 
this thesis and in the study by Scannell et al. (2013). However, notably in the paper by 
Navarro et al. (2010) it was reported that in HEK293T cells transient expression of EWS-
FLI1 blocked activation of canonical Wnt signalling, as measured using the TOPFlash 
reporter system. This directly contradicts my observations in hES cells. One possible 
explanation for this is that EWS-FLI1 has different effects on Wnt signalling depending on 
the cellular context, thus highlighting the importance of confirming my observations in 
other cell types.  
In this study I have used pluripotent hES cells to model tumour initiation. It would of 
course be important to show that activation of canonical Wnt signalling occurs when EWS-
FLI1 is expressed in the cell of origin of ESFT.  However, the identity of this cell (or cells) has 
not yet been elucidated. The most widely held hypothesis is that ESFT arise from MSCs 
(Tirode et al. 2007, Riggi et al. 2008, Riggi et al. 2010). Therefore it would be interesting to 
differentiate hES cells to a mesenchymal lineage (Outten et al. 2011), prior to inducing 
EWS-FLI1 expression and observe the effect of this in Wnt signalling activation. In the study 
by Navarro et al. (2010) the authors also demonstrated that EWS-FLI1 directly binds to 
LEF1, and hypothesised that the fusion protein may complete with β-catenin for binding, 
hence the inhibition of canonical Wnt signalling. Although my data disputes the fact that 
EWS-FLI1 inhibits canonical Wnt signalling, the observation that EWS-FLI1 binds to LEF1 is 
intriguing. It suggests that EWS-FLI1, behaving in its putative role as an aberrant 
transcription factor, may directly activate Wnt signalling. It has been estimated that EWS-
FLI1 regulates the expression of over 1000 genes, however the fusion protein has only 
been shown to directly interact with a handful of genes such as  such as NR0B1 (Garcia-
Aragoncillo et al. 2008) and CAV1 (Tirado et al. 2006). In other cases EWS-FLI1 has been 
shown to indirectly regulate expression; for example the fusion protein upregulates GLI1 
which in turn upregulates NKX2.2 (Beauchamp et al. 2009). Further studies have 
attempted to understand the interaction of EWS-FLI1 with its target genes using genome-
wide localisation studies such as chromatin immunoprecipitation (ChIP) followed by 
microarray analysis (ChIP-chip) and have shown that EWS-FLI binds to GGAA-containing 
microsatellites (Gangwal et al. 2008). It has been reported that these GGAA microsatellites 
are enriched in the promoters of genes that are upregulated by EWS-FLI1 such as NR0B1. 
Interestingly using this experimental technique over 900 genes were found to directly 
-222- 
 
 
interact with EWS-FLI1 including Wnt10B and DKK3 (Gangwal et al. 2008). Although mRNA 
expression of Wnt10B and DKK3 was not changed in my model systems, in future work 
techniques such as ChIP-chip and/or ChIP-seq could be employed to investigate whether 
EWS-FLI1 directly interacts with TCF/LEF and other Wnt signalling components. In the 
previous study by Navarro et al. (2010) immunoprecipitation (IP) followed by SDS-PAGE 
was used to identify EWS-FLI1 binding to LEF1, therefore more sensitive methods such as 
ChIP would provide important data to potentially confirm this interaction.  
An alternative hypothesis is that EWS-FLI1 indirectly activates canonical Wnt signalling in 
hES cells. Interestingly, the morphology of hES cells changed dramatically when EWS-FLI1 
was expressed; a transformation reminiscent of an EMT. Future studies staining for specific 
EMT markers such as loss of E-cadherin, gain of N-cadherin and vimentin expression will be 
important to examine this possibility. In addition to its role in the Wnt signalling pathway, 
β-catenin is also important in cell adhesion as a component of adherens junctions, where it 
is bound to both E-cadherin and the actin cytoskeleton (Adams and Nelson 1998). It has 
been demonstrated that when E-cadherin expression is reduced (for example during EMT), 
β-catenin is liberated from this structural complex (Eger et al. 2000). A decrease in E-
cadherin expression in pancreatic cancer cells has been reported to lead to increased 
expression of β-catenin in the nucleus and a subsequent increase in proliferation (Koenig 
et al. 2006). Therefore it is possible that EWS-FLI1 targets genes that alter the morphology 
of the cell, thus decreasing E-cadherin expression, and indirectly activating canonical Wnt 
signalling by increasing intracellular β-catenin. Although EMT often occurs in cancer cells 
and is linked to invasion and metastasis, this process is vitally important during normal 
embryonic development (Kalluri and Weinberg 2009). It has been demonstrated that Wnt 
signalling orchestrates an EMT during gastrulation (Liu et al. 1999) and also when the 
epithelial cells of the neuroectoderm give rise to migratory neural crest cells (Villanueva et 
al. 2002). Importantly, in breast cancer canonical Wnt signalling has been shown to 
regulate both Snail (Yook et al. 2005) and Slug (Wu et al. 2012), via GSK3β mediated 
phosphorylation. These proteins are both critical regulators of the EMT. Taken together 
with my data it is also possible that the phenotypic differences observed in hES cells upon 
EWS-FLI1 expression are a result of the activation of canonical Wnt signalling. Activation of 
noncanonical Wnt signalling may also have a role in this process and this will be discussed 
further in Section 7.3. 
Expression of the EWS-FLI1 fusion protein in hES cells increased expression of the receptor 
FZD8 and decreased expression of the inhibitor DKK4. Increased FZD8 expression has been 
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shown to increase the activity of the canonical Wnt signalling pathway and interestingly 
has been linked to chemoresistance in both lung (Wang et al. 2012) and triple negative 
breast cancer (Yin et al. 2013). DKK4 is an antagonist of canonical Wnt signalling (Niehrs 
2006, Fatima et al. 2012), therefore the decreased expression in hES cells with EWS-FLI1 
expression is consistent with increased canonical Wnt signalling. EWS-FLI1 has previously 
been reported to regulate the expression of components of the canonical Wnt signalling 
pathway such as DKK1 (Prieur et al. 2004, Kauer et al. 2009, Miyagawa et al. 2009) and 
DKK2 (Miyagawa et al. 2009). Therefore it is possible that by altering the expression of 
these and potentially other components of the Wnt signalling pathway that are as yet 
undescribed targets of EWS-FLI1, the fusion protein changes the activation of canonical 
Wnt signalling. 
7.2 Role of DKK proteins in the initiation of ESFT 
The results of this study highlight a potential role for the DKK family of proteins in ESFT 
initiation. This is interesting as both DKK1 and DKK2 have been previously identified as 
targets of EWS-FLI1. DKK1 has been reported to be downregulated by EWS-FLI1 (Prieur et 
al. 2004, Miyagawa et al. 2009, Navarro et al. 2010), whereas DKK2 is upregulated by the 
fusion protein (Miyagawa et al. 2009, Hauer et al. 2013). This is consistent with my data 
which showed higher expression of DKK2 than DKK1 in all ESFT cell lines. In addition, in the 
reprogrammed TTC466 cells, expression of DKK2 was significantly reduced compared to 
control (GFP) cells and the opposite was observed in hES cells with EWS-FLI1 expression; a 
significant increase in expression of DKK2 was observed after induction of expression of 
the fusion protein. In contrast, no significant difference in DKK1 expression was observed 
in either model system.  
A potential role for DKK2 in the initiation of ESFT has been suggested previously by 
Miyagawa et al. (2009) who showed that although DKK2 is not expressed in mesenchymal 
progenitor cells, expression of EWS-ETS fusions in these cells leads to an increase in DKK2 
expression. The authors also demonstrated that EWS-ETS fusion proteins directly bind to 
ETS binding sites in the promoter region of DKK2, thereby activating expression of the 
gene. This is consistent with my data. However, despite being implicated in the initiation of 
ESFT, the role of DKK2 in this process is not well understood. In the report by Miyagawa et 
al. (2009) the authors state that knockdown of DKK2 did not affect cell growth or cell 
death. However, more recently it has been reported that knockdown of DKK2 in ESFT cells 
reduced cell migration in vitro and also reduced tumour growth and lung metastases when 
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cells were injected subcutaneously into mice (Hauer et al. 2013). In addition, DKK2 
knockdown impaired differentiation into chondrogenic and osteogenic lineages and 
reduced migration to and infiltration into bone when injected into the tail vein of mice. 
This suggests that DKK2 may reprogram cells from neuronal to chondro-osseous 
differentiation. Interestingly, DKK2 has been shown to have a role in terminal osteoblast 
differentiation (Li et al. 2005), therefore aberrant expression of DKK2 may disrupt the 
normal differentiation of MSCs during ESFT initiation. 
Although DKK2 has been implicated as being important in the initiation of ESFT, only one 
previous study has linked this to canonical Wnt signalling. The DKK family of secreted 
proteins are generally considered to inhibit Wnt signalling by binding and sequestering the 
Wnt co-receptors LRP5/6 (Mao et al. 2001, Semënov et al. 2001). However, DKK2 has been 
shown to either activate or inhibit Wnt signalling, depending on the cellular context 
(Niehrs 2006). It has been suggested that in ESFT the latter may be true as it was 
demonstrated that knockdown of DKK2 in cell lines results in a decrease in canonical Wnt 
signalling target genes such as cyclin D1, LEF1, ID2 and Jun (Hauer et al. 2013). In my study 
using the inducible system I have observed an increase in DKK2 mRNA expression, and also 
an increase in canonical Wnt signalling. However, I cannot conclude from my data whether 
the increase in Wnt signalling is direct, indirect, or independent of the increase in DKK2 
expression. In future experiments an initial step would be to confirm that DKK2 expression 
is changed at the protein level in my model systems. To confirm that DKK2 is responsible 
for activating canonical Wnt signalling, it would be necessary to inhibit DKK2 and measure 
the effect this has on canonical Wnt signalling activity using the luciferase reporter system. 
We plan to investigate this in collaboration with Dr Guenther Richter from the Functional 
Genomics and Transplantation Biology Group in Munster, Germany who has developed 
ESFT cell lines with DKK2 knock-down (Hauer et al. 2013). 
Interestingly, expression of DKK4 was also significantly different in both model systems 
utilised in this study. DKK4 mRNA expression was increased in reprogrammed TTC466 cells 
and decreased in hES cells with EWS-FLI1 expression, suggesting that repression of DKK4 
expression may also be an important step in ESFT initiation. Expression of DKK4 has not 
previously been reported in ESFT. However it has been recently reported that DKK4 
functions as an inhibitor of osteoblastogenesis (Hiramitsu et al. 2013), therefore it would 
also be of interest to investigate the role of this DKK family member in ESFT initiation and 
in the activation of canonical Wnt signalling.  
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7.3 Noncanonical Wnt signalling in ESFT 
My original hypothesis was that the noncanonical Wnt signalling pathway is important in 
ESFT progression through its role in promoting metastasis and invasion. Interestingly, 
noncanonical Wnt signalling (specifically the Ca2+ pathway) has been shown to inhibit the 
canonical Wnt signalling pathway (Ishitani et al. 2003, Ishitani et al. 1999), and therefore 
Wnt5A has been described as being tumour suppressive in colorectal cancer (Ying et al. 
2008), thyroid cancer (Kremenevskaja et al. 2005) and myeloid leukaemia (Ying et al. 2007, 
Yuan et al. 2011). However, in my studies, inhibition of the canonical pathway was not 
evident in either the ESFT cell lines or model systems when treated with Wnt5A, as 
measured using the luciferase reporter assay. That said, interestingly, the cell lines with 
the highest level of endogenous active Rac1 expression (indicative of active noncanonical 
Wnt signalling) had the lowest levels of canonical Wnt signalling, as measured using the 
GFP and luciferase reporter assays. Therefore I cannot exclude the hypothesis that 
noncanonical Wnt signalling, activated by endogenous Wnt5A or other noncanonical 
ligands such as Wnt4 and/or Wnt11, could be acting to inhibit the canonical Wnt signalling 
pathway in some cell lines. 
Developing assays to measure the noncanonical Wnt signalling pathway was more 
challenging compared to the canonical pathway, since in noncanonical Wnt signalling there 
is no accepted key mediator, such as β-catenin which can easily be detected and 
quantified. In this study I therefore developed assays to detect the active form of Rac1 and 
Cdc42, effector proteins in the PCP and Ca2+ pathways, respectively. A pull-down assay was 
employed to detect the active, GTP-bound forms of these proteins. Although basal levels 
of active Rac1 could be detected in some ESFT cell lines, this was not consistently increased 
with the addition of recombinant Wnt5A. Furthermore, basal levels of active Cdc42 were 
extremely low in ESFT cell lines, although this probably reflects the fact that total levels of 
Cdc42 were also low. In the inducible model system, expression of active Rac1 was not 
increased in hES cells after EWS-FLI1 was induced. However, basal levels of active Cdc42 
did appear to be increased, although this was difficult to quantify since total levels of 
Cdc42 were so low. In my hands results from the pull-down assay were highly variable, 
consistent with observations from my colleagues (Dr Georgia Mavria, personal 
communication). In addition, this assay is not very sensitive meaning that subtle changes in 
levels of active Rac1/Cdc42 may have been missed. Pull-down assays are the most 
commonly used method to detect activation of small GTPases such as Rac1 and Cdc42. 
However, newer technologies such as FRET could be employed in future studies to more 
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accurately quantify the activation of Rac1/Cdc42 and also observe this activation in single 
cells rather than whole cell populations.  
Supporting the hypothesis that noncanonical Wnt signalling may be activated during the 
initiation of ESFT, hES cells with EWS-FLI1 expression showed significantly increased 
migration in vitro, along with increased mRNA expression of the noncanonical Wnt ligands 
Wnt5A and Wnt4 (Bernard et al. 2008).  However, since many of the downstream targets 
of EWS-FLI1 have previously been shown to increase migration such as CD99 and caveolin-
1 (Sáinz-Jaspeado et al. 2010, Kreppel et al. 2006) it was not possible in this study to 
demonstrate that the increase in migration was due to the activation of noncanonical Wnt 
signalling. That said, the fact that recombinant Wnt5A increased migration of these cells 
suggests that noncanonical Wnt signalling may have a role in this process. 
As previously discussed, the phenotype of hES cells changed dramatically when EWS-FLI1 
was expressed and it is possible that the noncanonical Wnt signalling pathway is important 
in this process. Noncanonical Wnt signalling, specifically Wnt5A, has been shown to have a 
role in EMT in ovarian (Qi et al. 2014), pancreatic (Bo et al. 2013) and gastric (Kanzawa et 
al. 2013) cancers. Noncanonical Wnt signalling is also known to mediate changes in the 
cytoskeleton through the PCP pathway. Interestingly an increase in Wnt4 expression has 
been described previously in hES cells differentiated to a neuronal lineage (Elizalde et al. 
2011). Therefore the increased expression of Wnt4 in hES cells with EWS-FLI1 expression 
supports the hypothesis that the fusion protein is responsible for the neuronal 
characteristics of ESFT.  
I originally hypothesised that the noncanonical Wnt signalling pathway may be more 
important during disease progression and in the process of metastasis. In support of this, 
Wnt5A expression has previously been reported to be higher in metastatic compared to 
localised ESFT tumour samples, and exogenous Wnt5A protein shown to increase the 
migration of ESFT cell lines (Jin et al. 2012). Although I have investigated the effect of 
Wnt5A on ESFT migration, this thesis has primarily focussed on Wnt signalling in the 
initiation of ESFT, rather than progression. However a mesenchymal phenotype has been 
shown to be important for the metastasis of ESFT (Wiles et al. 2013), therefore further 
understanding of the factors driving the morphological change in hES cells with EWS-FLI1 
expression would be important to increase our understanding of ESFT metastasis. Future 
work could attempt to determine the role of Wnt5A and the noncanonical Wnt signalling 
pathway on the migration of ESFT cell lines, and the effect of inhibition of noncanonical 
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Wnt signalling on tumour growth and metastasis in vivo when cells are injected 
subcutaneously and into the tail vein of mice. 
7.4 Use of model systems to investigate ESFT initiation 
My thesis has used two complementary model systems to investigate ESFT initiation. The 
first system used TTC466 cells which had been reprogrammed to a more primitive state in 
an attempt to investigate the cell of origin of ESFT. The second system used pluripotent 
hES cells in which expression of the EWS-FLI1 fusion could be induced driving hES cells 
towards an ESFT phenotype. It was hypothesised that by comparing the results generated 
by these two approaches, the role of Wnt signalling in the initiation of ESFT could be better 
understood. 
Using these models of ESFT initiation, greater differences in Wnt signalling were observed 
in the inducible system compared to in the reprogrammed cells. Although there were 
considerable changes in the Wnt signalling mRNA profile in reprogrammed (vs. control) 
cells, this may be because the factors within the reprogramming vector (Oct4, Sox2, c-Myc 
and Kfl4) are known to regulate components of the Wnt signalling pathway. Importantly, 
both DKK2 and DKK4 had significantly differential expression in both model systems. This 
further strengthens the hypothesis that the DKK family of proteins play an important role 
in the initiation of ESFT (Section 7.2). The basal activity of the canonical Wnt signalling 
pathway was increased in the inducible system, but was not changed in the reprogrammed 
cells. In fact, reprogrammed cells showed an increased response to recombinant Wnt3A 
protein, compared to control cells. This is perhaps surprising. If the hypothesis is correct 
that canonical Wnt signalling is increased during the initiation of ESFT, one may expect 
these more primitive cells would have decreased canonical Wnt signalling. However, my 
results may be confounded somewhat by the fact that reprogrammed (but not control) 
cells were cultured in mTeSR®1, which functions to maintain the self-renewal and 
pluripotency of stem cells (Sun et al. 2009, Chen et al. 2011)  and may therefore contain 
factors which increase Wnt signalling (discussed in Section 5.4). In addition, my hypothesis 
is that EWS-FLI1 activates canonical Wnt signalling, and reprogrammed cells still express a 
EWS-ETS fusion protein. It might therefore seem attractive to knock-down expression of 
the fusion in reprogrammed cells and investigate the effect of this on Wnt signalling. 
However, these studies may be very challenging as these reprogrammed cells may still 
depend on the expression of the fusion protein and knock-down may lead to cell death. 
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A potentially important fact to note is that the inducible system utilised in this study 
models the effect of EWS-FLI1 expression, whereas the TTC466 (parental reprogrammed) 
cells contain the EWS-ERG fusion. Interestingly, TTC466 cells had lower basal levels of 
canonical Wnt signalling, as measured by the GFP and luciferase reporter plasmids, 
compared to the other ESFT cell lines which all have a EWS-FLI1 fusion. This suggests that 
the different fusion proteins may differentially regulate the activity of canonical Wnt 
signalling. Although some studies using cell lines such as NIH/3T3 cells have concluded that 
there are some functional differences between EWS-FLI1 and EWS-ERG, other studies 
using cells which more closely resemble the cell of origin of ESFT, such as mesenchymal 
progenitor cells, have reported that expression of EWS-FLI1 and EWS-ERG in these cells 
lead to similar expression profiles (Miyagawa et al. 2008). Furthermore data from the Euro-
EWING 99 trial showed that the fusion type does not influence prognosis (Le Deley et al. 
2010) and tumours with EWS-FLI1 and EWS-ERG are phenotypically indistinguishable 
(Ginsberg et al. 1999). We might therefore reasonably expect there to be no difference in 
hES cells expressing EWS-FLI1 and EWS-ERG, justifying the comparison between the 
induced and reprogrammed models I have made. Nevertheless it would be interesting to 
investigate the effect of EWS-ERG expression in hES cells to determine if this fusion type 
has an effect on Wnt signalling.  
The use of in vitro model systems is essential to further elucidate the process of ESFT 
initiation. Of the two model systems used in this study the inducible system is potentially 
most useful as there are no OSCK factors expressed which could potentially have 
confounding effects on Wnt signalling. In addition, the effect of EWS-FLI1 can be directly 
measured by inducing expression of this (and potentially other) fusion proteins.  The use of 
model systems is especially important in the case of ESFT where the cell of origin is not 
known, and where unlike other cancers such as breast and colorectal, there are no known 
precursor lesions that can be examined. Research in ESFT is also hampered by the lack of a 
genetic EWS-FLI1 mouse model that accurately recapitulates ESFT without the necessity 
for additional mutations (Lin et al. 2008, Kovar et al. 2012). My studies have demonstrated 
that although there are some drawbacks, model systems can provide useful data and there 
are opportunities to develop these systems further in the future to continue to 
characterise the process of ESFT initiation, in particular to investigate the impact of genetic 
and environmental factors on ESFT initiation, and to identify treatments which may 
prevent relapse (Section 7.6). 
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7.5 Biological and clinical significance  
The data presented in this thesis was all generated using ESFT cell lines or models 
developed from ESFT or hES cell lines which have been in culture for a number of years, 
although cells with low passage numbers were used where possible. It is well recognised 
that cell lines, especially cancer cell lines that may be genetically unstable, will adapt over 
time when maintained in vitro ultimately leading to populations of cells which may differ 
dramatically to those found in the primary tumours (Schneider and Kulesz-Martin 2004). In 
the case of the hES cells, although cells with low passage numbers were originally utilised, 
to generate cells which contained the inducible expression system and luciferase reporter, 
a number of transfections (including lentiviral infections) and subsequent antibiotic 
selections were performed. This meant that it was inevitable that cells with higher passage 
numbers had to be used for the Wnt signalling assays. Although hES cells are karyotypically 
normal, it has been shown that after 30 passages culture adaptation can occur leading to 
changes in karyotypes (Amps et al. 2011). In all cases, the selection of cell lines which 
contained the reporter plasmid using antibiotics meant that the cell lines studied were a 
subpopulation, which may not be representative of the entire cell population. It would 
therefore be valuable to repeat my experiments with different clones to confirm the 
generality of my results.  
In this study, my data suggested that the ESFT cell lines may be predominantly canonical or 
noncanonical. However, as mentioned previously, these cells have been in culture for 
many years meaning they may not accurately represent the activity of Wnt signalling in the 
original tumour. Future studies could be performed using primary cell lines established 
directly from fresh tumour samples to investigate the activity of canonical and 
noncanonical Wnt signalling in cells which will more closely resemble the tumour in vivo. 
Although primary cell lines are challenging to work with as they are difficult to transfect 
and have a propensity to senesce, preliminary data has shown that primary ESFT cells can 
be transduced using lentiviral plasmids making this a potentially exciting avenue for future 
work. That said, even primary cell lines that are able to grow in in vitro culture conditions 
may not accurately reflect the in vivo situation, especially as the role of additional 
supporting tumour and normal cells is not considered. 
It would therefore be important to investigate Wnt signalling in primary tumour tissue. It 
would be possible to examine the expression of components of the Wnt signalling 
pathway, identified as potentially important in the initiation of tumour growth, in ESFT 
sections by immunohistochemistry (IHC) in order to confirm some of the findings of this 
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study. A commonly used method to investigate activation of canonical Wnt signalling in 
tumours is to probe for β-catenin and examine its subcellular localisation. Importantly, 
however it has previously been reported that β-catenin could not be detected in the 
cytoplasm or the nucleus of ESFT patient samples (Üren et al. 2004). It would therefore be 
of interest to investigate β-catenin localisation in patient samples using the antibody 
employed in my study. However, as my results have demonstrated, levels of nuclear 
and/or nonphosphorylated β-catenin do not always correlate with levels of activated 
canonical Wnt signalling as measured using a reporter assay, therefore the functional 
activity of the canonical Wnt signalling pathway could not be determined using this 
method. Furthermore, quantifying the expression of Wnt ligands and receptors in tumour 
samples may not be any more informative since the activation of downstream signalling 
pathways upon Wnt ligand binding has been shown to be dependent on the cellular 
context rather than the specific ligands and receptors that are expressed. In this study I did 
not investigate the genetic status of the ESFT cell lines. Recently, using whole-genome 
sequencing of over 100 ESFT tumours, it has been shown that there are very few recurring 
mutations found in tumour samples (Tirode et al. 2014). Specifically, mutations in CTNNB1 
(β-catenin) have been shown to be very rare in ESFT (Shukla et al. 2012). Nevertheless, in 
future, primary ESFT cells could be sequenced to ascertain if any mutations in Wnt 
signalling components exist, and if this correlates with changes in the activity of the 
pathway(s). Functional assays such as those I have optimised in this study would still be 
required to definitively measure Wnt signalling activity in ESFT. 
In this study I have demonstrated that canonical and very likely noncanonical Wnt 
signalling pathways are activated upon expression of EWS-FLI1. An important area of 
future work would be to understand the biological significance of this activation and what 
role (if any) Wnt signalling has in the tumorigenesis of ESFT. In the case of canonical Wnt 
signalling, treatment with Wnt3A did not increase the proliferation of ESFT cell lines, 
reprogrammed cells or hES cells with EWS-FLI1 expression. This is consistent with previous 
reports (Üren et al. 2004) and the observation that in ESFT cell lines no increase in cyclin 
D1 was observed after treatment with Wnt3A. To provide further evidence as to what 
effect canonical Wnt signalling has on ESFT cells it would be possible to perform large-scale 
expression profiling of the known targets of canonical Wnt signalling using RNAseq. 
However this would be time consuming and expensive and would still not provide direct 
evidence as to the biological effect of Wnt signalling in ESFT cells. Therefore it would be 
necessary to both activate and inhibit canonical Wnt signalling in ESFT cells to elucidate 
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what biological effect the observed activation of Wnt signalling is having during ESFT 
initiation (Section 7.6). 
7.6 Wnt signalling inhibition 
In order to validate the main results of this study in future work it would be necessary to 
inhibit Wnt signalling in ESFT cell lines and in my model systems. Many studies have used 
recombinant endogenous inhibitors of Wnt signalling such as the DKK and sFRP families of 
proteins in order to inhibit the pathways. However, as discussed, the DKK family have been 
suggested to be potentially important in ESFT initiation therefore would not be suitable to 
use as potential inhibitors in these studies. It has also been shown that the sFRP family 
members can either activate or inhibit Wnt signalling depending on the cellular context 
(Anastas and Moon 2013). As an alternative, a number of inhibitors of canonical Wnt 
signalling have been developed. For example iCRT 14 (Gonsalves et al. 2011) and PNU 
74654  (Trosset et al. 2006) which both act by inhibiting the interaction between β-catenin 
and TCF4. Other inhibitors that target other parts of the canonical pathway such as 
XAV939, which enhances Axin stability through tankyrase inhibition (Huang et al. 2009), 
have also been developed. To decipher which pathways within noncanonical Wnt signalling 
are important, specific inhibitors could be used. For example, the Ca2+ pathway could be 
inhibited using BAPTA-AM, a Ca2+ chelator or Go6983, an inhibitor of PKC. The PCP pathway 
could also be inhibited using the JNK-specific inhibitor SP600125. However a limitation of 
these agents is that they are not very specific and often affect other signalling pathways, 
therefore it would not be possible to directly link any downstream effects observed to Wnt 
signalling. A better approach would be to inhibit, using RNAi knockdown, and also 
overexpress key components which I have identified as being important in the initiation of 
ESFT, such as DKK2 and Wnt5A. Subsequent phenotypic assay such as proliferation, cell 
cycle analysis, colony formation and migration could then be performed to elucidate what 
biological effect the observed activation of Wnt signalling is having during ESFT initiation.  
6.4.1 Wnt signalling inhibition in the treatment of ESFT 
Although understanding the initiation of ESFT is an important goal, clinically, patients tend 
to present with advanced and often metastatic disease. ESFT display an aggressive 
phenotype and up to 50% of patients without clinically detectable metastasis at diagnosis 
will relapse with distant metastatic disease after surgery if systemic chemotherapy is not 
given. In addition, despite aggressive treatment the tumour recurs in 30-40% of patients. 
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Therefore there is a real need to understand the cell or cells that are responsible for this 
aggressive behaviour. Recently CICs have been identified from ESFT, on the basis of CD133 
expression (Suvà et al. 2009). Work in our laboratory has been focussed on characterising 
CICs from ESFT and our data has revealed that additional markers are required to isolate 
true CICs. Future studies in our laboratory will attempt to isolate CICs from primary tumour 
samples, and these cells could also be characterised in terms of Wnt signalling activity. If it 
is demonstrated that ESFT CICs have active Wnt signalling this could be a target for 
development of new therapeutics for the treatment of ESFT. Activation of canonical Wnt 
signalling has been implicated in the maintenance of leukaemic (Jamieson et al. 2004), 
colorectal cancer (Barker et al. 2009) and breast cancer (Hallett et al. 2012) initiating cells. 
Unfortunately, direct targeting of Wnt signalling in vivo has proven difficult. This is in part 
due to the lack of specific targets and the redundancy of many of the pathway 
components. The effectiveness and safety of small molecule inhibitors such as iCRT 14 and 
PNU 74654 has not yet been evaluated in clinical trials. However other non-specific 
compounds for example non-steroidal anti-inflammatory drugs (NSAIDS) such as aspirin, 
and the COX2 inhibitor celecoxib, have been shown to inhibit canonical Wnt signalling in 
colorectal cancer cells (Dihlmann et al. 2001, Tuynman et al. 2008). Interestingly celecoxib 
has been shown to inhibit invasion and migration of ESFT in  vitro (Barlow et al. 2012). In 
addition, a phase II study investigating celecoxib as an anti-angiogenic agent in ESFT 
reported that the drug was tolerated and improved event free survival for patients with 
pulmonary metastasis (Felgenhauer et al. 2013). Therefore, if in vitro analysis suggests 
these agents inhibit growth and/or metastasis of ESFT CICs isolated from tumour samples, 
my data would support further investigation of these agents to be given to prevent 
metastasis and/or tumour relapse. 
My data has indicated that the DKK family of proteins may have an important role in the 
initiation of ESFT. Interestingly this family of proteins have been shown to play a role in 
other bone disorders. For example, DKK1 has been shown to play an important role in 
myeloma bone disease (Tian et al. 2003) and Paget’s disease of the bone (Polyzos et al. 
2009). Therefore many DKK1 antibodies have been generated and have shown to be 
effective in treating bone disease in preclinical models (Pozzi et al. 2013, Zhou et al. 2013) 
(Miao et al. 2013). If future studies demonstrate that DKK2 is indeed important in the 
development and/or progression of ESFT then it is likely that anti-DKK2 antibodies could 
also be development and may prove to be effective in preventing relapse and/or 
metastasis. 
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7.7 Final conclusions and future work 
In conclusion, the studies described in this thesis have provided interesting data to indicate 
that activation of the canonical and also noncanonical Wnt signalling pathways may be an 
important step in the initiation of ESFT. These data could provide further understanding of 
how ESFT arise, as well as informing future work to develop more effective and less toxic 
treatment for patients with ESFT, especially those with metastatic disease for whom 
current treatment options are lacking. 
Future studies should specifically investigate: 
 If EWS-FLI1 activates canonical Wnt signalling in hES cells differentiated to a 
mesenchymal lineage. To confirm that my results are representative of the events 
which occur in the putative ESFT-cell of origin, MSCs, it would be important to 
investigate Wnt signalling activation in mesenchymal cells. 
 What effect inhibiting Wnt signalling has on cells with inducible EWS-FLI1 
expression. To confirm that Wnt signalling is responsible for the phenotypic 
differences observed when EWS-FLI1 is expressed, it would be important to inhibit 
Wnt signalling during this process. 
 What effect DKK2 and DKK4 knockdown and/or overexpression have on 
canonical Wnt signalling in ESFT cell lines, and in cells with inducible EWS-FLI1 
expression. Since my data has suggested that both DKK2 and DKK4 may be 
important in the initiation of ESFT, it would also be important to both inhibit and 
overexpress these proteins in cell lines and in my model systems to investigate the 
phenotypic effects, and the effect on the expression of other components of the 
Wnt signalling pathway, in order to further investigate what role DKK2 and DKK4 
have in this process. 
 If the noncanonical Wnt signalling pathway is responsible for the increased 
migration observed in cells with inducible EWS-FLI1 expression. Although an 
increase in migration was observed when EWS-FLI1 was induced in hES cells it was 
not possible to directly link this to an increase in noncanonical Wnt signalling. 
Therefore it would be important to inhibit and overexpress Wnt5A and investigate 
the effect of this on the migration of inducible cells, in order to ascertain if the 
noncanonical Wnt signalling pathway is important in this observed phenotype. 
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 The activity of canonical and noncanonical Wnt signalling in primary cell lines 
generated from ESFT samples. Since my study has only used established cell lines, 
which may have adapted to in vitro culture, it would be important to confirm my 
results in primary ESFT cell lines. It would also be interesting to sequence primary 
tumours to determine if any of the components of the Wnt signalling pathway are 
mutated in ESFT, and what effects this has on the activity of the pathway. 
 The activity of Wnt signalling in CICs isolated from primary ESFT samples, and the 
effect of Wnt signalling inhibitors on these cells. CICs have recently been 
identified in ESFT and they may be responsible for disease relapse and resistance 
to therapy. Therefore determining if Wnt signalling is active in CICs derived from 
ESFT, and whether inhibition of the pathway(s) can be used to target these cells, is 
an important avenue for future work. 
 Developing better assays to measure the activity of the noncanonical Wnt 
signalling pathway. The lack of informative assays to measure the noncanonical 
Wnt signalling pathway meant that I could not draw definite conclusions about the 
role of this pathway in ESFT initiation. Therefore it would be important to improve 
the current assays used to measure active Rac1/Cdc42 for example using FRET, and 
also to develop assays to measure other downstream components of the 
noncanonical pathways such as a reporter to measure NFAT-mediated activation of 
gene transcription, and assays to detect activation of PKC and JNK.  
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Sequencing of pLenti 7xTcf Ffluc SV40-Hygro (7TFH) 
Primer 1: 5’- CGTGGATTACGTCGCCAG-3’ 
 
CCGTGTAATTCTAGAGTCGATCGACCCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAG
GCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAG
TCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTC
CCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTG
ACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGA
GGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTTGCCAGCTGGGGCGCCCTCTGGTAAGG
TTGGGAAGCCCTGCAGATCTGATCCCGGGGGGCAATGAGATATGAAAAAGCCTGAACTCACCGCG
ACGTCTGTCGAGAAGTTTCTGATCGAAAAGTTCGACAGCGTCTCCGACCTGATGCAGCTCTCGGAG
GGCGAAGAATCTCGTGCTTTCAGCTTCGATGTAGGAGGGCGTGGATATGTCCTGCGGGTAAATAG
CTGCGCCGATGGTTTCTACAAAGATCGTTATGTTTATCGGCACTTTGCATCGGCCGCGCTCCCGATT 
 
Primer 2: 5’ – CCAGCAGGCAGAAGTATG-3’ 
 
AGTGGAAACCGACGCCCCAGCACTCGTCCGAGGGCAAAGGAATAGAGTAGATGCCGACCGGGAT
CTATCGTCGACAATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGT
TGCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCGTATGG
CTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTTGTGGCCCGTTGTC
AGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCAACCCCCACTGGTTGGGGCATTGCCAC
CACCTGTCAGCTCCTTTCCGGGACTTTCGCTTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGCCG
CCTGCCTTGCCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGG
GGAAGCTGACGTCCTTTCCATGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCT
TCTGCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCG
GCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCG 
 
Primer 3: 5’ - CACGCCACGTTGCCTGAC-3’ 
 
GCAACATAGTTAAGAATACCAGTCAATCTTTCACAAATTTTGTAATCCAGAGGTTGATTGTCGACGA
TAGATCCCGGTCGGCATCTACTCTATTCCTTTGCCCTCGGACGAGTGCTGGGGCGTCGGTTTCCACT
ATCGGCGAGTACTTCTACACAGCCATCGGTCCAGACGGCCGCGCTTCTGCGGGCGATTTGTGTACG
CCCGACAGTCCCGGCTCCGGATCGGACGATTGCGTCGCATCGACCCTGCGCCCAAGCTGCATCATC
GAAATTGCCGTCAACCAAGCTCTGATAGAGTTGGTCAAGACCAATGCGGAGCATATACGCCCGGA
GCCGCGGCGATCCTGCAAGCTCCGGATGCCTCCGCTCGAAGTAGCGCGTCTGCTGCTCCATACAAG
CCAACCACGGCCTCCAGAAGAAGATGTTGGCGACCTCGTATTGGGAATCCCCGAACATCGCCTCGC
TCCAGTCAATGACCGCTGTTATGCGGCCATTGTCCGTCAGGACATTGTTGGAGCCGAAATCCGCGT
GCACGAGGTGCCGGACTTCGGGGCAGTCCTCGGCCCAAAGCATCAGCTCATCGAGAGCCTGCGCG
ACGGACGCACTGACGGTGTCGTCCATCACAGTTTGCCAGTGATACACATGGGGATCAGCAATCGC 
 
7TFP 
HYRGO 
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